study_id,site_id,subject_id,project_name,region,country,input_files,cpmd,ssm,latest_visit_sv_source_rave_edc_bo4,subject_status_source_primary_form
Study 1,Site 1,Subject 1,Study 1,EMEA,FRA,0.0,1.0,8.0,Screening,Screen Failure
Study 1,Site 10,Subject 17,Study 1,EMEA,DEU,0.0,1.0,9.0,Screening,Screen Failure
Study 1,Site 10,Subject 18,Study 1,EMEA,DEU,0.0,21.0,279.0,Follow-up_Week 8 (1),Discontinued
Study 1,Site 10,Subject 19,Study 1,EMEA,DEU,0.0,14.0,254.0,End of Treatment (1),Discontinued
Study 1,Site 11,Subject 20,Study 1,ASIA,SGP,0.0,1.0,13.0,Screening,Screen Failure
Study 1,Site 11,Subject 21,Study 1,ASIA,SGP,0.0,1.0,10.0,Screening,
Study 1,Site 12,Subject 22,Study 1,ASIA,KOR,0.0,4.0,0.0,W1D4 (1),On Trial
Study 1,Site 13,Subject 23,Study 1,EMEA,ESP,0.0,1.0,0.0,Screening,Screen Failure
Study 1,Site 13,Subject 24,Study 1,EMEA,ESP,0.0,0.0,0.0,,
Study 1,Site 14,Subject 25,Study 1,EMEA,ESP,0.0,1.0,17.0,Screening,Screen Failure
Study 1,Site 14,Subject 26,Study 1,EMEA,ESP,0.0,23.0,298.0,Unplanned Visit (10),On Trial
Study 1,Site 14,Subject 27,Study 1,EMEA,ESP,0.0,1.0,9.0,Screening,Screen Failure
Study 1,Site 14,Subject 28,Study 1,EMEA,ESP,0.0,1.0,12.0,Screening,Screen Failure
Study 1,Site 14,Subject 29,Study 1,EMEA,ESP,0.0,1.0,13.0,Screening,Screen Failure
Study 1,Site 14,Subject 30,Study 1,EMEA,ESP,0.0,1.0,13.0,Screening,Screen Failure
Study 1,Site 14,Subject 31,Study 1,EMEA,ESP,0.0,1.0,16.0,Screening,Screen Failure
Study 1,Site 14,Subject 32,Study 1,EMEA,ESP,0.0,18.0,266.0,Follow-up_Week 8 (1),On Trial
Study 1,Site 14,Subject 33,Study 1,EMEA,ESP,0.0,1.0,12.0,Screening,Screen Failure
Study 1,Site 14,Subject 34,Study 1,EMEA,ESP,0.0,1.0,9.0,Screening,Screen Failure
Study 1,Site 14,Subject 35,Study 1,EMEA,ESP,0.0,1.0,9.0,Screening,Screen Failure
Study 1,Site 14,Subject 36,Study 1,EMEA,ESP,0.0,5.0,78.0,W7D1 (1),On Trial
Study 1,Site 14,Subject 37,Study 1,EMEA,ESP,0.0,1.0,9.0,Screening,Screen Failure
Study 1,Site 14,Subject 38,Study 1,EMEA,ESP,0.0,1.0,3.0,Screening,Screen Failure
Study 1,Site 15,Subject 39,Study 1,EMEA,ESP,0.0,16.0,253.0,Unplanned Visit (12),Discontinued
Study 1,Site 15,Subject 40,Study 1,EMEA,ESP,0.0,1.0,14.0,Screening,Screen Failure
Study 1,Site 15,Subject 41,Study 1,EMEA,ESP,0.0,1.0,13.0,Screening,Screen Failure
Study 1,Site 15,Subject 42,Study 1,EMEA,ESP,0.0,21.0,302.0,W40D1 (1),On Trial
Study 1,Site 15,Subject 43,Study 1,EMEA,ESP,0.0,1.0,10.0,Screening,Screen Failure
Study 1,Site 15,Subject 44,Study 1,EMEA,ESP,0.0,17.0,230.0,W28D1 (1),On Trial
Study 1,Site 15,Subject 45,Study 1,EMEA,ESP,0.0,12.0,166.0,End of Treatment (1),Discontinued
Study 1,Site 15,Subject 46,Study 1,EMEA,ESP,0.0,9.0,135.0,W8D7 (1),On Trial
Study 1,Site 15,Subject 47,Study 1,EMEA,ESP,0.0,14.0,172.0,W22D1 (1),On Trial
Study 1,Site 15,Subject 48,Study 1,EMEA,ESP,0.0,1.0,9.0,Screening,Screen Failure
Study 1,Site 15,Subject 49,Study 1,EMEA,ESP,0.0,1.0,19.0,Screening,Screen Failure
Study 1,Site 15,Subject 50,Study 1,EMEA,ESP,0.0,0.0,12.0,Screening,Screen Failure
Study 1,Site 15,Subject 51,Study 1,EMEA,ESP,0.0,0.0,0.0,,
Study 1,Site 15,Subject 52,Study 1,EMEA,ESP,0.0,3.0,57.0,W1D3 (1),On Trial
Study 1,Site 15,Subject 53,Study 1,EMEA,ESP,0.0,0.0,0.0,,
Study 1,Site 15,Subject 54,Study 1,EMEA,ESP,0.0,0.0,0.0,,
Study 1,Site 16,Subject 55,Study 1,EMEA,ESP,0.0,1.0,10.0,Screening,Discontinued
Study 1,Site 16,Subject 56,Study 1,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 1,Site 16,Subject 57,Study 1,EMEA,ESP,0.0,4.0,209.0,Unplanned Visit (22),Discontinued
Study 1,Site 16,Subject 58,Study 1,EMEA,ESP,0.0,1.0,52.0,Unplanned Visit (3),Screen Failure
Study 1,Site 16,Subject 59,Study 1,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 1,Site 17,Subject 60,Study 1,EMEA,ESP,0.0,1.0,0.0,Screening,Screen Failure
Study 1,Site 17,Subject 61,Study 1,EMEA,ESP,0.0,3.0,0.0,W1D3 (1),
Study 1,Site 17,Subject 62,Study 1,EMEA,ESP,0.0,5.0,0.0,W4D1 (1),
Study 1,Site 18,Subject 63,Study 1,AMERICA,USA,0.0,30.0,367.0,Follow-up_Week 48 (1),On Trial
Study 1,Site 18,Subject 64,Study 1,AMERICA,USA,0.0,19.0,331.0,Unplanned Visit (12),Discontinued
Study 1,Site 18,Subject 65,Study 1,AMERICA,USA,0.0,20.0,324.0,Follow-up_Week 48 (1),On Trial
Study 1,Site 18,Subject 66,Study 1,AMERICA,USA,0.0,22.0,352.0,Follow-up_Week 16 (1),Discontinued
Study 1,Site 18,Subject 67,Study 1,AMERICA,USA,0.0,21.0,387.0,Follow-up_Week 32 (1),On Trial
Study 1,Site 18,Subject 68,Study 1,AMERICA,USA,0.0,1.0,73.0,Unplanned Visit (6),Screen Failure
Study 1,Site 18,Subject 69,Study 1,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 1,Site 18,Subject 70,Study 1,AMERICA,USA,0.0,1.0,14.0,Screening,Screen Failure
Study 1,Site 18,Subject 71,Study 1,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 1,Site 18,Subject 72,Study 1,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 1,Site 18,Subject 73,Study 1,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 1,Site 18,Subject 74,Study 1,AMERICA,USA,0.0,6.0,96.0,Unplanned Visit (1),On Trial
Study 1,Site 18,Subject 75,Study 1,AMERICA,USA,0.0,6.0,87.0,W5D7 (1),On Trial
Study 1,Site 18,Subject 76,Study 1,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 1,Site 19,Subject 77,Study 1,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 1,Site 19,Subject 78,Study 1,AMERICA,USA,0.0,16.0,170.0,End of Treatment (1),On Trial
Study 1,Site 19,Subject 79,Study 1,AMERICA,USA,0.0,0.0,14.0,Screening,Screen Failure
Study 1,Site 19,Subject 80,Study 1,AMERICA,USA,0.0,4.0,0.0,W4D1 (1),On Trial
Study 1,Site 19,Subject 81,Study 1,AMERICA,USA,0.0,0.0,0.0,Screening,Screen Failure
Study 1,Site 2,Subject 2,Study 1,EMEA,FRA,0.0,18.0,216.0,Follow-up (1),Discontinued
Study 1,Site 2,Subject 3,Study 1,EMEA,FRA,0.0,20.0,216.0,Follow-up (1),Discontinued
Study 1,Site 2,Subject 4,Study 1,EMEA,FRA,0.0,1.0,43.0,Screening,On Trial
Study 1,Site 2,Subject 5,Study 1,EMEA,FRA,0.0,3.0,0.0,W1D3 (1),
Study 1,Site 20,Subject 82,Study 1,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 1,Site 21,Subject 83,Study 1,AMERICA,USA,0.0,15.0,99.0,W22D1 (1),On Trial
Study 1,Site 21,Subject 84,Study 1,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 1,Site 21,Subject 85,Study 1,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 1,Site 22,Subject 86,Study 1,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 1,Site 23,Subject 87,Study 1,AMERICA,USA,0.0,19.0,150.0,W25D1 (1),On Trial
Study 1,Site 23,Subject 88,Study 1,AMERICA,USA,0.0,3.0,0.0,W1D3 (1),On Trial
Study 1,Site 23,Subject 89,Study 1,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 1,Site 24,Subject 90,Study 1,AMERICA,USA,0.0,7.0,157.0,Unplanned Visit (2),Discontinued
Study 1,Site 25,Subject 91,Study 1,EMEA,GBR,0.0,22.0,253.0,End of Treatment (1),Discontinued
Study 1,Site 25,Subject 92,Study 1,EMEA,GBR,0.0,1.0,8.0,Screening,Screen Failure
Study 1,Site 26,Subject 93,Study 1,ASIA,CHN,0.0,0.0,0.0,,
Study 1,Site 26,Subject 94,Study 1,ASIA,CHN,0.0,0.0,0.0,,
Study 1,Site 26,Subject 95,Study 1,ASIA,CHN,0.0,0.0,0.0,,
Study 1,Site 27,Subject 96,Study 1,ASIA,CHN,0.0,6.0,69.0,W5D7 (1),On Trial
Study 1,Site 27,Subject 97,Study 1,ASIA,CHN,0.0,6.0,73.0,W5D7 (1),On Trial
Study 1,Site 27,Subject 98,Study 1,ASIA,CHN,0.0,1.0,11.0,Screening,Screen Failure
Study 1,Site 3,Subject 6,Study 1,EMEA,FRA,0.0,19.0,257.0,Follow-up_Week 8 (1),Discontinued
Study 1,Site 3,Subject 7,Study 1,EMEA,FRA,0.0,29.0,291.0,Follow-up_Week 104 (1),On Trial
Study 1,Site 3,Subject 8,Study 1,EMEA,FRA,0.0,18.0,207.0,Follow-up_Week 8 (1),Discontinued
Study 1,Site 4,Subject 10,Study 1,EMEA,FRA,0.0,18.0,169.0,End of Treatment (1),On Trial
Study 1,Site 4,Subject 9,Study 1,EMEA,FRA,0.0,16.0,304.0,Follow-up (1),On Trial
Study 1,Site 5,Subject 11,Study 1,EMEA,AUT,0.0,0.0,0.0,Screening,
Study 1,Site 6,Subject 12,Study 1,EMEA,AUT,0.0,5.0,1.0,W4D1 (1),
Study 1,Site 6,Subject 13,Study 1,EMEA,AUT,0.0,1.0,0.0,Screening,Screen Failure
Study 1,Site 7,Subject 14,Study 1,EMEA,ISR,0.0,13.0,192.0,W22D1 (1),On Trial
Study 1,Site 8,Subject 15,Study 1,EMEA,ISR,0.0,1.0,0.0,Screening,Screen Failure
Study 1,Site 9,Subject 16,Study 1,EMEA,CZE,0.0,1.0,0.0,Screening,
Study 10,Site 11,Subject 20,Study 10,EMEA,HUN,0.0,1.0,0.0,Screening,Screening
Study 10,Site 149,Subject 1401,Study 10,EMEA,POL,0.0,1.0,0.0,Screening,Screening
Study 10,Site 149,Subject 1402,Study 10,EMEA,POL,0.0,0.0,0.0,Screening,Screening
Study 10,Site 153,Subject 1417,Study 10,EMEA,ITA,0.0,1.0,0.0,Screening,Screening
Study 10,Site 154,Subject 1421,Study 10,EMEA,ITA,0.0,1.0,0.0,Screening,Screening
Study 10,Site 28,Subject 107,Study 10,AMERICA,USA,0.0,6.0,54.0,Week 8 (1),On Trial
Study 10,Site 28,Subject 108,Study 10,AMERICA,USA,0.0,6.0,45.0,Week 8 (1),On Trial
Study 10,Site 28,Subject 2233,Study 10,AMERICA,USA,0.0,1.0,18.0,Screening,Screen Failure
Study 10,Site 28,Subject 2234,Study 10,AMERICA,USA,0.0,1.0,0.0,Screening,Screening
Study 10,Site 29,Subject 109,Study 10,AMERICA,USA,0.0,5.0,0.0,Week 4 (1),On Trial
Study 10,Site 32,Subject 121,Study 10,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 10,Site 33,Subject 122,Study 10,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 10,Site 33,Subject 123,Study 10,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 10,Site 357,Subject 2860,Study 10,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 10,Site 36,Subject 137,Study 10,AMERICA,USA,0.0,10.0,53.0,Week 18 (1),On Trial
Study 10,Site 36,Subject 138,Study 10,AMERICA,USA,0.0,7.0,43.0,Week 12 (1),On Trial
Study 10,Site 36,Subject 139,Study 10,AMERICA,USA,0.0,0.0,0.0,Screening,Screening
Study 10,Site 38,Subject 142,Study 10,AMERICA,USA,0.0,1.0,15.0,Screening,Screen Failure
Study 10,Site 38,Subject 143,Study 10,AMERICA,USA,0.0,1.0,16.0,Screening,Screen Failure
Study 10,Site 38,Subject 144,Study 10,AMERICA,USA,0.0,7.0,54.0,Week 12 (1),On Trial
Study 10,Site 38,Subject 145,Study 10,AMERICA,USA,0.0,3.0,21.0,Week 1 (1),Screening
Study 10,Site 38,Subject 146,Study 10,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 10,Site 38,Subject 147,Study 10,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 10,Site 40,Subject 157,Study 10,AMERICA,USA,0.0,8.0,59.0,Week16/EOT1 (1),On Trial
Study 10,Site 40,Subject 158,Study 10,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 10,Site 40,Subject 159,Study 10,AMERICA,USA,0.0,2.0,14.0,Day1 (1),On Trial
Study 10,Site 42,Subject 164,Study 10,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 10,Site 42,Subject 165,Study 10,AMERICA,USA,0.0,5.0,28.0,Week 4 (1),On Trial
Study 10,Site 451,Subject 3484,Study 10,AMERICA,USA,0.0,7.0,53.0,Week 12 (1),On Trial
Study 10,Site 451,Subject 3485,Study 10,AMERICA,USA,0.0,8.0,53.0,Week16/EOT1 (1),On Trial
Study 10,Site 451,Subject 3486,Study 10,AMERICA,USA,0.0,6.0,48.0,Week 8 (1),On Trial
Study 10,Site 452,Subject 3487,Study 10,AMERICA,USA,0.0,4.0,20.0,Week 2 (1),On Trial
Study 10,Site 453,Subject 3488,Study 10,AMERICA,USA,0.0,9.0,69.0,Week 20 (1),On Trial
Study 10,Site 453,Subject 3489,Study 10,AMERICA,USA,0.0,1.0,17.0,Screening,Screen Failure
Study 10,Site 453,Subject 3490,Study 10,AMERICA,USA,0.0,9.0,56.0,Week 17 (1),On Trial
Study 10,Site 453,Subject 3491,Study 10,AMERICA,USA,0.0,7.0,53.0,Week 12 (1),On Trial
Study 10,Site 453,Subject 3492,Study 10,AMERICA,USA,0.0,1.0,13.0,Screening,Screen Failure
Study 10,Site 453,Subject 3493,Study 10,AMERICA,USA,0.0,1.0,0.0,Screening,Screening
Study 10,Site 454,Subject 3494,Study 10,AMERICA,USA,0.0,1.0,16.0,Screening,Screen Failure
Study 10,Site 454,Subject 3495,Study 10,AMERICA,USA,0.0,1.0,16.0,Screening,Screen Failure
Study 10,Site 455,Subject 3496,Study 10,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 10,Site 455,Subject 3497,Study 10,AMERICA,USA,0.0,5.0,0.0,Week 4 (1),On Trial
Study 10,Site 455,Subject 3498,Study 10,AMERICA,USA,0.0,5.0,0.0,Week 4 (1),On Trial
Study 10,Site 455,Subject 3499,Study 10,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 10,Site 455,Subject 3500,Study 10,AMERICA,USA,0.0,5.0,0.0,Week 4 (1),On Trial
Study 10,Site 455,Subject 3501,Study 10,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 10,Site 456,Subject 3502,Study 10,AMERICA,USA,0.0,0.0,0.0,,Screening
Study 10,Site 457,Subject 3503,Study 10,AMERICA,USA,0.0,11.0,0.0,Week 20 (1),On Trial
Study 10,Site 458,Subject 3504,Study 10,AMERICA,USA,0.0,4.0,0.0,Week 2 (1),On Trial
Study 10,Site 458,Subject 3505,Study 10,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 10,Site 459,Subject 3507,Study 10,ASIA,CHN,0.0,1.0,12.0,Screening,Screening
Study 10,Site 459,Subject 3508,Study 10,ASIA,CHN,0.0,0.0,0.0,Screening,Screening
Study 10,Site 460,Subject 3509,Study 10,ASIA,CHN,0.0,4.0,29.0,Week 2 (1),On Trial
Study 10,Site 460,Subject 3510,Study 10,ASIA,CHN,0.0,1.0,17.0,Screening,Screen Failure
Study 10,Site 460,Subject 3511,Study 10,ASIA,CHN,0.0,1.0,0.0,Screening,Screening
Study 10,Site 461,Subject 3514,Study 10,ASIA,JPN,0.0,5.0,49.0,Week 4 (1),On Trial
Study 10,Site 461,Subject 3515,Study 10,ASIA,JPN,0.0,5.0,42.0,Week 4 (1),On Trial
Study 10,Site 462,Subject 3516,Study 10,ASIA,JPN,0.0,4.0,0.0,Week 2 (1),Screening
Study 10,Site 462,Subject 3517,Study 10,ASIA,JPN,0.0,3.0,0.0,Week 1 (1),Screening
Study 10,Site 463,Subject 3518,Study 10,ASIA,JPN,0.0,7.0,0.0,Week 12 (1),On Trial
Study 10,Site 463,Subject 3519,Study 10,ASIA,JPN,0.0,6.0,0.0,Week 8 (1),On Trial
Study 10,Site 463,Subject 3520,Study 10,ASIA,JPN,0.0,4.0,0.0,Week 2 (1),On Trial
Study 10,Site 463,Subject 3521,Study 10,ASIA,JPN,0.0,1.0,0.0,Screening,Screening
Study 10,Site 464,Subject 3522,Study 10,EMEA,POL,0.0,0.0,0.0,Screening,Screening
Study 10,Site 464,Subject 3523,Study 10,EMEA,POL,0.0,0.0,0.0,Screening,Screening
Study 10,Site 465,Subject 3524,Study 10,EMEA,ESP,0.0,1.0,0.0,Screening,On Trial
Study 10,Site 465,Subject 3525,Study 10,EMEA,ESP,0.0,1.0,0.0,Screening,On Trial
Study 10,Site 465,Subject 3526,Study 10,EMEA,ESP,0.0,1.0,0.0,Screening,On Trial
Study 10,Site 50,Subject 271,Study 10,AMERICA,CAN,0.0,6.0,43.0,Week 8 (1),On Trial
Study 10,Site 50,Subject 272,Study 10,AMERICA,CAN,0.0,5.0,47.0,Week 4 (1),On Trial
Study 10,Site 51,Subject 292,Study 10,AMERICA,CAN,0.0,5.0,0.0,Week 4 (1),On Trial
Study 10,Site 51,Subject 293,Study 10,AMERICA,CAN,0.0,1.0,0.0,Screening,Screen Failure
Study 10,Site 51,Subject 294,Study 10,AMERICA,CAN,0.0,1.0,0.0,Screening,Screen Failure
Study 10,Site 79,Subject 587,Study 10,ASIA,CHN,0.0,3.0,0.0,Week 1 (1),Screening
Study 10,Site 8,Subject 15,Study 10,ASIA,CHN,0.0,1.0,17.0,Screening,On Trial
Study 10,Site 8,Subject 3506,Study 10,ASIA,CHN,0.0,0.0,0.0,Screening,Screening
Study 10,Site 8,Subject 598,Study 10,ASIA,CHN,0.0,0.0,0.0,Screening,Screening
Study 10,Site 87,Subject 627,Study 10,EMEA,CZE,0.0,1.0,0.0,Screening,Screening
Study 10,Site 9,Subject 16,Study 10,ASIA,JPN,0.0,5.0,0.0,Week 4 (1),On Trial
Study 10,Site 9,Subject 3512,Study 10,ASIA,JPN,0.0,4.0,0.0,Week 2 (1),On Trial
Study 10,Site 9,Subject 3513,Study 10,ASIA,JPN,0.0,1.0,0.0,Screening,On Trial
Study 11,Site 12,Subject 22,Study 11,EMEA,ESP,0.0,23.0,193.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 12,Subject 2846,Study 11,EMEA,ESP,0.0,2.0,12.0,Screening 2 (1),Screen Failure
Study 11,Site 125,Subject 1072,Study 11,EMEA,NLD,0.0,28.0,201.0,Week 76/F24/EOS (1),Completed
Study 11,Site 127,Subject 1117,Study 11,EMEA,NLD,0.0,24.0,205.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 128,Subject 1121,Study 11,EMEA,NLD,0.0,25.0,195.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 128,Subject 1122,Study 11,EMEA,NLD,0.0,24.0,183.0,Week 68/F16 (1),On Trial
Study 11,Site 128,Subject 1123,Study 11,EMEA,NLD,0.0,2.0,24.0,Screening 2 (1),Screen Failure
Study 11,Site 130,Subject 1137,Study 11,EMEA,POL,0.0,23.0,184.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 130,Subject 1138,Study 11,EMEA,POL,0.0,13.0,124.0,Week 52/EOT (1),Discontinued
Study 11,Site 131,Subject 1145,Study 11,EMEA,POL,0.0,26.0,198.0,Week 68/F16 (1),On Trial
Study 11,Site 131,Subject 1146,Study 11,EMEA,POL,0.0,11.0,110.0,Week 52/EOT (1),Discontinued
Study 11,Site 131,Subject 1147,Study 11,EMEA,POL,0.0,25.0,180.0,Week 64/F12 (1),On Trial
Study 11,Site 14,Subject 25,Study 11,AMERICA,CAN,0.0,24.0,197.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 148,Subject 1393,Study 11,EMEA,CHE,0.0,28.0,209.0,Week 76/F24/EOS (1),Completed
Study 11,Site 148,Subject 1394,Study 11,EMEA,CHE,0.0,7.0,67.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 148,Subject 1395,Study 11,EMEA,CHE,0.0,2.0,21.0,Screening 2 (1),Screen Failure
Study 11,Site 148,Subject 1396,Study 11,EMEA,CHE,0.0,27.0,224.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 148,Subject 1397,Study 11,EMEA,CHE,0.0,22.0,180.0,Week 52/EOT (1),Discontinued
Study 11,Site 148,Subject 1398,Study 11,EMEA,CHE,0.0,2.0,18.0,Screening 2 (1),Screen Failure
Study 11,Site 148,Subject 1399,Study 11,EMEA,CHE,0.0,20.0,185.0,Week 52/EOT (1),Discontinued
Study 11,Site 148,Subject 1400,Study 11,EMEA,CHE,0.0,2.0,21.0,Screening 2 (1),Discontinued
Study 11,Site 148,Subject 3755,Study 11,EMEA,CHE,0.0,24.0,200.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 148,Subject 3756,Study 11,EMEA,CHE,0.0,22.0,188.0,Week 52/EOT (1),Discontinued
Study 11,Site 149,Subject 1401,Study 11,EMEA,CHE,0.0,2.0,19.0,Screening 2 (1),Screen Failure
Study 11,Site 149,Subject 1402,Study 11,EMEA,CHE,0.0,28.0,238.0,Week 76/F24/EOS (1),Completed
Study 11,Site 149,Subject 1403,Study 11,EMEA,CHE,0.0,20.0,170.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 149,Subject 1404,Study 11,EMEA,CHE,0.0,23.0,204.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 149,Subject 1405,Study 11,EMEA,CHE,0.0,22.0,177.0,Week 76/F24/EOS (1),Completed
Study 11,Site 149,Subject 1406,Study 11,EMEA,CHE,0.0,2.0,18.0,Screening 2 (1),Screen Failure
Study 11,Site 149,Subject 1407,Study 11,EMEA,CHE,0.0,13.0,136.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 15,Subject 39,Study 11,AMERICA,CAN,0.0,2.0,17.0,Screening 2 (1),Screen Failure
Study 11,Site 155,Subject 1427,Study 11,EMEA,GBR,0.0,25.0,200.0,Week 64/F12 (1),On Trial
Study 11,Site 157,Subject 1439,Study 11,EMEA,GBR,0.0,28.0,191.0,Week 76/F24/EOS (1),On Trial
Study 11,Site 158,Subject 1442,Study 11,EMEA,GBR,0.0,2.0,16.0,Screening 2 (1),Screen Failure
Study 11,Site 158,Subject 1443,Study 11,EMEA,GBR,0.0,2.0,19.0,Screening 2 (1),Screen Failure
Study 11,Site 158,Subject 1444,Study 11,EMEA,GBR,0.0,1.0,14.0,Screening 1,Screen Failure
Study 11,Site 158,Subject 1445,Study 11,EMEA,GBR,0.0,2.0,16.0,Screening 2 (1),Screen Failure
Study 11,Site 158,Subject 1446,Study 11,EMEA,GBR,0.0,2.0,16.0,Screening 2 (1),Screen Failure
Study 11,Site 158,Subject 1447,Study 11,EMEA,GBR,0.0,23.0,193.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 178,Subject 1600,Study 11,AMERICA,USA,0.0,24.0,195.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 18,Subject 63,Study 11,AMERICA,USA,0.0,1.0,15.0,Screening 1,Screen Failure
Study 11,Site 18,Subject 64,Study 11,AMERICA,USA,0.0,1.0,18.0,Screening 1,Screen Failure
Study 11,Site 18,Subject 65,Study 11,AMERICA,USA,0.0,23.0,185.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 18,Subject 66,Study 11,AMERICA,USA,0.0,28.0,207.0,UNPLANNED (3),Completed
Study 11,Site 18,Subject 67,Study 11,AMERICA,USA,0.0,19.0,164.0,Week 52/EOT (1),Discontinued
Study 11,Site 181,Subject 1614,Study 11,AMERICA,USA,0.0,25.0,190.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 181,Subject 2670,Study 11,AMERICA,USA,0.0,2.0,18.0,Screening 2 (1),Screen Failure
Study 11,Site 183,Subject 1616,Study 11,AMERICA,USA,0.0,1.0,8.0,Screening 1,Screen Failure
Study 11,Site 184,Subject 1624,Study 11,AMERICA,USA,0.0,2.0,17.0,Screening 2 (1),Screen Failure
Study 11,Site 184,Subject 1625,Study 11,AMERICA,USA,0.0,2.0,21.0,Screening 2 (1),Screen Failure
Study 11,Site 186,Subject 1634,Study 11,AMERICA,USA,0.0,24.0,201.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 186,Subject 3826,Study 11,AMERICA,USA,0.0,25.0,183.0,Week 64/F12 (1),On Trial
Study 11,Site 188,Subject 1637,Study 11,AMERICA,USA,0.0,1.0,14.0,Screening 1,Screen Failure
Study 11,Site 189,Subject 1639,Study 11,AMERICA,USA,0.0,28.0,207.0,Week 76/F24/EOS (1),Completed
Study 11,Site 189,Subject 1640,Study 11,AMERICA,USA,0.0,27.0,189.0,Week 72/F20 (1),On Trial
Study 11,Site 189,Subject 3830,Study 11,AMERICA,USA,0.0,27.0,206.0,Week 72/F20 (1),On Trial
Study 11,Site 189,Subject 3831,Study 11,AMERICA,USA,0.0,2.0,16.0,Screening 2 (1),Screen Failure
Study 11,Site 2,Subject 2,Study 11,ASIA,JPN,0.0,25.0,211.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 2,Subject 3,Study 11,ASIA,JPN,0.0,24.0,200.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 2,Subject 4,Study 11,ASIA,JPN,0.0,26.0,205.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 20,Subject 1601,Study 11,AMERICA,USA,0.0,1.0,10.0,Screening 1,Screen Failure
Study 11,Site 20,Subject 1602,Study 11,AMERICA,USA,0.0,28.0,206.0,Week 76/F24/EOS (1),Completed
Study 11,Site 20,Subject 1603,Study 11,AMERICA,USA,0.0,23.0,196.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 20,Subject 2840,Study 11,AMERICA,USA,0.0,23.0,180.0,Week 64/F12 (1),On Trial
Study 11,Site 20,Subject 2841,Study 11,AMERICA,USA,0.0,1.0,10.0,UNPLANNED (1),Screen Failure
Study 11,Site 20,Subject 82,Study 11,AMERICA,USA,0.0,23.0,180.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 21,Subject 3818,Study 11,AMERICA,USA,0.0,26.0,199.0,Week 68/F16 (1),On Trial
Study 11,Site 21,Subject 3819,Study 11,AMERICA,USA,0.0,20.0,172.0,Week 76/F24/EOS (1),Completed
Study 11,Site 21,Subject 83,Study 11,AMERICA,USA,0.0,1.0,15.0,Screening 1,Screen Failure
Study 11,Site 21,Subject 84,Study 11,AMERICA,USA,0.0,23.0,189.0,Week 76/F24/EOS (1),Completed
Study 11,Site 21,Subject 85,Study 11,AMERICA,USA,0.0,20.0,163.0,Week 76/F24/EOS (1),Completed
Study 11,Site 24,Subject 90,Study 11,AMERICA,USA,0.0,1.0,8.0,Screening 1,Screen Failure
Study 11,Site 28,Subject 107,Study 11,ASIA,JPN,0.0,24.0,211.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 28,Subject 108,Study 11,ASIA,JPN,0.0,24.0,205.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 28,Subject 2233,Study 11,ASIA,JPN,0.0,23.0,198.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 29,Subject 109,Study 11,ASIA,JPN,0.0,15.0,157.0,Week 52/EOT (1),Discontinued
Study 11,Site 31,Subject 118,Study 11,ASIA,JPN,0.0,23.0,193.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 326,Subject 2652,Study 11,AMERICA,USA,0.0,23.0,183.0,Week 76/F24/EOS (1),Completed
Study 11,Site 330,Subject 2703,Study 11,AMERICA,USA,0.0,23.0,194.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 34,Subject 133,Study 11,ASIA,JPN,0.0,8.0,91.0,UNPLANNED (2),Discontinued
Study 11,Site 34,Subject 134,Study 11,ASIA,JPN,0.0,23.0,190.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 35,Subject 135,Study 11,ASIA,JPN,0.0,13.0,199.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 35,Subject 136,Study 11,ASIA,JPN,0.0,25.0,194.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 35,Subject 3528,Study 11,ASIA,JPN,0.0,2.0,18.0,Screening 2 (1),Screen Failure
Study 11,Site 35,Subject 3529,Study 11,ASIA,JPN,0.0,27.0,205.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 35,Subject 3530,Study 11,ASIA,JPN,0.0,12.0,113.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 35,Subject 3531,Study 11,ASIA,JPN,0.0,25.0,204.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 35,Subject 3532,Study 11,ASIA,JPN,0.0,28.0,226.0,Week 76/F24/EOS (1),Completed
Study 11,Site 35,Subject 3533,Study 11,ASIA,JPN,0.0,10.0,141.0,Week 52/EOT (1),Discontinued
Study 11,Site 35,Subject 3534,Study 11,ASIA,JPN,0.0,27.0,185.0,Week 72/F20 (1),On Trial
Study 11,Site 350,Subject 2836,Study 11,AMERICA,BRA,0.0,24.0,188.0,Week 60/F8 (1),On Trial
Study 11,Site 351,Subject 2837,Study 11,AMERICA,CHL,0.0,27.0,213.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 351,Subject 2838,Study 11,AMERICA,CHL,0.0,1.0,15.0,Screening 1,Screen Failure
Study 11,Site 351,Subject 2839,Study 11,AMERICA,CHL,0.0,23.0,193.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 351,Subject 3800,Study 11,AMERICA,CHL,0.0,1.0,8.0,Screening 1,Screen Failure
Study 11,Site 353,Subject 2844,Study 11,EMEA,ESP,0.0,27.0,206.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 353,Subject 2845,Study 11,EMEA,ESP,0.0,4.0,63.0,Week 52/EOT (1),Discontinued
Study 11,Site 353,Subject 3735,Study 11,EMEA,ESP,0.0,20.0,174.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 353,Subject 3736,Study 11,EMEA,ESP,0.0,2.0,23.0,UNPLANNED (1),Screen Failure
Study 11,Site 353,Subject 3737,Study 11,EMEA,ESP,0.0,26.0,188.0,Week 68/F16 (1),On Trial
Study 11,Site 357,Subject 2860,Study 11,ASIA,JPN,0.0,23.0,179.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 357,Subject 2861,Study 11,ASIA,JPN,0.0,22.0,183.0,Week 52/EOT (1),Discontinued
Study 11,Site 357,Subject 3527,Study 11,ASIA,JPN,0.0,27.0,224.0,Week 72/F20 (1),On Trial
Study 11,Site 358,Subject 2862,Study 11,EMEA,HUN,0.0,25.0,198.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 358,Subject 2863,Study 11,EMEA,HUN,0.0,24.0,194.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 358,Subject 2864,Study 11,EMEA,HUN,0.0,23.0,187.0,Week 60/F8 (1),Discontinued
Study 11,Site 358,Subject 2865,Study 11,EMEA,HUN,0.0,25.0,196.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 358,Subject 2866,Study 11,EMEA,HUN,0.0,23.0,194.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 358,Subject 2867,Study 11,EMEA,HUN,0.0,22.0,190.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 358,Subject 2868,Study 11,EMEA,HUN,0.0,25.0,199.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 358,Subject 2869,Study 11,EMEA,HUN,0.0,23.0,190.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 358,Subject 3702,Study 11,EMEA,HUN,0.0,25.0,199.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 358,Subject 3703,Study 11,EMEA,HUN,0.0,25.0,198.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 359,Subject 2870,Study 11,EMEA,HUN,0.0,2.0,16.0,Screening 2 (1),Discontinued
Study 11,Site 36,Subject 137,Study 11,ASIA,JPN,0.0,23.0,254.0,Week 76/F24/EOS (1),Completed
Study 11,Site 37,Subject 140,Study 11,ASIA,JPN,0.0,26.0,192.0,Week 68/F16 (1),On Trial
Study 11,Site 39,Subject 155,Study 11,ASIA,JPN,0.0,13.0,147.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 4,Subject 10,Study 11,ASIA,JPN,0.0,16.0,145.0,Week 52/EOT (1),Discontinued
Study 11,Site 4,Subject 105,Study 11,ASIA,JPN,0.0,28.0,214.0,Week 76/F24/EOS (1),Completed
Study 11,Site 4,Subject 106,Study 11,ASIA,JPN,0.0,2.0,12.0,Screening 2 (1),Screen Failure
Study 11,Site 4,Subject 787,Study 11,ASIA,JPN,0.0,24.0,199.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 4,Subject 788,Study 11,ASIA,JPN,0.0,27.0,227.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 4,Subject 9,Study 11,ASIA,JPN,0.0,23.0,187.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 41,Subject 162,Study 11,ASIA,JPN,0.0,25.0,233.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 41,Subject 163,Study 11,ASIA,JPN,0.0,24.0,191.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 41,Subject 3536,Study 11,ASIA,JPN,0.0,25.0,208.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 41,Subject 3537,Study 11,ASIA,JPN,0.0,28.0,198.0,Week 76/F24/EOS (1),Completed
Study 11,Site 41,Subject 3538,Study 11,ASIA,JPN,0.0,23.0,199.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 41,Subject 3539,Study 11,ASIA,JPN,0.0,28.0,230.0,Week 76/F24/EOS (1),Completed
Study 11,Site 41,Subject 3540,Study 11,ASIA,JPN,0.0,25.0,248.0,Week 64/F12 (1),On Trial
Study 11,Site 41,Subject 3541,Study 11,ASIA,JPN,0.0,25.0,200.0,Week 64/F12 (1),On Trial
Study 11,Site 417,Subject 3227,Study 11,EMEA,ITA,0.0,25.0,212.0,Week 64/F12 (1),On Trial
Study 11,Site 42,Subject 164,Study 11,ASIA,JPN,0.0,23.0,192.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 42,Subject 165,Study 11,ASIA,JPN,0.0,23.0,195.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 450,Subject 3397,Study 11,AMERICA,USA,0.0,27.0,192.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 450,Subject 3398,Study 11,AMERICA,USA,0.0,9.0,93.0,Week 52/EOT (1),Discontinued
Study 11,Site 450,Subject 3814,Study 11,AMERICA,USA,0.0,2.0,19.0,Screening 2 (1),Screen Failure
Study 11,Site 450,Subject 3815,Study 11,AMERICA,USA,0.0,2.0,21.0,Screening 2 (1),Screen Failure
Study 11,Site 450,Subject 3816,Study 11,AMERICA,USA,0.0,2.0,20.0,Screening 2 (1),Screen Failure
Study 11,Site 450,Subject 3817,Study 11,AMERICA,USA,0.0,8.0,75.0,Week 8 (1),Discontinued
Study 11,Site 452,Subject 3487,Study 11,ASIA,JPN,0.0,25.0,191.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 452,Subject 3535,Study 11,ASIA,JPN,0.0,28.0,195.0,Week 76/F24/EOS (1),Completed
Study 11,Site 453,Subject 3488,Study 11,ASIA,JPN,0.0,23.0,193.0,Week 56/F4 (1),Discontinued
Study 11,Site 454,Subject 3494,Study 11,ASIA,JPN,0.0,26.0,221.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 454,Subject 3495,Study 11,ASIA,JPN,0.0,24.0,236.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 454,Subject 3542,Study 11,ASIA,JPN,0.0,28.0,212.0,Week 76/F24/EOS (1),Completed
Study 11,Site 454,Subject 3543,Study 11,ASIA,JPN,0.0,26.0,210.0,Week 68/F16 (1),On Trial
Study 11,Site 455,Subject 3496,Study 11,ASIA,JPN,0.0,23.0,194.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 455,Subject 3497,Study 11,ASIA,JPN,0.0,25.0,208.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 459,Subject 3507,Study 11,EMEA,CZE,0.0,28.0,211.0,Week 76/F24/EOS (1),Completed
Study 11,Site 459,Subject 3508,Study 11,EMEA,CZE,0.0,28.0,205.0,Week 76/F24/EOS (1),Completed
Study 11,Site 459,Subject 3574,Study 11,EMEA,CZE,0.0,10.0,105.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 459,Subject 3575,Study 11,EMEA,CZE,0.0,28.0,206.0,Week 76/F24/EOS (1),Completed
Study 11,Site 459,Subject 3576,Study 11,EMEA,CZE,0.0,28.0,200.0,Week 76/F24/EOS (1),Completed
Study 11,Site 459,Subject 3577,Study 11,EMEA,CZE,0.0,27.0,200.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 466,Subject 3544,Study 11,ASIA,AUS,0.0,28.0,216.0,Week 76/F24/EOS (1),Completed
Study 11,Site 466,Subject 3545,Study 11,ASIA,AUS,0.0,23.0,186.0,Week 76/F24/EOS (1),Completed
Study 11,Site 466,Subject 3546,Study 11,ASIA,AUS,0.0,1.0,16.0,Screening 1,Screen Failure
Study 11,Site 466,Subject 3547,Study 11,ASIA,AUS,0.0,16.0,147.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 466,Subject 3548,Study 11,ASIA,AUS,0.0,22.0,201.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 466,Subject 3549,Study 11,ASIA,AUS,0.0,22.0,187.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 466,Subject 3550,Study 11,ASIA,AUS,0.0,22.0,183.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 466,Subject 3551,Study 11,ASIA,AUS,0.0,26.0,208.0,Week 76/F24/EOS (1),Completed
Study 11,Site 466,Subject 3552,Study 11,ASIA,AUS,0.0,26.0,200.0,Week 72/F20 (1),On Trial
Study 11,Site 467,Subject 3553,Study 11,ASIA,AUS,0.0,10.0,120.0,Week 52/EOT (1),Discontinued
Study 11,Site 467,Subject 3554,Study 11,ASIA,AUS,0.0,28.0,219.0,Week 76/F24/EOS (1),Completed
Study 11,Site 467,Subject 3555,Study 11,ASIA,AUS,0.0,11.0,123.0,Week 52/EOT (1),Discontinued
Study 11,Site 467,Subject 3556,Study 11,ASIA,AUS,0.0,19.0,175.0,Week 52/EOT (1),Discontinued
Study 11,Site 467,Subject 3557,Study 11,ASIA,AUS,0.0,27.0,227.0,Week 76/F24/EOS (1),Completed
Study 11,Site 467,Subject 3558,Study 11,ASIA,AUS,0.0,26.0,200.0,Week 72/F20 (1),On Trial
Study 11,Site 467,Subject 3559,Study 11,ASIA,AUS,0.0,26.0,176.0,Week 68/F16 (1),On Trial
Study 11,Site 468,Subject 3560,Study 11,ASIA,AUS,0.0,18.0,179.0,Week 52/EOT (1),Discontinued
Study 11,Site 468,Subject 3561,Study 11,ASIA,AUS,0.0,26.0,214.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 468,Subject 3562,Study 11,ASIA,AUS,0.0,27.0,202.0,Week 76/F24/EOS (1),Completed
Study 11,Site 468,Subject 3563,Study 11,ASIA,AUS,0.0,27.0,224.0,Week 76/F24/EOS (1),Completed
Study 11,Site 468,Subject 3564,Study 11,ASIA,AUS,0.0,2.0,20.0,Screening 2 (1),Screen Failure
Study 11,Site 469,Subject 3565,Study 11,EMEA,LBN,0.0,28.0,202.0,Week 76/F24/EOS (1),Completed
Study 11,Site 470,Subject 3570,Study 11,EMEA,ZAF,0.0,5.0,59.0,Week 52/EOT (1),Discontinued
Study 11,Site 470,Subject 3571,Study 11,EMEA,ZAF,0.0,28.0,209.0,Week 76/F24/EOS (1),Completed
Study 11,Site 471,Subject 3578,Study 11,EMEA,CZE,0.0,1.0,8.0,Screening 1,Screen Failure
Study 11,Site 471,Subject 3579,Study 11,EMEA,CZE,0.0,28.0,203.0,Week 76/F24/EOS (1),On Trial
Study 11,Site 472,Subject 3580,Study 11,EMEA,CZE,0.0,28.0,205.0,Week 76/F24/EOS (1),Completed
Study 11,Site 472,Subject 3581,Study 11,EMEA,CZE,0.0,2.0,22.0,Screening 2 (1),Screen Failure
Study 11,Site 472,Subject 3582,Study 11,EMEA,CZE,0.0,2.0,22.0,Screening 2 (1),Screen Failure
Study 11,Site 472,Subject 3583,Study 11,EMEA,CZE,0.0,26.0,189.0,Week 68/F16 (1),On Trial
Study 11,Site 472,Subject 3584,Study 11,EMEA,CZE,0.0,26.0,200.0,Week 68/F16 (1),On Trial
Study 11,Site 472,Subject 3585,Study 11,EMEA,CZE,0.0,26.0,211.0,Week 68/F16 (1),On Trial
Study 11,Site 472,Subject 3586,Study 11,EMEA,CZE,0.0,26.0,190.0,Week 68/F16 (1),On Trial
Study 11,Site 472,Subject 3587,Study 11,EMEA,CZE,0.0,25.0,179.0,Week 64/F12 (1),On Trial
Study 11,Site 473,Subject 3588,Study 11,EMEA,CZE,0.0,24.0,195.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 473,Subject 3589,Study 11,EMEA,CZE,0.0,24.0,184.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 473,Subject 3590,Study 11,EMEA,CZE,0.0,26.0,203.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 473,Subject 3591,Study 11,EMEA,CZE,0.0,27.0,209.0,Week 76/F24/EOS (1),Completed
Study 11,Site 474,Subject 3592,Study 11,EMEA,CZE,0.0,24.0,206.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 474,Subject 3593,Study 11,EMEA,CZE,0.0,24.0,199.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 474,Subject 3594,Study 11,EMEA,CZE,0.0,23.0,193.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 474,Subject 3595,Study 11,EMEA,CZE,0.0,24.0,201.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 474,Subject 3596,Study 11,EMEA,CZE,0.0,24.0,193.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 474,Subject 3597,Study 11,EMEA,CZE,0.0,24.0,196.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 474,Subject 3598,Study 11,EMEA,CZE,0.0,24.0,189.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 474,Subject 3599,Study 11,EMEA,CZE,0.0,24.0,195.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 475,Subject 3600,Study 11,EMEA,DNK,0.0,24.0,180.0,Week 60/F8 (1),On Trial
Study 11,Site 475,Subject 3601,Study 11,EMEA,DNK,0.0,23.0,176.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 475,Subject 3602,Study 11,EMEA,DNK,0.0,25.0,184.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 476,Subject 3603,Study 11,EMEA,DNK,0.0,21.0,178.0,Week 76/F24/EOS (1),Completed
Study 11,Site 476,Subject 3604,Study 11,EMEA,DNK,0.0,26.0,180.0,Week 76/F24/EOS (1),Completed
Study 11,Site 477,Subject 3605,Study 11,EMEA,DNK,0.0,27.0,201.0,Week 76/F24/EOS (1),Completed
Study 11,Site 477,Subject 3606,Study 11,EMEA,DNK,0.0,27.0,216.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 477,Subject 3607,Study 11,EMEA,DNK,0.0,28.0,189.0,Week 76/F24/EOS (1),Completed
Study 11,Site 477,Subject 3608,Study 11,EMEA,DNK,0.0,2.0,14.0,Screening 2 (1),Screen Failure
Study 11,Site 477,Subject 3609,Study 11,EMEA,DNK,0.0,25.0,182.0,Week 68/F16 (1),On Trial
Study 11,Site 477,Subject 3610,Study 11,EMEA,DNK,0.0,23.0,178.0,Week 64/F12 (1),On Trial
Study 11,Site 478,Subject 3611,Study 11,EMEA,DNK,0.0,22.0,191.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 478,Subject 3612,Study 11,EMEA,DNK,0.0,23.0,196.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 478,Subject 3613,Study 11,EMEA,DNK,0.0,28.0,220.0,Week 76/F24/EOS (1),Completed
Study 11,Site 479,Subject 3614,Study 11,EMEA,FRA,0.0,2.0,19.0,Screening 2 (1),Screen Failure
Study 11,Site 479,Subject 3615,Study 11,EMEA,FRA,0.0,26.0,191.0,Week 68/F16 (1),On Trial
Study 11,Site 479,Subject 3616,Study 11,EMEA,FRA,0.0,10.0,101.0,Week 16 (1),Discontinued
Study 11,Site 479,Subject 3617,Study 11,EMEA,FRA,0.0,23.0,199.0,Week 76/F24/EOS (1),Completed
Study 11,Site 480,Subject 3618,Study 11,EMEA,FRA,0.0,14.0,142.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 480,Subject 3619,Study 11,EMEA,FRA,0.0,2.0,20.0,Screening 2 (1),Screen Failure
Study 11,Site 480,Subject 3620,Study 11,EMEA,FRA,0.0,20.0,173.0,Week 76/F24/EOS (1),Completed
Study 11,Site 480,Subject 3621,Study 11,EMEA,FRA,0.0,25.0,198.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 480,Subject 3622,Study 11,EMEA,FRA,0.0,23.0,195.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 480,Subject 3623,Study 11,EMEA,FRA,0.0,2.0,19.0,Screening 2 (1),Screen Failure
Study 11,Site 480,Subject 3624,Study 11,EMEA,FRA,0.0,20.0,183.0,Week 76/F24/EOS (1),Completed
Study 11,Site 480,Subject 3625,Study 11,EMEA,FRA,0.0,2.0,23.0,UNPLANNED (1),Screen Failure
Study 11,Site 481,Subject 3626,Study 11,EMEA,FRA,0.0,2.0,18.0,Screening 2 (1),Screen Failure
Study 11,Site 482,Subject 3627,Study 11,EMEA,FRA,0.0,26.0,215.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 482,Subject 3628,Study 11,EMEA,FRA,0.0,28.0,212.0,Week 76/F24/EOS (1),Completed
Study 11,Site 482,Subject 3629,Study 11,EMEA,FRA,0.0,27.0,221.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 482,Subject 3630,Study 11,EMEA,FRA,0.0,22.0,178.0,Week 52/EOT (1),Discontinued
Study 11,Site 483,Subject 3631,Study 11,EMEA,FRA,0.0,28.0,206.0,Week 76/F24/EOS (1),Completed
Study 11,Site 483,Subject 3632,Study 11,EMEA,FRA,0.0,25.0,214.0,Week 76/F24/EOS (1),Completed
Study 11,Site 483,Subject 3633,Study 11,EMEA,FRA,0.0,28.0,205.0,Week 76/F24/EOS (1),Completed
Study 11,Site 483,Subject 3634,Study 11,EMEA,FRA,0.0,25.0,199.0,Week 76/F24/EOS (1),Completed
Study 11,Site 483,Subject 3635,Study 11,EMEA,FRA,0.0,27.0,198.0,Week 72/F20 (1),Discontinued
Study 11,Site 483,Subject 3636,Study 11,EMEA,FRA,0.0,21.0,192.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 483,Subject 3637,Study 11,EMEA,FRA,0.0,23.0,198.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 484,Subject 3638,Study 11,EMEA,FRA,0.0,2.0,17.0,Screening 2 (1),Screen Failure
Study 11,Site 484,Subject 3639,Study 11,EMEA,FRA,0.0,28.0,206.0,Week 76/F24/EOS (1),On Trial
Study 11,Site 485,Subject 3640,Study 11,EMEA,FRA,0.0,13.0,124.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 485,Subject 3641,Study 11,EMEA,FRA,0.0,1.0,9.0,Screening 1,Screen Failure
Study 11,Site 485,Subject 3642,Study 11,EMEA,FRA,0.0,17.0,156.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 485,Subject 3643,Study 11,EMEA,FRA,0.0,17.0,161.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 485,Subject 3644,Study 11,EMEA,FRA,0.0,2.0,23.0,Screening 2 (1),Screen Failure
Study 11,Site 485,Subject 3645,Study 11,EMEA,FRA,0.0,13.0,119.0,Week 52/EOT (1),Discontinued
Study 11,Site 486,Subject 3646,Study 11,EMEA,FRA,0.0,28.0,223.0,Week 76/F24/EOS (1),Completed
Study 11,Site 486,Subject 3647,Study 11,EMEA,FRA,0.0,28.0,240.0,Week 76/F24/EOS (1),On Trial
Study 11,Site 487,Subject 3648,Study 11,EMEA,FRA,0.0,28.0,216.0,Week 76/F24/EOS (1),Completed
Study 11,Site 487,Subject 3649,Study 11,EMEA,FRA,0.0,28.0,244.0,Week 76/F24/EOS (1),Completed
Study 11,Site 487,Subject 3650,Study 11,EMEA,FRA,0.0,2.0,22.0,Screening 2 (1),Screen Failure
Study 11,Site 487,Subject 3651,Study 11,EMEA,FRA,0.0,25.0,189.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 487,Subject 3652,Study 11,EMEA,FRA,0.0,23.0,201.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 488,Subject 3653,Study 11,EMEA,FRA,0.0,28.0,204.0,Week 76/F24/EOS (1),Completed
Study 11,Site 488,Subject 3654,Study 11,EMEA,FRA,0.0,20.0,181.0,Week 76/F24/EOS (1),Completed
Study 11,Site 488,Subject 3655,Study 11,EMEA,FRA,0.0,25.0,200.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 488,Subject 3656,Study 11,EMEA,FRA,0.0,26.0,181.0,Week 68/F16 (1),On Trial
Study 11,Site 489,Subject 3657,Study 11,EMEA,FRA,0.0,23.0,181.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 489,Subject 3658,Study 11,EMEA,FRA,0.0,23.0,196.0,Week 76/F24/EOS (1),Completed
Study 11,Site 489,Subject 3659,Study 11,EMEA,FRA,0.0,23.0,190.0,Week 76/F24/EOS (1),Completed
Study 11,Site 489,Subject 3660,Study 11,EMEA,FRA,0.0,27.0,195.0,Week 72/F20 (1),On Trial
Study 11,Site 489,Subject 3661,Study 11,EMEA,FRA,0.0,2.0,27.0,UNPLANNED (1),Discontinued
Study 11,Site 490,Subject 3662,Study 11,EMEA,FRA,0.0,21.0,180.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 490,Subject 3663,Study 11,EMEA,FRA,0.0,25.0,203.0,Week 76/F24/EOS (1),Completed
Study 11,Site 491,Subject 3664,Study 11,EMEA,FRA,0.0,2.0,20.0,Screening 2 (1),Discontinued
Study 11,Site 491,Subject 3665,Study 11,EMEA,FRA,0.0,16.0,151.0,Week 28 (1),Discontinued
Study 11,Site 491,Subject 3666,Study 11,EMEA,FRA,0.0,26.0,186.0,Week 68/F16 (1),On Trial
Study 11,Site 492,Subject 3667,Study 11,EMEA,FRA,0.0,25.0,216.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 492,Subject 3668,Study 11,EMEA,FRA,0.0,24.0,194.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 492,Subject 3669,Study 11,EMEA,FRA,0.0,19.0,165.0,Week 52/EOT (1),Completed
Study 11,Site 493,Subject 3670,Study 11,EMEA,DEU,0.0,28.0,214.0,Week 76/F24/EOS (1),Completed
Study 11,Site 493,Subject 3671,Study 11,EMEA,DEU,0.0,10.0,95.0,Week 16 (1),Discontinued
Study 11,Site 493,Subject 3672,Study 11,EMEA,DEU,0.0,15.0,119.0,Week 27 (1),Discontinued
Study 11,Site 493,Subject 3673,Study 11,EMEA,DEU,0.0,25.0,184.0,Week 68/F16 (1),On Trial
Study 11,Site 493,Subject 3674,Study 11,EMEA,DEU,0.0,25.0,175.0,Week 64/F12 (1),On Trial
Study 11,Site 494,Subject 3675,Study 11,EMEA,DEU,0.0,21.0,175.0,Week 52/EOT (1),Discontinued
Study 11,Site 494,Subject 3676,Study 11,EMEA,DEU,0.0,22.0,183.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 495,Subject 3677,Study 11,EMEA,DEU,0.0,13.0,139.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 495,Subject 3678,Study 11,EMEA,DEU,0.0,23.0,201.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 496,Subject 3679,Study 11,EMEA,DEU,0.0,28.0,206.0,Week 76/F24/EOS (1),Completed
Study 11,Site 496,Subject 3680,Study 11,EMEA,DEU,0.0,28.0,190.0,Week 76/F24/EOS (1),On Trial
Study 11,Site 496,Subject 3681,Study 11,EMEA,DEU,0.0,25.0,196.0,Week 64/F12 (1),On Trial
Study 11,Site 497,Subject 3682,Study 11,EMEA,DEU,0.0,23.0,184.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 497,Subject 3683,Study 11,EMEA,DEU,0.0,23.0,172.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 497,Subject 3684,Study 11,EMEA,DEU,0.0,28.0,212.0,Week 76/F24/EOS (1),Completed
Study 11,Site 498,Subject 3685,Study 11,EMEA,DEU,0.0,23.0,197.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 498,Subject 3686,Study 11,EMEA,DEU,0.0,23.0,195.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 498,Subject 3687,Study 11,EMEA,DEU,0.0,23.0,187.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 498,Subject 3688,Study 11,EMEA,DEU,0.0,17.0,166.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 498,Subject 3689,Study 11,EMEA,DEU,0.0,24.0,200.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 499,Subject 3690,Study 11,EMEA,DEU,0.0,2.0,22.0,Screening 2 (1),Screen Failure
Study 11,Site 499,Subject 3691,Study 11,EMEA,DEU,0.0,24.0,198.0,Week 64/F12 (1),On Trial
Study 11,Site 499,Subject 3692,Study 11,EMEA,DEU,0.0,1.0,8.0,Screening 1,Screen Failure
Study 11,Site 5,Subject 11,Study 11,EMEA,ZAF,0.0,24.0,202.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 5,Subject 3566,Study 11,EMEA,ZAF,0.0,2.0,18.0,Screening 2 (1),Screen Failure
Study 11,Site 5,Subject 3567,Study 11,EMEA,ZAF,0.0,23.0,183.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 5,Subject 3568,Study 11,EMEA,ZAF,0.0,12.0,116.0,Week 52/EOT (1),Discontinued
Study 11,Site 5,Subject 3569,Study 11,EMEA,ZAF,0.0,16.0,164.0,Week 52/EOT (1),Discontinued
Study 11,Site 50,Subject 271,Study 11,EMEA,TUR,0.0,2.0,12.0,Screening 2 (1),Screen Failure
Study 11,Site 500,Subject 3693,Study 11,EMEA,DEU,0.0,28.0,227.0,Week 76/F24/EOS (1),Completed
Study 11,Site 500,Subject 3694,Study 11,EMEA,DEU,0.0,28.0,211.0,Week 76/F24/EOS (1),Completed
Study 11,Site 500,Subject 3695,Study 11,EMEA,DEU,0.0,10.0,89.0,UNPLANNED (1),Discontinued
Study 11,Site 500,Subject 3696,Study 11,EMEA,DEU,0.0,26.0,207.0,Week 68/F16 (1),On Trial
Study 11,Site 501,Subject 3697,Study 11,EMEA,DEU,0.0,23.0,174.0,Week 76/F24/EOS (1),Completed
Study 11,Site 501,Subject 3698,Study 11,EMEA,DEU,0.0,1.0,8.0,Screening 1,Discontinued
Study 11,Site 501,Subject 3699,Study 11,EMEA,DEU,0.0,25.0,186.0,Week 64/F12 (1),On Trial
Study 11,Site 501,Subject 3700,Study 11,EMEA,DEU,0.0,2.0,18.0,Screening 2 (1),Screen Failure
Study 11,Site 501,Subject 3701,Study 11,EMEA,DEU,0.0,2.0,19.0,Screening 2 (1),Screen Failure
Study 11,Site 502,Subject 3704,Study 11,EMEA,ITA,0.0,15.0,131.0,Week 32 (1),Discontinued
Study 11,Site 502,Subject 3705,Study 11,EMEA,ITA,0.0,25.0,213.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 503,Subject 3706,Study 11,EMEA,ITA,0.0,28.0,216.0,Week 76/F24/EOS (1),Completed
Study 11,Site 503,Subject 3707,Study 11,EMEA,ITA,0.0,2.0,18.0,Screening 2 (1),Screen Failure
Study 11,Site 503,Subject 3708,Study 11,EMEA,ITA,0.0,1.0,10.0,Screening 1,Screen Failure
Study 11,Site 503,Subject 3709,Study 11,EMEA,ITA,0.0,22.0,181.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 503,Subject 3710,Study 11,EMEA,ITA,0.0,2.0,20.0,Screening 2 (1),Screen Failure
Study 11,Site 503,Subject 3711,Study 11,EMEA,ITA,0.0,23.0,174.0,Week 76/F24/EOS (1),Completed
Study 11,Site 503,Subject 3712,Study 11,EMEA,ITA,0.0,28.0,201.0,Week 76/F24/EOS (1),On Trial
Study 11,Site 503,Subject 3713,Study 11,EMEA,ITA,0.0,25.0,185.0,Week 64/F12 (1),On Trial
Study 11,Site 504,Subject 3714,Study 11,EMEA,ITA,0.0,2.0,22.0,Screening 2 (1),Discontinued
Study 11,Site 504,Subject 3715,Study 11,EMEA,ITA,0.0,2.0,22.0,Screening 2 (1),Discontinued
Study 11,Site 505,Subject 3716,Study 11,EMEA,ITA,0.0,2.0,20.0,Screening 2 (1),Screen Failure
Study 11,Site 505,Subject 3717,Study 11,EMEA,ITA,0.0,23.0,186.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 505,Subject 3718,Study 11,EMEA,ITA,0.0,24.0,192.0,Week 60/F8 (1),Discontinued
Study 11,Site 505,Subject 3719,Study 11,EMEA,ITA,0.0,27.0,190.0,Week 72/F20 (1),On Trial
Study 11,Site 505,Subject 3720,Study 11,EMEA,ITA,0.0,24.0,187.0,Week 60/F8 (1),Discontinued
Study 11,Site 505,Subject 3721,Study 11,EMEA,ITA,0.0,10.0,100.0,Week 16 (1),Discontinued
Study 11,Site 506,Subject 3722,Study 11,EMEA,ITA,0.0,12.0,107.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 506,Subject 3723,Study 11,EMEA,ITA,0.0,28.0,201.0,Week 76/F24/EOS (1),Completed
Study 11,Site 506,Subject 3724,Study 11,EMEA,ITA,0.0,27.0,200.0,Week 72/F20 (1),On Trial
Study 11,Site 506,Subject 3725,Study 11,EMEA,ITA,0.0,21.0,173.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 506,Subject 3726,Study 11,EMEA,ITA,0.0,12.0,106.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 507,Subject 3727,Study 11,EMEA,ITA,0.0,24.0,178.0,Week 72/F20 (1),On Trial
Study 11,Site 507,Subject 3728,Study 11,EMEA,ITA,0.0,21.0,176.0,Week 64/F12 (1),On Trial
Study 11,Site 508,Subject 3729,Study 11,EMEA,ITA,0.0,19.0,161.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 509,Subject 3730,Study 11,EMEA,POL,0.0,20.0,187.0,Week 52/EOT (1),Discontinued
Study 11,Site 510,Subject 3731,Study 11,EMEA,POL,0.0,27.0,218.0,Week 72/F20 (1),On Trial
Study 11,Site 510,Subject 3732,Study 11,EMEA,POL,0.0,2.0,22.0,Screening 2 (1),Discontinued
Study 11,Site 511,Subject 3733,Study 11,EMEA,POL,0.0,26.0,191.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 511,Subject 3734,Study 11,EMEA,POL,0.0,22.0,189.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 512,Subject 3738,Study 11,EMEA,ESP,0.0,2.0,21.0,Screening 2 (1),Screen Failure
Study 11,Site 512,Subject 3739,Study 11,EMEA,ESP,0.0,7.0,83.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 512,Subject 3740,Study 11,EMEA,ESP,0.0,9.0,97.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 512,Subject 3741,Study 11,EMEA,ESP,0.0,27.0,185.0,Week 72/F20 (1),On Trial
Study 11,Site 513,Subject 3742,Study 11,EMEA,ESP,0.0,24.0,199.0,Week 76/F24/EOS (1),Completed
Study 11,Site 513,Subject 3743,Study 11,EMEA,ESP,0.0,1.0,18.0,Screening 1,Screen Failure
Study 11,Site 513,Subject 3744,Study 11,EMEA,ESP,0.0,22.0,180.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 514,Subject 3745,Study 11,EMEA,ESP,0.0,12.0,115.0,Week 52/EOT (1),Discontinued
Study 11,Site 514,Subject 3746,Study 11,EMEA,ESP,0.0,23.0,184.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 514,Subject 3747,Study 11,EMEA,ESP,0.0,23.0,191.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 515,Subject 3748,Study 11,EMEA,ESP,0.0,23.0,194.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 515,Subject 3749,Study 11,EMEA,ESP,0.0,2.0,17.0,Screening 2 (1),Screen Failure
Study 11,Site 515,Subject 3750,Study 11,EMEA,ESP,0.0,2.0,12.0,Screening 2 (1),Screen Failure
Study 11,Site 515,Subject 3751,Study 11,EMEA,ESP,0.0,24.0,183.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 516,Subject 3752,Study 11,EMEA,ESP,0.0,28.0,190.0,Week 76/F24/EOS (1),Completed
Study 11,Site 516,Subject 3753,Study 11,EMEA,ESP,0.0,26.0,185.0,Week 76/F24/EOS (1),Completed
Study 11,Site 516,Subject 3754,Study 11,EMEA,ESP,0.0,24.0,184.0,Week 72/F20 (1),On Trial
Study 11,Site 516,Subject 3805,Study 11,EMEA,ESP,0.0,25.0,185.0,Week 64/F12 (1),On Trial
Study 11,Site 517,Subject 3757,Study 11,EMEA,CHE,0.0,23.0,173.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 518,Subject 3758,Study 11,EMEA,ISR,0.0,2.0,21.0,Screening 2 (1),Discontinued
Study 11,Site 518,Subject 3759,Study 11,EMEA,ISR,0.0,21.0,176.0,Week 64/F12 (1),On Trial
Study 11,Site 518,Subject 3760,Study 11,EMEA,ISR,0.0,12.0,107.0,Week 24 (1),Discontinued
Study 11,Site 518,Subject 3761,Study 11,EMEA,ISR,0.0,14.0,131.0,Week 32 (1),Discontinued
Study 11,Site 519,Subject 3762,Study 11,EMEA,ISR,0.0,2.0,18.0,Screening 2 (1),Screen Failure
Study 11,Site 519,Subject 3763,Study 11,EMEA,ISR,0.0,2.0,17.0,Screening 2 (1),Screen Failure
Study 11,Site 519,Subject 3764,Study 11,EMEA,ISR,0.0,2.0,18.0,Screening 2 (1),Screen Failure
Study 11,Site 519,Subject 3765,Study 11,EMEA,ISR,0.0,2.0,18.0,Screening 2 (1),Screen Failure
Study 11,Site 519,Subject 3766,Study 11,EMEA,ISR,0.0,9.0,89.0,Week 52/EOT (1),Discontinued
Study 11,Site 520,Subject 3767,Study 11,AMERICA,COL,0.0,1.0,18.0,Screening 1,Screen Failure
Study 11,Site 520,Subject 3768,Study 11,AMERICA,COL,0.0,26.0,194.0,Week 76/F24/EOS (1),Completed
Study 11,Site 520,Subject 3769,Study 11,AMERICA,COL,0.0,26.0,206.0,Week 68/F16 (1),On Trial
Study 11,Site 521,Subject 3770,Study 11,AMERICA,COL,0.0,24.0,207.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 521,Subject 3771,Study 11,AMERICA,COL,0.0,20.0,163.0,Week 44 (1),Discontinued
Study 11,Site 521,Subject 3772,Study 11,AMERICA,COL,0.0,26.0,205.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 521,Subject 3773,Study 11,AMERICA,COL,0.0,24.0,193.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 522,Subject 3774,Study 11,AMERICA,COL,0.0,28.0,198.0,Week 76/F24/EOS (1),Completed
Study 11,Site 523,Subject 3775,Study 11,AMERICA,COL,0.0,10.0,94.0,Week 52/EOT (1),Discontinued
Study 11,Site 523,Subject 3776,Study 11,AMERICA,COL,0.0,1.0,16.0,Screening 1,Screen Failure
Study 11,Site 523,Subject 3777,Study 11,AMERICA,COL,0.0,24.0,185.0,Week 64/F12 (1),On Trial
Study 11,Site 524,Subject 3778,Study 11,AMERICA,ARG,0.0,2.0,24.0,Screening 2 (1),Screen Failure
Study 11,Site 524,Subject 3779,Study 11,AMERICA,ARG,0.0,26.0,200.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 524,Subject 3780,Study 11,AMERICA,ARG,0.0,27.0,201.0,Week 72/F20 (1),On Trial
Study 11,Site 524,Subject 3781,Study 11,AMERICA,ARG,0.0,23.0,181.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 525,Subject 3782,Study 11,AMERICA,ARG,0.0,23.0,179.0,Week 76/F24/EOS (1),Completed
Study 11,Site 526,Subject 3783,Study 11,AMERICA,ARG,0.0,17.0,156.0,Week 32 (1),Discontinued
Study 11,Site 526,Subject 3784,Study 11,AMERICA,ARG,0.0,28.0,214.0,Week 76/F24/EOS (1),Completed
Study 11,Site 526,Subject 3785,Study 11,AMERICA,ARG,0.0,23.0,185.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 526,Subject 3786,Study 11,AMERICA,ARG,0.0,17.0,146.0,Week 52/EOT (1),Discontinued
Study 11,Site 526,Subject 3787,Study 11,AMERICA,ARG,0.0,28.0,203.0,Week 76/F24/EOS (1),Completed
Study 11,Site 526,Subject 3788,Study 11,AMERICA,ARG,0.0,28.0,218.0,Week 76/F24/EOS (1),On Trial
Study 11,Site 527,Subject 3789,Study 11,AMERICA,ARG,0.0,2.0,17.0,Screening 2 (1),Screen Failure
Study 11,Site 528,Subject 3790,Study 11,AMERICA,MEX,0.0,23.0,201.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 528,Subject 3791,Study 11,AMERICA,MEX,0.0,23.0,186.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 528,Subject 3792,Study 11,AMERICA,MEX,0.0,25.0,201.0,Week 64/F12 (1),Discontinued
Study 11,Site 528,Subject 3793,Study 11,AMERICA,MEX,0.0,22.0,196.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 528,Subject 3794,Study 11,AMERICA,MEX,0.0,15.0,137.0,Week 52/EOT (1),Discontinued
Study 11,Site 528,Subject 3795,Study 11,AMERICA,MEX,0.0,25.0,215.0,Week 64/F12 (1),On Trial
Study 11,Site 528,Subject 3796,Study 11,AMERICA,MEX,0.0,24.0,202.0,Week 60/F8 (1),On Trial
Study 11,Site 528,Subject 3797,Study 11,AMERICA,MEX,0.0,23.0,205.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 529,Subject 3798,Study 11,AMERICA,BRA,0.0,24.0,190.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 530,Subject 3799,Study 11,AMERICA,BRA,0.0,25.0,197.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 531,Subject 3801,Study 11,AMERICA,CHL,0.0,2.0,17.0,Screening 2 (1),Screen Failure
Study 11,Site 532,Subject 3802,Study 11,AMERICA,CHL,0.0,23.0,179.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 532,Subject 3803,Study 11,AMERICA,CHL,0.0,23.0,187.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 532,Subject 3804,Study 11,AMERICA,CHL,0.0,25.0,194.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 533,Subject 3806,Study 11,AMERICA,CHL,0.0,28.0,210.0,Week 76/F24/EOS (1),Completed
Study 11,Site 533,Subject 3807,Study 11,AMERICA,CHL,0.0,2.0,15.0,Screening 2 (1),Screen Failure
Study 11,Site 533,Subject 3808,Study 11,AMERICA,CHL,0.0,27.0,204.0,Week 76/F24/EOS (1),Completed
Study 11,Site 533,Subject 3809,Study 11,AMERICA,CHL,0.0,2.0,16.0,Screening 2 (1),Screen Failure
Study 11,Site 533,Subject 3810,Study 11,AMERICA,CHL,0.0,2.0,16.0,Screening 2 (1),Screen Failure
Study 11,Site 533,Subject 3811,Study 11,AMERICA,CHL,0.0,24.0,197.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 533,Subject 3812,Study 11,AMERICA,CHL,0.0,26.0,202.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 534,Subject 3813,Study 11,AMERICA,CHL,0.0,23.0,196.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 535,Subject 3820,Study 11,AMERICA,USA,0.0,23.0,196.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 536,Subject 3821,Study 11,AMERICA,USA,0.0,2.0,26.0,Screening 2 (1),Screen Failure
Study 11,Site 536,Subject 3822,Study 11,AMERICA,USA,0.0,24.0,187.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 536,Subject 3823,Study 11,AMERICA,USA,0.0,2.0,20.0,Screening 2 (1),Screen Failure
Study 11,Site 536,Subject 3824,Study 11,AMERICA,USA,0.0,2.0,24.0,Screening 2 (1),Screen Failure
Study 11,Site 537,Subject 3825,Study 11,AMERICA,USA,0.0,1.0,11.0,Screening 1,Screen Failure
Study 11,Site 538,Subject 3827,Study 11,AMERICA,USA,0.0,2.0,21.0,Screening 2 (1),Screen Failure
Study 11,Site 538,Subject 3828,Study 11,AMERICA,USA,0.0,27.0,220.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 538,Subject 3829,Study 11,AMERICA,USA,0.0,23.0,192.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 539,Subject 3832,Study 11,AMERICA,USA,0.0,1.0,9.0,Screening 1,Screen Failure
Study 11,Site 540,Subject 3833,Study 11,EMEA,ISL,0.0,2.0,27.0,UNPLANNED (2),Discontinued
Study 11,Site 541,Subject 3834,Study 11,EMEA,IRL,0.0,25.0,176.0,Week 64/F12 (1),On Trial
Study 11,Site 541,Subject 3835,Study 11,EMEA,IRL,0.0,25.0,180.0,Week 64/F12 (1),On Trial
Study 11,Site 541,Subject 3836,Study 11,EMEA,IRL,0.0,25.0,174.0,Week 64/F12 (1),On Trial
Study 11,Site 541,Subject 3837,Study 11,EMEA,IRL,0.0,24.0,182.0,Week 64/F12 (1),On Trial
Study 11,Site 542,Subject 3838,Study 11,EMEA,SWE,0.0,25.0,179.0,Week 64/F12 (1),On Trial
Study 11,Site 542,Subject 3839,Study 11,EMEA,SWE,0.0,24.0,212.0,Week 60/F8 (1),On Trial
Study 11,Site 543,Subject 3840,Study 11,AMERICA,USA,0.0,21.0,211.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 543,Subject 3841,Study 11,AMERICA,USA,0.0,3.0,34.0,Baseline (1),Screen Failure
Study 11,Site 543,Subject 3842,Study 11,AMERICA,USA,0.0,2.0,21.0,Screening 2 (1),Screen Failure
Study 11,Site 543,Subject 3843,Study 11,AMERICA,USA,0.0,2.0,11.0,Screening 2 (1),Screen Failure
Study 11,Site 544,Subject 3844,Study 11,AMERICA,USA,0.0,14.0,133.0,Week 52/EOT (1),Discontinued
Study 11,Site 544,Subject 3845,Study 11,AMERICA,USA,0.0,18.0,168.0,Week 52/EOT (1),Discontinued
Study 11,Site 544,Subject 3846,Study 11,AMERICA,USA,0.0,28.0,213.0,Week 76/F24/EOS (1),Completed
Study 11,Site 544,Subject 3847,Study 11,AMERICA,USA,0.0,20.0,179.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 544,Subject 3848,Study 11,AMERICA,USA,0.0,28.0,204.0,Week 76/F24/EOS (1),Completed
Study 11,Site 545,Subject 3849,Study 11,AMERICA,USA,0.0,1.0,14.0,Screening 1,Screen Failure
Study 11,Site 545,Subject 3850,Study 11,AMERICA,USA,0.0,27.0,205.0,Week 72/F20 (1),On Trial
Study 11,Site 545,Subject 3851,Study 11,AMERICA,USA,0.0,25.0,218.0,Week 68/F16 (1),On Trial
Study 11,Site 546,Subject 3852,Study 11,AMERICA,USA,0.0,10.0,100.0,Week 16 (1),Discontinued
Study 11,Site 547,Subject 3853,Study 11,AMERICA,USA,0.0,2.0,22.0,Screening 2 (1),Screen Failure
Study 11,Site 547,Subject 3854,Study 11,AMERICA,USA,0.0,1.0,12.0,Screening 1,Screen Failure
Study 11,Site 547,Subject 3855,Study 11,AMERICA,USA,0.0,6.0,65.0,Week 4 (1),Discontinued
Study 11,Site 548,Subject 3856,Study 11,AMERICA,USA,0.0,2.0,20.0,Screening 2 (1),Screen Failure
Study 11,Site 548,Subject 3857,Study 11,AMERICA,USA,0.0,9.0,92.0,Week 12 (1),Discontinued
Study 11,Site 549,Subject 3858,Study 11,AMERICA,USA,0.0,1.0,8.0,Screening 1,Screen Failure
Study 11,Site 550,Subject 3859,Study 11,AMERICA,USA,0.0,2.0,19.0,Screening 2 (1),Screen Failure
Study 11,Site 550,Subject 3860,Study 11,AMERICA,USA,0.0,2.0,16.0,Screening 2 (1),Screen Failure
Study 11,Site 550,Subject 3861,Study 11,AMERICA,USA,0.0,24.0,187.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 550,Subject 3862,Study 11,AMERICA,USA,0.0,23.0,183.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 551,Subject 3863,Study 11,AMERICA,USA,0.0,22.0,178.0,Week 52/EOT (1),Discontinued
Study 11,Site 551,Subject 3864,Study 11,AMERICA,USA,0.0,28.0,213.0,Week 76/F24/EOS (1),Completed
Study 11,Site 551,Subject 3865,Study 11,AMERICA,USA,0.0,28.0,206.0,Week 76/F24/EOS (1),Completed
Study 11,Site 552,Subject 3866,Study 11,AMERICA,USA,0.0,26.0,209.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 552,Subject 3867,Study 11,AMERICA,USA,0.0,2.0,20.0,Screening 2 (1),Screen Failure
Study 11,Site 553,Subject 3868,Study 11,AMERICA,USA,0.0,2.0,15.0,Screening 2 (1),Screen Failure
Study 11,Site 553,Subject 3869,Study 11,AMERICA,USA,0.0,22.0,181.0,Week 64/F12 (1),On Trial
Study 11,Site 6,Subject 12,Study 11,EMEA,ZAF,0.0,20.0,168.0,Week 76/F24/EOS (1),Completed
Study 11,Site 6,Subject 13,Study 11,EMEA,ZAF,0.0,1.0,8.0,Screening 1,Screen Failure
Study 11,Site 62,Subject 380,Study 11,EMEA,BEL,0.0,20.0,185.0,Week 76/F24/EOS (1),Completed
Study 11,Site 62,Subject 381,Study 11,EMEA,BEL,0.0,27.0,219.0,Week 76/F24/EOS (1),Completed
Study 11,Site 62,Subject 382,Study 11,EMEA,BEL,0.0,2.0,18.0,Screening 2 (1),Screen Failure
Study 11,Site 63,Subject 391,Study 11,EMEA,BEL,0.0,24.0,199.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 63,Subject 392,Study 11,EMEA,BEL,0.0,25.0,219.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 63,Subject 393,Study 11,EMEA,BEL,0.0,26.0,214.0,Week 68/F16 (1),On Trial
Study 11,Site 7,Subject 14,Study 11,EMEA,CZE,0.0,24.0,195.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 7,Subject 594,Study 11,EMEA,CZE,0.0,8.0,93.0,Week 52/EOT (1),Discontinued
Study 11,Site 7,Subject 595,Study 11,EMEA,CZE,0.0,23.0,198.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 8,Subject 15,Study 11,EMEA,CZE,0.0,28.0,229.0,Week 76/F24/EOS (1),Completed
Study 11,Site 8,Subject 3506,Study 11,EMEA,CZE,0.0,28.0,214.0,Week 76/F24/EOS (1),On Trial
Study 11,Site 8,Subject 3572,Study 11,EMEA,CZE,0.0,26.0,193.0,Week 72/F20 (1),On Trial
Study 11,Site 8,Subject 3573,Study 11,EMEA,CZE,0.0,26.0,195.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 8,Subject 598,Study 11,EMEA,CZE,0.0,27.0,216.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 87,Subject 627,Study 11,EMEA,HUN,0.0,23.0,176.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 87,Subject 628,Study 11,EMEA,HUN,0.0,23.0,178.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 87,Subject 629,Study 11,EMEA,HUN,0.0,24.0,179.0,Week 60/F8 (1),On Trial
Study 11,Site 88,Subject 632,Study 11,EMEA,HUN,0.0,22.0,178.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 88,Subject 633,Study 11,EMEA,HUN,0.0,25.0,202.0,Week 76/F24/EOS (1),Discontinued
Study 11,Site 88,Subject 634,Study 11,EMEA,HUN,0.0,2.0,16.0,Screening 2 (1),Screen Failure
Study 11,Site 88,Subject 635,Study 11,EMEA,HUN,0.0,24.0,178.0,Week 60/F8 (1),On Trial
Study 13,Site 109,Subject 835,Study 13,AMERICA,USA,0.0,11.0,137.0,Safety F/U,Discontinued
Study 13,Site 109,Subject 836,Study 13,AMERICA,USA,0.0,8.0,74.0,Unplanned visit (1),On Trial
Study 13,Site 110,Subject 893,Study 13,ASIA,AUS,0.0,3.0,0.0,Cycle 1 Day 2,On Trial
Study 13,Site 125,Subject 1072,Study 13,ASIA,KOR,0.0,10.0,124.0,EOT,Discontinued
Study 13,Site 130,Subject 1137,Study 13,ASIA,SGP,0.0,1.0,10.0,Screening,Screen Failure
Study 13,Site 130,Subject 1138,Study 13,ASIA,SGP,0.0,1.0,7.0,Screening,Screen Failure
Study 13,Site 130,Subject 1139,Study 13,ASIA,SGP,0.0,14.0,166.0,Safety F/U,Discontinued
Study 13,Site 130,Subject 1140,Study 13,ASIA,SGP,0.0,11.0,137.0,Safety F/U,Discontinued
Study 13,Site 130,Subject 1141,Study 13,ASIA,SGP,0.0,8.0,62.0,Cycle 2 Day 1,On Trial
Study 13,Site 2,Subject 2,Study 13,AMERICA,CAN,0.0,11.0,93.0,Safety F/U,Discontinued
Study 13,Site 2,Subject 3,Study 13,AMERICA,CAN,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 13,Site 353,Subject 2844,Study 13,ASIA,TWN,0.0,9.0,123.0,Safety F/U,Discontinued
Study 13,Site 417,Subject 3227,Study 13,ASIA,JPN,0.0,11.0,144.0,Safety F/U,Discontinued
Study 13,Site 417,Subject 3228,Study 13,ASIA,JPN,0.0,1.0,10.0,Screening,Screen Failure
Study 13,Site 417,Subject 3229,Study 13,ASIA,JPN,0.0,7.0,89.0,Unplanned visit (1),Discontinued
Study 13,Site 468,Subject 3560,Study 13,AMERICA,USA,0.0,0.0,0.0,,
Study 13,Site 588,Subject 3983,Study 13,EMEA,ISR,0.0,12.0,143.0,Safety F/U,Discontinued
Study 13,Site 589,Subject 3984,Study 13,EMEA,ISR,0.0,10.0,111.0,Safety F/U,Discontinued
Study 13,Site 589,Subject 3985,Study 13,EMEA,ISR,0.0,12.0,128.0,Safety F/U,Discontinued
Study 13,Site 597,Subject 4019,Study 13,AMERICA,USA,0.0,9.0,0.0,EOT,Discontinued
Study 13,Site 598,Subject 4020,Study 13,EMEA,DEU,0.0,1.0,0.0,Screening,
Study 13,Site 87,Subject 627,Study 13,ASIA,AUS,0.0,11.0,52.0,Cycle 3 Day 15,On Trial
Study 14,Site 502,Subject 3704,Study 14,AMERICA,CAN,0.0,5.0,10.0,Day 7,
Study 14,Site 502,Subject 3705,Study 14,AMERICA,CAN,0.0,1.0,0.0,Screening,
Study 14,Site 503,Subject 3706,Study 14,AMERICA,CAN,0.0,1.0,8.0,Screening,
Study 15,Site 2,Subject 100,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 15,Site 2,Subject 101,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 2,Subject 2,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 15,Site 2,Subject 3,Study 15,AMERICA,USA,0.0,2.0,0.0,Day 1,On Trial
Study 15,Site 2,Subject 3399,Study 15,AMERICA,USA,0.0,2.0,0.0,Baseline,
Study 15,Site 2,Subject 3400,Study 15,AMERICA,USA,0.0,2.0,0.0,Baseline,Completed
Study 15,Site 2,Subject 3401,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 2,Subject 3402,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 2,Subject 3403,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 15,Site 2,Subject 3404,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 2,Subject 3405,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 15,Site 2,Subject 3406,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 2,Subject 3407,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 2,Subject 3408,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 2,Subject 3409,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 15,Site 2,Subject 3410,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 15,Site 2,Subject 3411,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 15,Site 2,Subject 3412,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 2,Subject 4,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 15,Site 2,Subject 4021,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 2,Subject 4022,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 2,Subject 4023,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 15,Site 2,Subject 4024,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 15,Site 2,Subject 4025,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 2,Subject 5,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 15,Site 2,Subject 99,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 15,Site 3,Subject 102,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 103,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 104,Study 15,AMERICA,USA,0.0,5.0,0.0,Day 3,On Trial
Study 15,Site 3,Subject 4026,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 4027,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 4028,Study 15,AMERICA,USA,0.0,3.0,0.0,Day 1,On Trial
Study 15,Site 3,Subject 4029,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 4030,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 4031,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 4032,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 4033,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 15,Site 3,Subject 4034,Study 15,AMERICA,USA,0.0,3.0,0.0,Day 1,On Trial
Study 15,Site 3,Subject 4035,Study 15,AMERICA,USA,0.0,3.0,0.0,Day 1,On Trial
Study 15,Site 3,Subject 4036,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 4037,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 4038,Study 15,AMERICA,USA,0.0,3.0,0.0,Day 1,On Trial
Study 15,Site 3,Subject 4039,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 4040,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 4041,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 4042,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 4043,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 4044,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 4045,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 4046,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 15,Site 3,Subject 4047,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 15,Site 3,Subject 4048,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 4049,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 4050,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 4051,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 4052,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 15,Site 3,Subject 4053,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 15,Site 3,Subject 4054,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 4055,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 4056,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 4057,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 15,Site 3,Subject 4058,Study 15,AMERICA,USA,0.0,0.0,0.0,,
Study 15,Site 3,Subject 4059,Study 15,AMERICA,USA,0.0,0.0,0.0,,
Study 15,Site 3,Subject 4060,Study 15,AMERICA,USA,0.0,0.0,0.0,,
Study 15,Site 3,Subject 4061,Study 15,AMERICA,USA,0.0,0.0,0.0,,
Study 15,Site 3,Subject 4062,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 4063,Study 15,AMERICA,USA,0.0,0.0,0.0,,
Study 15,Site 3,Subject 4064,Study 15,AMERICA,USA,0.0,0.0,0.0,,
Study 15,Site 3,Subject 4065,Study 15,AMERICA,USA,0.0,0.0,0.0,,
Study 15,Site 3,Subject 4066,Study 15,AMERICA,USA,0.0,0.0,0.0,,
Study 15,Site 3,Subject 4067,Study 15,AMERICA,USA,0.0,0.0,0.0,,
Study 15,Site 3,Subject 4068,Study 15,AMERICA,USA,0.0,0.0,0.0,,
Study 15,Site 3,Subject 4069,Study 15,AMERICA,USA,0.0,0.0,0.0,,
Study 15,Site 3,Subject 4070,Study 15,AMERICA,USA,0.0,0.0,0.0,,
Study 15,Site 3,Subject 4071,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 15,Site 3,Subject 4072,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 15,Site 3,Subject 4073,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 15,Site 3,Subject 6,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 7,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 774,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 775,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 776,Study 15,AMERICA,USA,0.0,5.0,0.0,Day 3,On Trial
Study 15,Site 3,Subject 777,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 15,Site 3,Subject 778,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 779,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 780,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 781,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 15,Site 3,Subject 782,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 783,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 784,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 785,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 786,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 15,Site 3,Subject 8,Study 15,AMERICA,USA,0.0,1.0,0.0,Screening,Screening
Study 16,Site 599,Subject 4074,Study 16,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 599,Subject 4111,Study 16,AMERICA,USA,0.0,47.0,112.0,Week 94 (1),On Trial
Study 16,Site 600,Subject 4075,Study 16,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 16,Site 601,Subject 4076,Study 16,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 16,Site 601,Subject 4077,Study 16,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 16,Site 601,Subject 4078,Study 16,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 16,Site 601,Subject 4079,Study 16,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 601,Subject 4080,Study 16,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 601,Subject 4081,Study 16,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 16,Site 601,Subject 4082,Study 16,AMERICA,USA,0.0,0.0,8.0,Screening,Screen Failure
Study 16,Site 602,Subject 4083,Study 16,AMERICA,USA,0.0,54.0,244.0,Week 104 (EOT) (1),Completed
Study 16,Site 602,Subject 4084,Study 16,AMERICA,USA,0.0,54.0,244.0,Week 104 (EOT) (1),Completed
Study 16,Site 602,Subject 4085,Study 16,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 602,Subject 4086,Study 16,AMERICA,USA,0.0,54.0,249.0,Week 104 (EOT) (1),Completed
Study 16,Site 602,Subject 4087,Study 16,AMERICA,USA,0.0,54.0,230.0,Week 104 (EOT) (1),On Trial
Study 16,Site 602,Subject 4088,Study 16,AMERICA,USA,0.0,53.0,222.0,Week 102 (1),On Trial
Study 16,Site 602,Subject 4089,Study 16,AMERICA,USA,0.0,51.0,246.0,Week 98 (1),On Trial
Study 16,Site 602,Subject 4090,Study 16,AMERICA,USA,0.0,52.0,218.0,Week 100 (1),On Trial
Study 16,Site 602,Subject 4091,Study 16,AMERICA,USA,0.0,51.0,253.0,Week 98 (1),On Trial
Study 16,Site 602,Subject 4092,Study 16,AMERICA,USA,0.0,48.0,213.0,Week 92 (1),On Trial
Study 16,Site 602,Subject 4093,Study 16,AMERICA,USA,0.0,44.0,192.0,Early Discontinuation (1),Follow-Up
Study 16,Site 602,Subject 4094,Study 16,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 602,Subject 4095,Study 16,AMERICA,USA,0.0,44.0,224.0,Week 84 (1),On Trial
Study 16,Site 602,Subject 4096,Study 16,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 602,Subject 4097,Study 16,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 602,Subject 4098,Study 16,AMERICA,USA,0.0,39.0,192.0,Week 74 (1),On Trial
Study 16,Site 602,Subject 4099,Study 16,AMERICA,USA,0.0,36.0,192.0,Week 68 (1),On Trial
Study 16,Site 602,Subject 4100,Study 16,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 602,Subject 4101,Study 16,AMERICA,USA,0.0,32.0,146.0,Week 60 (1),On Trial
Study 16,Site 602,Subject 4102,Study 16,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 602,Subject 4103,Study 16,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 602,Subject 4104,Study 16,AMERICA,USA,0.0,13.0,74.0,Week 22 (1),On Trial
Study 16,Site 603,Subject 4105,Study 16,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 603,Subject 4106,Study 16,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 603,Subject 4107,Study 16,AMERICA,USA,0.0,14.0,66.0,Week 24 (1),On Trial
Study 16,Site 603,Subject 4108,Study 16,AMERICA,USA,0.0,7.0,42.0,Week 12 (1),On Trial
Study 16,Site 604,Subject 4109,Study 16,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 16,Site 604,Subject 4110,Study 16,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 16,Site 605,Subject 4112,Study 16,AMERICA,USA,0.0,41.0,50.0,Week 78 (1),On Trial
Study 16,Site 605,Subject 4113,Study 16,AMERICA,USA,0.0,30.0,53.0,Week 70 (1),On Trial
Study 16,Site 605,Subject 4114,Study 16,AMERICA,USA,0.0,13.0,0.0,Week 22 (1),On Trial
Study 16,Site 606,Subject 4115,Study 16,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 16,Site 606,Subject 4116,Study 16,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 16,Site 606,Subject 4117,Study 16,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 606,Subject 4118,Study 16,AMERICA,USA,0.0,30.0,135.0,Week 56 (1),On Trial
Study 16,Site 606,Subject 4119,Study 16,AMERICA,USA,0.0,15.0,86.0,Week 26 (1),On Trial
Study 16,Site 606,Subject 4120,Study 16,AMERICA,USA,0.0,8.0,55.0,Week 12 (1),On Trial
Study 16,Site 607,Subject 4121,Study 16,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 16,Site 607,Subject 4122,Study 16,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 16,Site 607,Subject 4123,Study 16,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 16,Site 608,Subject 4124,Study 16,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 16,Site 608,Subject 4125,Study 16,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 16,Site 608,Subject 4126,Study 16,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 608,Subject 4127,Study 16,AMERICA,USA,0.0,19.0,93.0,Week 34 (1),On Trial
Study 16,Site 608,Subject 4128,Study 16,AMERICA,USA,0.0,1.0,5.0,Screening,Screen Failure
Study 16,Site 608,Subject 4129,Study 16,AMERICA,USA,0.0,1.0,6.0,Screening,Screen Failure
Study 16,Site 609,Subject 4130,Study 16,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 16,Site 609,Subject 4131,Study 16,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 16,Site 610,Subject 4132,Study 16,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 610,Subject 4133,Study 16,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 610,Subject 4134,Study 16,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 610,Subject 4135,Study 16,AMERICA,USA,0.0,15.0,83.0,Week 26 (1),On Trial
Study 16,Site 610,Subject 4136,Study 16,AMERICA,USA,0.0,13.0,69.0,Week 22 (1),On Trial
Study 16,Site 610,Subject 4137,Study 16,AMERICA,USA,0.0,13.0,57.0,Week 22 (1),On Trial
Study 16,Site 610,Subject 4138,Study 16,AMERICA,USA,0.0,1.0,7.0,Screening,Completed
Study 16,Site 611,Subject 4139,Study 16,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 611,Subject 4140,Study 16,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 611,Subject 4141,Study 16,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 611,Subject 4142,Study 16,AMERICA,USA,0.0,39.0,85.0,Week 74 (1),On Trial
Study 16,Site 611,Subject 4143,Study 16,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 611,Subject 4144,Study 16,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 611,Subject 4145,Study 16,AMERICA,USA,0.0,1.0,6.0,Screening,Screen Failure
Study 16,Site 611,Subject 4146,Study 16,AMERICA,USA,0.0,1.0,6.0,Screening,Screen Failure
Study 16,Site 611,Subject 4147,Study 16,AMERICA,USA,0.0,15.0,32.0,Week 26 (1),On Trial
Study 16,Site 611,Subject 4148,Study 16,AMERICA,USA,0.0,1.0,2.0,Screening,Screen Failure
Study 16,Site 611,Subject 4149,Study 16,AMERICA,USA,0.0,9.0,0.0,Week 14 (1),On Trial
Study 16,Site 611,Subject 4150,Study 16,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 16,Site 612,Subject 4151,Study 16,AMERICA,USA,0.0,9.0,69.0,Week 14 (1),On Trial
Study 16,Site 613,Subject 4152,Study 16,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 16,Site 614,Subject 4153,Study 16,AMERICA,USA,0.0,54.0,274.0,Week 104 (EOT) (1),Completed
Study 16,Site 614,Subject 4154,Study 16,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 16,Site 614,Subject 4155,Study 16,AMERICA,USA,0.0,1.0,11.0,Screening,Screen Failure
Study 16,Site 615,Subject 4156,Study 16,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 615,Subject 4157,Study 16,AMERICA,USA,0.0,28.0,131.0,Week 52 (1),On Trial
Study 16,Site 615,Subject 4158,Study 16,AMERICA,USA,0.0,28.0,152.0,Week 52 (1),On Trial
Study 16,Site 615,Subject 4159,Study 16,AMERICA,USA,0.0,22.0,116.0,Week 40 (1),On Trial
Study 16,Site 616,Subject 4160,Study 16,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 617,Subject 4161,Study 16,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 16,Site 618,Subject 4162,Study 16,AMERICA,USA,0.0,34.0,164.0,Week 64 (1),On Trial
Study 16,Site 619,Subject 4163,Study 16,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 620,Subject 4164,Study 16,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 620,Subject 4165,Study 16,AMERICA,USA,0.0,14.0,87.0,Week 26 (1),On Trial
Study 16,Site 621,Subject 4166,Study 16,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 16,Site 621,Subject 4167,Study 16,AMERICA,USA,0.0,30.0,139.0,Week 56 (1),On Trial
Study 16,Site 621,Subject 4168,Study 16,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 621,Subject 4169,Study 16,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 621,Subject 4170,Study 16,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 621,Subject 4171,Study 16,AMERICA,USA,0.0,9.0,57.0,Week 14 (1),On Trial
Study 16,Site 621,Subject 4172,Study 16,AMERICA,USA,0.0,1.0,6.0,Screening,Screen Failure
Study 16,Site 622,Subject 4173,Study 16,AMERICA,USA,0.0,1.0,8.0,Unplanned Visit (1),Screen Failure
Study 16,Site 622,Subject 4174,Study 16,AMERICA,USA,0.0,30.0,151.0,Week 56 (1),On Trial
Study 16,Site 622,Subject 4175,Study 16,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 623,Subject 4176,Study 16,AMERICA,CAN,0.0,11.0,49.0,Week 40 (1),Follow-Up
Study 16,Site 623,Subject 4177,Study 16,AMERICA,CAN,0.0,8.0,45.0,Week 12 (1),On Trial
Study 16,Site 624,Subject 4178,Study 16,AMERICA,CAN,0.0,1.0,9.0,Screening,Screen Failure
Study 16,Site 624,Subject 4179,Study 16,AMERICA,CAN,0.0,39.0,180.0,Week 74 (1),On Trial
Study 16,Site 624,Subject 4180,Study 16,AMERICA,CAN,0.0,37.0,176.0,Week 70 (1),On Trial
Study 16,Site 624,Subject 4181,Study 16,AMERICA,CAN,0.0,6.0,53.0,Early Discontinuation (1),Follow-Up
Study 16,Site 624,Subject 4182,Study 16,AMERICA,CAN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 624,Subject 4183,Study 16,AMERICA,CAN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 624,Subject 4184,Study 16,AMERICA,CAN,0.0,22.0,127.0,Week 42 (1),On Trial
Study 16,Site 624,Subject 4185,Study 16,AMERICA,CAN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 624,Subject 4186,Study 16,AMERICA,CAN,0.0,13.0,74.0,Week 22 (1),On Trial
Study 16,Site 624,Subject 4187,Study 16,AMERICA,CAN,0.0,10.0,66.0,Week 16 (1),On Trial
Study 16,Site 624,Subject 4188,Study 16,AMERICA,CAN,0.0,9.0,63.0,Week 14 (1),On Trial
Study 16,Site 625,Subject 4189,Study 16,AMERICA,CAN,0.0,8.0,70.0,Week 12 (1),On Trial
Study 16,Site 625,Subject 4190,Study 16,AMERICA,CAN,0.0,8.0,77.0,Week 12 (1),On Trial
Study 16,Site 625,Subject 4191,Study 16,AMERICA,CAN,0.0,8.0,76.0,Week 12 (1),On Trial
Study 16,Site 626,Subject 4192,Study 16,AMERICA,CAN,0.0,11.0,42.0,Week 18 (1),On Trial
Study 16,Site 627,Subject 4193,Study 16,AMERICA,CAN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 627,Subject 4194,Study 16,AMERICA,CAN,0.0,14.0,69.0,Week 24 (1),On Trial
Study 16,Site 627,Subject 4195,Study 16,AMERICA,CAN,0.0,8.0,45.0,Week 12 (1),On Trial
Study 16,Site 627,Subject 4196,Study 16,AMERICA,CAN,0.0,8.0,52.0,Week 12 (1),On Trial
Study 16,Site 628,Subject 4197,Study 16,AMERICA,CAN,0.0,14.0,99.0,Unplanned Visit (2),On Trial
Study 16,Site 629,Subject 4198,Study 16,AMERICA,CAN,0.0,8.0,38.0,Week 12 (1),On Trial
Study 16,Site 629,Subject 4199,Study 16,AMERICA,CAN,0.0,1.0,12.0,Unplanned Visit (2),Screen Failure
Study 16,Site 630,Subject 4200,Study 16,EMEA,GRC,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 631,Subject 4201,Study 16,EMEA,GRC,0.0,25.0,137.0,Week 46 (1),On Trial
Study 16,Site 632,Subject 4202,Study 16,EMEA,GRC,0.0,1.0,6.0,Screening,Screen Failure
Study 16,Site 632,Subject 4203,Study 16,EMEA,GRC,0.0,22.0,50.0,Week 40 (1),On Trial
Study 16,Site 632,Subject 4204,Study 16,EMEA,GRC,0.0,20.0,41.0,Week 36 (1),On Trial
Study 16,Site 633,Subject 4205,Study 16,EMEA,GRC,0.0,14.0,30.0,Week 24 (1),On Trial
Study 16,Site 633,Subject 4206,Study 16,EMEA,GRC,0.0,1.0,6.0,Unplanned Visit (1),Screen Failure
Study 16,Site 634,Subject 4207,Study 16,EMEA,GRC,0.0,22.0,73.0,Week 40 (1),On Trial
Study 16,Site 635,Subject 4208,Study 16,EMEA,GRC,0.0,20.0,81.0,Week 36 (1),On Trial
Study 16,Site 636,Subject 4209,Study 16,EMEA,BEL,0.0,0.0,5.0,Screening,Screen Failure
Study 16,Site 637,Subject 4210,Study 16,EMEA,BEL,0.0,32.0,141.0,Week 60 (1),On Trial
Study 16,Site 637,Subject 4211,Study 16,EMEA,BEL,0.0,28.0,140.0,Week 52 (1),On Trial
Study 16,Site 637,Subject 4212,Study 16,EMEA,BEL,0.0,28.0,122.0,Week 52 (1),On Trial
Study 16,Site 637,Subject 4213,Study 16,EMEA,BEL,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 637,Subject 4214,Study 16,EMEA,BEL,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 637,Subject 4215,Study 16,EMEA,BEL,0.0,19.0,91.0,Week 36 (1),On Trial
Study 16,Site 637,Subject 4216,Study 16,EMEA,BEL,0.0,19.0,90.0,Week 36 (1),On Trial
Study 16,Site 637,Subject 4217,Study 16,EMEA,BEL,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 638,Subject 4218,Study 16,EMEA,BEL,0.0,8.0,63.0,Week 12 (1),On Trial
Study 16,Site 639,Subject 4219,Study 16,EMEA,BEL,0.0,28.0,146.0,Week 52 (1),On Trial
Study 16,Site 639,Subject 4220,Study 16,EMEA,BEL,0.0,28.0,115.0,Week 52 (1),On Trial
Study 16,Site 639,Subject 4221,Study 16,EMEA,BEL,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 639,Subject 4222,Study 16,EMEA,BEL,0.0,14.0,89.0,Week 24 (1),On Trial
Study 16,Site 640,Subject 4223,Study 16,EMEA,BEL,0.0,30.0,155.0,Week 56 (1),On Trial
Study 16,Site 640,Subject 4224,Study 16,EMEA,BEL,0.0,28.0,118.0,Week 52 (1),On Trial
Study 16,Site 640,Subject 4225,Study 16,EMEA,BEL,0.0,22.0,149.0,Week 40 (1),On Trial
Study 16,Site 640,Subject 4226,Study 16,EMEA,BEL,0.0,20.0,106.0,Week 36 (1),On Trial
Study 16,Site 640,Subject 4227,Study 16,EMEA,BEL,0.0,7.0,56.0,Week 12 (1),On Trial
Study 16,Site 641,Subject 4228,Study 16,EMEA,BEL,0.0,18.0,79.0,Week 36 (1),On Trial
Study 16,Site 642,Subject 4229,Study 16,EMEA,FRA,0.0,14.0,103.0,Week 24 (1),On Trial
Study 16,Site 642,Subject 4230,Study 16,EMEA,FRA,0.0,8.0,70.0,Week 12 (1),On Trial
Study 16,Site 643,Subject 4231,Study 16,EMEA,FRA,0.0,20.0,44.0,Week 36 (1),On Trial
Study 16,Site 643,Subject 4232,Study 16,EMEA,FRA,0.0,18.0,31.0,Week 32 (1),On Trial
Study 16,Site 644,Subject 4233,Study 16,EMEA,FRA,0.0,14.0,9.0,Week 24 (1),On Trial
Study 16,Site 644,Subject 4234,Study 16,EMEA,FRA,0.0,1.0,4.0,Screening,Screen Failure
Study 16,Site 645,Subject 4235,Study 16,EMEA,FRA,0.0,0.0,8.0,Screening,Screen Failure
Study 16,Site 645,Subject 4236,Study 16,EMEA,FRA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 645,Subject 4237,Study 16,EMEA,FRA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 645,Subject 4238,Study 16,EMEA,FRA,0.0,16.0,82.0,Week 28 (1),On Trial
Study 16,Site 646,Subject 4239,Study 16,EMEA,FRA,0.0,22.0,115.0,Week 40 (1),On Trial
Study 16,Site 647,Subject 4240,Study 16,EMEA,FRA,0.0,1.0,6.0,Screening,Screen Failure
Study 16,Site 648,Subject 4241,Study 16,EMEA,ESP,0.0,1.0,5.0,Screening,Screen Failure
Study 16,Site 648,Subject 4242,Study 16,EMEA,ESP,0.0,1.0,5.0,Screening,Screen Failure
Study 16,Site 648,Subject 4243,Study 16,EMEA,ESP,0.0,1.0,5.0,Screening,Screen Failure
Study 16,Site 648,Subject 4244,Study 16,EMEA,ESP,0.0,1.0,5.0,Screening,Screen Failure
Study 16,Site 648,Subject 4245,Study 16,EMEA,ESP,0.0,16.0,18.0,Week 32 (1),On Trial
Study 16,Site 648,Subject 4246,Study 16,EMEA,ESP,0.0,1.0,5.0,Screening,Screen Failure
Study 16,Site 649,Subject 4247,Study 16,EMEA,ESP,0.0,22.0,34.0,Week 40 (1),On Trial
Study 16,Site 650,Subject 4248,Study 16,EMEA,ESP,0.0,25.0,122.0,Week 46 (1),On Trial
Study 16,Site 650,Subject 4249,Study 16,EMEA,ESP,0.0,15.0,100.0,Week 30 (1),On Trial
Study 16,Site 651,Subject 4250,Study 16,EMEA,ESP,0.0,1.0,4.0,Screening,Screen Failure
Study 16,Site 651,Subject 4251,Study 16,EMEA,ESP,0.0,1.0,6.0,Screening,Screen Failure
Study 16,Site 652,Subject 4252,Study 16,EMEA,ESP,0.0,22.0,46.0,Week 40 (1),On Trial
Study 16,Site 653,Subject 4253,Study 16,EMEA,ESP,0.0,34.0,156.0,Week 64 (1),On Trial
Study 16,Site 653,Subject 4254,Study 16,EMEA,ESP,0.0,30.0,128.0,Week 56 (1),On Trial
Study 16,Site 653,Subject 4255,Study 16,EMEA,ESP,0.0,13.0,82.0,Week 40 (1),Follow-Up
Study 16,Site 653,Subject 4256,Study 16,EMEA,ESP,0.0,14.0,56.0,Week 24 (1),On Trial
Study 16,Site 654,Subject 4257,Study 16,EMEA,HRV,0.0,22.0,46.0,Week 40 (1),On Trial
Study 16,Site 654,Subject 4258,Study 16,EMEA,HRV,0.0,22.0,41.0,Week 40 (1),On Trial
Study 16,Site 654,Subject 4259,Study 16,EMEA,HRV,0.0,22.0,42.0,Week 40 (1),On Trial
Study 16,Site 654,Subject 4260,Study 16,EMEA,HRV,0.0,22.0,34.0,Week 40 (1),On Trial
Study 16,Site 655,Subject 4261,Study 16,EMEA,HRV,0.0,16.0,82.0,Week 28 (1),On Trial
Study 16,Site 656,Subject 4262,Study 16,EMEA,HRV,0.0,1.0,6.0,Screening,Screen Failure
Study 16,Site 657,Subject 4263,Study 16,EMEA,ITA,0.0,17.0,95.0,Week 34 (1),On Trial
Study 16,Site 657,Subject 4264,Study 16,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 657,Subject 4265,Study 16,EMEA,ITA,0.0,16.0,86.0,Week 28 (1),On Trial
Study 16,Site 657,Subject 4266,Study 16,EMEA,ITA,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 657,Subject 4267,Study 16,EMEA,ITA,0.0,11.0,82.0,Week 24 (1),On Trial
Study 16,Site 657,Subject 4268,Study 16,EMEA,ITA,0.0,13.0,80.0,Week 24 (1),On Trial
Study 16,Site 657,Subject 4269,Study 16,EMEA,ITA,0.0,13.0,80.0,Week 24 (1),On Trial
Study 16,Site 658,Subject 4270,Study 16,EMEA,ITA,0.0,14.0,78.0,Week 24 (1),On Trial
Study 16,Site 658,Subject 4271,Study 16,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 658,Subject 4272,Study 16,EMEA,ITA,0.0,14.0,77.0,Week 24 (1),On Trial
Study 16,Site 658,Subject 4273,Study 16,EMEA,ITA,0.0,8.0,52.0,Week 12 (1),On Trial
Study 16,Site 659,Subject 4274,Study 16,EMEA,ITA,0.0,17.0,49.0,Unplanned Visit (3),Follow-Up
Study 16,Site 659,Subject 4275,Study 16,EMEA,ITA,0.0,22.0,44.0,Week 40 (1),On Trial
Study 16,Site 660,Subject 4276,Study 16,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 661,Subject 4277,Study 16,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 661,Subject 4278,Study 16,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 661,Subject 4279,Study 16,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 661,Subject 4280,Study 16,EMEA,ITA,0.0,20.0,108.0,Week 36 (1),On Trial
Study 16,Site 661,Subject 4281,Study 16,EMEA,ITA,0.0,14.0,87.0,Week 24 (1),On Trial
Study 16,Site 661,Subject 4282,Study 16,EMEA,ITA,0.0,2.0,15.0,Day 1 (1),Discontinued
Study 16,Site 661,Subject 4283,Study 16,EMEA,ITA,0.0,8.0,58.0,Week 12 (1),On Trial
Study 16,Site 661,Subject 4284,Study 16,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 662,Subject 4285,Study 16,EMEA,ITA,0.0,8.0,56.0,Week 12 (1),On Trial
Study 16,Site 663,Subject 4286,Study 16,EMEA,ITA,0.0,12.0,73.0,Week 20 (1),On Trial
Study 16,Site 663,Subject 4287,Study 16,EMEA,ITA,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 664,Subject 4288,Study 16,EMEA,CZE,0.0,28.0,67.0,Week 52 (1),On Trial
Study 16,Site 664,Subject 4289,Study 16,EMEA,CZE,0.0,28.0,61.0,Week 52 (1),On Trial
Study 16,Site 664,Subject 4290,Study 16,EMEA,CZE,0.0,1.0,6.0,Screening,Screen Failure
Study 16,Site 664,Subject 4291,Study 16,EMEA,CZE,0.0,14.0,39.0,Week 24 (1),On Trial
Study 16,Site 665,Subject 4292,Study 16,EMEA,GBR,0.0,28.0,139.0,Week 52 (1),On Trial
Study 16,Site 666,Subject 4293,Study 16,EMEA,GBR,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 666,Subject 4294,Study 16,EMEA,GBR,0.0,1.0,9.0,Screening,Screen Failure
Study 16,Site 667,Subject 4295,Study 16,EMEA,GBR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 667,Subject 4296,Study 16,EMEA,GBR,0.0,27.0,129.0,Week 50 (1),On Trial
Study 16,Site 667,Subject 4297,Study 16,EMEA,GBR,0.0,12.0,91.0,Week 24 (1),On Trial
Study 16,Site 668,Subject 4298,Study 16,EMEA,GBR,0.0,1.0,6.0,Screening,Screen Failure
Study 16,Site 668,Subject 4299,Study 16,EMEA,GBR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 669,Subject 4300,Study 16,EMEA,DEU,0.0,28.0,126.0,Week 52 (1),On Trial
Study 16,Site 669,Subject 4301,Study 16,EMEA,DEU,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 669,Subject 4302,Study 16,EMEA,DEU,0.0,22.0,101.0,Week 40 (1),On Trial
Study 16,Site 669,Subject 4303,Study 16,EMEA,DEU,0.0,20.0,82.0,Week 36 (1),On Trial
Study 16,Site 669,Subject 4304,Study 16,EMEA,DEU,0.0,14.0,55.0,Week 24 (1),On Trial
Study 16,Site 670,Subject 4305,Study 16,EMEA,DEU,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 670,Subject 4306,Study 16,EMEA,DEU,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 671,Subject 4307,Study 16,EMEA,DEU,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 671,Subject 4308,Study 16,EMEA,DEU,0.0,22.0,113.0,Week 40 (1),On Trial
Study 16,Site 671,Subject 4309,Study 16,EMEA,DEU,0.0,8.0,63.0,Week 12 (1),On Trial
Study 16,Site 672,Subject 4310,Study 16,EMEA,DEU,0.0,8.0,74.0,Week 12 (1),On Trial
Study 16,Site 673,Subject 4311,Study 16,EMEA,DEU,0.0,20.0,97.0,Week 36 (1),On Trial
Study 16,Site 673,Subject 4312,Study 16,EMEA,DEU,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 674,Subject 4313,Study 16,EMEA,DEU,0.0,14.0,84.0,Week 24 (1),On Trial
Study 16,Site 674,Subject 4314,Study 16,EMEA,DEU,0.0,14.0,77.0,Week 24 (1),On Trial
Study 16,Site 675,Subject 4315,Study 16,AMERICA,MEX,0.0,22.0,91.0,Week 40 (1),On Trial
Study 16,Site 675,Subject 4316,Study 16,AMERICA,MEX,0.0,22.0,49.0,Week 40 (1),On Trial
Study 16,Site 675,Subject 4317,Study 16,AMERICA,MEX,0.0,1.0,6.0,Screening,Screen Failure
Study 16,Site 675,Subject 4318,Study 16,AMERICA,MEX,0.0,22.0,43.0,Week 40 (1),On Trial
Study 16,Site 675,Subject 4319,Study 16,AMERICA,MEX,0.0,1.0,5.0,Screening,Screen Failure
Study 16,Site 676,Subject 4320,Study 16,AMERICA,MEX,0.0,34.0,158.0,Week 64 (1),On Trial
Study 16,Site 676,Subject 4321,Study 16,AMERICA,MEX,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 676,Subject 4322,Study 16,AMERICA,MEX,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 676,Subject 4323,Study 16,AMERICA,MEX,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 676,Subject 4324,Study 16,AMERICA,MEX,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 676,Subject 4325,Study 16,AMERICA,MEX,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 676,Subject 4326,Study 16,AMERICA,MEX,0.0,20.0,110.0,Week 36 (1),On Trial
Study 16,Site 677,Subject 4327,Study 16,AMERICA,MEX,0.0,1.0,3.0,Screening,Screen Failure
Study 16,Site 678,Subject 4328,Study 16,AMERICA,ARG,0.0,44.0,209.0,Week 88 (1),On Trial
Study 16,Site 678,Subject 4329,Study 16,AMERICA,ARG,0.0,34.0,165.0,Week 64 (1),On Trial
Study 16,Site 678,Subject 4330,Study 16,AMERICA,ARG,0.0,36.0,187.0,Week 68 (1),On Trial
Study 16,Site 678,Subject 4331,Study 16,AMERICA,ARG,0.0,8.0,65.0,Week 12 (1),On Trial
Study 16,Site 679,Subject 4332,Study 16,AMERICA,ARG,0.0,40.0,95.0,Week 76 (1),On Trial
Study 16,Site 679,Subject 4333,Study 16,AMERICA,ARG,0.0,34.0,101.0,Week 64 (1),On Trial
Study 16,Site 679,Subject 4334,Study 16,AMERICA,ARG,0.0,8.0,46.0,Week 12 (1),On Trial
Study 16,Site 679,Subject 4335,Study 16,AMERICA,ARG,0.0,8.0,34.0,Week 12 (1),On Trial
Study 16,Site 680,Subject 4336,Study 16,AMERICA,ARG,0.0,41.0,168.0,Week 78 (1),On Trial
Study 16,Site 680,Subject 4337,Study 16,AMERICA,ARG,0.0,31.0,151.0,Week 58 (1),On Trial
Study 16,Site 680,Subject 4338,Study 16,AMERICA,ARG,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 680,Subject 4339,Study 16,AMERICA,ARG,0.0,15.0,73.0,Week 26 (1),On Trial
Study 16,Site 680,Subject 4340,Study 16,AMERICA,ARG,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 680,Subject 4341,Study 16,AMERICA,ARG,0.0,9.0,52.0,Week 14 (1),On Trial
Study 16,Site 680,Subject 4342,Study 16,AMERICA,ARG,0.0,10.0,54.0,Week 16 (1),On Trial
Study 16,Site 681,Subject 4343,Study 16,AMERICA,ARG,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 682,Subject 4344,Study 16,AMERICA,ARG,0.0,50.0,235.0,Week 96 (1),On Trial
Study 16,Site 682,Subject 4345,Study 16,AMERICA,ARG,0.0,1.0,9.0,Screening,Screen Failure
Study 16,Site 682,Subject 4346,Study 16,AMERICA,ARG,0.0,1.0,9.0,Screening,Screen Failure
Study 16,Site 682,Subject 4347,Study 16,AMERICA,ARG,0.0,37.0,163.0,Week 70 (1),On Trial
Study 16,Site 682,Subject 4348,Study 16,AMERICA,ARG,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 682,Subject 4349,Study 16,AMERICA,ARG,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 682,Subject 4350,Study 16,AMERICA,ARG,0.0,9.0,41.0,Week 14 (1),On Trial
Study 16,Site 682,Subject 4351,Study 16,AMERICA,ARG,0.0,7.0,31.0,Week 10 (1),On Trial
Study 16,Site 683,Subject 4352,Study 16,AMERICA,ARG,0.0,37.0,163.0,Week 70 (1),On Trial
Study 16,Site 683,Subject 4353,Study 16,AMERICA,ARG,0.0,8.0,41.0,Week 12 (1),On Trial
Study 16,Site 684,Subject 4354,Study 16,AMERICA,BRA,0.0,28.0,143.0,Week 52 (1),On Trial
Study 16,Site 684,Subject 4355,Study 16,AMERICA,BRA,0.0,28.0,144.0,Week 52 (1),On Trial
Study 16,Site 684,Subject 4356,Study 16,AMERICA,BRA,0.0,14.0,84.0,Week 24 (1),On Trial
Study 16,Site 684,Subject 4357,Study 16,AMERICA,BRA,0.0,14.0,85.0,Week 24 (1),On Trial
Study 16,Site 684,Subject 4358,Study 16,AMERICA,BRA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 684,Subject 4359,Study 16,AMERICA,BRA,0.0,14.0,84.0,Week 24 (1),On Trial
Study 16,Site 684,Subject 4360,Study 16,AMERICA,BRA,0.0,14.0,84.0,Week 24 (1),On Trial
Study 16,Site 684,Subject 4361,Study 16,AMERICA,BRA,0.0,1.0,9.0,Unplanned Visit (1),Screen Failure
Study 16,Site 685,Subject 4362,Study 16,AMERICA,BRA,0.0,29.0,143.0,Week 54 (1),On Trial
Study 16,Site 685,Subject 4363,Study 16,AMERICA,BRA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 685,Subject 4364,Study 16,AMERICA,BRA,0.0,25.0,133.0,Week 46 (1),On Trial
Study 16,Site 685,Subject 4365,Study 16,AMERICA,BRA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 685,Subject 4366,Study 16,AMERICA,BRA,0.0,17.0,97.0,Week 30 (1),On Trial
Study 16,Site 685,Subject 4367,Study 16,AMERICA,BRA,0.0,15.0,79.0,Week 26 (1),On Trial
Study 16,Site 685,Subject 4368,Study 16,AMERICA,BRA,0.0,15.0,91.0,Week 28 (1),On Trial
Study 16,Site 685,Subject 4369,Study 16,AMERICA,BRA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 685,Subject 4370,Study 16,AMERICA,BRA,0.0,8.0,44.0,Week 12 (1),On Trial
Study 16,Site 685,Subject 4371,Study 16,AMERICA,BRA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 685,Subject 4372,Study 16,AMERICA,BRA,0.0,1.0,5.0,Screening,Screen Failure
Study 16,Site 686,Subject 4373,Study 16,AMERICA,BRA,0.0,31.0,151.0,Week 58 (1),On Trial
Study 16,Site 686,Subject 4374,Study 16,AMERICA,BRA,0.0,27.0,136.0,Week 50 (1),On Trial
Study 16,Site 686,Subject 4375,Study 16,AMERICA,BRA,0.0,25.0,144.0,Week 46 (1),On Trial
Study 16,Site 686,Subject 4376,Study 16,AMERICA,BRA,0.0,19.0,101.0,Week 34 (1),On Trial
Study 16,Site 686,Subject 4377,Study 16,AMERICA,BRA,0.0,19.0,102.0,Week 34 (1),On Trial
Study 16,Site 686,Subject 4378,Study 16,AMERICA,BRA,0.0,13.0,84.0,Early Discontinuation (1),Follow-Up
Study 16,Site 686,Subject 4379,Study 16,AMERICA,BRA,0.0,12.0,80.0,Unplanned Visit (2),On Trial
Study 16,Site 686,Subject 4380,Study 16,AMERICA,BRA,0.0,8.0,59.0,Week 12 (1),On Trial
Study 16,Site 687,Subject 4381,Study 16,AMERICA,BRA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 687,Subject 4382,Study 16,AMERICA,BRA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 687,Subject 4383,Study 16,AMERICA,BRA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 687,Subject 4384,Study 16,AMERICA,BRA,0.0,17.0,99.0,Week 30 (1),On Trial
Study 16,Site 687,Subject 4385,Study 16,AMERICA,BRA,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 687,Subject 4386,Study 16,AMERICA,BRA,0.0,11.0,67.0,Week 18 (1),On Trial
Study 16,Site 688,Subject 4387,Study 16,AMERICA,BRA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 688,Subject 4388,Study 16,AMERICA,BRA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 688,Subject 4389,Study 16,AMERICA,BRA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 689,Subject 4390,Study 16,AMERICA,BRA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 689,Subject 4391,Study 16,AMERICA,BRA,0.0,31.0,156.0,Week 58 (1),On Trial
Study 16,Site 689,Subject 4392,Study 16,AMERICA,BRA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 689,Subject 4393,Study 16,AMERICA,BRA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 689,Subject 4394,Study 16,AMERICA,BRA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 689,Subject 4395,Study 16,AMERICA,BRA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 689,Subject 4396,Study 16,AMERICA,BRA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 689,Subject 4397,Study 16,AMERICA,BRA,0.0,27.0,136.0,Week 50 (1),On Trial
Study 16,Site 689,Subject 4398,Study 16,AMERICA,BRA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 689,Subject 4399,Study 16,AMERICA,BRA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 689,Subject 4400,Study 16,AMERICA,BRA,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 690,Subject 4401,Study 16,AMERICA,BRA,0.0,1.0,0.0,Screening,Screen Failure
Study 16,Site 690,Subject 4402,Study 16,AMERICA,BRA,0.0,1.0,0.0,Screening,Screen Failure
Study 16,Site 690,Subject 4403,Study 16,AMERICA,BRA,0.0,9.0,0.0,Week 14 (1),On Trial
Study 16,Site 690,Subject 4404,Study 16,AMERICA,BRA,0.0,1.0,0.0,Screening,Screen Failure
Study 16,Site 691,Subject 4405,Study 16,ASIA,MYS,0.0,1.0,6.0,Screening,Screen Failure
Study 16,Site 691,Subject 4406,Study 16,ASIA,MYS,0.0,1.0,6.0,Screening,Screen Failure
Study 16,Site 691,Subject 4407,Study 16,ASIA,MYS,0.0,1.0,6.0,Screening,Screen Failure
Study 16,Site 691,Subject 4408,Study 16,ASIA,MYS,0.0,15.0,48.0,Week 40 (1),Follow-Up
Study 16,Site 691,Subject 4409,Study 16,ASIA,MYS,0.0,24.0,43.0,Week 44 (1),On Trial
Study 16,Site 691,Subject 4410,Study 16,ASIA,MYS,0.0,20.0,40.0,Week 36 (1),On Trial
Study 16,Site 692,Subject 4411,Study 16,ASIA,MYS,0.0,1.0,6.0,Screening,Screen Failure
Study 16,Site 692,Subject 4412,Study 16,ASIA,MYS,0.0,20.0,56.0,Week 36 (1),On Trial
Study 16,Site 693,Subject 4413,Study 16,ASIA,MYS,0.0,32.0,169.0,Week 60 (1),On Trial
Study 16,Site 693,Subject 4414,Study 16,ASIA,MYS,0.0,12.0,83.0,Week 20 (1),On Trial
Study 16,Site 694,Subject 4415,Study 16,ASIA,MYS,0.0,40.0,209.0,Week 76 (1),On Trial
Study 16,Site 694,Subject 4416,Study 16,ASIA,MYS,0.0,40.0,205.0,Week 76 (1),On Trial
Study 16,Site 694,Subject 4417,Study 16,ASIA,MYS,0.0,31.0,183.0,Week 58 (1),On Trial
Study 16,Site 694,Subject 4418,Study 16,ASIA,MYS,0.0,22.0,138.0,Week 40 (1),On Trial
Study 16,Site 695,Subject 4419,Study 16,ASIA,MYS,0.0,38.0,197.0,Week 72 (1),On Trial
Study 16,Site 695,Subject 4420,Study 16,ASIA,MYS,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 695,Subject 4421,Study 16,ASIA,MYS,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 696,Subject 4422,Study 16,ASIA,AUS,0.0,14.0,89.0,Week 24 (1),Discontinued
Study 16,Site 696,Subject 4423,Study 16,ASIA,AUS,0.0,20.0,112.0,Week 36 (1),On Trial
Study 16,Site 696,Subject 4424,Study 16,ASIA,AUS,0.0,8.0,62.0,Week 12 (1),On Trial
Study 16,Site 696,Subject 4425,Study 16,ASIA,AUS,0.0,8.0,66.0,Week 12 (1),On Trial
Study 16,Site 697,Subject 4426,Study 16,ASIA,AUS,0.0,32.0,161.0,Week 60 (1),On Trial
Study 16,Site 697,Subject 4427,Study 16,ASIA,AUS,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 697,Subject 4428,Study 16,ASIA,AUS,0.0,1.0,9.0,Screening,Screen Failure
Study 16,Site 697,Subject 4429,Study 16,ASIA,AUS,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 697,Subject 4430,Study 16,ASIA,AUS,0.0,21.0,115.0,Week 38 (1),On Trial
Study 16,Site 698,Subject 4431,Study 16,ASIA,AUS,0.0,1.0,9.0,Screening,Screen Failure
Study 16,Site 698,Subject 4432,Study 16,ASIA,AUS,0.0,33.0,158.0,Week 64 (1),On Trial
Study 16,Site 698,Subject 4433,Study 16,ASIA,AUS,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 699,Subject 4434,Study 16,ASIA,AUS,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 699,Subject 4435,Study 16,ASIA,AUS,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 699,Subject 4436,Study 16,ASIA,AUS,0.0,40.0,180.0,Week 76 (1),On Trial
Study 16,Site 699,Subject 4437,Study 16,ASIA,AUS,0.0,32.0,149.0,Week 60 (1),On Trial
Study 16,Site 699,Subject 4438,Study 16,ASIA,AUS,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 699,Subject 4439,Study 16,ASIA,AUS,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 699,Subject 4440,Study 16,ASIA,AUS,0.0,8.0,58.0,Week 12 (1),On Trial
Study 16,Site 700,Subject 4441,Study 16,ASIA,AUS,0.0,1.0,9.0,Screening,Screen Failure
Study 16,Site 700,Subject 4442,Study 16,ASIA,AUS,0.0,17.0,136.0,Unplanned Visit (11),Discontinued
Study 16,Site 700,Subject 4443,Study 16,ASIA,AUS,0.0,27.0,148.0,Week 54 (1),On Trial
Study 16,Site 701,Subject 4444,Study 16,ASIA,AUS,0.0,37.0,202.0,Week 70 (1),On Trial
Study 16,Site 701,Subject 4445,Study 16,ASIA,AUS,0.0,18.0,151.0,Unplanned Visit (2),Follow-Up
Study 16,Site 701,Subject 4446,Study 16,ASIA,AUS,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 701,Subject 4447,Study 16,ASIA,AUS,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 701,Subject 4448,Study 16,ASIA,AUS,0.0,14.0,89.0,Week 24 (1),On Trial
Study 16,Site 701,Subject 4449,Study 16,ASIA,AUS,0.0,1.0,13.0,Screening,Screen Failure
Study 16,Site 701,Subject 4450,Study 16,ASIA,AUS,0.0,17.0,89.0,Week 30 (1),On Trial
Study 16,Site 702,Subject 4451,Study 16,ASIA,AUS,0.0,8.0,62.0,Week 12 (1),On Trial
Study 16,Site 702,Subject 4452,Study 16,ASIA,AUS,0.0,8.0,59.0,Week 12 (1),On Trial
Study 16,Site 702,Subject 4453,Study 16,ASIA,AUS,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 702,Subject 4454,Study 16,ASIA,AUS,0.0,7.0,64.0,Week 12 (1),On Trial
Study 16,Site 702,Subject 4455,Study 16,ASIA,AUS,0.0,8.0,57.0,Unplanned Visit (1),On Trial
Study 16,Site 702,Subject 4456,Study 16,ASIA,AUS,0.0,8.0,63.0,Week 12 (1),On Trial
Study 16,Site 702,Subject 4457,Study 16,ASIA,AUS,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 702,Subject 4458,Study 16,ASIA,AUS,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 703,Subject 4459,Study 16,ASIA,JPN,0.0,26.0,123.0,Week 48 (1),On Trial
Study 16,Site 703,Subject 4460,Study 16,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 703,Subject 4461,Study 16,ASIA,JPN,0.0,14.0,82.0,Week 24 (1),On Trial
Study 16,Site 703,Subject 4462,Study 16,ASIA,JPN,0.0,14.0,69.0,Week 24 (1),On Trial
Study 16,Site 703,Subject 4463,Study 16,ASIA,JPN,0.0,10.0,67.0,Week 16 (1),On Trial
Study 16,Site 704,Subject 4464,Study 16,ASIA,JPN,0.0,21.0,89.0,Week 38 (1),On Trial
Study 16,Site 705,Subject 4465,Study 16,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 705,Subject 4466,Study 16,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 705,Subject 4467,Study 16,ASIA,JPN,0.0,15.0,93.0,Week 26 (1),On Trial
Study 16,Site 706,Subject 4468,Study 16,ASIA,JPN,0.0,20.0,132.0,Week 36 (1),On Trial
Study 16,Site 706,Subject 4469,Study 16,ASIA,JPN,0.0,13.0,90.0,Week 22 (1),On Trial
Study 16,Site 706,Subject 4470,Study 16,ASIA,JPN,0.0,10.0,85.0,Week 16 (1),On Trial
Study 16,Site 707,Subject 4471,Study 16,ASIA,JPN,0.0,28.0,144.0,Week 52 (1),On Trial
Study 16,Site 707,Subject 4472,Study 16,ASIA,JPN,0.0,9.0,57.0,Week 14 (1),On Trial
Study 16,Site 708,Subject 4473,Study 16,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 708,Subject 4474,Study 16,ASIA,JPN,0.0,17.0,86.0,Week 30 (1),On Trial
Study 16,Site 708,Subject 4475,Study 16,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 708,Subject 4476,Study 16,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 708,Subject 4477,Study 16,ASIA,JPN,0.0,9.0,66.0,Week 14 (1),On Trial
Study 16,Site 708,Subject 4478,Study 16,ASIA,JPN,0.0,8.0,58.0,Week 12 (1),On Trial
Study 16,Site 709,Subject 4479,Study 16,ASIA,JPN,0.0,31.0,163.0,Week 58 (1),On Trial
Study 16,Site 709,Subject 4480,Study 16,ASIA,JPN,0.0,18.0,105.0,Week 32 (1),On Trial
Study 16,Site 710,Subject 4481,Study 16,ASIA,JPN,0.0,1.0,6.0,Screening,Screen Failure
Study 16,Site 710,Subject 4482,Study 16,ASIA,JPN,0.0,1.0,6.0,Screening,Screen Failure
Study 16,Site 711,Subject 4483,Study 16,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 711,Subject 4484,Study 16,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 711,Subject 4485,Study 16,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 711,Subject 4486,Study 16,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 711,Subject 4487,Study 16,ASIA,JPN,0.0,27.0,129.0,Week 50 (1),On Trial
Study 16,Site 711,Subject 4488,Study 16,ASIA,JPN,0.0,25.0,134.0,Week 46 (1),On Trial
Study 16,Site 711,Subject 4489,Study 16,ASIA,JPN,0.0,21.0,96.0,Week 38 (1),On Trial
Study 16,Site 711,Subject 4490,Study 16,ASIA,JPN,0.0,20.0,96.0,Week 36 (1),On Trial
Study 16,Site 711,Subject 4491,Study 16,ASIA,JPN,0.0,8.0,69.0,Week 24 (1),Follow-Up
Study 16,Site 711,Subject 4492,Study 16,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 711,Subject 4493,Study 16,ASIA,JPN,0.0,1.0,9.0,Screening,Screen Failure
Study 16,Site 711,Subject 4494,Study 16,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 711,Subject 4495,Study 16,ASIA,JPN,0.0,1.0,9.0,Screening,Screen Failure
Study 16,Site 711,Subject 4496,Study 16,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 712,Subject 4497,Study 16,ASIA,JPN,0.0,21.0,101.0,Week 38 (1),On Trial
Study 16,Site 712,Subject 4498,Study 16,ASIA,JPN,0.0,12.0,78.0,Week 20 (1),On Trial
Study 16,Site 712,Subject 4499,Study 16,ASIA,JPN,0.0,12.0,65.0,Week 20 (1),On Trial
Study 16,Site 712,Subject 4500,Study 16,ASIA,JPN,0.0,10.0,66.0,Week 16 (1),On Trial
Study 16,Site 713,Subject 4501,Study 16,ASIA,JPN,0.0,16.0,70.0,Week 28 (1),On Trial
Study 16,Site 713,Subject 4502,Study 16,ASIA,JPN,0.0,11.0,56.0,Week 18 (1),On Trial
Study 16,Site 714,Subject 4503,Study 16,ASIA,JPN,0.0,1.0,6.0,Screening,Screen Failure
Study 16,Site 714,Subject 4504,Study 16,ASIA,JPN,0.0,1.0,6.0,Screening,Screen Failure
Study 16,Site 714,Subject 4505,Study 16,ASIA,JPN,0.0,16.0,94.0,Week 28 (1),On Trial
Study 16,Site 715,Subject 4506,Study 16,ASIA,JPN,0.0,26.0,110.0,Week 48 (1),On Trial
Study 16,Site 715,Subject 4507,Study 16,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 715,Subject 4508,Study 16,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 716,Subject 4509,Study 16,ASIA,JPN,0.0,17.0,82.0,Week 30 (1),On Trial
Study 16,Site 717,Subject 4510,Study 16,ASIA,JPN,0.0,20.0,103.0,Week 36 (1),On Trial
Study 16,Site 717,Subject 4511,Study 16,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 717,Subject 4512,Study 16,ASIA,JPN,0.0,8.0,77.0,Week 12 (1),On Trial
Study 16,Site 718,Subject 4513,Study 16,ASIA,JPN,0.0,1.0,6.0,Screening,Screen Failure
Study 16,Site 719,Subject 4514,Study 16,ASIA,KOR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 719,Subject 4515,Study 16,ASIA,KOR,0.0,16.0,106.0,Week 28 (1),On Trial
Study 16,Site 720,Subject 4516,Study 16,ASIA,KOR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 720,Subject 4517,Study 16,ASIA,KOR,0.0,22.0,130.0,Week 40 (1),On Trial
Study 16,Site 720,Subject 4518,Study 16,ASIA,KOR,0.0,22.0,142.0,Week 40 (1),On Trial
Study 16,Site 721,Subject 4519,Study 16,ASIA,KOR,0.0,1.0,6.0,Screening,Screen Failure
Study 16,Site 721,Subject 4520,Study 16,ASIA,KOR,0.0,22.0,122.0,Week 40 (1),On Trial
Study 16,Site 721,Subject 4521,Study 16,ASIA,KOR,0.0,14.0,75.0,Week 24 (1),On Trial
Study 16,Site 722,Subject 4522,Study 16,ASIA,KOR,0.0,14.0,84.0,Week 24 (1),On Trial
Study 16,Site 722,Subject 4523,Study 16,ASIA,KOR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 722,Subject 4524,Study 16,ASIA,KOR,0.0,8.0,83.0,Week 12 (1),On Trial
Study 16,Site 723,Subject 4525,Study 16,ASIA,KOR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 723,Subject 4526,Study 16,ASIA,KOR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 723,Subject 4527,Study 16,ASIA,KOR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 723,Subject 4528,Study 16,ASIA,KOR,0.0,28.0,148.0,Week 52 (1),On Trial
Study 16,Site 723,Subject 4529,Study 16,ASIA,KOR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 723,Subject 4530,Study 16,ASIA,KOR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 723,Subject 4531,Study 16,ASIA,KOR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 723,Subject 4532,Study 16,ASIA,KOR,0.0,23.0,127.0,Week 42 (1),On Trial
Study 16,Site 723,Subject 4533,Study 16,ASIA,KOR,0.0,23.0,142.0,Week 42 (1),On Trial
Study 16,Site 723,Subject 4534,Study 16,ASIA,KOR,0.0,22.0,132.0,Week 40 (1),On Trial
Study 16,Site 724,Subject 4535,Study 16,ASIA,KOR,0.0,27.0,137.0,Week 50 (1),On Trial
Study 16,Site 724,Subject 4536,Study 16,ASIA,KOR,0.0,27.0,154.0,Week 50 (1),On Trial
Study 16,Site 724,Subject 4537,Study 16,ASIA,KOR,0.0,12.0,78.0,Week 20 (1),On Trial
Study 16,Site 725,Subject 4538,Study 16,ASIA,KOR,0.0,46.0,233.0,Week 88 (1),On Trial
Study 16,Site 725,Subject 4539,Study 16,ASIA,KOR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 725,Subject 4540,Study 16,ASIA,KOR,0.0,22.0,135.0,Week 40 (1),On Trial
Study 16,Site 725,Subject 4541,Study 16,ASIA,KOR,0.0,22.0,148.0,Week 40 (1),On Trial
Study 16,Site 725,Subject 4542,Study 16,ASIA,KOR,0.0,22.0,125.0,Week 40 (1),On Trial
Study 16,Site 725,Subject 4543,Study 16,ASIA,KOR,0.0,22.0,140.0,Week 40 (1),On Trial
Study 16,Site 725,Subject 4544,Study 16,ASIA,KOR,0.0,14.0,103.0,Week 24 (1),On Trial
Study 16,Site 725,Subject 4545,Study 16,ASIA,KOR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 725,Subject 4546,Study 16,ASIA,KOR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 725,Subject 4547,Study 16,ASIA,KOR,0.0,8.0,79.0,Week 12 (1),On Trial
Study 16,Site 725,Subject 4548,Study 16,ASIA,KOR,0.0,8.0,79.0,Week 12 (1),On Trial
Study 16,Site 726,Subject 4549,Study 16,ASIA,KOR,0.0,31.0,180.0,Week 58 (1),On Trial
Study 16,Site 726,Subject 4550,Study 16,ASIA,KOR,0.0,31.0,177.0,Week 58 (1),On Trial
Study 16,Site 726,Subject 4551,Study 16,ASIA,KOR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 726,Subject 4552,Study 16,ASIA,KOR,0.0,27.0,151.0,Week 50 (1),On Trial
Study 16,Site 726,Subject 4553,Study 16,ASIA,KOR,0.0,27.0,144.0,Week 50 (1),On Trial
Study 16,Site 727,Subject 4554,Study 16,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 727,Subject 4555,Study 16,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 727,Subject 4556,Study 16,ASIA,TWN,0.0,25.0,121.0,Week 52 (1),On Trial
Study 16,Site 727,Subject 4557,Study 16,ASIA,TWN,0.0,0.0,7.0,,Screen Failure
Study 16,Site 727,Subject 4558,Study 16,ASIA,TWN,0.0,8.0,51.0,Week 12 (1),On Trial
Study 16,Site 728,Subject 4559,Study 16,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 728,Subject 4560,Study 16,ASIA,TWN,0.0,9.0,44.0,Week 14 (1),On Trial
Study 16,Site 729,Subject 4561,Study 16,ASIA,TWN,0.0,34.0,155.0,Week 64 (1),On Trial
Study 16,Site 729,Subject 4562,Study 16,ASIA,TWN,0.0,1.0,11.0,Screening,Screen Failure
Study 16,Site 729,Subject 4563,Study 16,ASIA,TWN,0.0,19.0,86.0,Week 34 (1),On Trial
Study 16,Site 729,Subject 4564,Study 16,ASIA,TWN,0.0,14.0,76.0,Week 24 (1),On Trial
Study 16,Site 729,Subject 4565,Study 16,ASIA,TWN,0.0,9.0,41.0,Week 14 (1),On Trial
Study 16,Site 730,Subject 4566,Study 16,ASIA,TWN,0.0,28.0,144.0,Week 52 (1),On Trial
Study 16,Site 730,Subject 4567,Study 16,ASIA,TWN,0.0,17.0,95.0,Week 30 (1),On Trial
Study 16,Site 731,Subject 4568,Study 16,ASIA,TWN,0.0,1.0,9.0,Screening,Screen Failure
Study 16,Site 731,Subject 4569,Study 16,ASIA,TWN,0.0,1.0,9.0,Screening,Screen Failure
Study 16,Site 731,Subject 4570,Study 16,ASIA,TWN,0.0,32.0,167.0,Week 60 (1),On Trial
Study 16,Site 731,Subject 4571,Study 16,ASIA,TWN,0.0,14.0,66.0,Week 24 (1),On Trial
Study 16,Site 732,Subject 4572,Study 16,ASIA,TWN,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 732,Subject 4573,Study 16,ASIA,TWN,0.0,1.0,9.0,Screening,Screen Failure
Study 16,Site 732,Subject 4574,Study 16,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 732,Subject 4575,Study 16,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 732,Subject 4576,Study 16,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 733,Subject 4577,Study 16,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 733,Subject 4578,Study 16,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 733,Subject 4579,Study 16,ASIA,TWN,0.0,29.0,129.0,Week 54 (1),On Trial
Study 16,Site 733,Subject 4580,Study 16,ASIA,TWN,0.0,28.0,127.0,Week 52 (1),On Trial
Study 16,Site 733,Subject 4581,Study 16,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 734,Subject 4582,Study 16,ASIA,CHN,0.0,19.0,119.0,Week 34 (1),On Trial
Study 16,Site 734,Subject 4583,Study 16,ASIA,CHN,0.0,18.0,115.0,Week 32 (1),On Trial
Study 16,Site 734,Subject 4584,Study 16,ASIA,CHN,0.0,0.0,7.0,Screening,Screen Failure
Study 16,Site 735,Subject 4585,Study 16,ASIA,CHN,0.0,8.0,67.0,Week 12 (1),On Trial
Study 16,Site 735,Subject 4586,Study 16,ASIA,CHN,0.0,1.0,9.0,Screening,Screen Failure
Study 16,Site 735,Subject 4587,Study 16,ASIA,CHN,0.0,9.0,62.0,Week 14 (1),On Trial
Study 16,Site 735,Subject 4588,Study 16,ASIA,CHN,0.0,6.0,50.0,Week 10 (1),On Trial
Study 16,Site 735,Subject 4589,Study 16,ASIA,CHN,0.0,8.0,59.0,Week 12 (1),On Trial
Study 16,Site 735,Subject 4590,Study 16,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 736,Subject 4591,Study 16,ASIA,CHN,0.0,25.0,149.0,Week 46 (1),On Trial
Study 16,Site 736,Subject 4592,Study 16,ASIA,CHN,0.0,24.0,143.0,Week 44 (1),On Trial
Study 16,Site 736,Subject 4593,Study 16,ASIA,CHN,0.0,1.0,9.0,Screening,Screen Failure
Study 16,Site 736,Subject 4594,Study 16,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 736,Subject 4595,Study 16,ASIA,CHN,0.0,14.0,78.0,Week 24 (1),On Trial
Study 16,Site 736,Subject 4596,Study 16,ASIA,CHN,0.0,13.0,81.0,Week 22 (1),On Trial
Study 16,Site 736,Subject 4597,Study 16,ASIA,CHN,0.0,8.0,68.0,Week 12 (1),On Trial
Study 16,Site 737,Subject 4598,Study 16,ASIA,CHN,0.0,20.0,114.0,Week 36 (1),On Trial
Study 16,Site 737,Subject 4599,Study 16,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 737,Subject 4600,Study 16,ASIA,CHN,0.0,17.0,90.0,Week 30 (1),On Trial
Study 16,Site 737,Subject 4601,Study 16,ASIA,CHN,0.0,16.0,88.0,Week 28 (1),On Trial
Study 16,Site 737,Subject 4602,Study 16,ASIA,CHN,0.0,15.0,92.0,Week 28 (1),On Trial
Study 16,Site 737,Subject 4603,Study 16,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 737,Subject 4604,Study 16,ASIA,CHN,0.0,8.0,57.0,Week 12 (1),On Trial
Study 16,Site 738,Subject 4605,Study 16,ASIA,CHN,0.0,1.0,6.0,Screening,Screen Failure
Study 16,Site 739,Subject 4606,Study 16,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 739,Subject 4607,Study 16,ASIA,CHN,0.0,12.0,68.0,Week 20 (1),On Trial
Study 16,Site 740,Subject 4608,Study 16,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 740,Subject 4609,Study 16,ASIA,CHN,0.0,14.0,76.0,Week 24 (1),On Trial
Study 16,Site 740,Subject 4610,Study 16,ASIA,CHN,0.0,14.0,87.0,Week 24 (1),On Trial
Study 16,Site 740,Subject 4611,Study 16,ASIA,CHN,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 740,Subject 4612,Study 16,ASIA,CHN,0.0,12.0,73.0,Week 20 (1),On Trial
Study 16,Site 740,Subject 4613,Study 16,ASIA,CHN,0.0,7.0,51.0,Week 10 (1),On Trial
Study 16,Site 740,Subject 4614,Study 16,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 741,Subject 4615,Study 16,ASIA,CHN,0.0,15.0,90.0,Week 26 (1),On Trial
Study 16,Site 741,Subject 4616,Study 16,ASIA,CHN,0.0,9.0,63.0,Week 14 (1),On Trial
Study 16,Site 742,Subject 4617,Study 16,ASIA,CHN,0.0,22.0,132.0,Week 42 (1),On Trial
Study 16,Site 742,Subject 4618,Study 16,ASIA,CHN,0.0,1.0,13.0,Screening,Screen Failure
Study 16,Site 742,Subject 4619,Study 16,ASIA,CHN,0.0,14.0,85.0,Week 24 (1),On Trial
Study 16,Site 742,Subject 4620,Study 16,ASIA,CHN,0.0,14.0,84.0,Week 24 (1),On Trial
Study 16,Site 742,Subject 4621,Study 16,ASIA,CHN,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 742,Subject 4622,Study 16,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 742,Subject 4623,Study 16,ASIA,CHN,0.0,8.0,59.0,Week 12 (1),On Trial
Study 16,Site 742,Subject 4624,Study 16,ASIA,CHN,0.0,8.0,62.0,Week 12 (1),On Trial
Study 16,Site 743,Subject 4625,Study 16,ASIA,CHN,0.0,17.0,96.0,Week 34 (1),On Trial
Study 16,Site 743,Subject 4626,Study 16,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 743,Subject 4627,Study 16,ASIA,CHN,0.0,17.0,98.0,Week 30 (1),On Trial
Study 16,Site 743,Subject 4628,Study 16,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 743,Subject 4629,Study 16,ASIA,CHN,0.0,16.0,97.0,Week 28 (1),On Trial
Study 16,Site 744,Subject 4630,Study 16,ASIA,CHN,0.0,13.0,70.0,Week 22 (1),On Trial
Study 16,Site 745,Subject 4631,Study 16,ASIA,CHN,0.0,14.0,93.0,Unplanned Visit (2),Discontinued
Study 16,Site 745,Subject 4632,Study 16,ASIA,CHN,0.0,25.0,125.0,Week 46 (1),On Trial
Study 16,Site 745,Subject 4633,Study 16,ASIA,CHN,0.0,23.0,115.0,Week 42 (1),On Trial
Study 16,Site 745,Subject 4634,Study 16,ASIA,CHN,0.0,10.0,79.0,EOS (1),Discontinued
Study 16,Site 745,Subject 4635,Study 16,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 745,Subject 4636,Study 16,ASIA,CHN,0.0,13.0,72.0,Week 22 (1),On Trial
Study 16,Site 745,Subject 4637,Study 16,ASIA,CHN,0.0,14.0,87.0,Week 24 (1),On Trial
Study 16,Site 746,Subject 4638,Study 16,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 746,Subject 4639,Study 16,ASIA,CHN,0.0,19.0,108.0,Week 34 (1),On Trial
Study 16,Site 746,Subject 4640,Study 16,ASIA,CHN,0.0,16.0,92.0,Week 30 (1),On Trial
Study 16,Site 747,Subject 4641,Study 16,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 747,Subject 4642,Study 16,ASIA,CHN,0.0,18.0,98.0,Week 32 (1),On Trial
Study 16,Site 747,Subject 4643,Study 16,ASIA,CHN,0.0,13.0,77.0,Week 22 (1),On Trial
Study 16,Site 747,Subject 4644,Study 16,ASIA,CHN,0.0,13.0,70.0,Week 22 (1),On Trial
Study 16,Site 748,Subject 4645,Study 16,ASIA,CHN,0.0,20.0,118.0,Week 38 (1),On Trial
Study 16,Site 748,Subject 4646,Study 16,ASIA,CHN,0.0,1.0,6.0,Screening,Screen Failure
Study 16,Site 748,Subject 4647,Study 16,ASIA,CHN,0.0,1.0,6.0,Screening,Screen Failure
Study 16,Site 748,Subject 4648,Study 16,ASIA,CHN,0.0,16.0,87.0,Week 28 (1),On Trial
Study 16,Site 748,Subject 4649,Study 16,ASIA,CHN,0.0,10.0,65.0,Week 16 (1),On Trial
Study 16,Site 749,Subject 4650,Study 16,ASIA,CHN,0.0,17.0,86.0,Week 30 (1),On Trial
Study 16,Site 750,Subject 4651,Study 16,ASIA,CHN,0.0,15.0,92.0,Week 26 (1),On Trial
Study 16,Site 750,Subject 4652,Study 16,ASIA,CHN,0.0,15.0,79.0,Week 26 (1),On Trial
Study 16,Site 750,Subject 4653,Study 16,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 750,Subject 4654,Study 16,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 751,Subject 4655,Study 16,ASIA,CHN,0.0,24.0,130.0,Week 44 (1),On Trial
Study 16,Site 751,Subject 4656,Study 16,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 752,Subject 4657,Study 16,ASIA,CHN,0.0,12.0,62.0,Week 20 (1),On Trial
Study 16,Site 752,Subject 4658,Study 16,ASIA,CHN,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 753,Subject 4659,Study 16,ASIA,CHN,0.0,11.0,73.0,Week 22 (1),On Trial
Study 16,Site 753,Subject 4660,Study 16,ASIA,CHN,0.0,12.0,77.0,Week 20 (1),On Trial
Study 16,Site 753,Subject 4661,Study 16,ASIA,CHN,0.0,12.0,67.0,Week 20 (1),On Trial
Study 16,Site 753,Subject 4662,Study 16,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 754,Subject 4663,Study 16,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 754,Subject 4664,Study 16,ASIA,CHN,0.0,12.0,71.0,Week 20 (1),On Trial
Study 16,Site 754,Subject 4665,Study 16,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 754,Subject 4666,Study 16,ASIA,CHN,0.0,10.0,62.0,Week 16 (1),On Trial
Study 16,Site 755,Subject 4667,Study 16,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 755,Subject 4668,Study 16,ASIA,CHN,0.0,10.0,73.0,Week 16 (1),On Trial
Study 16,Site 756,Subject 4669,Study 16,ASIA,CHN,0.0,9.0,68.0,Week 14 (1),On Trial
Study 16,Site 756,Subject 4670,Study 16,ASIA,CHN,0.0,8.0,56.0,Week 12 (1),On Trial
Study 16,Site 756,Subject 4671,Study 16,ASIA,CHN,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 757,Subject 4672,Study 16,EMEA,TUR,0.0,30.0,142.0,Week 56 (1),On Trial
Study 16,Site 757,Subject 4673,Study 16,EMEA,TUR,0.0,29.0,137.0,Week 54 (1),On Trial
Study 16,Site 757,Subject 4674,Study 16,EMEA,TUR,0.0,28.0,142.0,Week 52 (1),On Trial
Study 16,Site 757,Subject 4675,Study 16,EMEA,TUR,0.0,10.0,79.0,Week 18 (1),On Trial
Study 16,Site 757,Subject 4676,Study 16,EMEA,TUR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 757,Subject 4677,Study 16,EMEA,TUR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 757,Subject 4678,Study 16,EMEA,TUR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 757,Subject 4679,Study 16,EMEA,TUR,0.0,12.0,71.0,Week 20 (1),On Trial
Study 16,Site 757,Subject 4680,Study 16,EMEA,TUR,0.0,11.0,73.0,Week 18 (1),On Trial
Study 16,Site 757,Subject 4681,Study 16,EMEA,TUR,0.0,11.0,66.0,Week 20 (1),On Trial
Study 16,Site 757,Subject 4682,Study 16,EMEA,TUR,0.0,12.0,68.0,Week 20 (1),On Trial
Study 16,Site 758,Subject 4683,Study 16,EMEA,TUR,0.0,27.0,72.0,Week 50 (1),On Trial
Study 16,Site 758,Subject 4684,Study 16,EMEA,TUR,0.0,0.0,5.0,,Screen Failure
Study 16,Site 759,Subject 4685,Study 16,EMEA,TUR,0.0,10.0,80.0,Week 18 (1),On Trial
Study 16,Site 760,Subject 4686,Study 16,EMEA,TUR,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 760,Subject 4687,Study 16,EMEA,TUR,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 760,Subject 4688,Study 16,EMEA,TUR,0.0,11.0,61.0,Week 18 (1),On Trial
Study 16,Site 760,Subject 4689,Study 16,EMEA,TUR,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 760,Subject 4690,Study 16,EMEA,TUR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 761,Subject 4691,Study 16,ASIA,IND,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 762,Subject 4692,Study 16,ASIA,IND,0.0,14.0,80.0,Week 24 (1),On Trial
Study 16,Site 762,Subject 4693,Study 16,ASIA,IND,0.0,9.0,65.0,Week 14 (1),On Trial
Study 16,Site 762,Subject 4694,Study 16,ASIA,IND,0.0,1.0,17.0,Screening,Screen Failure
Study 16,Site 763,Subject 4695,Study 16,ASIA,IND,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 763,Subject 4696,Study 16,ASIA,IND,0.0,8.0,74.0,Week 18 (1),On Trial
Study 16,Site 764,Subject 4697,Study 16,ASIA,IND,0.0,1.0,0.0,Screening,Screen Failure
Study 16,Site 764,Subject 4698,Study 16,ASIA,IND,0.0,20.0,0.0,Week 36 (1),On Trial
Study 16,Site 764,Subject 4699,Study 16,ASIA,IND,0.0,1.0,0.0,Screening,Screen Failure
Study 16,Site 764,Subject 4700,Study 16,ASIA,IND,0.0,1.0,0.0,Screening,Screen Failure
Study 16,Site 765,Subject 4701,Study 16,ASIA,IND,0.0,21.0,93.0,Week 38 (1),On Trial
Study 16,Site 765,Subject 4702,Study 16,ASIA,IND,0.0,1.0,6.0,Screening,Screen Failure
Study 16,Site 765,Subject 4703,Study 16,ASIA,IND,0.0,20.0,93.0,Week 36 (1),On Trial
Study 16,Site 765,Subject 4704,Study 16,ASIA,IND,0.0,12.0,70.0,Week 20 (1),On Trial
Study 16,Site 765,Subject 4705,Study 16,ASIA,IND,0.0,13.0,71.0,Week 22 (1),On Trial
Study 16,Site 765,Subject 4706,Study 16,ASIA,IND,0.0,11.0,69.0,Week 18 (1),On Trial
Study 16,Site 765,Subject 4707,Study 16,ASIA,IND,0.0,9.0,47.0,Week 14 (1),On Trial
Study 16,Site 765,Subject 4708,Study 16,ASIA,IND,0.0,10.0,54.0,Week 16 (1),On Trial
Study 16,Site 765,Subject 4709,Study 16,ASIA,IND,0.0,10.0,54.0,Week 16 (1),On Trial
Study 16,Site 766,Subject 4710,Study 16,ASIA,IND,0.0,19.0,51.0,Week 34 (1),On Trial
Study 16,Site 766,Subject 4711,Study 16,ASIA,IND,0.0,18.0,54.0,Week 32 (1),On Trial
Study 16,Site 766,Subject 4712,Study 16,ASIA,IND,0.0,16.0,43.0,Week 28 (1),On Trial
Study 16,Site 766,Subject 4713,Study 16,ASIA,IND,0.0,13.0,45.0,Week 22 (1),On Trial
Study 16,Site 767,Subject 4714,Study 16,ASIA,IND,0.0,0.0,0.0,Screening,Screen Failure
Study 16,Site 767,Subject 4715,Study 16,ASIA,IND,0.0,0.0,0.0,Screening,Screen Failure
Study 16,Site 768,Subject 4716,Study 16,ASIA,IND,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 768,Subject 4717,Study 16,ASIA,IND,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 768,Subject 4718,Study 16,ASIA,IND,0.0,13.0,73.0,Week 22 (1),On Trial
Study 16,Site 768,Subject 4719,Study 16,ASIA,IND,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 768,Subject 4720,Study 16,ASIA,IND,0.0,10.0,60.0,Week 16 (1),On Trial
Study 16,Site 768,Subject 4721,Study 16,ASIA,IND,0.0,8.0,47.0,Week 12 (1),On Trial
Study 16,Site 768,Subject 4722,Study 16,ASIA,IND,0.0,8.0,55.0,Week 12 (1),On Trial
Study 16,Site 769,Subject 4723,Study 16,ASIA,IND,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 769,Subject 4724,Study 16,ASIA,IND,0.0,22.0,97.0,Week 40 (1),On Trial
Study 16,Site 769,Subject 4725,Study 16,ASIA,IND,0.0,1.0,2.0,Screening,Screen Failure
Study 16,Site 769,Subject 4726,Study 16,ASIA,IND,0.0,1.0,0.0,Screening,Screen Failure
Study 16,Site 770,Subject 4727,Study 16,EMEA,ISR,0.0,20.0,80.0,Week 36 (1),On Trial
Study 16,Site 770,Subject 4728,Study 16,EMEA,ISR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 771,Subject 4729,Study 16,EMEA,ISR,0.0,1.0,7.0,Screening,Screen Failure
Study 16,Site 771,Subject 4730,Study 16,EMEA,ISR,0.0,23.0,111.0,Week 42 (1),On Trial
Study 16,Site 771,Subject 4731,Study 16,EMEA,ISR,0.0,20.0,110.0,Week 36 (1),On Trial
Study 16,Site 771,Subject 4732,Study 16,EMEA,ISR,0.0,14.0,83.0,Week 24 (1),On Trial
Study 16,Site 771,Subject 4733,Study 16,EMEA,ISR,0.0,14.0,80.0,Week 24 (1),On Trial
Study 16,Site 772,Subject 4734,Study 16,EMEA,ISR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 772,Subject 4735,Study 16,EMEA,ISR,0.0,8.0,75.0,Week 12 (1),On Trial
Study 16,Site 773,Subject 4736,Study 16,EMEA,ISR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 773,Subject 4737,Study 16,EMEA,ISR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 773,Subject 4738,Study 16,EMEA,ISR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 773,Subject 4739,Study 16,EMEA,ISR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 773,Subject 4740,Study 16,EMEA,ISR,0.0,13.0,66.0,Week 24 (1),On Trial
Study 16,Site 774,Subject 4741,Study 16,EMEA,ISR,0.0,1.0,8.0,Screening,Screen Failure
Study 16,Site 774,Subject 4742,Study 16,EMEA,ISR,0.0,28.0,136.0,Week 52 (1),On Trial
Study 16,Site 774,Subject 4743,Study 16,EMEA,ISR,0.0,1.0,12.0,Screening,Screen Failure
Study 18,Site 2,Subject 100,Study 18,AMERICA,USA,0.0,2.0,10.0,Unplanned visit (1),Screen Failure
Study 18,Site 2,Subject 101,Study 18,AMERICA,USA,0.0,13.0,95.0,Unplanned visit (2),On Trial
Study 18,Site 2,Subject 2,Study 18,AMERICA,USA,0.0,2.0,11.0,Baseline,Screen Failure
Study 18,Site 2,Subject 3,Study 18,AMERICA,USA,0.0,13.0,95.0,Day 56,On Trial
Study 18,Site 2,Subject 3399,Study 18,AMERICA,USA,0.0,13.0,98.0,Unplanned visit (3),On Trial
Study 18,Site 2,Subject 3400,Study 18,AMERICA,USA,0.0,1.0,10.0,Unplanned visit (1),Screen Failure
Study 18,Site 2,Subject 3401,Study 18,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 18,Site 2,Subject 3402,Study 18,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 18,Site 2,Subject 3403,Study 18,AMERICA,USA,0.0,1.0,10.0,Unplanned visit (1),Screen Failure
Study 18,Site 2,Subject 3404,Study 18,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 18,Site 2,Subject 3405,Study 18,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 18,Site 2,Subject 3406,Study 18,AMERICA,USA,0.0,13.0,94.0,Day 56,On Trial
Study 18,Site 2,Subject 3407,Study 18,AMERICA,USA,0.0,2.0,11.0,Baseline,Screen Failure
Study 18,Site 2,Subject 3408,Study 18,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 18,Site 2,Subject 3409,Study 18,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 18,Site 2,Subject 3410,Study 18,AMERICA,USA,0.0,1.0,10.0,Unplanned visit (1),Screen Failure
Study 18,Site 2,Subject 3411,Study 18,AMERICA,USA,0.0,13.0,99.0,Day 56,On Trial
Study 18,Site 2,Subject 3412,Study 18,AMERICA,USA,0.0,13.0,100.0,Unplanned visit (3),On Trial
Study 18,Site 2,Subject 4,Study 18,AMERICA,USA,0.0,13.0,97.0,Day 56,On Trial
Study 18,Site 2,Subject 4021,Study 18,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 18,Site 2,Subject 4022,Study 18,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 18,Site 2,Subject 4023,Study 18,AMERICA,USA,0.0,1.0,10.0,Unplanned visit (1),Screen Failure
Study 18,Site 2,Subject 4024,Study 18,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 18,Site 2,Subject 4025,Study 18,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 18,Site 2,Subject 4760,Study 18,AMERICA,USA,0.0,13.0,95.0,Day 56,On Trial
Study 18,Site 2,Subject 4761,Study 18,AMERICA,USA,0.0,13.0,92.0,Day 56,On Trial
Study 18,Site 2,Subject 4762,Study 18,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 18,Site 2,Subject 4763,Study 18,AMERICA,USA,0.0,1.0,10.0,Unplanned visit (1),Screen Failure
Study 18,Site 2,Subject 4764,Study 18,AMERICA,USA,0.0,13.0,102.0,Day 56,On Trial
Study 18,Site 2,Subject 4765,Study 18,AMERICA,USA,0.0,2.0,12.0,Baseline,Discontinued
Study 18,Site 2,Subject 4766,Study 18,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 18,Site 2,Subject 4767,Study 18,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 18,Site 2,Subject 4768,Study 18,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 18,Site 2,Subject 4769,Study 18,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 18,Site 2,Subject 4770,Study 18,AMERICA,USA,0.0,1.0,10.0,Unplanned visit (1),Screen Failure
Study 18,Site 2,Subject 4771,Study 18,AMERICA,USA,0.0,2.0,12.0,Baseline,Discontinued
Study 18,Site 2,Subject 4772,Study 18,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 18,Site 2,Subject 4773,Study 18,AMERICA,USA,0.0,2.0,11.0,Baseline,Screen Failure
Study 18,Site 2,Subject 4774,Study 18,AMERICA,USA,0.0,1.0,10.0,Unplanned visit (1),Screen Failure
Study 18,Site 2,Subject 4775,Study 18,AMERICA,USA,0.0,1.0,10.0,Unplanned visit (1),Screen Failure
Study 18,Site 2,Subject 4776,Study 18,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 18,Site 2,Subject 4777,Study 18,AMERICA,USA,0.0,1.0,10.0,Unplanned visit (1),Screen Failure
Study 18,Site 2,Subject 4778,Study 18,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 18,Site 2,Subject 4779,Study 18,AMERICA,USA,0.0,1.0,8.0,Screening,Discontinued
Study 18,Site 2,Subject 4780,Study 18,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 18,Site 2,Subject 4781,Study 18,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 18,Site 2,Subject 4782,Study 18,AMERICA,USA,0.0,1.0,6.0,Screening,
Study 18,Site 2,Subject 4783,Study 18,AMERICA,USA,0.0,1.0,3.0,Screening,
Study 18,Site 2,Subject 4784,Study 18,AMERICA,USA,0.0,4.0,3.0,Day 2,On Trial
Study 18,Site 2,Subject 4785,Study 18,AMERICA,USA,0.0,1.0,3.0,Screening,
Study 18,Site 2,Subject 4786,Study 18,AMERICA,USA,0.0,4.0,6.0,Day 2,On Trial
Study 18,Site 2,Subject 4787,Study 18,AMERICA,USA,0.0,1.0,6.0,Screening,
Study 18,Site 2,Subject 4788,Study 18,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 18,Site 2,Subject 4789,Study 18,AMERICA,USA,0.0,1.0,6.0,Screening,
Study 18,Site 2,Subject 4790,Study 18,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 18,Site 2,Subject 4791,Study 18,AMERICA,USA,0.0,1.0,3.0,Screening,
Study 18,Site 2,Subject 4792,Study 18,AMERICA,USA,0.0,1.0,6.0,Screening,
Study 18,Site 2,Subject 4793,Study 18,AMERICA,USA,0.0,1.0,6.0,Screening,
Study 18,Site 2,Subject 4794,Study 18,AMERICA,USA,0.0,1.0,6.0,Screening,
Study 18,Site 2,Subject 4795,Study 18,AMERICA,USA,0.0,1.0,3.0,Screening,
Study 18,Site 2,Subject 4796,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 4797,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 4798,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 4799,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 4800,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 4801,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 4802,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 4803,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 4804,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 18,Site 2,Subject 4805,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 4806,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 4807,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 4808,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 4809,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 4810,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 4811,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 4812,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 4813,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 4814,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 4815,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 4816,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 4817,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 4818,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 4819,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 4820,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 4821,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 4822,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 18,Site 2,Subject 5,Study 18,AMERICA,USA,0.0,13.0,91.0,Day 56,On Trial
Study 18,Site 2,Subject 99,Study 18,AMERICA,USA,0.0,13.0,92.0,Day 56,On Trial
Study 18,Site 3,Subject 102,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 103,Study 18,AMERICA,USA,0.0,2.0,15.0,Baseline,Screen Failure
Study 18,Site 3,Subject 104,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4026,Study 18,AMERICA,USA,0.0,12.0,82.0,Day 42,On Trial
Study 18,Site 3,Subject 4027,Study 18,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 18,Site 3,Subject 4028,Study 18,AMERICA,USA,0.0,12.0,88.0,Day 42,On Trial
Study 18,Site 3,Subject 4029,Study 18,AMERICA,USA,0.0,12.0,82.0,Day 42,On Trial
Study 18,Site 3,Subject 4030,Study 18,AMERICA,USA,0.0,12.0,82.0,Day 42,On Trial
Study 18,Site 3,Subject 4031,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4032,Study 18,AMERICA,USA,0.0,2.0,8.0,Baseline,Screen Failure
Study 18,Site 3,Subject 4033,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4034,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4035,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4036,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4037,Study 18,AMERICA,USA,0.0,2.0,7.0,Baseline,Screen Failure
Study 18,Site 3,Subject 4038,Study 18,AMERICA,USA,0.0,1.0,6.0,Screening,Screen Failure
Study 18,Site 3,Subject 4039,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4040,Study 18,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 18,Site 3,Subject 4041,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4042,Study 18,AMERICA,USA,0.0,1.0,6.0,Screening,Screen Failure
Study 18,Site 3,Subject 4043,Study 18,AMERICA,USA,0.0,12.0,108.0,Day 42,On Trial
Study 18,Site 3,Subject 4044,Study 18,AMERICA,USA,0.0,12.0,98.0,Day 42,On Trial
Study 18,Site 3,Subject 4045,Study 18,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 18,Site 3,Subject 4046,Study 18,AMERICA,USA,0.0,1.0,6.0,Screening,Screen Failure
Study 18,Site 3,Subject 4047,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4048,Study 18,AMERICA,USA,0.0,12.0,100.0,Day 42,On Trial
Study 18,Site 3,Subject 4049,Study 18,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 18,Site 3,Subject 4050,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4051,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4052,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4053,Study 18,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 18,Site 3,Subject 4054,Study 18,AMERICA,USA,0.0,12.0,109.0,Day 42,On Trial
Study 18,Site 3,Subject 4055,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4056,Study 18,AMERICA,USA,0.0,2.0,8.0,Baseline,Screen Failure
Study 18,Site 3,Subject 4057,Study 18,AMERICA,USA,0.0,11.0,27.0,Day 28,On Trial
Study 18,Site 3,Subject 4058,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4059,Study 18,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 18,Site 3,Subject 4060,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4061,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4062,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4063,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4064,Study 18,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 18,Site 3,Subject 4065,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4066,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4067,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4068,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4069,Study 18,AMERICA,USA,0.0,10.0,7.0,Day 21,On Trial
Study 18,Site 3,Subject 4070,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4071,Study 18,AMERICA,USA,0.0,2.0,7.0,Baseline,Screen Failure
Study 18,Site 3,Subject 4072,Study 18,AMERICA,USA,0.0,1.0,6.0,Screening,Screen Failure
Study 18,Site 3,Subject 4073,Study 18,AMERICA,USA,0.0,1.0,6.0,Screening,Screen Failure
Study 18,Site 3,Subject 4823,Study 18,AMERICA,USA,0.0,1.0,6.0,Screening,Screen Failure
Study 18,Site 3,Subject 4824,Study 18,AMERICA,USA,0.0,10.0,7.0,Day 21,On Trial
Study 18,Site 3,Subject 4825,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4826,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4827,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4828,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4829,Study 18,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 18,Site 3,Subject 4830,Study 18,AMERICA,USA,0.0,1.0,6.0,Screening,Screen Failure
Study 18,Site 3,Subject 4831,Study 18,AMERICA,USA,0.0,1.0,6.0,Screening,Screen Failure
Study 18,Site 3,Subject 4832,Study 18,AMERICA,USA,0.0,2.0,7.0,Baseline,Screen Failure
Study 18,Site 3,Subject 4833,Study 18,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 18,Site 3,Subject 4834,Study 18,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 18,Site 3,Subject 4835,Study 18,AMERICA,USA,0.0,11.0,32.0,Unplanned visit (11),On Trial
Study 18,Site 3,Subject 4836,Study 18,AMERICA,USA,0.0,2.0,7.0,Unplanned visit (1),Screen Failure
Study 18,Site 3,Subject 4837,Study 18,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 18,Site 3,Subject 4838,Study 18,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 18,Site 3,Subject 4839,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4840,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4841,Study 18,AMERICA,USA,0.0,9.0,6.0,Day 14,On Trial
Study 18,Site 3,Subject 4842,Study 18,AMERICA,USA,0.0,2.0,6.0,Baseline,Screen Failure
Study 18,Site 3,Subject 4843,Study 18,AMERICA,USA,0.0,1.0,6.0,Screening,Screen Failure
Study 18,Site 3,Subject 4844,Study 18,AMERICA,USA,0.0,2.0,7.0,Unplanned visit (1),Discontinued
Study 18,Site 3,Subject 4845,Study 18,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 18,Site 3,Subject 4846,Study 18,AMERICA,USA,0.0,2.0,6.0,Baseline,Screen Failure
Study 18,Site 3,Subject 4847,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 4848,Study 18,AMERICA,USA,0.0,10.0,7.0,Day 21,On Trial
Study 18,Site 3,Subject 4849,Study 18,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 18,Site 3,Subject 4850,Study 18,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 18,Site 3,Subject 4851,Study 18,AMERICA,USA,0.0,1.0,6.0,Screening,Screen Failure
Study 18,Site 3,Subject 4852,Study 18,AMERICA,USA,0.0,10.0,7.0,Day 21,On Trial
Study 18,Site 3,Subject 4853,Study 18,AMERICA,USA,0.0,10.0,6.0,Day 21,On Trial
Study 18,Site 3,Subject 4854,Study 18,AMERICA,USA,0.0,1.0,6.0,Screening,Screen Failure
Study 18,Site 3,Subject 4855,Study 18,AMERICA,USA,0.0,10.0,7.0,Day 21,On Trial
Study 18,Site 3,Subject 4856,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 18,Site 3,Subject 4857,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 18,Site 3,Subject 4858,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 18,Site 3,Subject 4859,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 18,Site 3,Subject 4860,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 18,Site 3,Subject 4861,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 18,Site 3,Subject 4862,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 18,Site 3,Subject 4863,Study 18,AMERICA,USA,0.0,2.0,0.0,Baseline,Screen Failure
Study 18,Site 3,Subject 4864,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 18,Site 3,Subject 4865,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 18,Site 3,Subject 4866,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 18,Site 3,Subject 4867,Study 18,AMERICA,USA,0.0,10.0,0.0,Day 21,On Trial
Study 18,Site 3,Subject 4868,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 18,Site 3,Subject 4869,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 18,Site 3,Subject 4870,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 18,Site 3,Subject 4871,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 18,Site 3,Subject 4872,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 18,Site 3,Subject 4873,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 18,Site 3,Subject 4874,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 18,Site 3,Subject 4875,Study 18,AMERICA,USA,0.0,10.0,0.0,Day 21,On Trial
Study 18,Site 3,Subject 4876,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 18,Site 3,Subject 4877,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 18,Site 3,Subject 4878,Study 18,AMERICA,USA,0.0,10.0,0.0,Day 21,On Trial
Study 18,Site 3,Subject 4879,Study 18,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 18,Site 3,Subject 6,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 7,Study 18,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 18,Site 3,Subject 774,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 775,Study 18,AMERICA,USA,0.0,2.0,20.0,Unplanned visit (1),Screen Failure
Study 18,Site 3,Subject 776,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 777,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 778,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 779,Study 18,AMERICA,USA,0.0,1.0,7.0,Unplanned visit (1),Screen Failure
Study 18,Site 3,Subject 780,Study 18,AMERICA,USA,0.0,12.0,88.0,Day 42,On Trial
Study 18,Site 3,Subject 781,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 782,Study 18,AMERICA,USA,0.0,12.0,100.0,Day 42,On Trial
Study 18,Site 3,Subject 783,Study 18,AMERICA,USA,0.0,2.0,8.0,Baseline,Screen Failure
Study 18,Site 3,Subject 784,Study 18,AMERICA,USA,0.0,12.0,96.0,Day 42,On Trial
Study 18,Site 3,Subject 785,Study 18,AMERICA,USA,0.0,12.0,85.0,Day 42,On Trial
Study 18,Site 3,Subject 786,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 18,Site 3,Subject 8,Study 18,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 19,Site 109,Subject 835,Study 19,ASIA,AUS,0.0,1.0,7.0,Screening,Screening
Study 19,Site 109,Subject 836,Study 19,ASIA,AUS,0.0,5.0,54.0,Cycle 1 Day 29 (1),On Trial
Study 19,Site 109,Subject 837,Study 19,ASIA,AUS,0.0,4.0,48.0,Cycle 1 Day 15 (1),On Trial
Study 19,Site 109,Subject 838,Study 19,ASIA,AUS,0.0,3.0,40.0,Cycle 1 Day 1 (1),On Trial
Study 19,Site 109,Subject 839,Study 19,ASIA,AUS,0.0,1.0,0.0,Screening,Screening
Study 19,Site 113,Subject 911,Study 19,None,PRK,0.0,3.0,0.0,Cycle 1 Day 1 (1),On Trial
Study 19,Site 113,Subject 912,Study 19,None,PRK,0.0,2.0,0.0,Unplanned Visit (3),On Trial
Study 19,Site 113,Subject 913,Study 19,None,PRK,0.0,2.0,0.0,Randomization (1),On Trial
Study 19,Site 113,Subject 914,Study 19,None,PRK,0.0,1.0,0.0,Unplanned Visit (1),Screening
Study 19,Site 155,Subject 1427,Study 19,ASIA,TWN,0.0,1.0,0.0,Screening,Screening
Study 19,Site 155,Subject 1428,Study 19,ASIA,TWN,0.0,1.0,0.0,Screening,Screening
Study 19,Site 417,Subject 3227,Study 19,ASIA,KOR,0.0,2.0,0.0,Randomization (1),On Trial
Study 19,Site 417,Subject 3228,Study 19,ASIA,KOR,0.0,1.0,0.0,Screening,Screening
Study 19,Site 417,Subject 3229,Study 19,ASIA,KOR,0.0,1.0,0.0,Screening,Screening
Study 19,Site 467,Subject 3553,Study 19,ASIA,AUS,0.0,1.0,0.0,Screening,Screening
Study 19,Site 468,Subject 3560,Study 19,ASIA,AUS,0.0,5.0,43.0,Cycle 1 Day 29 (1),On Trial
Study 19,Site 468,Subject 3561,Study 19,ASIA,AUS,0.0,4.0,28.0,Cycle 1 Day 15 (1),On Trial
Study 19,Site 468,Subject 3562,Study 19,ASIA,AUS,0.0,2.0,15.0,Randomization (1),On Trial
Study 19,Site 468,Subject 3563,Study 19,ASIA,AUS,0.0,3.0,10.0,Cycle 1 Day 1 (1),On Trial
Study 19,Site 468,Subject 3564,Study 19,ASIA,AUS,0.0,4.0,16.0,Cycle 1 Day 15 (1),On Trial
Study 19,Site 468,Subject 4880,Study 19,ASIA,AUS,0.0,1.0,4.0,Screening,Screening
Study 19,Site 493,Subject 3670,Study 19,EMEA,ISR,0.0,1.0,0.0,Screening,
Study 19,Site 493,Subject 3671,Study 19,EMEA,ISR,0.0,1.0,0.0,Screening,
Study 19,Site 493,Subject 3672,Study 19,EMEA,ISR,0.0,1.0,0.0,Screening,Screening
Study 19,Site 777,Subject 4881,Study 19,EMEA,DEU,0.0,0.0,0.0,,
Study 19,Site 777,Subject 4882,Study 19,EMEA,DEU,0.0,0.0,0.0,,
Study 19,Site 777,Subject 4883,Study 19,EMEA,DEU,0.0,0.0,0.0,,
Study 19,Site 778,Subject 4884,Study 19,EMEA,ISR,0.0,6.0,0.0,Cycle 2 Day 1 (1),On Trial
Study 19,Site 778,Subject 4885,Study 19,EMEA,ISR,0.0,1.0,0.0,Screening,Screening
Study 19,Site 778,Subject 4886,Study 19,EMEA,ISR,0.0,4.0,0.0,Cycle 1 Day 15 (1),On Trial
Study 19,Site 779,Subject 4887,Study 19,EMEA,ISR,0.0,1.0,0.0,Screening,
Study 19,Site 780,Subject 4888,Study 19,ASIA,SGP,0.0,1.0,8.0,Screening,Screening
Study 19,Site 780,Subject 4889,Study 19,ASIA,SGP,0.0,1.0,8.0,Screening,Screening
Study 19,Site 780,Subject 4890,Study 19,ASIA,SGP,0.0,11.0,109.0,Cycle 3 Day 15 (1),On Trial
Study 19,Site 780,Subject 4891,Study 19,ASIA,SGP,0.0,10.0,90.0,End of Treatment (1),On Trial
Study 19,Site 780,Subject 4892,Study 19,ASIA,SGP,0.0,9.0,78.0,Cycle 2 Day 29 (1),On Trial
Study 19,Site 780,Subject 4893,Study 19,ASIA,SGP,0.0,9.0,84.0,Cycle 2 Day 29 (1),On Trial
Study 19,Site 780,Subject 4894,Study 19,ASIA,SGP,0.0,1.0,7.0,Screening,Screening
Study 19,Site 780,Subject 4895,Study 19,ASIA,SGP,0.0,7.0,107.0,Unplanned Visit (6),On Trial
Study 19,Site 780,Subject 4896,Study 19,ASIA,SGP,0.0,1.0,4.0,Screening,Screening
Study 19,Site 780,Subject 4897,Study 19,ASIA,SGP,0.0,1.0,4.0,Screening,Screening
Study 19,Site 781,Subject 4898,Study 19,AMERICA,USA,0.0,1.0,0.0,Screening,Screening
Study 19,Site 782,Subject 4899,Study 19,AMERICA,USA,0.0,8.0,71.0,Cycle 2 Day 15 (1),On Trial
Study 19,Site 782,Subject 4900,Study 19,AMERICA,USA,0.0,2.0,46.0,Randomization (1),Discontinued
Study 19,Site 782,Subject 4901,Study 19,AMERICA,USA,0.0,4.0,20.0,Cycle 1 Day 15 (1),On Trial
Study 19,Site 782,Subject 4902,Study 19,AMERICA,USA,0.0,1.0,0.0,Screening,Screening
Study 19,Site 9,Subject 16,Study 19,EMEA,FRA,0.0,0.0,0.0,,
Study 19,Site 9,Subject 3512,Study 19,EMEA,FRA,0.0,2.0,0.0,Randomization (1),On Trial
Study 2,Site 2,Subject 100,Study 2,ASIA,CHN,0.0,24.0,255.0,Follow up 2 (1),Discontinued
Study 2,Site 2,Subject 101,Study 2,ASIA,CHN,0.0,9.0,127.0,Unplanned Visit (9),Discontinued
Study 2,Site 2,Subject 2,Study 2,ASIA,CHN,0.0,26.0,263.0,Follow up 2 (1),Discontinued
Study 2,Site 2,Subject 3,Study 2,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 2,Site 2,Subject 4,Study 2,ASIA,CHN,0.0,1.0,7.0,Screening,Screen Failure
Study 2,Site 2,Subject 5,Study 2,ASIA,CHN,0.0,24.0,295.0,Unplanned Visit (9),Discontinued
Study 2,Site 2,Subject 99,Study 2,ASIA,CHN,0.0,11.0,100.0,Cycle 3 Week 1 (1),Discontinued
Study 2,Site 28,Subject 107,Study 2,ASIA,CHN,0.0,10.0,127.0,30 day Safety FU (1),Discontinued
Study 2,Site 28,Subject 108,Study 2,ASIA,CHN,0.0,21.0,166.0,Cycle 6 Week 3 (1),Discontinued
Study 2,Site 29,Subject 109,Study 2,ASIA,CHN,0.0,12.0,121.0,Unplanned Recist (3),Discontinued
Study 2,Site 3,Subject 102,Study 2,ASIA,CHN,0.0,47.0,384.0,30 day Safety FU_CO (1),Survival
Study 2,Site 3,Subject 103,Study 2,ASIA,CHN,0.0,1.0,37.0,Screening,Discontinued
Study 2,Site 3,Subject 104,Study 2,ASIA,CHN,0.0,25.0,242.0,Unplanned Visit (1),Survival
Study 2,Site 3,Subject 6,Study 2,ASIA,CHN,0.0,1.0,7.0,Screening,Screen Failure
Study 2,Site 3,Subject 7,Study 2,ASIA,CHN,0.0,1.0,44.0,Screening,Discontinued
Study 2,Site 3,Subject 8,Study 2,ASIA,CHN,0.0,34.0,305.0,Unplanned Visit_CO (7),Discontinued
Study 2,Site 30,Subject 110,Study 2,ASIA,CHN,0.0,2.0,42.0,EOT (1),Discontinued
Study 2,Site 30,Subject 111,Study 2,ASIA,CHN,0.0,22.0,212.0,Cycle 3 Week 5_CO (1),Discontinued
Study 2,Site 30,Subject 112,Study 2,ASIA,CHN,0.0,8.0,89.0,Cycle 2 Week 1 (1),Discontinued
Study 2,Site 30,Subject 113,Study 2,ASIA,CHN,0.0,8.0,93.0,Follow up 1 (1),Discontinued
Study 2,Site 30,Subject 114,Study 2,ASIA,CHN,0.0,17.0,164.0,Unplanned Recist (2),Survival
Study 2,Site 30,Subject 115,Study 2,ASIA,CHN,0.0,25.0,239.0,Unplanned Recist (3),Survival
Study 2,Site 30,Subject 116,Study 2,ASIA,CHN,0.0,14.0,109.0,EOT (1),Discontinued
Study 2,Site 30,Subject 117,Study 2,ASIA,CHN,0.0,3.0,52.0,Cycle 1 Week 2 (1),Discontinued
Study 2,Site 31,Subject 118,Study 2,ASIA,CHN,0.0,1.0,48.0,Unplanned Visit (2),Discontinued
Study 2,Site 31,Subject 119,Study 2,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 2,Site 31,Subject 120,Study 2,ASIA,CHN,0.0,16.0,160.0,30 day Safety FU (1),Survival
Study 2,Site 32,Subject 121,Study 2,ASIA,CHN,0.0,17.0,157.0,30 day Safety FU (1),Survival
Study 2,Site 33,Subject 122,Study 2,ASIA,CHN,0.0,43.0,404.0,Follow up 4_CO (1),Follow-Up
Study 2,Site 33,Subject 123,Study 2,ASIA,CHN,0.0,17.0,146.0,Follow up 5 (1),Follow-Up
Study 2,Site 33,Subject 124,Study 2,ASIA,CHN,0.0,29.0,328.0,Follow up 5 (1),Follow-Up
Study 2,Site 33,Subject 125,Study 2,ASIA,CHN,0.0,5.0,76.0,Cycle 1 Week 4 (1),Discontinued
Study 2,Site 33,Subject 126,Study 2,ASIA,CHN,0.0,19.0,137.0,Follow up 6 (1),Follow-Up
Study 2,Site 33,Subject 127,Study 2,ASIA,CHN,0.0,26.0,256.0,Follow up 2 (1),Survival
Study 2,Site 33,Subject 128,Study 2,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 2,Site 33,Subject 129,Study 2,ASIA,CHN,0.0,28.0,244.0,Follow up 4 (1),Follow-Up
Study 2,Site 33,Subject 130,Study 2,ASIA,CHN,0.0,26.0,213.0,Follow up 2_CO (1),Survival
Study 2,Site 33,Subject 131,Study 2,ASIA,CHN,0.0,13.0,370.0,Unplanned Visit (50),Discontinued
Study 2,Site 33,Subject 132,Study 2,ASIA,CHN,0.0,33.0,266.0,Follow up 1_CO (1),Survival
Study 2,Site 34,Subject 133,Study 2,ASIA,CHN,0.0,11.0,116.0,30 day Safety FU (1),Discontinued
Study 2,Site 34,Subject 134,Study 2,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 2,Site 35,Subject 135,Study 2,ASIA,CHN,0.0,46.0,417.0,Unplanned Visit (11),Discontinued
Study 2,Site 35,Subject 136,Study 2,ASIA,CHN,0.0,9.0,123.0,Cycle 3 Week 1 (1),Discontinued
Study 2,Site 36,Subject 137,Study 2,ASIA,CHN,0.0,28.0,258.0,Cycle 12 Week 1 (1),On Trial
Study 2,Site 36,Subject 138,Study 2,ASIA,CHN,0.0,27.0,258.0,Cycle 12 Week 1 (1),On Trial
Study 2,Site 36,Subject 139,Study 2,ASIA,CHN,0.0,1.0,12.0,Screening,Screen Failure
Study 2,Site 37,Subject 140,Study 2,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 2,Site 37,Subject 141,Study 2,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 2,Site 38,Subject 142,Study 2,ASIA,CHN,0.0,40.0,338.0,Cycle 4 Week 5_CO (1),Discontinued
Study 2,Site 38,Subject 143,Study 2,ASIA,CHN,0.0,2.0,48.0,Cycle 1 Week 1 (1),Discontinued
Study 2,Site 38,Subject 144,Study 2,ASIA,CHN,0.0,19.0,195.0,Unplanned Visit_CO (4),Discontinued
Study 2,Site 38,Subject 145,Study 2,ASIA,CHN,0.0,1.0,7.0,Screening,Screen Failure
Study 2,Site 38,Subject 146,Study 2,ASIA,CHN,0.0,34.0,306.0,30 day Safety FU_CO (1),Follow-Up
Study 2,Site 38,Subject 147,Study 2,ASIA,CHN,0.0,21.0,233.0,Unplanned Recist (1),Discontinued
Study 2,Site 38,Subject 148,Study 2,ASIA,CHN,0.0,27.0,267.0,Cycle 11 Week 1 (1),On Trial
Study 2,Site 38,Subject 149,Study 2,ASIA,CHN,0.0,27.0,252.0,Cycle 11 Week 1 (1),On Trial
Study 2,Site 38,Subject 150,Study 2,ASIA,CHN,0.0,40.0,351.0,30 day Safety FU_CO (1),Survival
Study 2,Site 38,Subject 151,Study 2,ASIA,CHN,0.0,15.0,162.0,30 day Safety FU (1),Discontinued
Study 2,Site 38,Subject 152,Study 2,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 2,Site 38,Subject 153,Study 2,ASIA,CHN,0.0,45.0,387.0,Follow up 1_CO (1),Follow-Up
Study 2,Site 38,Subject 154,Study 2,ASIA,CHN,0.0,9.0,108.0,Cycle 2 Week 5 (1),Discontinued
Study 2,Site 39,Subject 155,Study 2,ASIA,CHN,0.0,1.0,5.0,Screening,Screen Failure
Study 2,Site 39,Subject 156,Study 2,ASIA,CHN,0.0,1.0,5.0,Screening,Screen Failure
Study 2,Site 4,Subject 10,Study 2,ASIA,CHN,0.0,47.0,397.0,EOT2 (1),Survival
Study 2,Site 4,Subject 105,Study 2,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 2,Site 4,Subject 106,Study 2,ASIA,CHN,0.0,28.0,268.0,Follow up 4 (1),Follow-Up
Study 2,Site 4,Subject 9,Study 2,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 2,Site 40,Subject 157,Study 2,ASIA,CHN,0.0,28.0,279.0,Follow up 4 (1),Follow-Up
Study 2,Site 40,Subject 158,Study 2,ASIA,CHN,0.0,17.0,184.0,Unplanned Visit (3),Survival
Study 2,Site 40,Subject 159,Study 2,ASIA,CHN,0.0,28.0,258.0,Follow up 4 (1),Follow-Up
Study 2,Site 40,Subject 160,Study 2,ASIA,CHN,0.0,21.0,221.0,Unplanned Visit (2),Discontinued
Study 2,Site 40,Subject 161,Study 2,ASIA,CHN,0.0,24.0,235.0,Unplanned Recist (1),Survival
Study 2,Site 41,Subject 162,Study 2,ASIA,CHN,0.0,25.0,245.0,Unplanned Visit (6),Survival
Study 2,Site 41,Subject 163,Study 2,ASIA,CHN,0.0,32.0,271.0,Cycle 5 Week 3_CO (1),Discontinued
Study 2,Site 42,Subject 164,Study 2,ASIA,CHN,0.0,26.0,254.0,Follow up 3 (1),Follow-Up
Study 2,Site 42,Subject 165,Study 2,ASIA,CHN,0.0,9.0,128.0,Unplanned Visit (4),Survival
Study 2,Site 42,Subject 166,Study 2,ASIA,CHN,0.0,12.0,120.0,30 day Safety FU (1),Discontinued
Study 2,Site 42,Subject 167,Study 2,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 2,Site 42,Subject 168,Study 2,ASIA,CHN,0.0,25.0,246.0,Follow up 1 (1),Follow-Up
Study 20,Site 124,Subject 1067,Study 20,EMEA,NLD,0.0,2.0,0.0,Cycle 1 Day 1 (1),On Trial
Study 20,Site 353,Subject 2844,Study 20,ASIA,SGP,0.0,8.0,58.0,Unplanned Visit (6),On Trial
Study 20,Site 353,Subject 2845,Study 20,ASIA,SGP,0.0,8.0,30.0,Cycle 4 Day 1 (1),On Trial
Study 20,Site 353,Subject 3735,Study 20,ASIA,SGP,0.0,1.0,0.0,Screening,Screen Failure
Study 20,Site 353,Subject 3736,Study 20,ASIA,SGP,0.0,1.0,0.0,Screening,Screen Failure
Study 20,Site 353,Subject 3737,Study 20,ASIA,SGP,0.0,2.0,0.0,Cycle 1 Day 1 (1),On Trial
Study 20,Site 417,Subject 3227,Study 20,ASIA,KOR,0.0,1.0,0.0,Screening,Screening
Study 20,Site 466,Subject 3544,Study 20,ASIA,AUS,0.0,5.0,0.0,Cycle 2 Day 15 (1),On Trial
Study 20,Site 466,Subject 3545,Study 20,ASIA,AUS,0.0,1.0,0.0,Screening,Screen Failure
Study 20,Site 47,Subject 190,Study 20,ASIA,AUS,0.0,1.0,0.0,Screening,Screening
Study 20,Site 575,Subject 3947,Study 20,AMERICA,USA,0.0,1.0,0.0,Screening,Screening
Study 20,Site 575,Subject 3948,Study 20,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 20,Site 575,Subject 3949,Study 20,AMERICA,USA,0.0,3.0,0.0,Cycle 1 Day 15 (1),On Trial
Study 20,Site 783,Subject 4903,Study 20,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 20,Site 783,Subject 4904,Study 20,AMERICA,USA,0.0,7.0,50.0,Cycle 3 Day 15 (1),On Trial
Study 20,Site 784,Subject 4905,Study 20,AMERICA,USA,0.0,1.0,0.0,Screening,Screening
Study 20,Site 784,Subject 4906,Study 20,AMERICA,USA,0.0,1.0,0.0,Screening,Screening
Study 20,Site 785,Subject 4907,Study 20,AMERICA,USA,0.0,1.0,0.0,Screening,Screening
Study 20,Site 8,Subject 15,Study 20,EMEA,CZE,0.0,0.0,0.0,Screening,Screening
Study 20,Site 87,Subject 627,Study 20,EMEA,ITA,0.0,3.0,0.0,Unplanned Visit (3),On Trial
Study 20,Site 9,Subject 16,Study 20,EMEA,FRA,0.0,2.0,0.0,Cycle 1 Day 1 (1),On Trial
Study 20,Site 9,Subject 3512,Study 20,EMEA,FRA,0.0,1.0,0.0,Screening,Screening
Study 24,Site 1,Subject 1,Study 24,ASIA,AUS,0.0,7.0,43.0,Unplanned visit (1),On Trial
Study 24,Site 1,Subject 169,Study 24,ASIA,AUS,0.0,7.0,39.0,Cycle 4 Day 1,On Trial
Study 24,Site 1,Subject 752,Study 24,ASIA,AUS,0.0,7.0,44.0,Cycle 4 Day 1,On Trial
Study 24,Site 1,Subject 753,Study 24,ASIA,AUS,0.0,1.0,5.0,Screening,Screen Failure
Study 24,Site 10,Subject 17,Study 24,ASIA,HKG,0.0,9.0,61.0,Unplanned visit (4),On Trial
Study 24,Site 10,Subject 18,Study 24,ASIA,HKG,0.0,8.0,56.0,30 Day Safety Follow-up,On Trial
Study 24,Site 10,Subject 19,Study 24,ASIA,HKG,0.0,8.0,44.0,Cycle 5 Day 1,On Trial
Study 24,Site 10,Subject 851,Study 24,ASIA,HKG,0.0,7.0,40.0,Unplanned visit (1),On Trial
Study 24,Site 10,Subject 852,Study 24,ASIA,HKG,0.0,6.0,31.0,Cycle 3 Day 1,On Trial
Study 24,Site 10,Subject 853,Study 24,ASIA,HKG,0.0,6.0,40.0,Cycle 3 Day 1,On Trial
Study 24,Site 10,Subject 854,Study 24,ASIA,HKG,0.0,6.0,40.0,Unplanned visit (1),On Trial
Study 24,Site 1018,Subject 14933,Study 24,AMERICA,USA,0.0,0.0,7.0,Screening,Screen Failure
Study 24,Site 1018,Subject 14934,Study 24,AMERICA,USA,0.0,2.0,32.0,Cycle 1 Day 1,On Trial
Study 24,Site 1018,Subject 14935,Study 24,AMERICA,USA,0.0,2.0,32.0,Cycle 1 Day 1,On Trial
Study 24,Site 1018,Subject 14936,Study 24,AMERICA,USA,0.0,2.0,37.0,Cycle 1 Day 1,On Trial
Study 24,Site 1034,Subject 15652,Study 24,AMERICA,USA,0.0,10.0,40.0,Cycle 7 Day 1,On Trial
Study 24,Site 1034,Subject 15653,Study 24,AMERICA,USA,0.0,10.0,40.0,Cycle 7 Day 1,On Trial
Study 24,Site 1034,Subject 15654,Study 24,AMERICA,USA,0.0,9.0,38.0,Cycle 6 Day 1,On Trial
Study 24,Site 1034,Subject 15655,Study 24,AMERICA,USA,0.0,1.0,5.0,Screening,Screen Failure
Study 24,Site 1034,Subject 15656,Study 24,AMERICA,USA,0.0,5.0,27.0,Cycle 2 Day 15,On Trial
Study 24,Site 1034,Subject 15657,Study 24,AMERICA,USA,0.0,2.0,5.0,Cycle 1 Day 1,On Trial
Study 24,Site 1034,Subject 15658,Study 24,AMERICA,USA,0.0,4.0,2.0,Cycle 2 Day 1,On Trial
Study 24,Site 1034,Subject 15659,Study 24,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 24,Site 1037,Subject 15713,Study 24,AMERICA,USA,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 1037,Subject 15714,Study 24,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 24,Site 1042,Subject 15782,Study 24,AMERICA,USA,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 110,Subject 893,Study 24,ASIA,HKG,0.0,4.0,0.0,Unplanned visit (1),On Trial
Study 24,Site 113,Subject 6238,Study 24,ASIA,CHN,0.0,6.0,58.0,Unplanned visit (5),On Trial
Study 24,Site 113,Subject 6239,Study 24,ASIA,CHN,0.0,6.0,59.0,Unplanned visit (5),On Trial
Study 24,Site 113,Subject 6240,Study 24,ASIA,CHN,0.0,0.0,6.0,Screening,Screen Failure
Study 24,Site 113,Subject 6241,Study 24,ASIA,CHN,0.0,5.0,46.0,Unplanned visit (2),On Trial
Study 24,Site 113,Subject 6242,Study 24,ASIA,CHN,0.0,3.0,41.0,Unplanned visit (1),On Trial
Study 24,Site 113,Subject 6243,Study 24,ASIA,CHN,0.0,4.0,41.0,Unplanned visit (2),On Trial
Study 24,Site 113,Subject 6244,Study 24,ASIA,CHN,0.0,4.0,48.0,Unplanned visit (3),On Trial
Study 24,Site 113,Subject 6245,Study 24,ASIA,CHN,0.0,4.0,48.0,Unplanned visit (3),On Trial
Study 24,Site 113,Subject 6246,Study 24,ASIA,CHN,0.0,2.0,29.0,Cycle 1 Day 1,On Trial
Study 24,Site 113,Subject 6247,Study 24,ASIA,CHN,0.0,4.0,44.0,Unplanned visit (2),On Trial
Study 24,Site 113,Subject 6248,Study 24,ASIA,CHN,0.0,3.0,38.0,Unplanned visit (1),On Trial
Study 24,Site 113,Subject 6249,Study 24,ASIA,CHN,0.0,0.0,6.0,Screening,Screen Failure
Study 24,Site 113,Subject 6250,Study 24,ASIA,CHN,0.0,3.0,37.0,Unplanned visit (1),On Trial
Study 24,Site 113,Subject 6251,Study 24,ASIA,CHN,0.0,3.0,41.0,Unplanned visit (1),On Trial
Study 24,Site 113,Subject 6252,Study 24,ASIA,CHN,0.0,0.0,6.0,Screening,Screen Failure
Study 24,Site 113,Subject 6253,Study 24,ASIA,CHN,0.0,2.0,31.0,Cycle 1 Day 1,On Trial
Study 24,Site 113,Subject 911,Study 24,ASIA,CHN,0.0,6.0,57.0,Unplanned visit (3),On Trial
Study 24,Site 113,Subject 912,Study 24,ASIA,CHN,0.0,6.0,64.0,Unplanned visit (4),On Trial
Study 24,Site 113,Subject 913,Study 24,ASIA,CHN,0.0,6.0,83.0,Unplanned visit (6),On Trial
Study 24,Site 113,Subject 914,Study 24,ASIA,CHN,0.0,5.0,68.0,Unplanned visit (5),On Trial
Study 24,Site 113,Subject 915,Study 24,ASIA,CHN,0.0,0.0,7.0,Screening,Screen Failure
Study 24,Site 113,Subject 916,Study 24,ASIA,CHN,0.0,0.0,7.0,Screening,Screen Failure
Study 24,Site 113,Subject 917,Study 24,ASIA,CHN,0.0,6.0,57.0,Cycle 3 Day 1,On Trial
Study 24,Site 1645,Subject 30314,Study 24,ASIA,IND,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 1645,Subject 30315,Study 24,ASIA,IND,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 1646,Subject 30346,Study 24,ASIA,IND,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 1646,Subject 30347,Study 24,ASIA,IND,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 1646,Subject 30348,Study 24,ASIA,IND,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 1648,Subject 30393,Study 24,ASIA,IND,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 1648,Subject 30394,Study 24,ASIA,IND,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 1648,Subject 30395,Study 24,ASIA,IND,0.0,1.0,0.0,Screening,Screen Failure
Study 24,Site 1648,Subject 30396,Study 24,ASIA,IND,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 1648,Subject 30397,Study 24,ASIA,IND,0.0,1.0,0.0,Screening,Screen Failure
Study 24,Site 1648,Subject 30398,Study 24,ASIA,IND,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 1648,Subject 30399,Study 24,ASIA,IND,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 1673,Subject 30790,Study 24,ASIA,TWN,0.0,6.0,49.0,Cycle 3 Day 1,On Trial
Study 24,Site 1673,Subject 30791,Study 24,ASIA,TWN,0.0,3.0,36.0,Cycle 1 Day 15,On Trial
Study 24,Site 1673,Subject 30792,Study 24,ASIA,TWN,0.0,0.0,0.0,,Screening
Study 24,Site 1673,Subject 30793,Study 24,ASIA,TWN,0.0,0.0,0.0,,Screening
Study 24,Site 1673,Subject 30794,Study 24,ASIA,TWN,0.0,0.0,0.0,,Screening
Study 24,Site 1674,Subject 30855,Study 24,ASIA,TWN,0.0,6.0,43.0,Cycle 3 Day 1,On Trial
Study 24,Site 1674,Subject 30856,Study 24,ASIA,TWN,0.0,4.0,38.0,Cycle 2 Day 1,On Trial
Study 24,Site 1674,Subject 30857,Study 24,ASIA,TWN,0.0,5.0,40.0,Cycle 2 Day 15,On Trial
Study 24,Site 1674,Subject 30858,Study 24,ASIA,TWN,0.0,1.0,6.0,Screening,Screen Failure
Study 24,Site 1674,Subject 30859,Study 24,ASIA,TWN,0.0,5.0,35.0,Cycle 2 Day 15,On Trial
Study 24,Site 1674,Subject 30860,Study 24,ASIA,TWN,0.0,4.0,29.0,Cycle 2 Day 1,On Trial
Study 24,Site 1674,Subject 30861,Study 24,ASIA,TWN,0.0,4.0,39.0,Cycle 2 Day 1,On Trial
Study 24,Site 1674,Subject 30862,Study 24,ASIA,TWN,0.0,4.0,41.0,Cycle 2 Day 1,On Trial
Study 24,Site 1674,Subject 30863,Study 24,ASIA,TWN,0.0,3.0,34.0,Cycle 1 Day 15,On Trial
Study 24,Site 1674,Subject 30864,Study 24,ASIA,TWN,0.0,4.0,36.0,Cycle 2 Day 1,On Trial
Study 24,Site 1675,Subject 30869,Study 24,ASIA,TWN,0.0,1.0,7.0,Screening,Screen Failure
Study 24,Site 1675,Subject 30870,Study 24,ASIA,TWN,0.0,5.0,45.0,Cycle 2 Day 15,On Trial
Study 24,Site 1675,Subject 30871,Study 24,ASIA,TWN,0.0,2.0,41.0,Cycle 1 Day 1,On Trial
Study 24,Site 1675,Subject 30872,Study 24,ASIA,TWN,0.0,1.0,7.0,Screening,Screen Failure
Study 24,Site 1675,Subject 30873,Study 24,ASIA,TWN,0.0,3.0,34.0,Cycle 1 Day 15,On Trial
Study 24,Site 1675,Subject 30874,Study 24,ASIA,TWN,0.0,4.0,42.0,Cycle 2 Day 1,On Trial
Study 24,Site 1675,Subject 30875,Study 24,ASIA,TWN,0.0,2.0,20.0,Cycle 1 Day 1,On Trial
Study 24,Site 1676,Subject 30882,Study 24,ASIA,TWN,0.0,1.0,7.0,Screening,Screen Failure
Study 24,Site 1676,Subject 30883,Study 24,ASIA,TWN,0.0,8.0,43.0,Cycle 5 Day 1,On Trial
Study 24,Site 1676,Subject 30884,Study 24,ASIA,TWN,0.0,8.0,55.0,Cycle 5 Day 1,On Trial
Study 24,Site 1676,Subject 30885,Study 24,ASIA,TWN,0.0,6.0,32.0,Unplanned visit (4),On Trial
Study 24,Site 1676,Subject 30886,Study 24,ASIA,TWN,0.0,7.0,60.0,Cycle 4 Day 1,On Trial
Study 24,Site 1676,Subject 30887,Study 24,ASIA,TWN,0.0,1.0,5.0,Screening,Screening
Study 24,Site 1676,Subject 30888,Study 24,ASIA,TWN,0.0,1.0,0.0,Screening,Screen Failure
Study 24,Site 1676,Subject 30889,Study 24,ASIA,TWN,0.0,1.0,0.0,Screening,Screen Failure
Study 24,Site 178,Subject 1600,Study 24,AMERICA,USA,0.0,6.0,41.0,Cycle 3 Day 1,On Trial
Study 24,Site 178,Subject 3393,Study 24,AMERICA,USA,0.0,6.0,41.0,Unplanned visit (9),On Trial
Study 24,Site 178,Subject 3394,Study 24,AMERICA,USA,0.0,6.0,35.0,Cycle 3 Day 1,On Trial
Study 24,Site 178,Subject 40402,Study 24,AMERICA,USA,0.0,4.0,29.0,Cycle 2 Day 1,On Trial
Study 24,Site 178,Subject 40403,Study 24,AMERICA,USA,0.0,2.0,1.0,Cycle 1 Day 1,On Trial
Study 24,Site 1791,Subject 34337,Study 24,EMEA,ISR,0.0,6.0,32.0,Cycle 3 Day 1,On Trial
Study 24,Site 1791,Subject 34338,Study 24,EMEA,ISR,0.0,6.0,32.0,Cycle 3 Day 1,On Trial
Study 24,Site 1791,Subject 34339,Study 24,EMEA,ISR,0.0,6.0,30.0,Cycle 3 Day 1,On Trial
Study 24,Site 1846,Subject 35377,Study 24,EMEA,PRT,0.0,1.0,0.0,Screening,Screening
Study 24,Site 1846,Subject 35378,Study 24,EMEA,PRT,0.0,1.0,0.0,Screening,Screening
Study 24,Site 1962,Subject 38936,Study 24,AMERICA,CAN,0.0,1.0,0.0,Screening,Screening
Study 24,Site 1962,Subject 38937,Study 24,AMERICA,CAN,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 2008,Subject 41054,Study 24,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 24,Site 2013,Subject 41288,Study 24,AMERICA,USA,0.0,9.0,56.0,30 Day Safety Follow-up,On Trial
Study 24,Site 2013,Subject 41289,Study 24,AMERICA,USA,0.0,9.0,53.0,Unplanned visit (8),On Trial
Study 24,Site 2013,Subject 41290,Study 24,AMERICA,USA,0.0,1.0,6.0,Screening,Screen Failure
Study 24,Site 2013,Subject 41291,Study 24,AMERICA,USA,0.0,1.0,23.0,Unplanned visit (1),Screen Failure
Study 24,Site 2013,Subject 41292,Study 24,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 24,Site 2013,Subject 41293,Study 24,AMERICA,USA,0.0,5.0,0.0,Cycle 2 Day 15,On Trial
Study 24,Site 2014,Subject 41295,Study 24,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 24,Site 2015,Subject 41299,Study 24,AMERICA,USA,0.0,8.0,72.0,Unplanned visit (6),On Trial
Study 24,Site 2015,Subject 41300,Study 24,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 24,Site 2015,Subject 41301,Study 24,AMERICA,USA,0.0,6.0,48.0,Cycle 3 Day 1,On Trial
Study 24,Site 2015,Subject 41302,Study 24,AMERICA,USA,0.0,6.0,40.0,Cycle 3 Day 1,On Trial
Study 24,Site 2015,Subject 41303,Study 24,AMERICA,USA,0.0,4.0,35.0,Cycle 2 Day 1,On Trial
Study 24,Site 2015,Subject 41304,Study 24,AMERICA,USA,0.0,4.0,24.0,Cycle 2 Day 1,On Trial
Study 24,Site 2015,Subject 41305,Study 24,AMERICA,USA,0.0,2.0,27.0,Cycle 1 Day 1,On Trial
Study 24,Site 2024,Subject 41576,Study 24,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 24,Site 2025,Subject 41610,Study 24,AMERICA,USA,0.0,0.0,0.0,,Screening
Study 24,Site 2030,Subject 41800,Study 24,AMERICA,USA,0.0,0.0,10.0,Screening,Screen Failure
Study 24,Site 2030,Subject 41801,Study 24,AMERICA,USA,0.0,8.0,40.0,30 Day Safety Follow-up,On Trial
Study 24,Site 2030,Subject 41802,Study 24,AMERICA,USA,0.0,7.0,36.0,Unplanned visit (7),On Trial
Study 24,Site 2030,Subject 41803,Study 24,AMERICA,USA,0.0,4.0,32.0,Follow-up 1,On Trial
Study 24,Site 2030,Subject 41804,Study 24,AMERICA,USA,0.0,7.0,36.0,Cycle 4 Day 1,On Trial
Study 24,Site 2030,Subject 41805,Study 24,AMERICA,USA,0.0,7.0,27.0,Cycle 4 Day 1,On Trial
Study 24,Site 2030,Subject 41806,Study 24,AMERICA,USA,0.0,1.0,0.0,Screening,Screening
Study 24,Site 2030,Subject 41807,Study 24,AMERICA,USA,0.0,1.0,0.0,Screening,Screening
Study 24,Site 2030,Subject 41808,Study 24,AMERICA,USA,0.0,1.0,0.0,Screening,Screening
Study 24,Site 2036,Subject 41877,Study 24,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 24,Site 2036,Subject 41878,Study 24,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 24,Site 2043,Subject 42069,Study 24,AMERICA,USA,0.0,0.0,0.0,,Enrolled
Study 24,Site 2161,Subject 46765,Study 24,EMEA,TUR,0.0,1.0,9.0,Screening,Screen Failure
Study 24,Site 2161,Subject 47661,Study 24,EMEA,TUR,0.0,9.0,79.0,Unplanned visit (7),On Trial
Study 24,Site 2161,Subject 47662,Study 24,EMEA,TUR,0.0,9.0,80.0,Unplanned visit (7),On Trial
Study 24,Site 2161,Subject 47663,Study 24,EMEA,TUR,0.0,8.0,94.0,Unplanned visit (8),On Trial
Study 24,Site 2163,Subject 47571,Study 24,ASIA,IND,0.0,5.0,35.0,Cycle 2 Day 15,On Trial
Study 24,Site 2163,Subject 47572,Study 24,ASIA,IND,0.0,4.0,23.0,Cycle 2 Day 1,On Trial
Study 24,Site 2164,Subject 47601,Study 24,ASIA,KOR,0.0,0.0,7.0,Screening,Screen Failure
Study 24,Site 2164,Subject 47602,Study 24,ASIA,KOR,0.0,1.0,7.0,Screening,Screen Failure
Study 24,Site 2164,Subject 47603,Study 24,ASIA,KOR,0.0,7.0,54.0,Cycle 4 Day 1,On Trial
Study 24,Site 2164,Subject 47604,Study 24,ASIA,KOR,0.0,6.0,65.0,Cycle 3 Day 1,On Trial
Study 24,Site 2164,Subject 47605,Study 24,ASIA,KOR,0.0,6.0,49.0,Cycle 3 Day 1,On Trial
Study 24,Site 2164,Subject 47606,Study 24,ASIA,KOR,0.0,6.0,48.0,Unplanned visit (2),On Trial
Study 24,Site 2164,Subject 47607,Study 24,ASIA,KOR,0.0,6.0,41.0,Cycle 3 Day 1,On Trial
Study 24,Site 2165,Subject 47608,Study 24,ASIA,KOR,0.0,8.0,81.0,Unplanned visit (10),On Trial
Study 24,Site 2165,Subject 47609,Study 24,ASIA,KOR,0.0,9.0,74.0,Unplanned visit (6),On Trial
Study 24,Site 2165,Subject 47610,Study 24,ASIA,KOR,0.0,8.0,81.0,Unplanned visit (4),On Trial
Study 24,Site 2165,Subject 47611,Study 24,ASIA,KOR,0.0,8.0,75.0,Unplanned visit (5),On Trial
Study 24,Site 2165,Subject 47612,Study 24,ASIA,KOR,0.0,8.0,26.0,Cycle 5 Day 1,On Trial
Study 24,Site 2165,Subject 47613,Study 24,ASIA,KOR,0.0,6.0,67.0,Unplanned visit (7),On Trial
Study 24,Site 2165,Subject 47614,Study 24,ASIA,KOR,0.0,6.0,69.0,Unplanned visit (7),On Trial
Study 24,Site 2165,Subject 47615,Study 24,ASIA,KOR,0.0,6.0,56.0,Cycle 3 Day 1,On Trial
Study 24,Site 2166,Subject 47616,Study 24,ASIA,KOR,0.0,7.0,32.0,Unplanned visit (7),On Trial
Study 24,Site 2166,Subject 47617,Study 24,ASIA,KOR,0.0,7.0,34.0,Unplanned visit (7),On Trial
Study 24,Site 2166,Subject 47618,Study 24,ASIA,KOR,0.0,6.0,23.0,Unplanned visit (5),On Trial
Study 24,Site 2166,Subject 47619,Study 24,ASIA,KOR,0.0,6.0,24.0,Follow-up 1,On Trial
Study 24,Site 2167,Subject 47620,Study 24,ASIA,KOR,0.0,7.0,45.0,Cycle 4 Day 1,On Trial
Study 24,Site 2167,Subject 47621,Study 24,ASIA,KOR,0.0,7.0,45.0,Cycle 4 Day 1,On Trial
Study 24,Site 2167,Subject 47622,Study 24,ASIA,KOR,0.0,7.0,45.0,Cycle 4 Day 1,On Trial
Study 24,Site 2167,Subject 47623,Study 24,ASIA,KOR,0.0,1.0,17.0,Screening,Screen Failure
Study 24,Site 2167,Subject 47624,Study 24,ASIA,KOR,0.0,7.0,44.0,Cycle 4 Day 1,On Trial
Study 24,Site 2167,Subject 47625,Study 24,ASIA,KOR,0.0,6.0,48.0,Unplanned visit (3),On Trial
Study 24,Site 2167,Subject 47626,Study 24,ASIA,KOR,0.0,6.0,45.0,Cycle 3 Day 1,On Trial
Study 24,Site 2167,Subject 47627,Study 24,ASIA,KOR,0.0,6.0,44.0,Cycle 3 Day 1,On Trial
Study 24,Site 2168,Subject 47628,Study 24,ASIA,KOR,0.0,8.0,45.0,Cycle 5 Day 1,On Trial
Study 24,Site 2168,Subject 47629,Study 24,ASIA,KOR,0.0,1.0,6.0,Screening,Screen Failure
Study 24,Site 2168,Subject 47630,Study 24,ASIA,KOR,0.0,8.0,55.0,Cycle 5 Day 1,On Trial
Study 24,Site 2168,Subject 47631,Study 24,ASIA,KOR,0.0,0.0,0.0,,Screening
Study 24,Site 2168,Subject 47632,Study 24,ASIA,KOR,0.0,8.0,61.0,Cycle 5 Day 1,On Trial
Study 24,Site 2168,Subject 47633,Study 24,ASIA,KOR,0.0,8.0,76.0,Unplanned visit (4),On Trial
Study 24,Site 2168,Subject 47634,Study 24,ASIA,KOR,0.0,8.0,65.0,Cycle 5 Day 1,On Trial
Study 24,Site 2168,Subject 47635,Study 24,ASIA,KOR,0.0,8.0,57.0,Cycle 5 Day 1,On Trial
Study 24,Site 2168,Subject 47636,Study 24,ASIA,KOR,0.0,8.0,58.0,Cycle 5 Day 1,On Trial
Study 24,Site 2168,Subject 47637,Study 24,ASIA,KOR,0.0,7.0,43.0,Unplanned visit (1),On Trial
Study 24,Site 2168,Subject 47638,Study 24,ASIA,KOR,0.0,1.0,6.0,Screening,Screen Failure
Study 24,Site 2169,Subject 47639,Study 24,ASIA,KOR,0.0,1.0,6.0,Screening,Screen Failure
Study 24,Site 2169,Subject 47640,Study 24,ASIA,KOR,0.0,1.0,6.0,Screening,Screen Failure
Study 24,Site 2169,Subject 47641,Study 24,ASIA,KOR,0.0,1.0,6.0,Screening,Screen Failure
Study 24,Site 2169,Subject 47642,Study 24,ASIA,KOR,0.0,10.0,53.0,Cycle 7 Day 1,On Trial
Study 24,Site 2169,Subject 47643,Study 24,ASIA,KOR,0.0,10.0,54.0,Cycle 7 Day 1,On Trial
Study 24,Site 2169,Subject 47644,Study 24,ASIA,KOR,0.0,8.0,45.0,Unplanned visit (8),On Trial
Study 24,Site 2169,Subject 47645,Study 24,ASIA,KOR,0.0,8.0,47.0,Cycle 5 Day 1,On Trial
Study 24,Site 2169,Subject 47646,Study 24,ASIA,KOR,0.0,7.0,39.0,Cycle 4 Day 1,On Trial
Study 24,Site 2169,Subject 47647,Study 24,ASIA,KOR,0.0,8.0,37.0,Cycle 5 Day 1,On Trial
Study 24,Site 2169,Subject 47648,Study 24,ASIA,KOR,0.0,7.0,26.0,Unplanned visit (8),On Trial
Study 24,Site 2169,Subject 47649,Study 24,ASIA,KOR,0.0,1.0,0.0,Screening,Screening
Study 24,Site 2169,Subject 47650,Study 24,ASIA,KOR,0.0,4.0,0.0,Cycle 2 Day 1,On Trial
Study 24,Site 2170,Subject 47651,Study 24,EMEA,TUR,0.0,9.0,92.0,Unplanned visit (8),On Trial
Study 24,Site 2170,Subject 47652,Study 24,EMEA,TUR,0.0,9.0,110.0,Unplanned visit (13),On Trial
Study 24,Site 2170,Subject 47653,Study 24,EMEA,TUR,0.0,9.0,94.0,Unplanned visit (7),On Trial
Study 24,Site 2170,Subject 47654,Study 24,EMEA,TUR,0.0,4.0,58.0,Unplanned visit (4),On Trial
Study 24,Site 2171,Subject 47655,Study 24,EMEA,TUR,0.0,8.0,56.0,Cycle 5 Day 1,On Trial
Study 24,Site 2171,Subject 47656,Study 24,EMEA,TUR,0.0,7.0,61.0,Cycle 4 Day 1,On Trial
Study 24,Site 2171,Subject 47657,Study 24,EMEA,TUR,0.0,4.0,33.0,Cycle 2 Day 1,On Trial
Study 24,Site 2172,Subject 47658,Study 24,EMEA,TUR,0.0,9.0,112.0,Unplanned visit (15),Screening
Study 24,Site 2172,Subject 47659,Study 24,EMEA,TUR,0.0,9.0,95.0,30 Day Safety Follow-up,On Trial
Study 24,Site 2172,Subject 47660,Study 24,EMEA,TUR,0.0,8.0,74.0,Unplanned visit (7),On Trial
Study 24,Site 2173,Subject 47664,Study 24,EMEA,TUR,0.0,8.0,35.0,Unplanned visit (5),On Trial
Study 24,Site 2173,Subject 47665,Study 24,EMEA,TUR,0.0,8.0,34.0,Cycle 5 Day 1,On Trial
Study 24,Site 2173,Subject 47666,Study 24,EMEA,TUR,0.0,8.0,30.0,Cycle 5 Day 1,On Trial
Study 24,Site 2173,Subject 47667,Study 24,EMEA,TUR,0.0,4.0,0.0,Cycle 2 Day 1,On Trial
Study 24,Site 2174,Subject 47668,Study 24,EMEA,TUR,0.0,6.0,29.0,Cycle 3 Day 1,On Trial
Study 24,Site 2174,Subject 47669,Study 24,EMEA,TUR,0.0,6.0,30.0,Cycle 3 Day 1,On Trial
Study 24,Site 2175,Subject 47670,Study 24,EMEA,TUR,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 2175,Subject 47671,Study 24,EMEA,TUR,0.0,1.0,0.0,Screening,Screening
Study 24,Site 2175,Subject 47672,Study 24,EMEA,TUR,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 2176,Subject 47673,Study 24,EMEA,TUR,0.0,6.0,56.0,Cycle 3 Day 1,On Trial
Study 24,Site 2176,Subject 47674,Study 24,EMEA,TUR,0.0,7.0,54.0,Cycle 4 Day 1,On Trial
Study 24,Site 2176,Subject 47675,Study 24,EMEA,TUR,0.0,2.0,27.0,Cycle 1 Day 1,On Trial
Study 24,Site 2176,Subject 47676,Study 24,EMEA,TUR,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 2177,Subject 47677,Study 24,EMEA,TUR,0.0,6.0,67.0,Unplanned visit (5),On Trial
Study 24,Site 2177,Subject 47678,Study 24,EMEA,TUR,0.0,4.0,50.0,Unplanned visit (2),On Trial
Study 24,Site 2177,Subject 47679,Study 24,EMEA,TUR,0.0,4.0,39.0,Unplanned visit (2),On Trial
Study 24,Site 2177,Subject 47680,Study 24,EMEA,TUR,0.0,1.0,3.0,Screening,Screening
Study 24,Site 2178,Subject 47681,Study 24,EMEA,TUR,0.0,7.0,60.0,Unplanned visit (3),On Trial
Study 24,Site 2178,Subject 47682,Study 24,EMEA,TUR,0.0,7.0,46.0,Cycle 4 Day 1,On Trial
Study 24,Site 2178,Subject 47683,Study 24,EMEA,TUR,0.0,4.0,33.0,Cycle 2 Day 1,On Trial
Study 24,Site 2179,Subject 47684,Study 24,EMEA,TUR,0.0,8.0,41.0,Cycle 5 Day 1,On Trial
Study 24,Site 2179,Subject 47685,Study 24,EMEA,TUR,0.0,8.0,31.0,Cycle 5 Day 1,On Trial
Study 24,Site 2179,Subject 47686,Study 24,EMEA,TUR,0.0,1.0,0.0,Screening,Screen Failure
Study 24,Site 2179,Subject 47687,Study 24,EMEA,TUR,0.0,1.0,0.0,Screening,Screening
Study 24,Site 2180,Subject 47688,Study 24,EMEA,TUR,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 2180,Subject 47689,Study 24,EMEA,TUR,0.0,0.0,0.0,,Screening
Study 24,Site 2181,Subject 47690,Study 24,EMEA,TUR,0.0,4.0,31.0,Cycle 2 Day 1,On Trial
Study 24,Site 2181,Subject 47691,Study 24,EMEA,TUR,0.0,4.0,29.0,Cycle 2 Day 1,On Trial
Study 24,Site 2181,Subject 47692,Study 24,EMEA,TUR,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 2182,Subject 47693,Study 24,EMEA,TUR,0.0,6.0,44.0,Cycle 3 Day 1,On Trial
Study 24,Site 2182,Subject 47694,Study 24,EMEA,TUR,0.0,4.0,36.0,Cycle 2 Day 1,On Trial
Study 24,Site 2182,Subject 47695,Study 24,EMEA,TUR,0.0,4.0,34.0,Cycle 2 Day 1,On Trial
Study 24,Site 2183,Subject 47697,Study 24,ASIA,CHN,0.0,1.0,0.0,Screening,Screening
Study 24,Site 2183,Subject 47698,Study 24,ASIA,CHN,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 2183,Subject 47699,Study 24,ASIA,CHN,0.0,4.0,0.0,Cycle 2 Day 1,On Trial
Study 24,Site 2183,Subject 47700,Study 24,ASIA,CHN,0.0,4.0,0.0,Cycle 2 Day 1,On Trial
Study 24,Site 2183,Subject 47701,Study 24,ASIA,CHN,0.0,4.0,0.0,Cycle 2 Day 1,On Trial
Study 24,Site 2183,Subject 47702,Study 24,ASIA,CHN,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 2184,Subject 47703,Study 24,ASIA,CHN,0.0,5.0,37.0,Cycle 2 Day 15,On Trial
Study 24,Site 2184,Subject 47704,Study 24,ASIA,CHN,0.0,5.0,36.0,Cycle 2 Day 15,On Trial
Study 24,Site 2184,Subject 47705,Study 24,ASIA,CHN,0.0,4.0,30.0,Cycle 2 Day 1,On Trial
Study 24,Site 2184,Subject 47706,Study 24,ASIA,CHN,0.0,1.0,7.0,Screening,Screen Failure
Study 24,Site 2184,Subject 47707,Study 24,ASIA,CHN,0.0,3.0,31.0,Cycle 1 Day 15,On Trial
Study 24,Site 2184,Subject 47708,Study 24,ASIA,CHN,0.0,3.0,32.0,Cycle 1 Day 15,On Trial
Study 24,Site 2184,Subject 47709,Study 24,ASIA,CHN,0.0,2.0,30.0,Cycle 1 Day 1,On Trial
Study 24,Site 2184,Subject 47710,Study 24,ASIA,CHN,0.0,1.0,7.0,Screening,Screen Failure
Study 24,Site 2184,Subject 47711,Study 24,ASIA,CHN,0.0,1.0,19.0,Screening,Enrolled
Study 24,Site 2184,Subject 47712,Study 24,ASIA,CHN,0.0,1.0,0.0,Screening,Screening
Study 24,Site 2185,Subject 47717,Study 24,ASIA,CHN,0.0,5.0,29.0,Cycle 2 Day 15,On Trial
Study 24,Site 2185,Subject 47718,Study 24,ASIA,CHN,0.0,4.0,27.0,Cycle 2 Day 1,On Trial
Study 24,Site 2185,Subject 47719,Study 24,ASIA,CHN,0.0,1.0,5.0,Screening,Screening
Study 24,Site 2185,Subject 47720,Study 24,ASIA,CHN,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 2185,Subject 47721,Study 24,ASIA,CHN,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 2185,Subject 47722,Study 24,ASIA,CHN,0.0,0.0,0.0,,Screening
Study 24,Site 2185,Subject 47723,Study 24,ASIA,CHN,0.0,0.0,0.0,,Screening
Study 24,Site 2186,Subject 47724,Study 24,ASIA,CHN,0.0,6.0,24.0,Cycle 3 Day 1,On Trial
Study 24,Site 2186,Subject 47725,Study 24,ASIA,CHN,0.0,5.0,24.0,Cycle 2 Day 15,On Trial
Study 24,Site 2186,Subject 47726,Study 24,ASIA,CHN,0.0,3.0,27.0,Cycle 1 Day 15,On Trial
Study 24,Site 2186,Subject 47727,Study 24,ASIA,CHN,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 2186,Subject 47728,Study 24,ASIA,CHN,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 2187,Subject 47737,Study 24,EMEA,DEU,0.0,6.0,35.0,Cycle 3 Day 1,On Trial
Study 24,Site 2187,Subject 47738,Study 24,EMEA,DEU,0.0,1.0,10.0,Screening,Enrolled
Study 24,Site 2187,Subject 47739,Study 24,EMEA,DEU,0.0,3.0,23.0,Cycle 1 Day 15,On Trial
Study 24,Site 2187,Subject 47740,Study 24,EMEA,DEU,0.0,2.0,14.0,Cycle 1 Day 1,On Trial
Study 24,Site 2187,Subject 47741,Study 24,EMEA,DEU,0.0,1.0,14.0,Screening,Enrolled
Study 24,Site 2187,Subject 47742,Study 24,EMEA,DEU,0.0,2.0,16.0,Cycle 1 Day 1,On Trial
Study 24,Site 2187,Subject 47743,Study 24,EMEA,DEU,0.0,1.0,15.0,Screening,Enrolled
Study 24,Site 2188,Subject 47744,Study 24,EMEA,ISR,0.0,6.0,52.0,Unplanned visit (6),On Trial
Study 24,Site 2188,Subject 47745,Study 24,EMEA,ISR,0.0,6.0,33.0,Cycle 3 Day 1,On Trial
Study 24,Site 2188,Subject 47746,Study 24,EMEA,ISR,0.0,4.0,29.0,Cycle 2 Day 1,On Trial
Study 24,Site 2189,Subject 47763,Study 24,AMERICA,USA,0.0,6.0,38.0,Cycle 3 Day 1,On Trial
Study 24,Site 2189,Subject 47764,Study 24,AMERICA,USA,0.0,1.0,6.0,Screening,Screen Failure
Study 24,Site 2190,Subject 47765,Study 24,AMERICA,USA,0.0,0.0,0.0,,Screening
Study 24,Site 2190,Subject 47766,Study 24,AMERICA,USA,0.0,0.0,0.0,,Screening
Study 24,Site 2191,Subject 47767,Study 24,AMERICA,USA,0.0,1.0,0.0,Screening,On Trial
Study 24,Site 259,Subject 2236,Study 24,ASIA,AUS,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 259,Subject 4990,Study 24,ASIA,AUS,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 259,Subject 4991,Study 24,ASIA,AUS,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 28,Subject 107,Study 24,ASIA,AUS,0.0,3.0,34.0,Cycle 1 Day 15,On Trial
Study 24,Site 28,Subject 108,Study 24,ASIA,AUS,0.0,3.0,28.0,Cycle 2 Day 1,On Trial
Study 24,Site 28,Subject 2233,Study 24,ASIA,AUS,0.0,4.0,36.0,Cycle 2 Day 1,On Trial
Study 24,Site 28,Subject 2234,Study 24,ASIA,AUS,0.0,2.0,20.0,Cycle 1 Day 1,On Trial
Study 24,Site 281,Subject 2364,Study 24,EMEA,DEU,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 281,Subject 2365,Study 24,EMEA,DEU,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 281,Subject 2366,Study 24,EMEA,DEU,0.0,4.0,0.0,Cycle 2 Day 1,On Trial
Study 24,Site 281,Subject 47729,Study 24,EMEA,DEU,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 281,Subject 47730,Study 24,EMEA,DEU,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 281,Subject 47731,Study 24,EMEA,DEU,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 281,Subject 47732,Study 24,EMEA,DEU,0.0,0.0,0.0,,Screening
Study 24,Site 281,Subject 47733,Study 24,EMEA,DEU,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 281,Subject 47734,Study 24,EMEA,DEU,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 281,Subject 47735,Study 24,EMEA,DEU,0.0,1.0,0.0,Screening,Screen Failure
Study 24,Site 281,Subject 47736,Study 24,EMEA,DEU,0.0,0.0,0.0,,Screening
Study 24,Site 281,Subject 9328,Study 24,EMEA,DEU,0.0,3.0,0.0,Unplanned visit (1),On Trial
Study 24,Site 281,Subject 9329,Study 24,EMEA,DEU,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 281,Subject 9330,Study 24,EMEA,DEU,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 281,Subject 9331,Study 24,EMEA,DEU,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 281,Subject 9332,Study 24,EMEA,DEU,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 281,Subject 9333,Study 24,EMEA,DEU,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 281,Subject 9334,Study 24,EMEA,DEU,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 281,Subject 9335,Study 24,EMEA,DEU,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 281,Subject 9336,Study 24,EMEA,DEU,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 281,Subject 9337,Study 24,EMEA,DEU,0.0,1.0,0.0,Screening,Screen Failure
Study 24,Site 281,Subject 9338,Study 24,EMEA,DEU,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 281,Subject 9339,Study 24,EMEA,DEU,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 286,Subject 2386,Study 24,EMEA,DEU,0.0,7.0,37.0,Cycle 4 Day 1,On Trial
Study 24,Site 286,Subject 2387,Study 24,EMEA,DEU,0.0,1.0,3.0,Screening,Screen Failure
Study 24,Site 286,Subject 2388,Study 24,EMEA,DEU,0.0,5.0,30.0,Cycle 2 Day 15,On Trial
Study 24,Site 286,Subject 2389,Study 24,EMEA,DEU,0.0,5.0,31.0,Cycle 2 Day 15,On Trial
Study 24,Site 286,Subject 2390,Study 24,EMEA,DEU,0.0,3.0,19.0,Cycle 1 Day 15,On Trial
Study 24,Site 286,Subject 9776,Study 24,EMEA,DEU,0.0,3.0,3.0,Cycle 1 Day 15,On Trial
Study 24,Site 286,Subject 9777,Study 24,EMEA,DEU,0.0,1.0,3.0,Screening,Enrolled
Study 24,Site 286,Subject 9778,Study 24,EMEA,DEU,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 3,Subject 102,Study 24,ASIA,AUS,0.0,9.0,49.0,Cycle 6 Day 1,On Trial
Study 24,Site 3,Subject 103,Study 24,ASIA,AUS,0.0,1.0,6.0,Screening,Screen Failure
Study 24,Site 3,Subject 104,Study 24,ASIA,AUS,0.0,8.0,51.0,Unplanned visit (1),On Trial
Study 24,Site 3,Subject 6,Study 24,ASIA,AUS,0.0,1.0,7.0,Screening,Screen Failure
Study 24,Site 3,Subject 7,Study 24,ASIA,AUS,0.0,1.0,7.0,Screening,Screen Failure
Study 24,Site 3,Subject 774,Study 24,ASIA,AUS,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 3,Subject 8,Study 24,ASIA,AUS,0.0,10.0,48.0,Cycle 7 Day 1,On Trial
Study 24,Site 326,Subject 2652,Study 24,AMERICA,USA,0.0,4.0,0.0,Cycle 2 Day 1,On Trial
Study 24,Site 326,Subject 2653,Study 24,AMERICA,USA,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 326,Subject 2654,Study 24,AMERICA,USA,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 326,Subject 2655,Study 24,AMERICA,USA,0.0,0.0,0.0,,Screening
Study 24,Site 327,Subject 2664,Study 24,AMERICA,USA,0.0,10.0,44.0,Cycle 7 Day 1,On Trial
Study 24,Site 327,Subject 2665,Study 24,AMERICA,USA,0.0,7.0,39.0,Cycle 5 Day 1,On Trial
Study 24,Site 338,Subject 2749,Study 24,AMERICA,USA,0.0,3.0,39.0,Cycle 1 Day 15,On Trial
Study 24,Site 349,Subject 2829,Study 24,EMEA,PRT,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 349,Subject 2830,Study 24,EMEA,PRT,0.0,1.0,0.0,Screening,Screen Failure
Study 24,Site 420,Subject 3234,Study 24,ASIA,CHN,0.0,5.0,38.0,Cycle 2 Day 15,On Trial
Study 24,Site 420,Subject 47696,Study 24,ASIA,CHN,0.0,1.0,3.0,Screening,Screening
Study 24,Site 420,Subject 6457,Study 24,ASIA,CHN,0.0,2.0,29.0,Cycle 1 Day 1,On Trial
Study 24,Site 420,Subject 6458,Study 24,ASIA,CHN,0.0,4.0,52.0,Unplanned visit (6),On Trial
Study 24,Site 420,Subject 6459,Study 24,ASIA,CHN,0.0,2.0,9.0,Cycle 1 Day 1,On Trial
Study 24,Site 420,Subject 6460,Study 24,ASIA,CHN,0.0,2.0,24.0,Cycle 1 Day 1,On Trial
Study 24,Site 421,Subject 3235,Study 24,ASIA,CHN,0.0,1.0,0.0,Screening,On Trial
Study 24,Site 421,Subject 3236,Study 24,ASIA,CHN,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 423,Subject 3245,Study 24,ASIA,CHN,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 423,Subject 3246,Study 24,ASIA,CHN,0.0,0.0,0.0,,Screening
Study 24,Site 423,Subject 3247,Study 24,ASIA,CHN,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 423,Subject 6489,Study 24,ASIA,CHN,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 423,Subject 6490,Study 24,ASIA,CHN,0.0,1.0,0.0,Screening,On Trial
Study 24,Site 423,Subject 6491,Study 24,ASIA,CHN,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 423,Subject 6492,Study 24,ASIA,CHN,0.0,0.0,0.0,,Screening
Study 24,Site 425,Subject 3256,Study 24,ASIA,CHN,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 426,Subject 3257,Study 24,ASIA,CHN,0.0,3.0,32.0,Cycle 1 Day 15,On Trial
Study 24,Site 426,Subject 3258,Study 24,ASIA,CHN,0.0,3.0,31.0,Cycle 1 Day 15,On Trial
Study 24,Site 426,Subject 3259,Study 24,ASIA,CHN,0.0,1.0,11.0,Screening,Screen Failure
Study 24,Site 426,Subject 3260,Study 24,ASIA,CHN,0.0,3.0,32.0,Cycle 1 Day 15,On Trial
Study 24,Site 426,Subject 47713,Study 24,ASIA,CHN,0.0,3.0,25.0,Cycle 1 Day 15,On Trial
Study 24,Site 426,Subject 47714,Study 24,ASIA,CHN,0.0,2.0,4.0,Cycle 1 Day 1,On Trial
Study 24,Site 426,Subject 47715,Study 24,ASIA,CHN,0.0,1.0,4.0,Screening,Screening
Study 24,Site 426,Subject 47716,Study 24,ASIA,CHN,0.0,1.0,0.0,Screening,Screen Failure
Study 24,Site 469,Subject 3565,Study 24,ASIA,TWN,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 469,Subject 4744,Study 24,ASIA,TWN,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 48,Subject 208,Study 24,ASIA,KOR,0.0,9.0,44.0,Cycle 6 Day 1,On Trial
Study 24,Site 48,Subject 209,Study 24,ASIA,KOR,0.0,8.0,46.0,Cycle 5 Day 1,On Trial
Study 24,Site 48,Subject 210,Study 24,ASIA,KOR,0.0,8.0,47.0,Cycle 5 Day 1,On Trial
Study 24,Site 48,Subject 211,Study 24,ASIA,KOR,0.0,1.0,16.0,Screening,Enrolled
Study 24,Site 48,Subject 212,Study 24,ASIA,KOR,0.0,8.0,46.0,Cycle 5 Day 1,On Trial
Study 24,Site 48,Subject 213,Study 24,ASIA,KOR,0.0,7.0,55.0,Unplanned visit (3),On Trial
Study 24,Site 48,Subject 214,Study 24,ASIA,KOR,0.0,7.0,42.0,Cycle 4 Day 1,On Trial
Study 24,Site 48,Subject 215,Study 24,ASIA,KOR,0.0,1.0,14.0,Screening,Screen Failure
Study 24,Site 48,Subject 216,Study 24,ASIA,KOR,0.0,7.0,49.0,Unplanned visit (3),On Trial
Study 24,Site 48,Subject 217,Study 24,ASIA,KOR,0.0,1.0,9.0,Screening,Screen Failure
Study 24,Site 48,Subject 218,Study 24,ASIA,KOR,0.0,7.0,31.0,Unplanned visit (1),On Trial
Study 24,Site 48,Subject 219,Study 24,ASIA,KOR,0.0,7.0,39.0,Cycle 4 Day 1,On Trial
Study 24,Site 48,Subject 220,Study 24,ASIA,KOR,0.0,6.0,33.0,Cycle 3 Day 1,On Trial
Study 24,Site 48,Subject 221,Study 24,ASIA,KOR,0.0,6.0,37.0,Cycle 3 Day 1,On Trial
Study 24,Site 48,Subject 222,Study 24,ASIA,KOR,0.0,6.0,35.0,Cycle 3 Day 1,On Trial
Study 24,Site 48,Subject 223,Study 24,ASIA,KOR,0.0,6.0,34.0,Cycle 3 Day 1,On Trial
Study 24,Site 48,Subject 224,Study 24,ASIA,KOR,0.0,5.0,31.0,Cycle 2 Day 15,On Trial
Study 24,Site 49,Subject 232,Study 24,ASIA,KOR,0.0,1.0,6.0,Screening,Screen Failure
Study 24,Site 49,Subject 233,Study 24,ASIA,KOR,0.0,7.0,60.0,Cycle 4 Day 1,On Trial
Study 24,Site 49,Subject 234,Study 24,ASIA,KOR,0.0,7.0,82.0,Unplanned visit (12),On Trial
Study 24,Site 49,Subject 235,Study 24,ASIA,KOR,0.0,7.0,54.0,Unplanned visit (3),On Trial
Study 24,Site 49,Subject 236,Study 24,ASIA,KOR,0.0,7.0,54.0,Unplanned visit (3),On Trial
Study 24,Site 49,Subject 237,Study 24,ASIA,KOR,0.0,1.0,6.0,Screening,Screen Failure
Study 24,Site 49,Subject 238,Study 24,ASIA,KOR,0.0,7.0,42.0,Cycle 4 Day 1,On Trial
Study 24,Site 49,Subject 239,Study 24,ASIA,KOR,0.0,1.0,7.0,Screening,Screen Failure
Study 24,Site 49,Subject 240,Study 24,ASIA,KOR,0.0,1.0,7.0,Screening,Screen Failure
Study 24,Site 49,Subject 241,Study 24,ASIA,KOR,0.0,7.0,53.0,Unplanned visit (4),On Trial
Study 24,Site 49,Subject 242,Study 24,ASIA,KOR,0.0,6.0,55.0,Cycle 3 Day 1,On Trial
Study 24,Site 49,Subject 243,Study 24,ASIA,KOR,0.0,7.0,63.0,Unplanned visit (5),On Trial
Study 24,Site 49,Subject 244,Study 24,ASIA,KOR,0.0,6.0,51.0,Cycle 3 Day 1,On Trial
Study 24,Site 49,Subject 245,Study 24,ASIA,KOR,0.0,6.0,37.0,Cycle 3 Day 1,On Trial
Study 24,Site 5,Subject 11,Study 24,EMEA,TUR,0.0,7.0,56.0,Cycle 4 Day 1,On Trial
Study 24,Site 5,Subject 3566,Study 24,EMEA,TUR,0.0,4.0,39.0,Cycle 2 Day 1,On Trial
Study 24,Site 5,Subject 3567,Study 24,EMEA,TUR,0.0,3.0,19.0,Cycle 1 Day 15,On Trial
Study 24,Site 50,Subject 271,Study 24,ASIA,KOR,0.0,9.0,35.0,Cycle 6 Day 1,On Trial
Study 24,Site 50,Subject 272,Study 24,ASIA,KOR,0.0,8.0,22.0,Unplanned visit (4),Enrolled
Study 24,Site 50,Subject 273,Study 24,ASIA,KOR,0.0,8.0,28.0,Cycle 5 Day 1,On Trial
Study 24,Site 50,Subject 274,Study 24,ASIA,KOR,0.0,8.0,30.0,Cycle 5 Day 1,On Trial
Study 24,Site 50,Subject 275,Study 24,ASIA,KOR,0.0,7.0,18.0,Cycle 4 Day 1,On Trial
Study 24,Site 50,Subject 276,Study 24,ASIA,KOR,0.0,7.0,19.0,Cycle 4 Day 1,On Trial
Study 24,Site 50,Subject 277,Study 24,ASIA,KOR,0.0,7.0,19.0,Unplanned visit (3),On Trial
Study 24,Site 50,Subject 278,Study 24,ASIA,KOR,0.0,7.0,17.0,Cycle 4 Day 1,On Trial
Study 24,Site 50,Subject 279,Study 24,ASIA,KOR,0.0,7.0,0.0,Unplanned visit (7),On Trial
Study 24,Site 50,Subject 280,Study 24,ASIA,KOR,0.0,6.0,0.0,Cycle 3 Day 1,On Trial
Study 24,Site 50,Subject 281,Study 24,ASIA,KOR,0.0,6.0,0.0,Cycle 3 Day 1,On Trial
Study 24,Site 50,Subject 282,Study 24,ASIA,KOR,0.0,1.0,0.0,Screening,Screen Failure
Study 24,Site 50,Subject 283,Study 24,ASIA,KOR,0.0,1.0,0.0,Unplanned visit (3),Enrolled
Study 24,Site 50,Subject 284,Study 24,ASIA,KOR,0.0,6.0,0.0,Cycle 3 Day 1,On Trial
Study 24,Site 50,Subject 285,Study 24,ASIA,KOR,0.0,5.0,48.0,Cycle 2 Day 15,On Trial
Study 24,Site 50,Subject 286,Study 24,ASIA,KOR,0.0,1.0,0.0,Screening,Screen Failure
Study 24,Site 50,Subject 287,Study 24,ASIA,KOR,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 50,Subject 288,Study 24,ASIA,KOR,0.0,3.0,0.0,Unplanned visit (1),On Trial
Study 24,Site 50,Subject 289,Study 24,ASIA,KOR,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 503,Subject 3706,Study 24,ASIA,CHN,0.0,1.0,0.0,Screening,Screening
Study 24,Site 503,Subject 3707,Study 24,ASIA,CHN,0.0,1.0,0.0,Screening,Screening
Study 24,Site 503,Subject 3708,Study 24,ASIA,CHN,0.0,1.0,0.0,Screening,Screening
Study 24,Site 503,Subject 3709,Study 24,ASIA,CHN,0.0,1.0,0.0,Screening,Screening
Study 24,Site 506,Subject 3722,Study 24,ASIA,CHN,0.0,6.0,41.0,Cycle 3 Day 1,On Trial
Study 24,Site 506,Subject 3723,Study 24,ASIA,CHN,0.0,6.0,34.0,Cycle 3 Day 1,On Trial
Study 24,Site 506,Subject 3724,Study 24,ASIA,CHN,0.0,3.0,33.0,Cycle 1 Day 15,On Trial
Study 24,Site 506,Subject 3725,Study 24,ASIA,CHN,0.0,3.0,32.0,Cycle 1 Day 15,On Trial
Study 24,Site 506,Subject 3726,Study 24,ASIA,CHN,0.0,2.0,4.0,Cycle 1 Day 1,On Trial
Study 24,Site 507,Subject 3727,Study 24,ASIA,CHN,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 507,Subject 3728,Study 24,ASIA,CHN,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 507,Subject 6384,Study 24,ASIA,CHN,0.0,0.0,0.0,,Screening
Study 24,Site 507,Subject 6385,Study 24,ASIA,CHN,0.0,0.0,0.0,,Screening
Study 24,Site 507,Subject 6386,Study 24,ASIA,CHN,0.0,0.0,0.0,,Screening
Study 24,Site 507,Subject 6387,Study 24,ASIA,CHN,0.0,0.0,0.0,,Screening
Study 24,Site 51,Subject 292,Study 24,ASIA,KOR,0.0,9.0,56.0,Cycle 6 Day 1,On Trial
Study 24,Site 51,Subject 293,Study 24,ASIA,KOR,0.0,9.0,55.0,Cycle 6 Day 1,On Trial
Study 24,Site 51,Subject 294,Study 24,ASIA,KOR,0.0,7.0,43.0,Unplanned visit (6),On Trial
Study 24,Site 51,Subject 295,Study 24,ASIA,KOR,0.0,7.0,47.0,Cycle 4 Day 1,On Trial
Study 24,Site 51,Subject 296,Study 24,ASIA,KOR,0.0,6.0,40.0,Cycle 3 Day 1,On Trial
Study 24,Site 51,Subject 297,Study 24,ASIA,KOR,0.0,1.0,7.0,Screening,Screening
Study 24,Site 51,Subject 298,Study 24,ASIA,KOR,0.0,1.0,12.0,Screening,Screen Failure
Study 24,Site 51,Subject 299,Study 24,ASIA,KOR,0.0,5.0,41.0,Unplanned visit (3),On Trial
Study 24,Site 51,Subject 300,Study 24,ASIA,KOR,0.0,1.0,7.0,Screening,Screen Failure
Study 24,Site 51,Subject 301,Study 24,ASIA,KOR,0.0,4.0,32.0,Unplanned visit (1),On Trial
Study 24,Site 51,Subject 302,Study 24,ASIA,KOR,0.0,5.0,39.0,Unplanned visit (3),On Trial
Study 24,Site 51,Subject 303,Study 24,ASIA,KOR,0.0,1.0,7.0,Screening,Screen Failure
Study 24,Site 51,Subject 304,Study 24,ASIA,KOR,0.0,4.0,30.0,Cycle 2 Day 1,On Trial
Study 24,Site 51,Subject 305,Study 24,ASIA,KOR,0.0,1.0,7.0,Screening,Screen Failure
Study 24,Site 52,Subject 309,Study 24,ASIA,KOR,0.0,9.0,0.0,Cycle 6 Day 1,On Trial
Study 24,Site 52,Subject 310,Study 24,ASIA,KOR,0.0,1.0,0.0,Screening,Screen Failure
Study 24,Site 52,Subject 311,Study 24,ASIA,KOR,0.0,7.0,0.0,Unplanned visit (2),On Trial
Study 24,Site 52,Subject 312,Study 24,ASIA,KOR,0.0,8.0,0.0,Cycle 5 Day 1,On Trial
Study 24,Site 52,Subject 313,Study 24,ASIA,KOR,0.0,8.0,0.0,Unplanned visit (2),On Trial
Study 24,Site 52,Subject 314,Study 24,ASIA,KOR,0.0,8.0,0.0,Cycle 5 Day 1,On Trial
Study 24,Site 52,Subject 47573,Study 24,ASIA,KOR,0.0,8.0,0.0,Cycle 5 Day 1,On Trial
Study 24,Site 52,Subject 47574,Study 24,ASIA,KOR,0.0,8.0,0.0,Cycle 5 Day 1,On Trial
Study 24,Site 52,Subject 47575,Study 24,ASIA,KOR,0.0,8.0,0.0,Cycle 5 Day 1,On Trial
Study 24,Site 52,Subject 47576,Study 24,ASIA,KOR,0.0,8.0,0.0,Cycle 5 Day 1,On Trial
Study 24,Site 52,Subject 47577,Study 24,ASIA,KOR,0.0,0.0,0.0,Screening,Screen Failure
Study 24,Site 52,Subject 47578,Study 24,ASIA,KOR,0.0,7.0,0.0,Cycle 4 Day 1,On Trial
Study 24,Site 52,Subject 47579,Study 24,ASIA,KOR,0.0,7.0,0.0,Cycle 4 Day 1,On Trial
Study 24,Site 52,Subject 47580,Study 24,ASIA,KOR,0.0,7.0,0.0,Cycle 4 Day 1,On Trial
Study 24,Site 52,Subject 47581,Study 24,ASIA,KOR,0.0,1.0,0.0,Screening,Screen Failure
Study 24,Site 52,Subject 47582,Study 24,ASIA,KOR,0.0,7.0,0.0,Cycle 4 Day 1,On Trial
Study 24,Site 52,Subject 47583,Study 24,ASIA,KOR,0.0,0.0,0.0,Screening,Screen Failure
Study 24,Site 52,Subject 47584,Study 24,ASIA,KOR,0.0,7.0,0.0,Cycle 4 Day 1,On Trial
Study 24,Site 52,Subject 47585,Study 24,ASIA,KOR,0.0,6.0,0.0,Unplanned visit (1),Discontinued
Study 24,Site 52,Subject 47586,Study 24,ASIA,KOR,0.0,7.0,0.0,Cycle 4 Day 1,On Trial
Study 24,Site 52,Subject 47587,Study 24,ASIA,KOR,0.0,6.0,0.0,Cycle 3 Day 1,On Trial
Study 24,Site 52,Subject 47588,Study 24,ASIA,KOR,0.0,6.0,0.0,Cycle 3 Day 1,On Trial
Study 24,Site 52,Subject 47589,Study 24,ASIA,KOR,0.0,7.0,0.0,Cycle 4 Day 1,On Trial
Study 24,Site 52,Subject 47590,Study 24,ASIA,KOR,0.0,6.0,0.0,Cycle 3 Day 1,On Trial
Study 24,Site 52,Subject 47591,Study 24,ASIA,KOR,0.0,6.0,0.0,Unplanned visit (1),On Trial
Study 24,Site 52,Subject 47592,Study 24,ASIA,KOR,0.0,6.0,0.0,Unplanned visit (1),On Trial
Study 24,Site 52,Subject 47593,Study 24,ASIA,KOR,0.0,6.0,0.0,Cycle 3 Day 1,On Trial
Study 24,Site 52,Subject 47594,Study 24,ASIA,KOR,0.0,6.0,0.0,Cycle 3 Day 1,On Trial
Study 24,Site 52,Subject 47595,Study 24,ASIA,KOR,0.0,6.0,0.0,Cycle 3 Day 1,On Trial
Study 24,Site 52,Subject 47596,Study 24,ASIA,KOR,0.0,6.0,0.0,Cycle 3 Day 1,On Trial
Study 24,Site 52,Subject 47597,Study 24,ASIA,KOR,0.0,4.0,0.0,Cycle 2 Day 1,On Trial
Study 24,Site 52,Subject 47598,Study 24,ASIA,KOR,0.0,6.0,0.0,Cycle 3 Day 1,On Trial
Study 24,Site 52,Subject 47599,Study 24,ASIA,KOR,0.0,5.0,0.0,Cycle 2 Day 15,On Trial
Study 24,Site 52,Subject 47600,Study 24,ASIA,KOR,0.0,5.0,0.0,Cycle 2 Day 15,On Trial
Study 24,Site 520,Subject 3767,Study 24,EMEA,DEU,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 520,Subject 3768,Study 24,EMEA,DEU,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 520,Subject 3769,Study 24,EMEA,DEU,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 520,Subject 8867,Study 24,EMEA,DEU,0.0,1.0,0.0,Screening,Screening
Study 24,Site 520,Subject 8868,Study 24,EMEA,DEU,0.0,1.0,0.0,Screening,Screening
Study 24,Site 521,Subject 3770,Study 24,EMEA,DEU,0.0,1.0,6.0,Screening,Enrolled
Study 24,Site 521,Subject 3771,Study 24,EMEA,DEU,0.0,6.0,55.0,Cycle 3 Day 1,On Trial
Study 24,Site 521,Subject 3772,Study 24,EMEA,DEU,0.0,5.0,45.0,End of Treatment,Completed
Study 24,Site 521,Subject 3773,Study 24,EMEA,DEU,0.0,4.0,39.0,Cycle 2 Day 1,On Trial
Study 24,Site 521,Subject 8892,Study 24,EMEA,DEU,0.0,3.0,32.0,Cycle 1 Day 15,On Trial
Study 24,Site 521,Subject 8893,Study 24,EMEA,DEU,0.0,2.0,30.0,Cycle 1 Day 1,On Trial
Study 24,Site 522,Subject 3774,Study 24,EMEA,DEU,0.0,7.0,45.0,Cycle 4 Day 1,On Trial
Study 24,Site 522,Subject 8927,Study 24,EMEA,DEU,0.0,7.0,37.0,Cycle 4 Day 1,On Trial
Study 24,Site 522,Subject 8928,Study 24,EMEA,DEU,0.0,3.0,31.0,Cycle 1 Day 15,On Trial
Study 24,Site 524,Subject 3778,Study 24,EMEA,ISR,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 525,Subject 3782,Study 24,EMEA,ISR,0.0,6.0,41.0,Cycle 3 Day 1,On Trial
Study 24,Site 525,Subject 47747,Study 24,EMEA,ISR,0.0,1.0,19.0,Screening,Screen Failure
Study 24,Site 525,Subject 47748,Study 24,EMEA,ISR,0.0,6.0,39.0,Cycle 3 Day 1,On Trial
Study 24,Site 525,Subject 47749,Study 24,EMEA,ISR,0.0,6.0,34.0,Cycle 3 Day 1,On Trial
Study 24,Site 53,Subject 315,Study 24,ASIA,KOR,0.0,7.0,35.0,Cycle 4 Day 1,On Trial
Study 24,Site 53,Subject 316,Study 24,ASIA,KOR,0.0,8.0,38.0,Cycle 5 Day 1,On Trial
Study 24,Site 53,Subject 317,Study 24,ASIA,KOR,0.0,8.0,40.0,Cycle 5 Day 1,On Trial
Study 24,Site 53,Subject 318,Study 24,ASIA,KOR,0.0,7.0,36.0,Cycle 4 Day 1,On Trial
Study 24,Site 53,Subject 319,Study 24,ASIA,KOR,0.0,7.0,40.0,Cycle 4 Day 1,On Trial
Study 24,Site 53,Subject 320,Study 24,ASIA,KOR,0.0,7.0,36.0,Cycle 4 Day 1,On Trial
Study 24,Site 53,Subject 321,Study 24,ASIA,KOR,0.0,7.0,33.0,Cycle 4 Day 1,On Trial
Study 24,Site 53,Subject 322,Study 24,ASIA,KOR,0.0,6.0,25.0,Cycle 3 Day 1,On Trial
Study 24,Site 530,Subject 35413,Study 24,EMEA,PRT,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 530,Subject 35414,Study 24,EMEA,PRT,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 530,Subject 35415,Study 24,EMEA,PRT,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 530,Subject 35416,Study 24,EMEA,PRT,0.0,1.0,0.0,Screening,Screening
Study 24,Site 530,Subject 3799,Study 24,EMEA,PRT,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 536,Subject 3821,Study 24,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 24,Site 536,Subject 3822,Study 24,AMERICA,USA,0.0,4.0,0.0,30 Day Safety Follow-up,Discontinued
Study 24,Site 536,Subject 3823,Study 24,AMERICA,USA,0.0,4.0,0.0,Cycle 2 Day 1,On Trial
Study 24,Site 536,Subject 3824,Study 24,AMERICA,USA,0.0,0.0,0.0,Screening,Screen Failure
Study 24,Site 536,Subject 40719,Study 24,AMERICA,USA,0.0,0.0,0.0,Screening,Screening
Study 24,Site 536,Subject 40720,Study 24,AMERICA,USA,0.0,0.0,0.0,Screening,Screening
Study 24,Site 536,Subject 40721,Study 24,AMERICA,USA,0.0,1.0,0.0,Screening,Screening
Study 24,Site 536,Subject 40722,Study 24,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 24,Site 558,Subject 3890,Study 24,EMEA,TUR,0.0,5.0,0.0,Cycle 2 Day 15,On Trial
Study 24,Site 594,Subject 4014,Study 24,AMERICA,USA,0.0,7.0,35.0,Cycle 4 Day 1,On Trial
Study 24,Site 594,Subject 4015,Study 24,AMERICA,USA,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 597,Subject 30317,Study 24,ASIA,IND,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 597,Subject 30318,Study 24,ASIA,IND,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 597,Subject 4019,Study 24,ASIA,IND,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 6,Subject 12,Study 24,EMEA,TUR,0.0,8.0,113.0,Unplanned visit (11),On Trial
Study 24,Site 6,Subject 13,Study 24,EMEA,TUR,0.0,8.0,78.0,Unplanned visit (6),On Trial
Study 24,Site 6,Subject 31074,Study 24,EMEA,TUR,0.0,6.0,69.0,Unplanned visit (4),On Trial
Study 24,Site 87,Subject 627,Study 24,ASIA,HKG,0.0,0.0,0.0,,Screening
Study 24,Site 875,Subject 8964,Study 24,EMEA,DEU,0.0,8.0,46.0,Cycle 5 Day 1,On Trial
Study 24,Site 875,Subject 8965,Study 24,EMEA,DEU,0.0,8.0,41.0,30 Day Safety Follow-up,On Trial
Study 24,Site 875,Subject 8966,Study 24,EMEA,DEU,0.0,7.0,40.0,Cycle 4 Day 1,On Trial
Study 24,Site 875,Subject 8967,Study 24,EMEA,DEU,0.0,7.0,42.0,Cycle 4 Day 1,On Trial
Study 24,Site 875,Subject 8968,Study 24,EMEA,DEU,0.0,6.0,34.0,Cycle 3 Day 1,On Trial
Study 24,Site 875,Subject 8969,Study 24,EMEA,DEU,0.0,6.0,36.0,Cycle 3 Day 1,On Trial
Study 24,Site 875,Subject 8970,Study 24,EMEA,DEU,0.0,6.0,37.0,Cycle 3 Day 1,On Trial
Study 24,Site 875,Subject 8971,Study 24,EMEA,DEU,0.0,6.0,39.0,Cycle 3 Day 1,On Trial
Study 24,Site 875,Subject 8972,Study 24,EMEA,DEU,0.0,5.0,34.0,Cycle 2 Day 15,On Trial
Study 24,Site 875,Subject 8973,Study 24,EMEA,DEU,0.0,5.0,45.0,Cycle 2 Day 15,On Trial
Study 24,Site 875,Subject 8974,Study 24,EMEA,DEU,0.0,6.0,41.0,Cycle 3 Day 1,On Trial
Study 24,Site 875,Subject 8975,Study 24,EMEA,DEU,0.0,5.0,33.0,Cycle 2 Day 15,On Trial
Study 24,Site 875,Subject 8976,Study 24,EMEA,DEU,0.0,5.0,33.0,Cycle 2 Day 15,On Trial
Study 24,Site 875,Subject 8977,Study 24,EMEA,DEU,0.0,4.0,12.0,Cycle 2 Day 1,On Trial
Study 24,Site 875,Subject 8978,Study 24,EMEA,DEU,0.0,5.0,29.0,Cycle 2 Day 15,On Trial
Study 24,Site 875,Subject 8979,Study 24,EMEA,DEU,0.0,4.0,17.0,Cycle 2 Day 1,On Trial
Study 24,Site 875,Subject 8980,Study 24,EMEA,DEU,0.0,4.0,31.0,Cycle 2 Day 1,On Trial
Study 24,Site 875,Subject 8981,Study 24,EMEA,DEU,0.0,4.0,16.0,Cycle 2 Day 1,On Trial
Study 24,Site 875,Subject 8982,Study 24,EMEA,DEU,0.0,3.0,20.0,Cycle 1 Day 15,On Trial
Study 24,Site 875,Subject 8983,Study 24,EMEA,DEU,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 875,Subject 8984,Study 24,EMEA,DEU,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 875,Subject 8985,Study 24,EMEA,DEU,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 875,Subject 8986,Study 24,EMEA,DEU,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 876,Subject 8989,Study 24,EMEA,DEU,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 876,Subject 8990,Study 24,EMEA,DEU,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 876,Subject 8991,Study 24,EMEA,DEU,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 876,Subject 8992,Study 24,EMEA,DEU,0.0,1.0,0.0,Screening,Screen Failure
Study 24,Site 876,Subject 8993,Study 24,EMEA,DEU,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 876,Subject 8994,Study 24,EMEA,DEU,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 877,Subject 9060,Study 24,EMEA,DEU,0.0,5.0,41.0,Cycle 2 Day 15,On Trial
Study 24,Site 877,Subject 9061,Study 24,EMEA,DEU,0.0,1.0,7.0,Screening,Screen Failure
Study 24,Site 877,Subject 9062,Study 24,EMEA,DEU,0.0,3.0,36.0,Cycle 1 Day 15,On Trial
Study 24,Site 879,Subject 9110,Study 24,EMEA,DEU,0.0,3.0,37.0,Cycle 1 Day 15,On Trial
Study 24,Site 879,Subject 9111,Study 24,EMEA,DEU,0.0,2.0,33.0,Cycle 1 Day 1,On Trial
Study 24,Site 879,Subject 9112,Study 24,EMEA,DEU,0.0,1.0,21.0,Screening,Enrolled
Study 24,Site 879,Subject 9113,Study 24,EMEA,DEU,0.0,1.0,24.0,Screening,On Trial
Study 24,Site 88,Subject 632,Study 24,ASIA,HKG,0.0,1.0,7.0,Screening,Screen Failure
Study 24,Site 88,Subject 633,Study 24,ASIA,HKG,0.0,6.0,38.0,Cycle 3 Day 1,On Trial
Study 24,Site 88,Subject 634,Study 24,ASIA,HKG,0.0,4.0,36.0,Cycle 2 Day 1,On Trial
Study 24,Site 880,Subject 9115,Study 24,EMEA,DEU,0.0,1.0,18.0,Screening,Screen Failure
Study 24,Site 880,Subject 9116,Study 24,EMEA,DEU,0.0,5.0,0.0,Cycle 2 Day 15,On Trial
Study 24,Site 880,Subject 9117,Study 24,EMEA,DEU,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 880,Subject 9118,Study 24,EMEA,DEU,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 880,Subject 9119,Study 24,EMEA,DEU,0.0,4.0,0.0,End of Treatment,On Trial
Study 24,Site 880,Subject 9120,Study 24,EMEA,DEU,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 880,Subject 9121,Study 24,EMEA,DEU,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 880,Subject 9122,Study 24,EMEA,DEU,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 880,Subject 9123,Study 24,EMEA,DEU,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 880,Subject 9124,Study 24,EMEA,DEU,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 880,Subject 9125,Study 24,EMEA,DEU,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 880,Subject 9126,Study 24,EMEA,DEU,0.0,0.0,0.0,,Screening
Study 24,Site 883,Subject 9190,Study 24,EMEA,DEU,0.0,6.0,0.0,Cycle 3 Day 1,On Trial
Study 24,Site 883,Subject 9191,Study 24,EMEA,DEU,0.0,3.0,0.0,Cycle 2 Day 1,On Trial
Study 24,Site 883,Subject 9192,Study 24,EMEA,DEU,0.0,4.0,0.0,Cycle 2 Day 1,On Trial
Study 24,Site 884,Subject 9217,Study 24,EMEA,DEU,0.0,4.0,0.0,Cycle 2 Day 1,On Trial
Study 24,Site 884,Subject 9218,Study 24,EMEA,DEU,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 884,Subject 9219,Study 24,EMEA,DEU,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 884,Subject 9220,Study 24,EMEA,DEU,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 887,Subject 9280,Study 24,EMEA,DEU,0.0,4.0,0.0,Cycle 2 Day 1,On Trial
Study 24,Site 887,Subject 9281,Study 24,EMEA,DEU,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 888,Subject 9286,Study 24,EMEA,DEU,0.0,1.0,14.0,Screening,Enrolled
Study 24,Site 888,Subject 9287,Study 24,EMEA,DEU,0.0,6.0,36.0,End of Treatment,Discontinued
Study 24,Site 888,Subject 9288,Study 24,EMEA,DEU,0.0,4.0,37.0,Unplanned visit (12),On Trial
Study 24,Site 888,Subject 9289,Study 24,EMEA,DEU,0.0,2.0,28.0,Cycle 1 Day 1,Screen Failure
Study 24,Site 888,Subject 9290,Study 24,EMEA,DEU,0.0,1.0,8.0,Screening,Enrolled
Study 24,Site 888,Subject 9291,Study 24,EMEA,DEU,0.0,6.0,41.0,Cycle 3 Day 1,On Trial
Study 24,Site 888,Subject 9292,Study 24,EMEA,DEU,0.0,1.0,15.0,Screening,On Trial
Study 24,Site 888,Subject 9293,Study 24,EMEA,DEU,0.0,4.0,21.0,End of Treatment,On Trial
Study 24,Site 888,Subject 9294,Study 24,EMEA,DEU,0.0,6.0,39.0,Cycle 3 Day 1,On Trial
Study 24,Site 888,Subject 9295,Study 24,EMEA,DEU,0.0,1.0,13.0,Screening,Enrolled
Study 24,Site 888,Subject 9296,Study 24,EMEA,DEU,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 888,Subject 9297,Study 24,EMEA,DEU,0.0,4.0,33.0,Cycle 2 Day 1,On Trial
Study 24,Site 888,Subject 9298,Study 24,EMEA,DEU,0.0,5.0,0.0,Cycle 2 Day 15,On Trial
Study 24,Site 888,Subject 9299,Study 24,EMEA,DEU,0.0,4.0,3.0,Cycle 2 Day 1,On Trial
Study 24,Site 888,Subject 9300,Study 24,EMEA,DEU,0.0,5.0,30.0,Cycle 2 Day 15,On Trial
Study 24,Site 888,Subject 9301,Study 24,EMEA,DEU,0.0,5.0,0.0,Cycle 2 Day 15,On Trial
Study 24,Site 888,Subject 9302,Study 24,EMEA,DEU,0.0,4.0,0.0,Cycle 2 Day 1,On Trial
Study 24,Site 888,Subject 9303,Study 24,EMEA,DEU,0.0,4.0,0.0,Unplanned visit (1),On Trial
Study 24,Site 888,Subject 9304,Study 24,EMEA,DEU,0.0,4.0,0.0,Cycle 2 Day 1,On Trial
Study 24,Site 888,Subject 9305,Study 24,EMEA,DEU,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 888,Subject 9306,Study 24,EMEA,DEU,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 888,Subject 9307,Study 24,EMEA,DEU,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 888,Subject 9308,Study 24,EMEA,DEU,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 904,Subject 9600,Study 24,EMEA,DEU,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 904,Subject 9601,Study 24,EMEA,DEU,0.0,1.0,0.0,Screening,Enrolled
Study 24,Site 904,Subject 9602,Study 24,EMEA,DEU,0.0,0.0,0.0,,Screening
Study 24,Site 904,Subject 9603,Study 24,EMEA,DEU,0.0,0.0,0.0,,Screening
Study 24,Site 952,Subject 13635,Study 24,AMERICA,CAN,0.0,3.0,29.0,Cycle 1 Day 15,On Trial
Study 24,Site 952,Subject 13636,Study 24,AMERICA,CAN,0.0,0.0,1.0,,Screening
Study 24,Site 952,Subject 13637,Study 24,AMERICA,CAN,0.0,3.0,25.0,Cycle 1 Day 15,On Trial
Study 24,Site 952,Subject 13638,Study 24,AMERICA,CAN,0.0,1.0,3.0,Screening,Screening
Study 24,Site 952,Subject 13639,Study 24,AMERICA,CAN,0.0,2.0,24.0,Screening,On Trial
Study 24,Site 952,Subject 13640,Study 24,AMERICA,CAN,0.0,0.0,0.0,,Screening
Study 24,Site 953,Subject 13650,Study 24,AMERICA,CAN,0.0,1.0,7.0,Screening,Screen Failure
Study 24,Site 953,Subject 13651,Study 24,AMERICA,CAN,0.0,6.0,32.0,Cycle 3 Day 1,On Trial
Study 24,Site 953,Subject 13652,Study 24,AMERICA,CAN,0.0,3.0,32.0,Cycle 1 Day 15,On Trial
Study 24,Site 953,Subject 13653,Study 24,AMERICA,CAN,0.0,3.0,34.0,Cycle 1 Day 15,On Trial
Study 24,Site 953,Subject 13654,Study 24,AMERICA,CAN,0.0,1.0,7.0,Screening,Enrolled
Study 24,Site 953,Subject 13655,Study 24,AMERICA,CAN,0.0,2.0,32.0,Cycle 1 Day 1,On Trial
Study 24,Site 953,Subject 13656,Study 24,AMERICA,CAN,0.0,3.0,23.0,Cycle 1 Day 15,On Trial
Study 24,Site 953,Subject 47750,Study 24,AMERICA,CAN,0.0,3.0,28.0,Cycle 1 Day 15,On Trial
Study 24,Site 953,Subject 47751,Study 24,AMERICA,CAN,0.0,2.0,31.0,Cycle 1 Day 1,On Trial
Study 24,Site 953,Subject 47752,Study 24,AMERICA,CAN,0.0,3.0,27.0,Cycle 1 Day 15,On Trial
Study 24,Site 953,Subject 47753,Study 24,AMERICA,CAN,0.0,2.0,21.0,Cycle 1 Day 1,On Trial
Study 24,Site 954,Subject 13657,Study 24,AMERICA,CAN,0.0,0.0,0.0,Screening,Screen Failure
Study 24,Site 954,Subject 13658,Study 24,AMERICA,CAN,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 955,Subject 13667,Study 24,AMERICA,CAN,0.0,8.0,48.0,Cycle 5 Day 1,On Trial
Study 24,Site 955,Subject 13668,Study 24,AMERICA,CAN,0.0,6.0,36.0,Cycle 3 Day 1,On Trial
Study 24,Site 955,Subject 13669,Study 24,AMERICA,CAN,0.0,0.0,6.0,Screening,Screen Failure
Study 24,Site 955,Subject 13670,Study 24,AMERICA,CAN,0.0,4.0,30.0,Cycle 2 Day 1,On Trial
Study 24,Site 955,Subject 13671,Study 24,AMERICA,CAN,0.0,5.0,27.0,Cycle 2 Day 15,On Trial
Study 24,Site 955,Subject 38951,Study 24,AMERICA,CAN,0.0,4.0,25.0,Cycle 2 Day 1,On Trial
Study 24,Site 955,Subject 38952,Study 24,AMERICA,CAN,0.0,2.0,21.0,Cycle 1 Day 1,On Trial
Study 24,Site 955,Subject 38953,Study 24,AMERICA,CAN,0.0,1.0,6.0,Screening,Screen Failure
Study 24,Site 955,Subject 47754,Study 24,AMERICA,CAN,0.0,0.0,0.0,Screening,Enrolled
Study 24,Site 955,Subject 47755,Study 24,AMERICA,CAN,0.0,3.0,29.0,Cycle 1 Day 15,On Trial
Study 24,Site 955,Subject 47756,Study 24,AMERICA,CAN,0.0,2.0,27.0,Cycle 1 Day 1,On Trial
Study 24,Site 955,Subject 47757,Study 24,AMERICA,CAN,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 955,Subject 47758,Study 24,AMERICA,CAN,0.0,1.0,11.0,Screening,Enrolled
Study 24,Site 955,Subject 47759,Study 24,AMERICA,CAN,0.0,2.0,17.0,Cycle 1 Day 1,On Trial
Study 24,Site 955,Subject 47760,Study 24,AMERICA,CAN,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 955,Subject 47761,Study 24,AMERICA,CAN,0.0,1.0,4.0,Screening,Screening
Study 24,Site 955,Subject 47762,Study 24,AMERICA,CAN,0.0,1.0,0.0,Screening,Screening
Study 24,Site 963,Subject 13826,Study 24,AMERICA,CAN,0.0,6.0,26.0,Cycle 4 Day 1,On Trial
Study 24,Site 963,Subject 13827,Study 24,AMERICA,CAN,0.0,7.0,22.0,Cycle 4 Day 1,On Trial
Study 24,Site 963,Subject 13828,Study 24,AMERICA,CAN,0.0,1.0,3.0,Screening,Screen Failure
Study 24,Site 963,Subject 13829,Study 24,AMERICA,CAN,0.0,7.0,16.0,Cycle 4 Day 1,On Trial
Study 24,Site 963,Subject 13830,Study 24,AMERICA,CAN,0.0,0.0,1.0,Screening,Screen Failure
Study 24,Site 963,Subject 13831,Study 24,AMERICA,CAN,0.0,0.0,1.0,Screening,Screening
Study 24,Site 963,Subject 13832,Study 24,AMERICA,CAN,0.0,7.0,22.0,Cycle 4 Day 1,On Trial
Study 24,Site 963,Subject 13833,Study 24,AMERICA,CAN,0.0,6.0,2.0,Cycle 3 Day 1,On Trial
Study 24,Site 963,Subject 13834,Study 24,AMERICA,CAN,0.0,5.0,0.0,Cycle 2 Day 15,On Trial
Study 24,Site 963,Subject 13835,Study 24,AMERICA,CAN,0.0,4.0,0.0,Cycle 2 Day 1,On Trial
Study 24,Site 963,Subject 13836,Study 24,AMERICA,CAN,0.0,5.0,2.0,Cycle 2 Day 15,On Trial
Study 24,Site 963,Subject 13837,Study 24,AMERICA,CAN,0.0,4.0,0.0,Cycle 2 Day 1,On Trial
Study 24,Site 963,Subject 13838,Study 24,AMERICA,CAN,0.0,0.0,0.0,,Screening
Study 24,Site 963,Subject 13839,Study 24,AMERICA,CAN,0.0,4.0,0.0,Cycle 2 Day 1,On Trial
Study 24,Site 963,Subject 39017,Study 24,AMERICA,CAN,0.0,3.0,0.0,Cycle 1 Day 15,On Trial
Study 24,Site 963,Subject 39018,Study 24,AMERICA,CAN,0.0,2.0,0.0,Cycle 1 Day 1,On Trial
Study 24,Site 963,Subject 39019,Study 24,AMERICA,CAN,0.0,0.0,0.0,,Enrolled
Study 24,Site 986,Subject 14214,Study 24,AMERICA,MEX,0.0,1.0,0.0,Screening,Enrolled
Study 25,Site 1003,Subject 14674,Study 25,EMEA,SVK,0.0,1.0,25.0,Unplanned Visit (1),Screen Failure
Study 25,Site 1004,Subject 14712,Study 25,EMEA,SVK,0.0,13.0,136.0,Unplanned Visit (4),Completed
Study 25,Site 1004,Subject 14713,Study 25,EMEA,SVK,0.0,2.0,36.0,Baseline (1),Screen Failure
Study 25,Site 1008,Subject 14782,Study 25,EMEA,SVN,0.0,2.0,30.0,Baseline (1),Screen Failure
Study 25,Site 1008,Subject 14783,Study 25,EMEA,SVN,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 1008,Subject 14784,Study 25,EMEA,SVN,0.0,13.0,147.0,EOS (1),Completed
Study 25,Site 1010,Subject 14855,Study 25,EMEA,ZAF,0.0,0.0,9.0,Screening,Screen Failure
Study 25,Site 1010,Subject 14856,Study 25,EMEA,ZAF,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 1010,Subject 14857,Study 25,EMEA,ZAF,0.0,1.0,15.0,Screening,Screen Failure
Study 25,Site 1010,Subject 14858,Study 25,EMEA,ZAF,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 109,Subject 835,Study 25,ASIA,AUS,0.0,13.0,150.0,EOS (1),Completed
Study 25,Site 109,Subject 836,Study 25,ASIA,AUS,0.0,13.0,158.0,EOS (1),Completed
Study 25,Site 109,Subject 837,Study 25,ASIA,AUS,0.0,13.0,127.0,EOS (1),Completed
Study 25,Site 109,Subject 838,Study 25,ASIA,AUS,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 109,Subject 839,Study 25,ASIA,AUS,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 109,Subject 840,Study 25,ASIA,AUS,0.0,1.0,11.0,Screening,Screen Failure
Study 25,Site 109,Subject 842,Study 25,ASIA,AUS,0.0,13.0,119.0,EOS (1),Completed
Study 25,Site 109,Subject 843,Study 25,ASIA,AUS,0.0,1.0,14.0,Screening,Screen Failure
Study 25,Site 11,Subject 20,Study 25,ASIA,IND,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 12,Subject 22,Study 25,EMEA,ISR,0.0,13.0,131.0,EOS (1),Completed
Study 25,Site 125,Subject 1072,Study 25,EMEA,HUN,0.0,1.0,10.0,Screening,Screen Failure
Study 25,Site 125,Subject 1073,Study 25,EMEA,HUN,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 125,Subject 1074,Study 25,EMEA,HUN,0.0,13.0,120.0,EOS (1),Completed
Study 25,Site 125,Subject 1075,Study 25,EMEA,HUN,0.0,13.0,130.0,EOS (1),Completed
Study 25,Site 126,Subject 1091,Study 25,EMEA,HUN,0.0,2.0,25.0,Baseline (1),Screen Failure
Study 25,Site 126,Subject 1092,Study 25,EMEA,HUN,0.0,13.0,133.0,EOS (1),Completed
Study 25,Site 126,Subject 1093,Study 25,EMEA,HUN,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 126,Subject 1094,Study 25,EMEA,HUN,0.0,13.0,134.0,EOS (1),Completed
Study 25,Site 127,Subject 1117,Study 25,EMEA,HUN,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 127,Subject 1118,Study 25,EMEA,HUN,0.0,13.0,131.0,EOS (1),Completed
Study 25,Site 13,Subject 1477,Study 25,EMEA,NLD,0.0,2.0,29.0,Baseline (1),Screen Failure
Study 25,Site 13,Subject 1478,Study 25,EMEA,NLD,0.0,10.0,99.0,Month 15 (1),Discontinued
Study 25,Site 13,Subject 1479,Study 25,EMEA,NLD,0.0,2.0,30.0,Baseline (1),Screen Failure
Study 25,Site 13,Subject 1480,Study 25,EMEA,NLD,0.0,2.0,29.0,Baseline (1),Screen Failure
Study 25,Site 13,Subject 1481,Study 25,EMEA,NLD,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 13,Subject 1482,Study 25,EMEA,NLD,0.0,2.0,29.0,Baseline (1),Screen Failure
Study 25,Site 13,Subject 1483,Study 25,EMEA,NLD,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 13,Subject 1484,Study 25,EMEA,NLD,0.0,13.0,112.0,EOS (1),Completed
Study 25,Site 13,Subject 23,Study 25,EMEA,NLD,0.0,10.0,99.0,Month 15 (1),Discontinued
Study 25,Site 13,Subject 24,Study 25,EMEA,NLD,0.0,1.0,15.0,Screening,Screen Failure
Study 25,Site 13,Subject 637,Study 25,EMEA,NLD,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 130,Subject 1137,Study 25,ASIA,IND,0.0,2.0,32.0,Baseline (1),Screen Failure
Study 25,Site 130,Subject 1138,Study 25,ASIA,IND,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 130,Subject 1139,Study 25,ASIA,IND,0.0,2.0,32.0,Baseline (1),Screen Failure
Study 25,Site 130,Subject 1140,Study 25,ASIA,IND,0.0,8.0,91.0,EOS (1),Discontinued
Study 25,Site 130,Subject 1141,Study 25,ASIA,IND,0.0,13.0,120.0,EOS (1),Completed
Study 25,Site 130,Subject 1142,Study 25,ASIA,IND,0.0,13.0,130.0,EOS (1),Completed
Study 25,Site 130,Subject 1143,Study 25,ASIA,IND,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 131,Subject 1145,Study 25,ASIA,IND,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 131,Subject 1146,Study 25,ASIA,IND,0.0,2.0,32.0,Baseline (1),Screen Failure
Study 25,Site 131,Subject 1147,Study 25,ASIA,IND,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 131,Subject 6648,Study 25,ASIA,IND,0.0,13.0,139.0,EOS (1),Completed
Study 25,Site 131,Subject 6649,Study 25,ASIA,IND,0.0,13.0,127.0,Unplanned Visit (1),Completed
Study 25,Site 131,Subject 6650,Study 25,ASIA,IND,0.0,13.0,128.0,EOS (1),Completed
Study 25,Site 131,Subject 6651,Study 25,ASIA,IND,0.0,2.0,31.0,Baseline (1),Screen Failure
Study 25,Site 148,Subject 1393,Study 25,EMEA,ITA,0.0,1.0,11.0,Screening,Screen Failure
Study 25,Site 148,Subject 1394,Study 25,EMEA,ITA,0.0,1.0,10.0,Screening,Screen Failure
Study 25,Site 148,Subject 1395,Study 25,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 149,Subject 1401,Study 25,EMEA,ITA,0.0,13.0,134.0,EOS (1),Completed
Study 25,Site 149,Subject 1402,Study 25,EMEA,ITA,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 149,Subject 1403,Study 25,EMEA,ITA,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 149,Subject 1404,Study 25,EMEA,ITA,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 149,Subject 1405,Study 25,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 149,Subject 1406,Study 25,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 149,Subject 1407,Study 25,EMEA,ITA,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 149,Subject 32904,Study 25,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 149,Subject 32905,Study 25,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 149,Subject 32906,Study 25,EMEA,ITA,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 149,Subject 32907,Study 25,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 149,Subject 32908,Study 25,EMEA,ITA,0.0,13.0,142.0,EOS (1),Completed
Study 25,Site 149,Subject 32909,Study 25,EMEA,ITA,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 149,Subject 32910,Study 25,EMEA,ITA,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 149,Subject 32911,Study 25,EMEA,ITA,0.0,1.0,12.0,Screening,Screen Failure
Study 25,Site 149,Subject 32912,Study 25,EMEA,ITA,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 149,Subject 32913,Study 25,EMEA,ITA,0.0,13.0,122.0,EOS (1),Completed
Study 25,Site 149,Subject 32914,Study 25,EMEA,ITA,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 149,Subject 32915,Study 25,EMEA,ITA,0.0,13.0,118.0,EOS (1),Completed
Study 25,Site 149,Subject 32916,Study 25,EMEA,ITA,0.0,13.0,126.0,EOS (1),Completed
Study 25,Site 149,Subject 6975,Study 25,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 154,Subject 1421,Study 25,ASIA,JPN,0.0,13.0,127.0,EOS (1),Completed
Study 25,Site 155,Subject 1427,Study 25,ASIA,JPN,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 155,Subject 1428,Study 25,ASIA,JPN,0.0,1.0,10.0,Screening,Screen Failure
Study 25,Site 155,Subject 1429,Study 25,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 155,Subject 1430,Study 25,ASIA,JPN,0.0,2.0,25.0,Baseline (1),Screen Failure
Study 25,Site 155,Subject 7276,Study 25,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 155,Subject 7277,Study 25,ASIA,JPN,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 155,Subject 7278,Study 25,ASIA,JPN,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 155,Subject 7279,Study 25,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 155,Subject 7280,Study 25,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 158,Subject 1442,Study 25,ASIA,JPN,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 158,Subject 1443,Study 25,ASIA,JPN,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 158,Subject 1444,Study 25,ASIA,JPN,0.0,2.0,25.0,Baseline (1),Screen Failure
Study 25,Site 158,Subject 1445,Study 25,ASIA,JPN,0.0,13.0,119.0,EOS (1),Completed
Study 25,Site 158,Subject 1446,Study 25,ASIA,JPN,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 160,Subject 1453,Study 25,ASIA,JPN,0.0,1.0,12.0,Screening,Screen Failure
Study 25,Site 160,Subject 1454,Study 25,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 160,Subject 1455,Study 25,ASIA,JPN,0.0,13.0,126.0,EOS (1),Completed
Study 25,Site 160,Subject 7712,Study 25,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 162,Subject 1459,Study 25,ASIA,KOR,0.0,13.0,132.0,EOS (1),Completed
Study 25,Site 162,Subject 1460,Study 25,ASIA,KOR,0.0,13.0,134.0,EOS (1),Completed
Study 25,Site 162,Subject 1461,Study 25,ASIA,KOR,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 162,Subject 1462,Study 25,ASIA,KOR,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 162,Subject 1463,Study 25,ASIA,KOR,0.0,13.0,118.0,EOS (1),Completed
Study 25,Site 162,Subject 1464,Study 25,ASIA,KOR,0.0,1.0,22.0,Screening,Screen Failure
Study 25,Site 162,Subject 1465,Study 25,ASIA,KOR,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 162,Subject 1466,Study 25,ASIA,KOR,0.0,13.0,118.0,EOS (1),Completed
Study 25,Site 162,Subject 1467,Study 25,ASIA,KOR,0.0,13.0,129.0,EOS (1),Completed
Study 25,Site 162,Subject 1468,Study 25,ASIA,KOR,0.0,13.0,118.0,EOS (1),Completed
Study 25,Site 1673,Subject 30790,Study 25,AMERICA,BRA,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 1673,Subject 30791,Study 25,AMERICA,BRA,0.0,2.0,32.0,Unplanned Visit (2),Screen Failure
Study 25,Site 1673,Subject 30792,Study 25,AMERICA,BRA,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 1673,Subject 30793,Study 25,AMERICA,BRA,0.0,13.0,130.0,EOS (1),Completed
Study 25,Site 1673,Subject 30794,Study 25,AMERICA,BRA,0.0,2.0,36.0,Unplanned Visit (1),Screen Failure
Study 25,Site 1674,Subject 30855,Study 25,AMERICA,BRA,0.0,1.0,14.0,Screening,Screen Failure
Study 25,Site 1674,Subject 30856,Study 25,AMERICA,BRA,0.0,1.0,13.0,Screening,Screen Failure
Study 25,Site 1674,Subject 30857,Study 25,AMERICA,BRA,0.0,13.0,133.0,Unplanned Visit (1),Completed
Study 25,Site 1674,Subject 30858,Study 25,AMERICA,BRA,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 1674,Subject 30859,Study 25,AMERICA,BRA,0.0,2.0,32.0,Baseline (1),Screen Failure
Study 25,Site 1676,Subject 30882,Study 25,AMERICA,BRA,0.0,13.0,136.0,EOS (1),Completed
Study 25,Site 1676,Subject 30883,Study 25,AMERICA,BRA,0.0,2.0,22.0,Baseline (1),Screen Failure
Study 25,Site 1676,Subject 30884,Study 25,AMERICA,BRA,0.0,1.0,14.0,Screening,Screen Failure
Study 25,Site 1676,Subject 30885,Study 25,AMERICA,BRA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 1676,Subject 30886,Study 25,AMERICA,BRA,0.0,13.0,137.0,EOS (1),Completed
Study 25,Site 1677,Subject 30890,Study 25,AMERICA,BRA,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 1677,Subject 30891,Study 25,AMERICA,BRA,0.0,2.0,36.0,Unplanned Visit (1),Screen Failure
Study 25,Site 1677,Subject 30892,Study 25,AMERICA,BRA,0.0,13.0,120.0,EOS (1),Completed
Study 25,Site 1677,Subject 30893,Study 25,AMERICA,BRA,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 1677,Subject 30894,Study 25,AMERICA,BRA,0.0,1.0,23.0,Unplanned Visit (1),Screen Failure
Study 25,Site 1677,Subject 30895,Study 25,AMERICA,BRA,0.0,13.0,119.0,EOS (1),Completed
Study 25,Site 1677,Subject 30896,Study 25,AMERICA,BRA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 1677,Subject 30897,Study 25,AMERICA,BRA,0.0,2.0,33.0,Baseline (1),Screen Failure
Study 25,Site 1677,Subject 30898,Study 25,AMERICA,BRA,0.0,13.0,112.0,EOS (1),Completed
Study 25,Site 1678,Subject 30907,Study 25,AMERICA,BRA,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 1678,Subject 30908,Study 25,AMERICA,BRA,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 1678,Subject 30909,Study 25,AMERICA,BRA,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 1678,Subject 30910,Study 25,AMERICA,BRA,0.0,1.0,18.0,Unplanned Visit (1),Screen Failure
Study 25,Site 1716,Subject 32626,Study 25,EMEA,ISR,0.0,1.0,14.0,Screening,Screen Failure
Study 25,Site 1716,Subject 47897,Study 25,EMEA,ISR,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 1734,Subject 33037,Study 25,ASIA,JPN,0.0,2.0,32.0,Baseline (1),Screen Failure
Study 25,Site 1734,Subject 33038,Study 25,ASIA,JPN,0.0,2.0,33.0,Baseline (1),Screen Failure
Study 25,Site 1734,Subject 33039,Study 25,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 1734,Subject 33040,Study 25,ASIA,JPN,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 1734,Subject 33041,Study 25,ASIA,JPN,0.0,1.0,15.0,Screening,Screen Failure
Study 25,Site 1734,Subject 33042,Study 25,ASIA,JPN,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 1735,Subject 33048,Study 25,ASIA,JPN,0.0,13.0,129.0,EOS (1),Completed
Study 25,Site 1735,Subject 33049,Study 25,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 1736,Subject 32960,Study 25,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 1736,Subject 32961,Study 25,ASIA,JPN,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 1737,Subject 32996,Study 25,ASIA,JPN,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 1738,Subject 33005,Study 25,ASIA,JPN,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 1738,Subject 33006,Study 25,ASIA,JPN,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 1738,Subject 33007,Study 25,ASIA,JPN,0.0,2.0,25.0,Baseline (1),Screen Failure
Study 25,Site 1738,Subject 33008,Study 25,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 1738,Subject 33009,Study 25,ASIA,JPN,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 1738,Subject 33010,Study 25,ASIA,JPN,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 1738,Subject 33011,Study 25,ASIA,JPN,0.0,13.0,120.0,EOS (1),Completed
Study 25,Site 1738,Subject 33012,Study 25,ASIA,JPN,0.0,13.0,140.0,EOS (1),Completed
Study 25,Site 1738,Subject 33013,Study 25,ASIA,JPN,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 1738,Subject 33014,Study 25,ASIA,JPN,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 1738,Subject 33015,Study 25,ASIA,JPN,0.0,13.0,117.0,EOS (1),Completed
Study 25,Site 1738,Subject 33016,Study 25,ASIA,JPN,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 1738,Subject 33017,Study 25,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 1738,Subject 33018,Study 25,ASIA,JPN,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 1738,Subject 33019,Study 25,ASIA,JPN,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 1739,Subject 33028,Study 25,ASIA,JPN,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 1739,Subject 33029,Study 25,ASIA,JPN,0.0,13.0,121.0,EOS (1),Completed
Study 25,Site 1739,Subject 33030,Study 25,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 1739,Subject 33031,Study 25,ASIA,JPN,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 1739,Subject 33032,Study 25,ASIA,JPN,0.0,13.0,118.0,EOS (1),Completed
Study 25,Site 1739,Subject 33033,Study 25,ASIA,JPN,0.0,2.0,22.0,Baseline (1),Screen Failure
Study 25,Site 1739,Subject 33034,Study 25,ASIA,JPN,0.0,13.0,118.0,EOS (1),Completed
Study 25,Site 1739,Subject 33035,Study 25,ASIA,JPN,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 1739,Subject 33036,Study 25,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 1739,Subject 47900,Study 25,ASIA,JPN,0.0,13.0,119.0,EOS (1),Completed
Study 25,Site 1740,Subject 33068,Study 25,ASIA,JPN,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 1740,Subject 33069,Study 25,ASIA,JPN,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 1740,Subject 47901,Study 25,ASIA,JPN,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 1740,Subject 47902,Study 25,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 1740,Subject 47903,Study 25,ASIA,JPN,0.0,13.0,135.0,EOS (1),Completed
Study 25,Site 1740,Subject 47904,Study 25,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 1740,Subject 47905,Study 25,ASIA,JPN,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 1740,Subject 47906,Study 25,ASIA,JPN,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 1740,Subject 47907,Study 25,ASIA,JPN,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 1740,Subject 47908,Study 25,ASIA,JPN,0.0,13.0,125.0,EOS (1),Completed
Study 25,Site 1743,Subject 33101,Study 25,ASIA,JPN,0.0,2.0,32.0,Baseline (1),Screen Failure
Study 25,Site 1743,Subject 33102,Study 25,ASIA,JPN,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 1743,Subject 33103,Study 25,ASIA,JPN,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 1744,Subject 33107,Study 25,ASIA,JPN,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 1744,Subject 33108,Study 25,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 1744,Subject 33109,Study 25,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 1744,Subject 33110,Study 25,ASIA,JPN,0.0,13.0,150.0,EOS (1),Completed
Study 25,Site 1744,Subject 33111,Study 25,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 1744,Subject 33112,Study 25,ASIA,JPN,0.0,13.0,126.0,EOS (1),Completed
Study 25,Site 1745,Subject 33121,Study 25,ASIA,JPN,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 1745,Subject 33122,Study 25,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 1745,Subject 33123,Study 25,ASIA,JPN,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 1745,Subject 33124,Study 25,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 1745,Subject 33125,Study 25,ASIA,JPN,0.0,1.0,12.0,Screening,Screen Failure
Study 25,Site 1747,Subject 33197,Study 25,ASIA,MYS,0.0,13.0,131.0,EOS (1),Completed
Study 25,Site 1747,Subject 33198,Study 25,ASIA,MYS,0.0,13.0,154.0,EOS (1),Completed
Study 25,Site 1747,Subject 33199,Study 25,ASIA,MYS,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 1747,Subject 33200,Study 25,ASIA,MYS,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 1747,Subject 33201,Study 25,ASIA,MYS,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 1747,Subject 33202,Study 25,ASIA,MYS,0.0,13.0,121.0,EOS (1),Completed
Study 25,Site 1747,Subject 33203,Study 25,ASIA,MYS,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 1770,Subject 33583,Study 25,AMERICA,MEX,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 1770,Subject 33584,Study 25,AMERICA,MEX,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 1770,Subject 33585,Study 25,AMERICA,MEX,0.0,13.0,138.0,EOS (1),Discontinued
Study 25,Site 1770,Subject 33586,Study 25,AMERICA,MEX,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 1770,Subject 33587,Study 25,AMERICA,MEX,0.0,2.0,32.0,Baseline (1),Screen Failure
Study 25,Site 1771,Subject 33594,Study 25,AMERICA,MEX,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 1771,Subject 33595,Study 25,AMERICA,MEX,0.0,1.0,22.0,Screening,Screen Failure
Study 25,Site 1771,Subject 33596,Study 25,AMERICA,MEX,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 1772,Subject 33620,Study 25,AMERICA,MEX,0.0,13.0,132.0,EOS (1),Completed
Study 25,Site 1772,Subject 33621,Study 25,AMERICA,MEX,0.0,13.0,141.0,EOS (1),Completed
Study 25,Site 1791,Subject 34337,Study 25,EMEA,RUS,0.0,13.0,122.0,EOS (1),Completed
Study 25,Site 1791,Subject 34338,Study 25,EMEA,RUS,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 1791,Subject 34339,Study 25,EMEA,RUS,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 1791,Subject 34340,Study 25,EMEA,RUS,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 1795,Subject 34382,Study 25,EMEA,RUS,0.0,1.0,6.0,Screening,Screen Failure
Study 25,Site 1795,Subject 34383,Study 25,EMEA,RUS,0.0,1.0,6.0,Screening,Screen Failure
Study 25,Site 1816,Subject 34792,Study 25,ASIA,SGP,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 1816,Subject 34793,Study 25,ASIA,SGP,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 1816,Subject 34794,Study 25,ASIA,SGP,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 1816,Subject 34795,Study 25,ASIA,SGP,0.0,1.0,14.0,Screening,Screen Failure
Study 25,Site 1816,Subject 34796,Study 25,ASIA,SGP,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 1816,Subject 34797,Study 25,ASIA,SGP,0.0,13.0,121.0,EOS (1),Completed
Study 25,Site 1816,Subject 34798,Study 25,ASIA,SGP,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 1816,Subject 34799,Study 25,ASIA,SGP,0.0,13.0,113.0,EOS (1),Completed
Study 25,Site 1845,Subject 35326,Study 25,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 1845,Subject 35327,Study 25,EMEA,ESP,0.0,1.0,14.0,Screening,Screen Failure
Study 25,Site 1846,Subject 35377,Study 25,EMEA,ESP,0.0,7.0,74.0,EOS (1),Discontinued
Study 25,Site 1846,Subject 35378,Study 25,EMEA,ESP,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 1847,Subject 35425,Study 25,EMEA,ESP,0.0,2.0,24.0,Baseline (1),Screen Failure
Study 25,Site 1848,Subject 35435,Study 25,EMEA,ESP,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 1849,Subject 35507,Study 25,EMEA,ESP,0.0,13.0,125.0,EOS (1),Completed
Study 25,Site 1849,Subject 35508,Study 25,EMEA,ESP,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 1850,Subject 35526,Study 25,EMEA,ESP,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 1850,Subject 35527,Study 25,EMEA,ESP,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 1906,Subject 36522,Study 25,EMEA,SWE,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 1906,Subject 36523,Study 25,EMEA,SWE,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 1906,Subject 36524,Study 25,EMEA,SWE,0.0,1.0,22.0,Screening,Screen Failure
Study 25,Site 1906,Subject 36525,Study 25,EMEA,SWE,0.0,1.0,11.0,Screening,Screen Failure
Study 25,Site 1906,Subject 36526,Study 25,EMEA,SWE,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 1906,Subject 36527,Study 25,EMEA,SWE,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 1906,Subject 36528,Study 25,EMEA,SWE,0.0,2.0,34.0,Baseline (1),Screen Failure
Study 25,Site 1909,Subject 36579,Study 25,ASIA,TWN,0.0,13.0,141.0,EOS (1),Completed
Study 25,Site 1909,Subject 36580,Study 25,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 1909,Subject 36581,Study 25,ASIA,TWN,0.0,2.0,32.0,Baseline (1),Screen Failure
Study 25,Site 1909,Subject 36582,Study 25,ASIA,TWN,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 1909,Subject 36583,Study 25,ASIA,TWN,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 1909,Subject 36584,Study 25,ASIA,TWN,0.0,13.0,128.0,EOS (1),Completed
Study 25,Site 1909,Subject 36585,Study 25,ASIA,TWN,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 1951,Subject 38228,Study 25,ASIA,VNM,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 1951,Subject 38229,Study 25,ASIA,VNM,0.0,6.0,68.0,Month 3 (1),Discontinued
Study 25,Site 1951,Subject 38230,Study 25,ASIA,VNM,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 1951,Subject 38231,Study 25,ASIA,VNM,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 1951,Subject 38232,Study 25,ASIA,VNM,0.0,13.0,123.0,EOS (1),Completed
Study 25,Site 1951,Subject 38233,Study 25,ASIA,VNM,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 1951,Subject 38234,Study 25,ASIA,VNM,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 1951,Subject 38235,Study 25,ASIA,VNM,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 1951,Subject 38236,Study 25,ASIA,VNM,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 1957,Subject 38627,Study 25,AMERICA,USA,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 1958,Subject 38877,Study 25,AMERICA,USA,0.0,1.0,12.0,Screening,Screen Failure
Study 25,Site 1960,Subject 38900,Study 25,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 1960,Subject 38901,Study 25,AMERICA,USA,0.0,13.0,141.0,EOS (1),Completed
Study 25,Site 1960,Subject 38902,Study 25,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 1960,Subject 38903,Study 25,AMERICA,USA,0.0,2.0,36.0,Unplanned Visit (1),Screen Failure
Study 25,Site 1960,Subject 38904,Study 25,AMERICA,USA,0.0,13.0,141.0,EOS (1),Completed
Study 25,Site 1960,Subject 38905,Study 25,AMERICA,USA,0.0,13.0,127.0,EOS (1),Completed
Study 25,Site 1981,Subject 39688,Study 25,EMEA,SVN,0.0,13.0,123.0,EOS (1),Completed
Study 25,Site 1981,Subject 39689,Study 25,EMEA,SVN,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 1981,Subject 39690,Study 25,EMEA,SVN,0.0,13.0,130.0,EOS (1),Completed
Study 25,Site 1981,Subject 39691,Study 25,EMEA,SVN,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 1981,Subject 39692,Study 25,EMEA,SVN,0.0,2.0,12.0,Baseline (1),Screen Failure
Study 25,Site 1981,Subject 39693,Study 25,EMEA,SVN,0.0,1.0,11.0,Screening,Screen Failure
Study 25,Site 1981,Subject 39694,Study 25,EMEA,SVN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 1981,Subject 39695,Study 25,EMEA,SVN,0.0,13.0,130.0,EOS (1),Completed
Study 25,Site 1981,Subject 39696,Study 25,EMEA,SVN,0.0,2.0,25.0,Baseline (1),Screen Failure
Study 25,Site 1981,Subject 48211,Study 25,EMEA,SVN,0.0,13.0,126.0,EOS (1),Completed
Study 25,Site 1981,Subject 48212,Study 25,EMEA,SVN,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 1981,Subject 48213,Study 25,EMEA,SVN,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 1981,Subject 48214,Study 25,EMEA,SVN,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2,Subject 100,Study 25,AMERICA,ARG,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 2,Subject 2,Study 25,AMERICA,ARG,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 2,Subject 3,Study 25,AMERICA,ARG,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 2,Subject 4,Study 25,AMERICA,ARG,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 2,Subject 5,Study 25,AMERICA,ARG,0.0,13.0,119.0,EOS (1),Completed
Study 25,Site 2,Subject 99,Study 25,AMERICA,ARG,0.0,13.0,133.0,EOS (1),Completed
Study 25,Site 2184,Subject 47703,Study 25,EMEA,DEU,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2184,Subject 47704,Study 25,EMEA,DEU,0.0,13.0,129.0,EOS (1),Completed
Study 25,Site 2188,Subject 47744,Study 25,EMEA,RUS,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2188,Subject 47745,Study 25,EMEA,RUS,0.0,9.0,72.0,EOS (1),Completed
Study 25,Site 2188,Subject 47746,Study 25,EMEA,RUS,0.0,2.0,21.0,Baseline (1),Screen Failure
Study 25,Site 2188,Subject 47915,Study 25,EMEA,RUS,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2188,Subject 47916,Study 25,EMEA,RUS,0.0,1.0,11.0,Screening,Screen Failure
Study 25,Site 2188,Subject 47917,Study 25,EMEA,RUS,0.0,13.0,128.0,EOS (1),Completed
Study 25,Site 2188,Subject 47918,Study 25,EMEA,RUS,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2188,Subject 47919,Study 25,EMEA,RUS,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2188,Subject 47920,Study 25,EMEA,RUS,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2188,Subject 47921,Study 25,EMEA,RUS,0.0,13.0,129.0,EOS (1),Completed
Study 25,Site 2188,Subject 47922,Study 25,EMEA,RUS,0.0,2.0,20.0,Baseline (1),Screen Failure
Study 25,Site 2188,Subject 47923,Study 25,EMEA,RUS,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2188,Subject 47924,Study 25,EMEA,RUS,0.0,13.0,133.0,EOS (1),Completed
Study 25,Site 2188,Subject 47925,Study 25,EMEA,RUS,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2192,Subject 47786,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2192,Subject 47787,Study 25,ASIA,CHN,0.0,1.0,10.0,Screening,Screen Failure
Study 25,Site 2192,Subject 47788,Study 25,ASIA,CHN,0.0,13.0,133.0,Unplanned Visit (6),Completed
Study 25,Site 2192,Subject 47789,Study 25,ASIA,CHN,0.0,13.0,105.0,EOS (1),Completed
Study 25,Site 2192,Subject 47790,Study 25,ASIA,CHN,0.0,2.0,25.0,Baseline (1),Screen Failure
Study 25,Site 2192,Subject 47791,Study 25,ASIA,CHN,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2193,Subject 47792,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2193,Subject 47793,Study 25,ASIA,CHN,0.0,13.0,129.0,EOS (1),Completed
Study 25,Site 2193,Subject 47794,Study 25,ASIA,CHN,0.0,13.0,109.0,EOS (1),Completed
Study 25,Site 2193,Subject 47795,Study 25,ASIA,CHN,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 2193,Subject 47796,Study 25,ASIA,CHN,0.0,2.0,27.0,Baseline (1),Screen Failure
Study 25,Site 2193,Subject 47797,Study 25,ASIA,CHN,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 2193,Subject 47798,Study 25,ASIA,CHN,0.0,1.0,13.0,Screening,Screen Failure
Study 25,Site 2193,Subject 47799,Study 25,ASIA,CHN,0.0,1.0,12.0,Screening,Screen Failure
Study 25,Site 2193,Subject 47800,Study 25,ASIA,CHN,0.0,1.0,13.0,Screening,Screen Failure
Study 25,Site 2193,Subject 47801,Study 25,ASIA,CHN,0.0,13.0,121.0,EOS (1),Completed
Study 25,Site 2193,Subject 47802,Study 25,ASIA,CHN,0.0,13.0,112.0,Unplanned Visit (2),Completed
Study 25,Site 2193,Subject 47803,Study 25,ASIA,CHN,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 2193,Subject 47804,Study 25,ASIA,CHN,0.0,1.0,13.0,Screening,Screen Failure
Study 25,Site 2193,Subject 47805,Study 25,ASIA,CHN,0.0,13.0,105.0,EOS (1),Completed
Study 25,Site 2193,Subject 47806,Study 25,ASIA,CHN,0.0,2.0,31.0,Baseline (1),Screen Failure
Study 25,Site 2193,Subject 47807,Study 25,ASIA,CHN,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 2193,Subject 47808,Study 25,ASIA,CHN,0.0,13.0,127.0,EOS (1),Completed
Study 25,Site 2193,Subject 47809,Study 25,ASIA,CHN,0.0,13.0,108.0,EOS (1),Completed
Study 25,Site 2193,Subject 47810,Study 25,ASIA,CHN,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 2193,Subject 47811,Study 25,ASIA,CHN,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 2193,Subject 47812,Study 25,ASIA,CHN,0.0,13.0,104.0,EOS (1),Completed
Study 25,Site 2193,Subject 47813,Study 25,ASIA,CHN,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 2193,Subject 47814,Study 25,ASIA,CHN,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 2193,Subject 47815,Study 25,ASIA,CHN,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 2193,Subject 47816,Study 25,ASIA,CHN,0.0,13.0,153.0,EOS (1),Completed
Study 25,Site 2193,Subject 47817,Study 25,ASIA,CHN,0.0,13.0,104.0,EOS (1),Completed
Study 25,Site 2193,Subject 47818,Study 25,ASIA,CHN,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 2193,Subject 47819,Study 25,ASIA,CHN,0.0,2.0,31.0,Baseline (1),Screen Failure
Study 25,Site 2193,Subject 47820,Study 25,ASIA,CHN,0.0,13.0,135.0,EOS (1),Completed
Study 25,Site 2193,Subject 47821,Study 25,ASIA,CHN,0.0,13.0,107.0,EOS (1),Completed
Study 25,Site 2193,Subject 47822,Study 25,ASIA,CHN,0.0,13.0,117.0,EOS (1),Completed
Study 25,Site 2193,Subject 47823,Study 25,ASIA,CHN,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 2194,Subject 47824,Study 25,ASIA,CHN,0.0,13.0,107.0,EOS (1),Completed
Study 25,Site 2194,Subject 47825,Study 25,ASIA,CHN,0.0,1.0,10.0,Screening,Screen Failure
Study 25,Site 2194,Subject 47826,Study 25,ASIA,CHN,0.0,13.0,107.0,EOS (1),Completed
Study 25,Site 2194,Subject 47827,Study 25,ASIA,CHN,0.0,1.0,10.0,Screening,Screen Failure
Study 25,Site 2194,Subject 47828,Study 25,ASIA,CHN,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 2194,Subject 47829,Study 25,ASIA,CHN,0.0,1.0,11.0,Screening,Screen Failure
Study 25,Site 2194,Subject 47830,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2194,Subject 47831,Study 25,ASIA,CHN,0.0,13.0,123.0,EOS (1),Completed
Study 25,Site 2194,Subject 47832,Study 25,ASIA,CHN,0.0,2.0,25.0,Baseline (1),Screen Failure
Study 25,Site 2194,Subject 47833,Study 25,ASIA,CHN,0.0,10.0,94.0,EOS (1),Discontinued
Study 25,Site 2194,Subject 47834,Study 25,ASIA,CHN,0.0,9.0,95.0,EOS (1),Discontinued
Study 25,Site 2194,Subject 47835,Study 25,ASIA,CHN,0.0,13.0,100.0,EOS (1),Completed
Study 25,Site 2194,Subject 47836,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2194,Subject 47837,Study 25,ASIA,CHN,0.0,1.0,24.0,Unplanned Visit (1),Screen Failure
Study 25,Site 2194,Subject 47838,Study 25,ASIA,CHN,0.0,13.0,107.0,EOS (1),Completed
Study 25,Site 2194,Subject 47839,Study 25,ASIA,CHN,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2194,Subject 47840,Study 25,ASIA,CHN,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2194,Subject 47841,Study 25,ASIA,CHN,0.0,13.0,104.0,EOS (1),Completed
Study 25,Site 2194,Subject 47842,Study 25,ASIA,CHN,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2194,Subject 47843,Study 25,ASIA,CHN,0.0,2.0,30.0,Baseline (1),Screen Failure
Study 25,Site 2195,Subject 47844,Study 25,ASIA,CHN,0.0,1.0,10.0,Screening,Screen Failure
Study 25,Site 2195,Subject 47845,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2196,Subject 47846,Study 25,ASIA,CHN,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2196,Subject 47847,Study 25,ASIA,CHN,0.0,13.0,106.0,EOS (1),Completed
Study 25,Site 2196,Subject 47848,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2196,Subject 47849,Study 25,ASIA,CHN,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2197,Subject 47850,Study 25,ASIA,CHN,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 2197,Subject 47851,Study 25,ASIA,CHN,0.0,13.0,106.0,EOS (1),Completed
Study 25,Site 2197,Subject 47852,Study 25,ASIA,CHN,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 2197,Subject 47853,Study 25,ASIA,CHN,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 2197,Subject 47854,Study 25,ASIA,CHN,0.0,2.0,24.0,Baseline (1),Screen Failure
Study 25,Site 2198,Subject 47855,Study 25,ASIA,CHN,0.0,13.0,108.0,EOS (1),Completed
Study 25,Site 2198,Subject 47856,Study 25,ASIA,CHN,0.0,13.0,121.0,EOS (1),Completed
Study 25,Site 2198,Subject 47857,Study 25,ASIA,CHN,0.0,13.0,104.0,EOS (1),Completed
Study 25,Site 2199,Subject 47858,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2199,Subject 47859,Study 25,ASIA,CHN,0.0,2.0,24.0,Baseline (1),Screen Failure
Study 25,Site 2199,Subject 47860,Study 25,ASIA,CHN,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 2199,Subject 47861,Study 25,ASIA,CHN,0.0,13.0,105.0,EOS (1),Completed
Study 25,Site 2199,Subject 47862,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2200,Subject 47863,Study 25,ASIA,CHN,0.0,2.0,24.0,Baseline (1),Screen Failure
Study 25,Site 2200,Subject 47864,Study 25,ASIA,CHN,0.0,13.0,104.0,EOS (1),Completed
Study 25,Site 2201,Subject 47865,Study 25,ASIA,CHN,0.0,13.0,109.0,EOS (1),Completed
Study 25,Site 2202,Subject 47866,Study 25,ASIA,CHN,0.0,1.0,13.0,Screening,Screen Failure
Study 25,Site 2202,Subject 47867,Study 25,ASIA,CHN,0.0,1.0,11.0,Screening,Screen Failure
Study 25,Site 2202,Subject 47868,Study 25,ASIA,CHN,0.0,1.0,14.0,Screening,Screen Failure
Study 25,Site 2202,Subject 47869,Study 25,ASIA,CHN,0.0,1.0,14.0,Screening,Screen Failure
Study 25,Site 2202,Subject 47870,Study 25,ASIA,CHN,0.0,1.0,13.0,Screening,Screen Failure
Study 25,Site 2202,Subject 47871,Study 25,ASIA,CHN,0.0,1.0,13.0,Screening,Screen Failure
Study 25,Site 2202,Subject 47872,Study 25,ASIA,CHN,0.0,13.0,109.0,EOS (1),Completed
Study 25,Site 2202,Subject 47873,Study 25,ASIA,CHN,0.0,1.0,12.0,Screening,Screen Failure
Study 25,Site 2203,Subject 47874,Study 25,ASIA,CHN,0.0,13.0,108.0,EOS (1),Completed
Study 25,Site 2204,Subject 47875,Study 25,ASIA,CHN,0.0,2.0,23.0,Baseline (1),Screen Failure
Study 25,Site 2204,Subject 47876,Study 25,ASIA,CHN,0.0,1.0,10.0,Screening,Screen Failure
Study 25,Site 2204,Subject 47877,Study 25,ASIA,CHN,0.0,2.0,23.0,Baseline (1),Screen Failure
Study 25,Site 2205,Subject 47878,Study 25,ASIA,CHN,0.0,2.0,24.0,Baseline (1),Screen Failure
Study 25,Site 2206,Subject 47889,Study 25,EMEA,DEU,0.0,1.0,21.0,Unplanned Visit (1),Screen Failure
Study 25,Site 2206,Subject 47890,Study 25,EMEA,DEU,0.0,2.0,31.0,Baseline (1),Screen Failure
Study 25,Site 2206,Subject 6421,Study 25,EMEA,DEU,0.0,13.0,123.0,EOS (1),Completed
Study 25,Site 2207,Subject 47885,Study 25,EMEA,DEU,0.0,13.0,127.0,EOS (1),Completed
Study 25,Site 2207,Subject 47886,Study 25,EMEA,DEU,0.0,1.0,12.0,Screening,Screen Failure
Study 25,Site 2207,Subject 47887,Study 25,EMEA,DEU,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 2207,Subject 47888,Study 25,EMEA,DEU,0.0,1.0,6.0,Screening,Screen Failure
Study 25,Site 2208,Subject 47898,Study 25,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2208,Subject 47899,Study 25,ASIA,JPN,0.0,13.0,128.0,EOS (1),Completed
Study 25,Site 2209,Subject 47909,Study 25,ASIA,JPN,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2210,Subject 47910,Study 25,ASIA,JPN,0.0,13.0,129.0,EOS (1),Completed
Study 25,Site 2210,Subject 47911,Study 25,ASIA,JPN,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 2210,Subject 47912,Study 25,ASIA,JPN,0.0,2.0,29.0,Baseline (1),Screen Failure
Study 25,Site 2211,Subject 47913,Study 25,AMERICA,MEX,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 2211,Subject 47914,Study 25,AMERICA,MEX,0.0,13.0,125.0,EOS (1),Completed
Study 25,Site 2212,Subject 47928,Study 25,ASIA,TWN,0.0,1.0,11.0,Screening,Screen Failure
Study 25,Site 2212,Subject 47929,Study 25,ASIA,TWN,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 2213,Subject 47930,Study 25,ASIA,THA,0.0,13.0,134.0,EOS (1),Completed
Study 25,Site 2213,Subject 47931,Study 25,ASIA,THA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2213,Subject 47932,Study 25,ASIA,THA,0.0,13.0,127.0,EOS (1),Completed
Study 25,Site 2213,Subject 47933,Study 25,ASIA,THA,0.0,13.0,131.0,EOS (1),Completed
Study 25,Site 2213,Subject 47934,Study 25,ASIA,THA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2213,Subject 47935,Study 25,ASIA,THA,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2213,Subject 47936,Study 25,ASIA,THA,0.0,13.0,131.0,EOS (1),Completed
Study 25,Site 2213,Subject 47937,Study 25,ASIA,THA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2213,Subject 47938,Study 25,ASIA,THA,0.0,13.0,123.0,EOS (1),Completed
Study 25,Site 2214,Subject 47939,Study 25,ASIA,THA,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 2214,Subject 47940,Study 25,ASIA,THA,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 2214,Subject 47941,Study 25,ASIA,THA,0.0,13.0,118.0,EOS (1),Completed
Study 25,Site 2214,Subject 47942,Study 25,ASIA,THA,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 2214,Subject 47943,Study 25,ASIA,THA,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 2214,Subject 47944,Study 25,ASIA,THA,0.0,13.0,128.0,EOS (1),Completed
Study 25,Site 2214,Subject 47945,Study 25,ASIA,THA,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 2214,Subject 47946,Study 25,ASIA,THA,0.0,2.0,36.0,Baseline (1),Screen Failure
Study 25,Site 2214,Subject 47947,Study 25,ASIA,THA,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 2214,Subject 47948,Study 25,ASIA,THA,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 2214,Subject 47949,Study 25,ASIA,THA,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 2214,Subject 47950,Study 25,ASIA,THA,0.0,8.0,94.0,Month 9 (1),Discontinued
Study 25,Site 2214,Subject 47951,Study 25,ASIA,THA,0.0,13.0,144.0,EOS (1),Completed
Study 25,Site 2215,Subject 47952,Study 25,ASIA,THA,0.0,2.0,31.0,Baseline (1),Screen Failure
Study 25,Site 2215,Subject 47953,Study 25,ASIA,THA,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 2215,Subject 47954,Study 25,ASIA,THA,0.0,13.0,134.0,EOS (1),Completed
Study 25,Site 2215,Subject 47955,Study 25,ASIA,THA,0.0,13.0,131.0,EOS (1),Completed
Study 25,Site 2215,Subject 47956,Study 25,ASIA,THA,0.0,2.0,40.0,Baseline (1),Screen Failure
Study 25,Site 2216,Subject 47957,Study 25,ASIA,THA,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 2216,Subject 47958,Study 25,ASIA,THA,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 2216,Subject 47959,Study 25,ASIA,THA,0.0,1.0,12.0,Screening,Screen Failure
Study 25,Site 2216,Subject 47960,Study 25,ASIA,THA,0.0,13.0,143.0,EOS (1),Completed
Study 25,Site 2216,Subject 47961,Study 25,ASIA,THA,0.0,13.0,126.0,EOS (1),Completed
Study 25,Site 2217,Subject 47962,Study 25,ASIA,THA,0.0,2.0,33.0,Baseline (1),Screen Failure
Study 25,Site 2217,Subject 47963,Study 25,ASIA,THA,0.0,2.0,33.0,Baseline (1),Screen Failure
Study 25,Site 2217,Subject 47964,Study 25,ASIA,THA,0.0,8.0,99.0,EOS (1),Discontinued
Study 25,Site 2217,Subject 47965,Study 25,ASIA,THA,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 2218,Subject 47966,Study 25,EMEA,TUR,0.0,13.0,122.0,EOS (1),Completed
Study 25,Site 2218,Subject 47967,Study 25,EMEA,TUR,0.0,10.0,110.0,EOS (1),Discontinued
Study 25,Site 2218,Subject 47968,Study 25,EMEA,TUR,0.0,2.0,33.0,Baseline (1),Screen Failure
Study 25,Site 2218,Subject 47969,Study 25,EMEA,TUR,0.0,1.0,15.0,Screening,Screen Failure
Study 25,Site 2218,Subject 47970,Study 25,EMEA,TUR,0.0,13.0,135.0,EOS (1),Completed
Study 25,Site 2219,Subject 47971,Study 25,EMEA,TUR,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 2219,Subject 47972,Study 25,EMEA,TUR,0.0,1.0,23.0,Screening,Screen Failure
Study 25,Site 2219,Subject 47973,Study 25,EMEA,TUR,0.0,9.0,107.0,Unplanned Visit (1),Discontinued
Study 25,Site 2219,Subject 47974,Study 25,EMEA,TUR,0.0,13.0,129.0,EOS (1),Completed
Study 25,Site 2219,Subject 47975,Study 25,EMEA,TUR,0.0,13.0,127.0,EOS (1),Completed
Study 25,Site 2219,Subject 47976,Study 25,EMEA,TUR,0.0,1.0,15.0,Screening,Screen Failure
Study 25,Site 2219,Subject 47977,Study 25,EMEA,TUR,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 2219,Subject 47978,Study 25,EMEA,TUR,0.0,13.0,144.0,Unplanned Visit (3),Completed
Study 25,Site 2219,Subject 47979,Study 25,EMEA,TUR,0.0,13.0,139.0,EOS (1),Completed
Study 25,Site 2219,Subject 47980,Study 25,EMEA,TUR,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 2219,Subject 47981,Study 25,EMEA,TUR,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 2219,Subject 47982,Study 25,EMEA,TUR,0.0,2.0,32.0,Baseline (1),Screen Failure
Study 25,Site 2219,Subject 47983,Study 25,EMEA,TUR,0.0,13.0,130.0,EOS (1),Completed
Study 25,Site 2219,Subject 47984,Study 25,EMEA,TUR,0.0,13.0,123.0,EOS (1),Completed
Study 25,Site 2219,Subject 47985,Study 25,EMEA,TUR,0.0,13.0,123.0,EOS (1),Completed
Study 25,Site 2219,Subject 47986,Study 25,EMEA,TUR,0.0,2.0,35.0,Baseline (1),Screen Failure
Study 25,Site 2219,Subject 47987,Study 25,EMEA,TUR,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 2219,Subject 47988,Study 25,EMEA,TUR,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 2219,Subject 47989,Study 25,EMEA,TUR,0.0,13.0,123.0,EOS (1),Completed
Study 25,Site 2219,Subject 47990,Study 25,EMEA,TUR,0.0,2.0,28.0,Baseline (1),Screen Failure
Study 25,Site 2219,Subject 47991,Study 25,EMEA,TUR,0.0,13.0,117.0,EOS (1),Completed
Study 25,Site 2219,Subject 47992,Study 25,EMEA,TUR,0.0,13.0,122.0,EOS (1),Completed
Study 25,Site 2219,Subject 47993,Study 25,EMEA,TUR,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 2219,Subject 47994,Study 25,EMEA,TUR,0.0,13.0,119.0,EOS (1),Completed
Study 25,Site 2219,Subject 47995,Study 25,EMEA,TUR,0.0,2.0,33.0,Baseline (1),Screen Failure
Study 25,Site 2219,Subject 47996,Study 25,EMEA,TUR,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 2220,Subject 47997,Study 25,EMEA,TUR,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 2220,Subject 47998,Study 25,EMEA,TUR,0.0,13.0,121.0,EOS (1),Completed
Study 25,Site 2220,Subject 47999,Study 25,EMEA,TUR,0.0,13.0,122.0,EOS (1),Completed
Study 25,Site 2220,Subject 48000,Study 25,EMEA,TUR,0.0,1.0,27.0,Screening,Screen Failure
Study 25,Site 2220,Subject 48001,Study 25,EMEA,TUR,0.0,1.0,25.0,Unplanned Visit (1),Screen Failure
Study 25,Site 2220,Subject 48002,Study 25,EMEA,TUR,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 2220,Subject 48003,Study 25,EMEA,TUR,0.0,13.0,122.0,EOS (1),Completed
Study 25,Site 2220,Subject 48004,Study 25,EMEA,TUR,0.0,1.0,22.0,Unplanned Visit (1),Screen Failure
Study 25,Site 2220,Subject 48005,Study 25,EMEA,TUR,0.0,1.0,15.0,Screening,Screen Failure
Study 25,Site 2220,Subject 48006,Study 25,EMEA,TUR,0.0,2.0,32.0,Baseline (1),Screen Failure
Study 25,Site 2220,Subject 48007,Study 25,EMEA,TUR,0.0,13.0,133.0,EOS (1),Completed
Study 25,Site 2220,Subject 48008,Study 25,EMEA,TUR,0.0,2.0,33.0,Baseline (1),Screen Failure
Study 25,Site 2220,Subject 48009,Study 25,EMEA,TUR,0.0,13.0,132.0,EOS (1),Completed
Study 25,Site 2220,Subject 48010,Study 25,EMEA,TUR,0.0,13.0,129.0,EOS (1),Completed
Study 25,Site 2221,Subject 48011,Study 25,EMEA,TUR,0.0,7.0,78.0,Month 6 (1),Discontinued
Study 25,Site 2221,Subject 48012,Study 25,EMEA,TUR,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2221,Subject 48013,Study 25,EMEA,TUR,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 2221,Subject 48014,Study 25,EMEA,TUR,0.0,13.0,153.0,EOS (1),Completed
Study 25,Site 2221,Subject 48015,Study 25,EMEA,TUR,0.0,13.0,132.0,EOS (1),Completed
Study 25,Site 2221,Subject 48016,Study 25,EMEA,TUR,0.0,13.0,150.0,EOS (1),Completed
Study 25,Site 2221,Subject 48017,Study 25,EMEA,TUR,0.0,13.0,123.0,EOS (1),Completed
Study 25,Site 2221,Subject 48018,Study 25,EMEA,TUR,0.0,1.0,24.0,Unplanned Visit (2),Screen Failure
Study 25,Site 2221,Subject 48019,Study 25,EMEA,TUR,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 2221,Subject 48020,Study 25,EMEA,TUR,0.0,13.0,123.0,EOS (1),Completed
Study 25,Site 2221,Subject 48021,Study 25,EMEA,TUR,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 2221,Subject 48022,Study 25,EMEA,TUR,0.0,13.0,126.0,EOS (1),Completed
Study 25,Site 2221,Subject 48023,Study 25,EMEA,TUR,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 2221,Subject 48024,Study 25,EMEA,TUR,0.0,8.0,87.0,EOS (1),Discontinued
Study 25,Site 2221,Subject 48025,Study 25,EMEA,TUR,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 2221,Subject 48026,Study 25,EMEA,TUR,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 2221,Subject 48027,Study 25,EMEA,TUR,0.0,13.0,127.0,EOS (1),Completed
Study 25,Site 2221,Subject 48028,Study 25,EMEA,TUR,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 2221,Subject 48029,Study 25,EMEA,TUR,0.0,13.0,131.0,Unplanned Visit (1),Completed
Study 25,Site 2221,Subject 48030,Study 25,EMEA,TUR,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 2221,Subject 48031,Study 25,EMEA,TUR,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 2221,Subject 48032,Study 25,EMEA,TUR,0.0,13.0,120.0,EOS (1),Completed
Study 25,Site 2221,Subject 48033,Study 25,EMEA,TUR,0.0,2.0,33.0,Baseline (1),Screen Failure
Study 25,Site 2221,Subject 48034,Study 25,EMEA,TUR,0.0,13.0,144.0,EOS (1),Completed
Study 25,Site 2221,Subject 48035,Study 25,EMEA,TUR,0.0,1.0,20.0,Unplanned Visit (1),Screen Failure
Study 25,Site 2221,Subject 48036,Study 25,EMEA,TUR,0.0,13.0,120.0,EOS (1),Completed
Study 25,Site 2221,Subject 48037,Study 25,EMEA,TUR,0.0,2.0,32.0,Baseline (1),Screen Failure
Study 25,Site 2221,Subject 48038,Study 25,EMEA,TUR,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2221,Subject 48039,Study 25,EMEA,TUR,0.0,13.0,117.0,EOS (1),Completed
Study 25,Site 2221,Subject 48040,Study 25,EMEA,TUR,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2222,Subject 48041,Study 25,EMEA,TUR,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 2222,Subject 48042,Study 25,EMEA,TUR,0.0,13.0,134.0,EOS (1),Completed
Study 25,Site 2222,Subject 48043,Study 25,EMEA,TUR,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 2222,Subject 48044,Study 25,EMEA,TUR,0.0,2.0,35.0,Baseline (1),Screen Failure
Study 25,Site 2222,Subject 48045,Study 25,EMEA,TUR,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 2222,Subject 48046,Study 25,EMEA,TUR,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 2222,Subject 48047,Study 25,EMEA,TUR,0.0,13.0,117.0,EOS (1),Completed
Study 25,Site 2222,Subject 48048,Study 25,EMEA,TUR,0.0,2.0,33.0,Baseline (1),Screen Failure
Study 25,Site 2222,Subject 48049,Study 25,EMEA,TUR,0.0,13.0,123.0,EOS (1),Completed
Study 25,Site 2223,Subject 48050,Study 25,EMEA,TUR,0.0,1.0,14.0,Screening,Screen Failure
Study 25,Site 2223,Subject 48051,Study 25,EMEA,TUR,0.0,13.0,123.0,EOS (1),Completed
Study 25,Site 2224,Subject 48052,Study 25,EMEA,TUR,0.0,13.0,133.0,EOS (1),Completed
Study 25,Site 2224,Subject 48053,Study 25,EMEA,TUR,0.0,13.0,147.0,EOS (1),Completed
Study 25,Site 2224,Subject 48054,Study 25,EMEA,TUR,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2224,Subject 48055,Study 25,EMEA,TUR,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2224,Subject 48056,Study 25,EMEA,TUR,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2224,Subject 48057,Study 25,EMEA,TUR,0.0,13.0,141.0,EOS (1),Completed
Study 25,Site 2224,Subject 48058,Study 25,EMEA,TUR,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2224,Subject 48059,Study 25,EMEA,TUR,0.0,2.0,23.0,Baseline (1),Screen Failure
Study 25,Site 2224,Subject 48060,Study 25,EMEA,TUR,0.0,13.0,153.0,EOS (1),Completed
Study 25,Site 2224,Subject 48061,Study 25,EMEA,TUR,0.0,13.0,135.0,Unplanned Visit (2),Completed
Study 25,Site 2224,Subject 48062,Study 25,EMEA,TUR,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 2224,Subject 48063,Study 25,EMEA,TUR,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2224,Subject 48064,Study 25,EMEA,TUR,0.0,13.0,146.0,EOS (1),Completed
Study 25,Site 2224,Subject 48065,Study 25,EMEA,TUR,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2224,Subject 48066,Study 25,EMEA,TUR,0.0,13.0,132.0,EOS (1),Completed
Study 25,Site 2224,Subject 48067,Study 25,EMEA,TUR,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2224,Subject 48068,Study 25,EMEA,TUR,0.0,13.0,118.0,EOS (1),Completed
Study 25,Site 2224,Subject 48069,Study 25,EMEA,TUR,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2225,Subject 48070,Study 25,EMEA,TUR,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2225,Subject 48071,Study 25,EMEA,TUR,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2225,Subject 48072,Study 25,EMEA,TUR,0.0,13.0,134.0,EOS (1),Completed
Study 25,Site 2225,Subject 48073,Study 25,EMEA,TUR,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2225,Subject 48074,Study 25,EMEA,TUR,0.0,11.0,140.0,Month 18 (1),Discontinued
Study 25,Site 2225,Subject 48075,Study 25,EMEA,TUR,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2225,Subject 48076,Study 25,EMEA,TUR,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2225,Subject 48077,Study 25,EMEA,TUR,0.0,13.0,148.0,EOS (1),Completed
Study 25,Site 2226,Subject 48078,Study 25,EMEA,TUR,0.0,13.0,142.0,EOS (1),Completed
Study 25,Site 2226,Subject 48079,Study 25,EMEA,TUR,0.0,2.0,36.0,Baseline (1),Screen Failure
Study 25,Site 2227,Subject 48080,Study 25,EMEA,GBR,0.0,13.0,127.0,EOS (1),Completed
Study 25,Site 2227,Subject 48081,Study 25,EMEA,GBR,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 2227,Subject 48082,Study 25,EMEA,GBR,0.0,1.0,14.0,Screening,Screen Failure
Study 25,Site 2228,Subject 48083,Study 25,EMEA,GBR,0.0,13.0,147.0,EOS (1),Completed
Study 25,Site 2228,Subject 48084,Study 25,EMEA,GBR,0.0,2.0,39.0,Unplanned Visit (1),Screen Failure
Study 25,Site 2228,Subject 48085,Study 25,EMEA,GBR,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 2228,Subject 48086,Study 25,EMEA,GBR,0.0,1.0,19.0,Unplanned Visit (1),Screen Failure
Study 25,Site 2229,Subject 48087,Study 25,EMEA,GBR,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 2229,Subject 48088,Study 25,EMEA,GBR,0.0,13.0,132.0,EOS (1),Completed
Study 25,Site 2229,Subject 48089,Study 25,EMEA,GBR,0.0,2.0,32.0,Baseline (1),Screen Failure
Study 25,Site 2230,Subject 48090,Study 25,EMEA,GBR,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2230,Subject 48091,Study 25,EMEA,GBR,0.0,13.0,129.0,EOS (1),Completed
Study 25,Site 2230,Subject 48092,Study 25,EMEA,GBR,0.0,12.0,122.0,EOS (1),Completed
Study 25,Site 2230,Subject 48093,Study 25,EMEA,GBR,0.0,2.0,25.0,Baseline (1),Screen Failure
Study 25,Site 2230,Subject 48094,Study 25,EMEA,GBR,0.0,13.0,128.0,EOS (1),Completed
Study 25,Site 2230,Subject 48095,Study 25,EMEA,GBR,0.0,13.0,123.0,EOS (1),Completed
Study 25,Site 2231,Subject 48096,Study 25,EMEA,GBR,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 2231,Subject 48097,Study 25,EMEA,GBR,0.0,13.0,158.0,EOS (1),Completed
Study 25,Site 2231,Subject 48098,Study 25,EMEA,GBR,0.0,2.0,36.0,Baseline (1),Screen Failure
Study 25,Site 2231,Subject 48099,Study 25,EMEA,GBR,0.0,2.0,37.0,Baseline (1),Screen Failure
Study 25,Site 2231,Subject 48100,Study 25,EMEA,GBR,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 2232,Subject 48101,Study 25,AMERICA,USA,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 2232,Subject 48102,Study 25,AMERICA,USA,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 2232,Subject 48103,Study 25,AMERICA,USA,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 2232,Subject 48104,Study 25,AMERICA,USA,0.0,13.0,98.0,EOS (1),Completed
Study 25,Site 2232,Subject 48105,Study 25,AMERICA,USA,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 2232,Subject 48106,Study 25,AMERICA,USA,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 2232,Subject 48107,Study 25,AMERICA,USA,0.0,7.0,80.0,Unplanned Visit (1),Discontinued
Study 25,Site 2232,Subject 48108,Study 25,AMERICA,USA,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 2232,Subject 48109,Study 25,AMERICA,USA,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 2232,Subject 48110,Study 25,AMERICA,USA,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 2232,Subject 48111,Study 25,AMERICA,USA,0.0,4.0,61.0,Week 2 (1),Discontinued
Study 25,Site 2232,Subject 48112,Study 25,AMERICA,USA,0.0,2.0,32.0,Baseline (1),Screen Failure
Study 25,Site 2232,Subject 48113,Study 25,AMERICA,USA,0.0,13.0,125.0,EOS (1),Completed
Study 25,Site 2232,Subject 48114,Study 25,AMERICA,USA,0.0,13.0,133.0,EOS (1),Completed
Study 25,Site 2232,Subject 48115,Study 25,AMERICA,USA,0.0,13.0,129.0,EOS (1),Completed
Study 25,Site 2232,Subject 48116,Study 25,AMERICA,USA,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 2232,Subject 48117,Study 25,AMERICA,USA,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 2233,Subject 48118,Study 25,AMERICA,USA,0.0,13.0,137.0,EOS (1),Completed
Study 25,Site 2233,Subject 48119,Study 25,AMERICA,USA,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 2233,Subject 48120,Study 25,AMERICA,USA,0.0,9.0,111.0,Month 12 (1),Discontinued
Study 25,Site 2234,Subject 48121,Study 25,AMERICA,USA,0.0,1.0,12.0,Screening,Screen Failure
Study 25,Site 2234,Subject 48122,Study 25,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2235,Subject 48123,Study 25,AMERICA,USA,0.0,2.0,30.0,Baseline (1),Screen Failure
Study 25,Site 2236,Subject 48124,Study 25,AMERICA,USA,0.0,1.0,23.0,Unplanned Visit (2),Screen Failure
Study 25,Site 2237,Subject 48125,Study 25,AMERICA,USA,0.0,1.0,23.0,Screening,Screen Failure
Study 25,Site 2237,Subject 48126,Study 25,AMERICA,USA,0.0,1.0,15.0,Screening,Screen Failure
Study 25,Site 2237,Subject 48127,Study 25,AMERICA,USA,0.0,13.0,128.0,EOS (1),Completed
Study 25,Site 2237,Subject 48128,Study 25,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2237,Subject 48129,Study 25,AMERICA,USA,0.0,1.0,24.0,Unplanned Visit (1),Screen Failure
Study 25,Site 2238,Subject 48130,Study 25,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2238,Subject 48131,Study 25,AMERICA,USA,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 2238,Subject 48132,Study 25,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2238,Subject 48133,Study 25,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2238,Subject 48134,Study 25,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2238,Subject 48135,Study 25,AMERICA,USA,0.0,1.0,6.0,Screening,Screen Failure
Study 25,Site 2238,Subject 48136,Study 25,AMERICA,USA,0.0,2.0,29.0,Baseline (1),Screen Failure
Study 25,Site 2238,Subject 48137,Study 25,AMERICA,USA,0.0,2.0,31.0,Baseline (1),Screen Failure
Study 25,Site 2239,Subject 48138,Study 25,AMERICA,USA,0.0,1.0,12.0,Screening,Screen Failure
Study 25,Site 2239,Subject 48139,Study 25,AMERICA,USA,0.0,2.0,31.0,Baseline (1),Screen Failure
Study 25,Site 2240,Subject 48140,Study 25,AMERICA,USA,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 2240,Subject 48141,Study 25,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 25,Site 2240,Subject 48142,Study 25,AMERICA,USA,0.0,1.0,15.0,Screening,Screen Failure
Study 25,Site 2240,Subject 48143,Study 25,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2240,Subject 48144,Study 25,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2240,Subject 48145,Study 25,AMERICA,USA,0.0,13.0,101.0,EOS (1),Completed
Study 25,Site 2240,Subject 48146,Study 25,AMERICA,USA,0.0,1.0,15.0,Screening,Screen Failure
Study 25,Site 2241,Subject 48147,Study 25,AMERICA,USA,0.0,13.0,126.0,EOS (1),Completed
Study 25,Site 2241,Subject 48148,Study 25,AMERICA,USA,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 2241,Subject 48149,Study 25,AMERICA,USA,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 2241,Subject 48150,Study 25,AMERICA,USA,0.0,13.0,123.0,EOS (1),Completed
Study 25,Site 2241,Subject 48151,Study 25,AMERICA,USA,0.0,13.0,121.0,EOS (1),Completed
Study 25,Site 2241,Subject 48152,Study 25,AMERICA,USA,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 2242,Subject 48153,Study 25,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2242,Subject 48154,Study 25,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2243,Subject 48155,Study 25,AMERICA,USA,0.0,1.0,23.0,Unplanned Visit (1),Screen Failure
Study 25,Site 2243,Subject 48156,Study 25,AMERICA,USA,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 2243,Subject 48157,Study 25,AMERICA,USA,0.0,1.0,22.0,Unplanned Visit (1),Screen Failure
Study 25,Site 2243,Subject 48158,Study 25,AMERICA,USA,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 2243,Subject 48159,Study 25,AMERICA,USA,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 2243,Subject 48160,Study 25,AMERICA,USA,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 2243,Subject 48161,Study 25,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2243,Subject 48162,Study 25,AMERICA,USA,0.0,1.0,23.0,Screening,Screen Failure
Study 25,Site 2243,Subject 48163,Study 25,AMERICA,USA,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 2244,Subject 48164,Study 25,AMERICA,USA,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 2245,Subject 48165,Study 25,AMERICA,USA,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 2245,Subject 48166,Study 25,AMERICA,USA,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 2245,Subject 48167,Study 25,AMERICA,USA,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 2245,Subject 48168,Study 25,AMERICA,USA,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 2245,Subject 48169,Study 25,AMERICA,USA,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 2246,Subject 48170,Study 25,AMERICA,USA,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 2246,Subject 48171,Study 25,AMERICA,USA,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 2246,Subject 48172,Study 25,AMERICA,USA,0.0,13.0,135.0,EOS (1),Completed
Study 25,Site 2247,Subject 48173,Study 25,AMERICA,USA,0.0,2.0,32.0,Baseline (1),Screen Failure
Study 25,Site 2247,Subject 48174,Study 25,AMERICA,USA,0.0,10.0,80.0,Month 15 (1),Discontinued
Study 25,Site 2247,Subject 48175,Study 25,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2247,Subject 48176,Study 25,AMERICA,USA,0.0,2.0,32.0,Baseline (1),Screen Failure
Study 25,Site 2247,Subject 48177,Study 25,AMERICA,USA,0.0,13.0,144.0,EOS (1),Completed
Study 25,Site 2247,Subject 48178,Study 25,AMERICA,USA,0.0,13.0,128.0,EOS (1),Completed
Study 25,Site 2247,Subject 48179,Study 25,AMERICA,USA,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 2247,Subject 48180,Study 25,AMERICA,USA,0.0,2.0,23.0,Baseline (1),Screen Failure
Study 25,Site 2247,Subject 48181,Study 25,AMERICA,USA,0.0,8.0,99.0,Month 9 (1),Discontinued
Study 25,Site 2247,Subject 48182,Study 25,AMERICA,USA,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 2248,Subject 48183,Study 25,AMERICA,USA,0.0,1.0,14.0,Screening,Screen Failure
Study 25,Site 2248,Subject 48184,Study 25,AMERICA,USA,0.0,7.0,74.0,Month 6 (1),Discontinued
Study 25,Site 2248,Subject 48185,Study 25,AMERICA,USA,0.0,1.0,13.0,Screening,Screen Failure
Study 25,Site 2248,Subject 48186,Study 25,AMERICA,USA,0.0,1.0,11.0,Screening,Screen Failure
Study 25,Site 2249,Subject 48187,Study 25,AMERICA,USA,0.0,2.0,25.0,Baseline (1),Screen Failure
Study 25,Site 2250,Subject 48188,Study 25,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 25,Site 2250,Subject 48189,Study 25,AMERICA,USA,0.0,13.0,122.0,EOS (1),Completed
Study 25,Site 2250,Subject 48190,Study 25,AMERICA,USA,0.0,13.0,121.0,EOS (1),Completed
Study 25,Site 2250,Subject 48191,Study 25,AMERICA,USA,0.0,1.0,23.0,Unplanned Visit (1),Screen Failure
Study 25,Site 2250,Subject 48192,Study 25,AMERICA,USA,0.0,13.0,122.0,EOS (1),Completed
Study 25,Site 2250,Subject 48193,Study 25,AMERICA,USA,0.0,13.0,123.0,EOS (1),Completed
Study 25,Site 2250,Subject 48194,Study 25,AMERICA,USA,0.0,1.0,13.0,Unplanned Visit (1),Screen Failure
Study 25,Site 2251,Subject 48195,Study 25,AMERICA,USA,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 2251,Subject 48196,Study 25,AMERICA,USA,0.0,13.0,125.0,EOS (1),Completed
Study 25,Site 2252,Subject 48197,Study 25,AMERICA,USA,0.0,13.0,160.0,EOS (1),Completed
Study 25,Site 2252,Subject 48198,Study 25,AMERICA,USA,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 2252,Subject 48199,Study 25,AMERICA,USA,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 2252,Subject 48200,Study 25,AMERICA,USA,0.0,13.0,128.0,EOS (1),Completed
Study 25,Site 2252,Subject 48201,Study 25,AMERICA,USA,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 2252,Subject 48202,Study 25,AMERICA,USA,0.0,13.0,125.0,EOS (1),Completed
Study 25,Site 2252,Subject 48203,Study 25,AMERICA,USA,0.0,1.0,15.0,Screening,Screen Failure
Study 25,Site 2252,Subject 48204,Study 25,AMERICA,USA,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 2253,Subject 48205,Study 25,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2253,Subject 48206,Study 25,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2253,Subject 48207,Study 25,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2253,Subject 48208,Study 25,AMERICA,USA,0.0,13.0,125.0,EOS (1),Completed
Study 25,Site 2253,Subject 48209,Study 25,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2253,Subject 48210,Study 25,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 2254,Subject 48215,Study 25,EMEA,ZAF,0.0,1.0,11.0,Unplanned Visit (1),Screen Failure
Study 25,Site 2254,Subject 48216,Study 25,EMEA,ZAF,0.0,1.0,11.0,Unplanned Visit (1),Screen Failure
Study 25,Site 2254,Subject 48217,Study 25,EMEA,ZAF,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 2254,Subject 48218,Study 25,EMEA,ZAF,0.0,13.0,140.0,EOS (1),Completed
Study 25,Site 2254,Subject 48219,Study 25,EMEA,ZAF,0.0,13.0,145.0,EOS (1),Completed
Study 25,Site 29,Subject 109,Study 25,AMERICA,ARG,0.0,13.0,146.0,EOS (1),Completed
Study 25,Site 29,Subject 30098,Study 25,AMERICA,ARG,0.0,13.0,139.0,EOS (1),Completed
Study 25,Site 29,Subject 30099,Study 25,AMERICA,ARG,0.0,13.0,123.0,EOS (1),Completed
Study 25,Site 3,Subject 102,Study 25,AMERICA,ARG,0.0,2.0,25.0,Baseline (1),Screen Failure
Study 25,Site 3,Subject 103,Study 25,AMERICA,ARG,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 3,Subject 104,Study 25,AMERICA,ARG,0.0,13.0,132.0,EOS (1),Completed
Study 25,Site 3,Subject 6,Study 25,AMERICA,ARG,0.0,13.0,127.0,EOS (1),Completed
Study 25,Site 3,Subject 7,Study 25,AMERICA,ARG,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 3,Subject 774,Study 25,AMERICA,ARG,0.0,2.0,30.0,Baseline (1),Screen Failure
Study 25,Site 3,Subject 8,Study 25,AMERICA,ARG,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 30,Subject 110,Study 25,AMERICA,ARG,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 30,Subject 111,Study 25,AMERICA,ARG,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 30,Subject 112,Study 25,AMERICA,ARG,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 30,Subject 113,Study 25,AMERICA,ARG,0.0,13.0,125.0,EOS (1),Completed
Study 25,Site 30,Subject 114,Study 25,AMERICA,ARG,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 30,Subject 115,Study 25,AMERICA,ARG,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 30,Subject 116,Study 25,AMERICA,ARG,0.0,13.0,122.0,EOS (1),Completed
Study 25,Site 31,Subject 118,Study 25,AMERICA,ARG,0.0,13.0,136.0,EOS (1),Completed
Study 25,Site 323,Subject 2637,Study 25,ASIA,VNM,0.0,2.0,32.0,Baseline (1),Screen Failure
Study 25,Site 323,Subject 3361,Study 25,ASIA,VNM,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 323,Subject 38215,Study 25,ASIA,VNM,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 323,Subject 38216,Study 25,ASIA,VNM,0.0,2.0,33.0,Baseline (1),Screen Failure
Study 25,Site 323,Subject 38217,Study 25,ASIA,VNM,0.0,13.0,119.0,EOS (1),Completed
Study 25,Site 323,Subject 38218,Study 25,ASIA,VNM,0.0,13.0,127.0,EOS (1),Completed
Study 25,Site 351,Subject 2837,Study 25,EMEA,SWE,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 351,Subject 2838,Study 25,EMEA,SWE,0.0,13.0,120.0,EOS (1),Completed
Study 25,Site 351,Subject 2839,Study 25,EMEA,SWE,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 351,Subject 47927,Study 25,EMEA,SWE,0.0,13.0,117.0,EOS (1),Completed
Study 25,Site 353,Subject 2844,Study 25,EMEA,ISR,0.0,13.0,134.0,EOS (1),Completed
Study 25,Site 353,Subject 2845,Study 25,EMEA,ISR,0.0,13.0,142.0,EOS (1),Completed
Study 25,Site 353,Subject 3735,Study 25,EMEA,ISR,0.0,13.0,118.0,EOS (1),Completed
Study 25,Site 353,Subject 3736,Study 25,EMEA,ISR,0.0,13.0,125.0,EOS (1),Completed
Study 25,Site 360,Subject 2874,Study 25,EMEA,FRA,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 360,Subject 2875,Study 25,EMEA,FRA,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 360,Subject 2876,Study 25,EMEA,FRA,0.0,13.0,129.0,EOS (1),Completed
Study 25,Site 361,Subject 2879,Study 25,EMEA,FRA,0.0,13.0,132.0,EOS (1),Completed
Study 25,Site 361,Subject 2880,Study 25,EMEA,FRA,0.0,13.0,133.0,EOS (1),Completed
Study 25,Site 361,Subject 2881,Study 25,EMEA,FRA,0.0,11.0,107.0,EOS (1),Completed
Study 25,Site 362,Subject 2883,Study 25,EMEA,FRA,0.0,10.0,111.0,EOS (1),Discontinued
Study 25,Site 362,Subject 2884,Study 25,EMEA,FRA,0.0,13.0,126.0,EOS (1),Completed
Study 25,Site 417,Subject 31799,Study 25,EMEA,DEU,0.0,2.0,26.0,Baseline (1),Screen Failure
Study 25,Site 417,Subject 3227,Study 25,EMEA,DEU,0.0,1.0,15.0,Screening,Screen Failure
Study 25,Site 417,Subject 3228,Study 25,EMEA,DEU,0.0,1.0,11.0,Screening,Screen Failure
Study 25,Site 417,Subject 3229,Study 25,EMEA,DEU,0.0,13.0,119.0,EOS (1),Completed
Study 25,Site 417,Subject 3230,Study 25,EMEA,DEU,0.0,2.0,31.0,Baseline (1),Screen Failure
Study 25,Site 417,Subject 47280,Study 25,EMEA,DEU,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 417,Subject 47281,Study 25,EMEA,DEU,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 417,Subject 47282,Study 25,EMEA,DEU,0.0,13.0,119.0,EOS (1),Completed
Study 25,Site 419,Subject 3233,Study 25,EMEA,DEU,0.0,11.0,123.0,EOS (1),Completed
Study 25,Site 419,Subject 47880,Study 25,EMEA,DEU,0.0,1.0,19.0,Unplanned Visit (2),Screen Failure
Study 25,Site 419,Subject 47881,Study 25,EMEA,DEU,0.0,13.0,126.0,EOS (1),Completed
Study 25,Site 419,Subject 47882,Study 25,EMEA,DEU,0.0,13.0,129.0,EOS (1),Completed
Study 25,Site 419,Subject 47883,Study 25,EMEA,DEU,0.0,13.0,129.0,EOS (1),Completed
Study 25,Site 419,Subject 47884,Study 25,EMEA,DEU,0.0,13.0,122.0,EOS (1),Completed
Study 25,Site 419,Subject 6450,Study 25,EMEA,DEU,0.0,1.0,19.0,Unplanned Visit (1),Screen Failure
Study 25,Site 419,Subject 6451,Study 25,EMEA,DEU,0.0,1.0,19.0,Unplanned Visit (1),Screen Failure
Study 25,Site 419,Subject 6452,Study 25,EMEA,DEU,0.0,13.0,126.0,EOS (1),Completed
Study 25,Site 419,Subject 6453,Study 25,EMEA,DEU,0.0,13.0,130.0,EOS (1),Completed
Study 25,Site 419,Subject 6454,Study 25,EMEA,DEU,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 419,Subject 6455,Study 25,EMEA,DEU,0.0,1.0,15.0,Screening,Screen Failure
Study 25,Site 419,Subject 6456,Study 25,EMEA,DEU,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 420,Subject 3234,Study 25,EMEA,DEU,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 420,Subject 6457,Study 25,EMEA,DEU,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 422,Subject 3243,Study 25,EMEA,DEU,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 422,Subject 3244,Study 25,EMEA,DEU,0.0,2.0,32.0,Baseline (1),Screen Failure
Study 25,Site 422,Subject 6472,Study 25,EMEA,DEU,0.0,13.0,142.0,EOS (1),Completed
Study 25,Site 422,Subject 6473,Study 25,EMEA,DEU,0.0,13.0,130.0,EOS (1),Completed
Study 25,Site 423,Subject 3245,Study 25,EMEA,DEU,0.0,13.0,127.0,EOS (1),Completed
Study 25,Site 423,Subject 3246,Study 25,EMEA,DEU,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 424,Subject 3248,Study 25,EMEA,DEU,0.0,1.0,17.0,Unplanned Visit (1),Screen Failure
Study 25,Site 424,Subject 3249,Study 25,EMEA,DEU,0.0,13.0,129.0,EOS (1),Completed
Study 25,Site 424,Subject 3250,Study 25,EMEA,DEU,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 464,Subject 3522,Study 25,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 464,Subject 3523,Study 25,EMEA,ITA,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 464,Subject 6976,Study 25,EMEA,ITA,0.0,13.0,125.0,EOS (1),Completed
Study 25,Site 464,Subject 6977,Study 25,EMEA,ITA,0.0,1.0,10.0,Screening,Screen Failure
Study 25,Site 464,Subject 6978,Study 25,EMEA,ITA,0.0,13.0,115.0,EOS (1),Completed
Study 25,Site 466,Subject 3544,Study 25,ASIA,AUS,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 466,Subject 3545,Study 25,ASIA,AUS,0.0,1.0,12.0,Screening,Screen Failure
Study 25,Site 466,Subject 3546,Study 25,ASIA,AUS,0.0,13.0,107.0,EOS (1),Completed
Study 25,Site 466,Subject 3547,Study 25,ASIA,AUS,0.0,13.0,138.0,EOS (1),Completed
Study 25,Site 466,Subject 3548,Study 25,ASIA,AUS,0.0,1.0,23.0,Unplanned Visit (1),Screen Failure
Study 25,Site 466,Subject 3549,Study 25,ASIA,AUS,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 467,Subject 3553,Study 25,ASIA,AUS,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 467,Subject 3554,Study 25,ASIA,AUS,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 467,Subject 3555,Study 25,ASIA,AUS,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 467,Subject 841,Study 25,ASIA,AUS,0.0,13.0,137.0,EOS (1),Completed
Study 25,Site 468,Subject 3560,Study 25,ASIA,AUS,0.0,13.0,117.0,EOS (1),Completed
Study 25,Site 469,Subject 3565,Study 25,AMERICA,BRA,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 469,Subject 46602,Study 25,AMERICA,BRA,0.0,13.0,141.0,EOS (1),Completed
Study 25,Site 469,Subject 46603,Study 25,AMERICA,BRA,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 469,Subject 46604,Study 25,AMERICA,BRA,0.0,1.0,24.0,Unplanned Visit (1),Screen Failure
Study 25,Site 469,Subject 46605,Study 25,AMERICA,BRA,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 469,Subject 4744,Study 25,AMERICA,BRA,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 469,Subject 4745,Study 25,AMERICA,BRA,0.0,1.0,10.0,Screening,Screen Failure
Study 25,Site 469,Subject 4746,Study 25,AMERICA,BRA,0.0,13.0,125.0,EOS (1),Completed
Study 25,Site 469,Subject 4747,Study 25,AMERICA,BRA,0.0,13.0,123.0,EOS (1),Completed
Study 25,Site 469,Subject 4748,Study 25,AMERICA,BRA,0.0,13.0,119.0,EOS (1),Completed
Study 25,Site 469,Subject 4749,Study 25,AMERICA,BRA,0.0,13.0,117.0,EOS (1),Completed
Study 25,Site 469,Subject 4750,Study 25,AMERICA,BRA,0.0,13.0,118.0,EOS (1),Completed
Study 25,Site 469,Subject 4751,Study 25,AMERICA,BRA,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 47,Subject 190,Study 25,ASIA,AUS,0.0,2.0,33.0,Baseline (1),Screen Failure
Study 25,Site 47,Subject 191,Study 25,ASIA,AUS,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 47,Subject 192,Study 25,ASIA,AUS,0.0,13.0,129.0,EOS (1),Completed
Study 25,Site 47,Subject 193,Study 25,ASIA,AUS,0.0,13.0,131.0,EOS (1),Completed
Study 25,Site 47,Subject 194,Study 25,ASIA,AUS,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 47,Subject 195,Study 25,ASIA,AUS,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 47,Subject 196,Study 25,ASIA,AUS,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 47,Subject 197,Study 25,ASIA,AUS,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 475,Subject 31367,Study 25,EMEA,CZE,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 475,Subject 31368,Study 25,EMEA,CZE,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 475,Subject 31369,Study 25,EMEA,CZE,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 475,Subject 31370,Study 25,EMEA,CZE,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 475,Subject 31371,Study 25,EMEA,CZE,0.0,2.0,27.0,Baseline (1),Screen Failure
Study 25,Site 475,Subject 31372,Study 25,EMEA,CZE,0.0,13.0,121.0,EOS (1),Completed
Study 25,Site 475,Subject 31373,Study 25,EMEA,CZE,0.0,13.0,119.0,EOS (1),Completed
Study 25,Site 475,Subject 31374,Study 25,EMEA,CZE,0.0,13.0,122.0,EOS (1),Completed
Study 25,Site 475,Subject 31375,Study 25,EMEA,CZE,0.0,13.0,119.0,EOS (1),Completed
Study 25,Site 475,Subject 31376,Study 25,EMEA,CZE,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 475,Subject 31377,Study 25,EMEA,CZE,0.0,13.0,118.0,EOS (1),Completed
Study 25,Site 475,Subject 31378,Study 25,EMEA,CZE,0.0,13.0,120.0,EOS (1),Completed
Study 25,Site 475,Subject 3600,Study 25,EMEA,CZE,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 475,Subject 3601,Study 25,EMEA,CZE,0.0,13.0,125.0,EOS (1),Completed
Study 25,Site 475,Subject 3602,Study 25,EMEA,CZE,0.0,13.0,122.0,EOS (1),Completed
Study 25,Site 479,Subject 3614,Study 25,EMEA,DNK,0.0,13.0,140.0,EOS (1),Completed
Study 25,Site 479,Subject 3615,Study 25,EMEA,DNK,0.0,13.0,119.0,EOS (1),Completed
Study 25,Site 48,Subject 208,Study 25,EMEA,BEL,0.0,2.0,24.0,Baseline (1),Screen Failure
Study 25,Site 48,Subject 209,Study 25,EMEA,BEL,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 48,Subject 210,Study 25,EMEA,BEL,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 48,Subject 211,Study 25,EMEA,BEL,0.0,13.0,150.0,EOS (1),Completed
Study 25,Site 48,Subject 212,Study 25,EMEA,BEL,0.0,2.0,31.0,Baseline (1),Screen Failure
Study 25,Site 48,Subject 213,Study 25,EMEA,BEL,0.0,13.0,129.0,EOS (1),Completed
Study 25,Site 48,Subject 214,Study 25,EMEA,BEL,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 48,Subject 215,Study 25,EMEA,BEL,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 48,Subject 216,Study 25,EMEA,BEL,0.0,2.0,42.0,Baseline (1),Screen Failure
Study 25,Site 48,Subject 217,Study 25,EMEA,BEL,0.0,1.0,33.0,Unplanned Visit (1),Screen Failure
Study 25,Site 48,Subject 218,Study 25,EMEA,BEL,0.0,1.0,14.0,Screening,Screen Failure
Study 25,Site 480,Subject 3618,Study 25,EMEA,DNK,0.0,13.0,131.0,EOS (1),Completed
Study 25,Site 480,Subject 3619,Study 25,EMEA,DNK,0.0,1.0,23.0,Unplanned Visit (1),Screen Failure
Study 25,Site 480,Subject 3620,Study 25,EMEA,DNK,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 480,Subject 3621,Study 25,EMEA,DNK,0.0,13.0,131.0,EOS (1),Completed
Study 25,Site 480,Subject 3622,Study 25,EMEA,DNK,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 480,Subject 3623,Study 25,EMEA,DNK,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 480,Subject 3624,Study 25,EMEA,DNK,0.0,1.0,14.0,Screening,Screen Failure
Study 25,Site 480,Subject 3625,Study 25,EMEA,DNK,0.0,13.0,122.0,Unplanned Visit (1),Completed
Study 25,Site 49,Subject 232,Study 25,EMEA,BEL,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 49,Subject 233,Study 25,EMEA,BEL,0.0,13.0,123.0,EOS (1),Completed
Study 25,Site 49,Subject 234,Study 25,EMEA,BEL,0.0,13.0,123.0,EOS (1),Completed
Study 25,Site 49,Subject 235,Study 25,EMEA,BEL,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 49,Subject 236,Study 25,EMEA,BEL,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 49,Subject 237,Study 25,EMEA,BEL,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 5,Subject 11,Study 25,AMERICA,CAN,0.0,13.0,137.0,EOS (1),Completed
Study 25,Site 5,Subject 3566,Study 25,AMERICA,CAN,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 50,Subject 271,Study 25,EMEA,BEL,0.0,1.0,14.0,Screening,Screen Failure
Study 25,Site 50,Subject 272,Study 25,EMEA,BEL,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 50,Subject 273,Study 25,EMEA,BEL,0.0,13.0,125.0,EOS (1),Completed
Study 25,Site 50,Subject 274,Study 25,EMEA,BEL,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 50,Subject 275,Study 25,EMEA,BEL,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 50,Subject 276,Study 25,EMEA,BEL,0.0,1.0,14.0,Screening,Screen Failure
Study 25,Site 50,Subject 277,Study 25,EMEA,BEL,0.0,2.0,32.0,Baseline (1),Screen Failure
Study 25,Site 50,Subject 278,Study 25,EMEA,BEL,0.0,2.0,32.0,Baseline (1),Screen Failure
Study 25,Site 50,Subject 279,Study 25,EMEA,BEL,0.0,13.0,123.0,EOS (1),Completed
Study 25,Site 50,Subject 280,Study 25,EMEA,BEL,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 504,Subject 3714,Study 25,EMEA,DEU,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 504,Subject 3715,Study 25,EMEA,DEU,0.0,13.0,135.0,EOS (1),Completed
Study 25,Site 504,Subject 6340,Study 25,EMEA,DEU,0.0,1.0,18.0,Unplanned Visit (1),Screen Failure
Study 25,Site 504,Subject 6341,Study 25,EMEA,DEU,0.0,2.0,32.0,Baseline (1),Screen Failure
Study 25,Site 504,Subject 6342,Study 25,EMEA,DEU,0.0,7.0,96.0,Unplanned Visit (3),Discontinued
Study 25,Site 504,Subject 6343,Study 25,EMEA,DEU,0.0,8.0,109.0,EOS (1),Discontinued
Study 25,Site 504,Subject 6344,Study 25,EMEA,DEU,0.0,2.0,37.0,Baseline (1),Screen Failure
Study 25,Site 504,Subject 6345,Study 25,EMEA,DEU,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 507,Subject 3727,Study 25,EMEA,DEU,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 507,Subject 3728,Study 25,EMEA,DEU,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 507,Subject 6384,Study 25,EMEA,DEU,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 507,Subject 6385,Study 25,EMEA,DEU,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 507,Subject 6386,Study 25,EMEA,DEU,0.0,2.0,24.0,Baseline (1),Screen Failure
Study 25,Site 507,Subject 6387,Study 25,EMEA,DEU,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 507,Subject 6388,Study 25,EMEA,DEU,0.0,13.0,126.0,EOS (1),Completed
Study 25,Site 507,Subject 6389,Study 25,EMEA,DEU,0.0,13.0,119.0,EOS (1),Completed
Study 25,Site 508,Subject 3729,Study 25,EMEA,DEU,0.0,13.0,143.0,EOS (1),Completed
Study 25,Site 508,Subject 6395,Study 25,EMEA,DEU,0.0,11.0,131.0,EOS (1),Discontinued
Study 25,Site 508,Subject 6396,Study 25,EMEA,DEU,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 508,Subject 6397,Study 25,EMEA,DEU,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 508,Subject 6398,Study 25,EMEA,DEU,0.0,2.0,33.0,Baseline (1),Screen Failure
Study 25,Site 508,Subject 6399,Study 25,EMEA,DEU,0.0,13.0,135.0,EOS (1),Completed
Study 25,Site 508,Subject 6400,Study 25,EMEA,DEU,0.0,13.0,128.0,EOS (1),Completed
Study 25,Site 509,Subject 3730,Study 25,ASIA,IND,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 509,Subject 6663,Study 25,ASIA,IND,0.0,13.0,125.0,EOS (1),Completed
Study 25,Site 509,Subject 6664,Study 25,ASIA,IND,0.0,2.0,34.0,Baseline (1),Screen Failure
Study 25,Site 509,Subject 6665,Study 25,ASIA,IND,0.0,2.0,33.0,Baseline (1),Screen Failure
Study 25,Site 509,Subject 6666,Study 25,ASIA,IND,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 509,Subject 6667,Study 25,ASIA,IND,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 509,Subject 6668,Study 25,ASIA,IND,0.0,13.0,130.0,EOS (1),Completed
Study 25,Site 509,Subject 6669,Study 25,ASIA,IND,0.0,13.0,120.0,EOS (1),Completed
Study 25,Site 510,Subject 3731,Study 25,ASIA,IND,0.0,13.0,122.0,EOS (1),Completed
Study 25,Site 510,Subject 3732,Study 25,ASIA,IND,0.0,13.0,121.0,EOS (1),Completed
Study 25,Site 510,Subject 47891,Study 25,ASIA,IND,0.0,13.0,125.0,EOS (1),Completed
Study 25,Site 510,Subject 47892,Study 25,ASIA,IND,0.0,13.0,123.0,EOS (1),Completed
Study 25,Site 510,Subject 47893,Study 25,ASIA,IND,0.0,13.0,118.0,EOS (1),Completed
Study 25,Site 510,Subject 47894,Study 25,ASIA,IND,0.0,2.0,24.0,Baseline (1),Screen Failure
Study 25,Site 510,Subject 47895,Study 25,ASIA,IND,0.0,2.0,33.0,Baseline (1),Screen Failure
Study 25,Site 510,Subject 47896,Study 25,ASIA,IND,0.0,13.0,132.0,EOS (1),Completed
Study 25,Site 512,Subject 3738,Study 25,EMEA,ISR,0.0,1.0,15.0,Screening,Screen Failure
Study 25,Site 518,Subject 33181,Study 25,ASIA,MYS,0.0,13.0,159.0,EOS (1),Completed
Study 25,Site 518,Subject 33182,Study 25,ASIA,MYS,0.0,13.0,127.0,EOS (1),Completed
Study 25,Site 518,Subject 33183,Study 25,ASIA,MYS,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 518,Subject 33184,Study 25,ASIA,MYS,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 518,Subject 33185,Study 25,ASIA,MYS,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 518,Subject 33186,Study 25,ASIA,MYS,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 518,Subject 33187,Study 25,ASIA,MYS,0.0,13.0,128.0,EOS (1),Completed
Study 25,Site 518,Subject 33188,Study 25,ASIA,MYS,0.0,2.0,33.0,Baseline (1),Screen Failure
Study 25,Site 518,Subject 3758,Study 25,ASIA,MYS,0.0,2.0,33.0,Baseline (1),Screen Failure
Study 25,Site 518,Subject 3759,Study 25,ASIA,MYS,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 518,Subject 3760,Study 25,ASIA,MYS,0.0,13.0,130.0,EOS (1),Completed
Study 25,Site 518,Subject 3761,Study 25,ASIA,MYS,0.0,13.0,150.0,EOS (1),Completed
Study 25,Site 521,Subject 3770,Study 25,EMEA,NOR,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 521,Subject 3771,Study 25,EMEA,NOR,0.0,13.0,130.0,EOS (1),Completed
Study 25,Site 521,Subject 3772,Study 25,EMEA,NOR,0.0,13.0,128.0,EOS (1),Completed
Study 25,Site 521,Subject 3773,Study 25,EMEA,NOR,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 525,Subject 3782,Study 25,EMEA,RUS,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 525,Subject 47747,Study 25,EMEA,RUS,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 525,Subject 47748,Study 25,EMEA,RUS,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 525,Subject 47749,Study 25,EMEA,RUS,0.0,13.0,145.0,EOS (1),Completed
Study 25,Site 525,Subject 47926,Study 25,EMEA,RUS,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 526,Subject 3783,Study 25,EMEA,RUS,0.0,2.0,25.0,Baseline (1),Screen Failure
Study 25,Site 526,Subject 3784,Study 25,EMEA,RUS,0.0,1.0,15.0,Screening,Screen Failure
Study 25,Site 526,Subject 3785,Study 25,EMEA,RUS,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 526,Subject 3786,Study 25,EMEA,RUS,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 526,Subject 3787,Study 25,EMEA,RUS,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 529,Subject 35389,Study 25,EMEA,ESP,0.0,13.0,119.0,EOS (1),Completed
Study 25,Site 529,Subject 3798,Study 25,EMEA,ESP,0.0,13.0,119.0,EOS (1),Completed
Study 25,Site 530,Subject 35413,Study 25,EMEA,ESP,0.0,13.0,126.0,EOS (1),Completed
Study 25,Site 530,Subject 35414,Study 25,EMEA,ESP,0.0,13.0,133.0,EOS (1),Completed
Study 25,Site 530,Subject 35415,Study 25,EMEA,ESP,0.0,13.0,123.0,EOS (1),Completed
Study 25,Site 530,Subject 3799,Study 25,EMEA,ESP,0.0,13.0,123.0,EOS (1),Completed
Study 25,Site 567,Subject 3928,Study 25,EMEA,DEU,0.0,1.0,12.0,Screening,Screen Failure
Study 25,Site 567,Subject 3929,Study 25,EMEA,DEU,0.0,8.0,93.0,Month 9 (1),Discontinued
Study 25,Site 567,Subject 3930,Study 25,EMEA,DEU,0.0,1.0,10.0,Screening,Screen Failure
Study 25,Site 567,Subject 3931,Study 25,EMEA,DEU,0.0,1.0,11.0,Screening,Screen Failure
Study 25,Site 567,Subject 47879,Study 25,EMEA,DEU,0.0,13.0,118.0,EOS (1),Completed
Study 25,Site 575,Subject 3947,Study 25,ASIA,KOR,0.0,1.0,22.0,Unplanned Visit (1),Screen Failure
Study 25,Site 575,Subject 3948,Study 25,ASIA,KOR,0.0,13.0,143.0,EOS (1),Completed
Study 25,Site 575,Subject 3949,Study 25,ASIA,KOR,0.0,13.0,132.0,EOS (1),Completed
Study 25,Site 575,Subject 3950,Study 25,ASIA,KOR,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 575,Subject 3951,Study 25,ASIA,KOR,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 575,Subject 3952,Study 25,ASIA,KOR,0.0,13.0,126.0,EOS (1),Completed
Study 25,Site 575,Subject 3953,Study 25,ASIA,KOR,0.0,13.0,126.0,EOS (1),Completed
Study 25,Site 575,Subject 8235,Study 25,ASIA,KOR,0.0,1.0,14.0,Screening,Screen Failure
Study 25,Site 575,Subject 8236,Study 25,ASIA,KOR,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 586,Subject 3979,Study 25,EMEA,SWE,0.0,2.0,37.0,Baseline (1),Screen Failure
Study 25,Site 588,Subject 36648,Study 25,ASIA,TWN,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 588,Subject 36649,Study 25,ASIA,TWN,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 588,Subject 36650,Study 25,ASIA,TWN,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 588,Subject 36651,Study 25,ASIA,TWN,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 588,Subject 36652,Study 25,ASIA,TWN,0.0,2.0,34.0,Baseline (1),Screen Failure
Study 25,Site 588,Subject 36653,Study 25,ASIA,TWN,0.0,13.0,125.0,EOS (1),Completed
Study 25,Site 588,Subject 36654,Study 25,ASIA,TWN,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 588,Subject 36655,Study 25,ASIA,TWN,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 588,Subject 36656,Study 25,ASIA,TWN,0.0,13.0,118.0,EOS (1),Completed
Study 25,Site 588,Subject 3983,Study 25,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 589,Subject 36660,Study 25,ASIA,TWN,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 589,Subject 36661,Study 25,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 589,Subject 36662,Study 25,ASIA,TWN,0.0,2.0,33.0,Baseline (1),Screen Failure
Study 25,Site 589,Subject 36663,Study 25,ASIA,TWN,0.0,2.0,33.0,Baseline (1),Screen Failure
Study 25,Site 589,Subject 36664,Study 25,ASIA,TWN,0.0,2.0,33.0,Baseline (1),Screen Failure
Study 25,Site 589,Subject 36665,Study 25,ASIA,TWN,0.0,13.0,138.0,EOS (1),Completed
Study 25,Site 589,Subject 36666,Study 25,ASIA,TWN,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 589,Subject 36667,Study 25,ASIA,TWN,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 589,Subject 36668,Study 25,ASIA,TWN,0.0,13.0,120.0,EOS (1),Completed
Study 25,Site 589,Subject 36669,Study 25,ASIA,TWN,0.0,13.0,119.0,EOS (1),Completed
Study 25,Site 589,Subject 36670,Study 25,ASIA,TWN,0.0,13.0,120.0,EOS (1),Completed
Study 25,Site 589,Subject 36671,Study 25,ASIA,TWN,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 589,Subject 36672,Study 25,ASIA,TWN,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 589,Subject 36673,Study 25,ASIA,TWN,0.0,2.0,37.0,Baseline (1),Screen Failure
Study 25,Site 589,Subject 3984,Study 25,ASIA,TWN,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 589,Subject 3985,Study 25,ASIA,TWN,0.0,13.0,125.0,EOS (1),Completed
Study 25,Site 589,Subject 3986,Study 25,ASIA,TWN,0.0,1.0,20.0,Unplanned Visit (1),Screen Failure
Study 25,Site 589,Subject 3987,Study 25,ASIA,TWN,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 589,Subject 3988,Study 25,ASIA,TWN,0.0,13.0,128.0,EOS (1),Completed
Study 25,Site 590,Subject 3989,Study 25,ASIA,TWN,0.0,13.0,137.0,EOS (1),Completed
Study 25,Site 590,Subject 3990,Study 25,ASIA,TWN,0.0,13.0,121.0,EOS (1),Completed
Study 25,Site 590,Subject 3991,Study 25,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 590,Subject 3992,Study 25,ASIA,TWN,0.0,13.0,120.0,EOS (1),Completed
Study 25,Site 592,Subject 3997,Study 25,ASIA,TWN,0.0,13.0,125.0,EOS (1),Completed
Study 25,Site 592,Subject 3998,Study 25,ASIA,TWN,0.0,13.0,139.0,EOS (1),Completed
Study 25,Site 592,Subject 3999,Study 25,ASIA,TWN,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 592,Subject 4000,Study 25,ASIA,TWN,0.0,13.0,139.0,EOS (1),Discontinued
Study 25,Site 592,Subject 4001,Study 25,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 592,Subject 4002,Study 25,ASIA,TWN,0.0,13.0,131.0,EOS (1),Completed
Study 25,Site 592,Subject 4003,Study 25,ASIA,TWN,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 598,Subject 34776,Study 25,ASIA,SGP,0.0,13.0,126.0,EOS (1),Completed
Study 25,Site 598,Subject 34777,Study 25,ASIA,SGP,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 598,Subject 34778,Study 25,ASIA,SGP,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 598,Subject 34779,Study 25,ASIA,SGP,0.0,2.0,30.0,Baseline (1),Screen Failure
Study 25,Site 598,Subject 4020,Study 25,ASIA,SGP,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 6,Subject 12,Study 25,AMERICA,CAN,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 61,Subject 31081,Study 25,ASIA,CHN,0.0,2.0,30.0,Baseline (1),Screen Failure
Study 25,Site 61,Subject 31082,Study 25,ASIA,CHN,0.0,13.0,110.0,EOS (1),Completed
Study 25,Site 61,Subject 31083,Study 25,ASIA,CHN,0.0,13.0,105.0,EOS (1),Completed
Study 25,Site 61,Subject 31084,Study 25,ASIA,CHN,0.0,13.0,103.0,EOS (1),Completed
Study 25,Site 61,Subject 31085,Study 25,ASIA,CHN,0.0,13.0,113.0,EOS (1),Completed
Study 25,Site 61,Subject 31086,Study 25,ASIA,CHN,0.0,13.0,116.0,EOS (1),Completed
Study 25,Site 61,Subject 31087,Study 25,ASIA,CHN,0.0,13.0,104.0,EOS (1),Completed
Study 25,Site 61,Subject 31088,Study 25,ASIA,CHN,0.0,1.0,15.0,Screening,Screen Failure
Study 25,Site 61,Subject 31089,Study 25,ASIA,CHN,0.0,13.0,110.0,EOS (1),Completed
Study 25,Site 61,Subject 31090,Study 25,ASIA,CHN,0.0,13.0,104.0,EOS (1),Completed
Study 25,Site 61,Subject 31091,Study 25,ASIA,CHN,0.0,2.0,24.0,Baseline (1),Screen Failure
Study 25,Site 61,Subject 370,Study 25,ASIA,CHN,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 61,Subject 371,Study 25,ASIA,CHN,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 61,Subject 372,Study 25,ASIA,CHN,0.0,1.0,10.0,Screening,Screen Failure
Study 25,Site 61,Subject 373,Study 25,ASIA,CHN,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 61,Subject 374,Study 25,ASIA,CHN,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 61,Subject 375,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 61,Subject 376,Study 25,ASIA,CHN,0.0,2.0,29.0,Baseline (1),Screen Failure
Study 25,Site 61,Subject 377,Study 25,ASIA,CHN,0.0,1.0,10.0,Screening,Screen Failure
Study 25,Site 61,Subject 378,Study 25,ASIA,CHN,0.0,2.0,24.0,Baseline (1),Screen Failure
Study 25,Site 61,Subject 379,Study 25,ASIA,CHN,0.0,1.0,13.0,Screening,Screen Failure
Study 25,Site 62,Subject 380,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 62,Subject 381,Study 25,ASIA,CHN,0.0,13.0,111.0,EOS (1),Completed
Study 25,Site 62,Subject 382,Study 25,ASIA,CHN,0.0,12.0,107.0,EOS (1),Discontinued
Study 25,Site 62,Subject 383,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 62,Subject 384,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 62,Subject 385,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 62,Subject 386,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 62,Subject 387,Study 25,ASIA,CHN,0.0,13.0,104.0,EOS (1),Completed
Study 25,Site 62,Subject 388,Study 25,ASIA,CHN,0.0,1.0,10.0,Screening,Screen Failure
Study 25,Site 62,Subject 389,Study 25,ASIA,CHN,0.0,9.0,90.0,EOS (1),Discontinued
Study 25,Site 63,Subject 391,Study 25,ASIA,CHN,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 63,Subject 392,Study 25,ASIA,CHN,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 63,Subject 393,Study 25,ASIA,CHN,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 63,Subject 394,Study 25,ASIA,CHN,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 63,Subject 395,Study 25,ASIA,CHN,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 63,Subject 396,Study 25,ASIA,CHN,0.0,13.0,105.0,EOS (1),Completed
Study 25,Site 63,Subject 397,Study 25,ASIA,CHN,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 63,Subject 398,Study 25,ASIA,CHN,0.0,13.0,104.0,EOS (1),Completed
Study 25,Site 63,Subject 399,Study 25,ASIA,CHN,0.0,13.0,113.0,EOS (1),Completed
Study 25,Site 63,Subject 400,Study 25,ASIA,CHN,0.0,13.0,104.0,EOS (1),Completed
Study 25,Site 63,Subject 401,Study 25,ASIA,CHN,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 63,Subject 402,Study 25,ASIA,CHN,0.0,13.0,103.0,EOS (1),Completed
Study 25,Site 63,Subject 403,Study 25,ASIA,CHN,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 63,Subject 404,Study 25,ASIA,CHN,0.0,11.0,93.0,Month 18 (1),Discontinued
Study 25,Site 63,Subject 405,Study 25,ASIA,CHN,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 63,Subject 406,Study 25,ASIA,CHN,0.0,13.0,105.0,EOS (1),Completed
Study 25,Site 63,Subject 407,Study 25,ASIA,CHN,0.0,1.0,11.0,Screening,Screen Failure
Study 25,Site 63,Subject 408,Study 25,ASIA,CHN,0.0,13.0,105.0,EOS (1),Completed
Study 25,Site 63,Subject 409,Study 25,ASIA,CHN,0.0,2.0,23.0,Baseline (1),Screen Failure
Study 25,Site 63,Subject 410,Study 25,ASIA,CHN,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 63,Subject 411,Study 25,ASIA,CHN,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 63,Subject 412,Study 25,ASIA,CHN,0.0,13.0,115.0,EOS (1),Completed
Study 25,Site 63,Subject 413,Study 25,ASIA,CHN,0.0,3.0,37.0,Randomization (1),Discontinued
Study 25,Site 65,Subject 442,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 65,Subject 443,Study 25,ASIA,CHN,0.0,13.0,105.0,EOS (1),Completed
Study 25,Site 65,Subject 444,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 65,Subject 445,Study 25,ASIA,CHN,0.0,9.0,83.0,EOS (1),Discontinued
Study 25,Site 65,Subject 446,Study 25,ASIA,CHN,0.0,2.0,31.0,Baseline (1),Screen Failure
Study 25,Site 65,Subject 447,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 65,Subject 448,Study 25,ASIA,CHN,0.0,13.0,118.0,EOS (1),Completed
Study 25,Site 65,Subject 449,Study 25,ASIA,CHN,0.0,2.0,31.0,Baseline (1),Screen Failure
Study 25,Site 66,Subject 47780,Study 25,ASIA,CHN,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 66,Subject 47781,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 66,Subject 47782,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 66,Subject 47783,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 66,Subject 47784,Study 25,ASIA,CHN,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 66,Subject 47785,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 66,Subject 573,Study 25,ASIA,CHN,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 66,Subject 574,Study 25,ASIA,CHN,0.0,13.0,114.0,EOS (1),Completed
Study 25,Site 66,Subject 575,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 66,Subject 576,Study 25,ASIA,CHN,0.0,13.0,107.0,EOS (1),Completed
Study 25,Site 67,Subject 31114,Study 25,ASIA,CHN,0.0,13.0,110.0,EOS (1),Completed
Study 25,Site 67,Subject 31115,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 67,Subject 31116,Study 25,ASIA,CHN,0.0,2.0,26.0,Baseline (1),Screen Failure
Study 25,Site 67,Subject 477,Study 25,ASIA,CHN,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 67,Subject 47768,Study 25,ASIA,CHN,0.0,13.0,106.0,EOS (1),Completed
Study 25,Site 67,Subject 478,Study 25,ASIA,CHN,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 67,Subject 479,Study 25,ASIA,CHN,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 67,Subject 480,Study 25,ASIA,CHN,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 67,Subject 481,Study 25,ASIA,CHN,0.0,13.0,105.0,EOS (1),Completed
Study 25,Site 67,Subject 482,Study 25,ASIA,CHN,0.0,13.0,109.0,EOS (1),Completed
Study 25,Site 67,Subject 483,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 67,Subject 484,Study 25,ASIA,CHN,0.0,1.0,11.0,Screening,Screen Failure
Study 25,Site 67,Subject 485,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 67,Subject 486,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 67,Subject 487,Study 25,ASIA,CHN,0.0,13.0,105.0,EOS (1),Completed
Study 25,Site 67,Subject 488,Study 25,ASIA,CHN,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 67,Subject 489,Study 25,ASIA,CHN,0.0,13.0,104.0,EOS (1),Completed
Study 25,Site 68,Subject 31117,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 68,Subject 31118,Study 25,ASIA,CHN,0.0,2.0,21.0,Baseline (1),Screen Failure
Study 25,Site 68,Subject 31119,Study 25,ASIA,CHN,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 68,Subject 490,Study 25,ASIA,CHN,0.0,1.0,15.0,Screening,Screen Failure
Study 25,Site 68,Subject 491,Study 25,ASIA,CHN,0.0,13.0,106.0,EOS (1),Completed
Study 25,Site 68,Subject 492,Study 25,ASIA,CHN,0.0,9.0,90.0,EOS (1),Discontinued
Study 25,Site 68,Subject 493,Study 25,ASIA,CHN,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 68,Subject 494,Study 25,ASIA,CHN,0.0,13.0,105.0,EOS (1),Completed
Study 25,Site 69,Subject 495,Study 25,ASIA,CHN,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 69,Subject 496,Study 25,ASIA,CHN,0.0,2.0,24.0,Baseline (1),Screen Failure
Study 25,Site 69,Subject 497,Study 25,ASIA,CHN,0.0,8.0,85.0,EOS (1),Discontinued
Study 25,Site 69,Subject 498,Study 25,ASIA,CHN,0.0,1.0,11.0,Screening,Screen Failure
Study 25,Site 7,Subject 14,Study 25,AMERICA,COL,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 7,Subject 594,Study 25,AMERICA,COL,0.0,1.0,10.0,Screening,Screen Failure
Study 25,Site 7,Subject 595,Study 25,AMERICA,COL,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 7,Subject 596,Study 25,AMERICA,COL,0.0,1.0,14.0,Screening,Screen Failure
Study 25,Site 7,Subject 597,Study 25,AMERICA,COL,0.0,1.0,10.0,Screening,Screen Failure
Study 25,Site 7,Subject 6176,Study 25,AMERICA,COL,0.0,1.0,11.0,Screening,Screen Failure
Study 25,Site 7,Subject 6177,Study 25,AMERICA,COL,0.0,2.0,22.0,Baseline (1),Screen Failure
Study 25,Site 7,Subject 6178,Study 25,AMERICA,COL,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 7,Subject 6179,Study 25,AMERICA,COL,0.0,1.0,12.0,Screening,Screen Failure
Study 25,Site 7,Subject 6180,Study 25,AMERICA,COL,0.0,13.0,116.0,EOS (1),Completed
Study 25,Site 7,Subject 6181,Study 25,AMERICA,COL,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 7,Subject 6182,Study 25,AMERICA,COL,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 7,Subject 6183,Study 25,AMERICA,COL,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 7,Subject 6184,Study 25,AMERICA,COL,0.0,1.0,12.0,Screening,Screen Failure
Study 25,Site 7,Subject 6185,Study 25,AMERICA,COL,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 7,Subject 6186,Study 25,AMERICA,COL,0.0,13.0,131.0,EOS (1),Completed
Study 25,Site 70,Subject 47769,Study 25,ASIA,CHN,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 70,Subject 47770,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 70,Subject 47771,Study 25,ASIA,CHN,0.0,13.0,105.0,EOS (1),Completed
Study 25,Site 70,Subject 47772,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 70,Subject 47773,Study 25,ASIA,CHN,0.0,13.0,105.0,EOS (1),Completed
Study 25,Site 70,Subject 47774,Study 25,ASIA,CHN,0.0,13.0,110.0,EOS (1),Completed
Study 25,Site 70,Subject 504,Study 25,ASIA,CHN,0.0,13.0,113.0,EOS (1),Completed
Study 25,Site 70,Subject 505,Study 25,ASIA,CHN,0.0,1.0,10.0,Screening,Screen Failure
Study 25,Site 70,Subject 506,Study 25,ASIA,CHN,0.0,2.0,30.0,Baseline (1),Screen Failure
Study 25,Site 70,Subject 507,Study 25,ASIA,CHN,0.0,13.0,109.0,EOS (1),Completed
Study 25,Site 70,Subject 508,Study 25,ASIA,CHN,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 70,Subject 509,Study 25,ASIA,CHN,0.0,7.0,67.0,EOS (1),Discontinued
Study 25,Site 70,Subject 510,Study 25,ASIA,CHN,0.0,2.0,24.0,Baseline (1),Screen Failure
Study 25,Site 70,Subject 511,Study 25,ASIA,CHN,0.0,2.0,24.0,Baseline (1),Screen Failure
Study 25,Site 70,Subject 512,Study 25,ASIA,CHN,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 70,Subject 513,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 70,Subject 514,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 70,Subject 515,Study 25,ASIA,CHN,0.0,13.0,108.0,EOS (1),Completed
Study 25,Site 71,Subject 516,Study 25,ASIA,CHN,0.0,2.0,28.0,Baseline (1),Screen Failure
Study 25,Site 71,Subject 517,Study 25,ASIA,CHN,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 71,Subject 518,Study 25,ASIA,CHN,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 71,Subject 519,Study 25,ASIA,CHN,0.0,13.0,105.0,EOS (1),Completed
Study 25,Site 71,Subject 520,Study 25,ASIA,CHN,0.0,11.0,91.0,EOS (1),Completed
Study 25,Site 71,Subject 521,Study 25,ASIA,CHN,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 71,Subject 522,Study 25,ASIA,CHN,0.0,1.0,14.0,Screening,Screen Failure
Study 25,Site 71,Subject 523,Study 25,ASIA,CHN,0.0,13.0,104.0,EOS (1),Completed
Study 25,Site 71,Subject 524,Study 25,ASIA,CHN,0.0,13.0,111.0,EOS (1),Completed
Study 25,Site 71,Subject 525,Study 25,ASIA,CHN,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 71,Subject 526,Study 25,ASIA,CHN,0.0,13.0,107.0,EOS (1),Completed
Study 25,Site 71,Subject 527,Study 25,ASIA,CHN,0.0,13.0,104.0,EOS (1),Completed
Study 25,Site 72,Subject 528,Study 25,ASIA,CHN,0.0,1.0,11.0,Screening,Screen Failure
Study 25,Site 72,Subject 529,Study 25,ASIA,CHN,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 72,Subject 530,Study 25,ASIA,CHN,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 72,Subject 531,Study 25,ASIA,CHN,0.0,1.0,11.0,Screening,Screen Failure
Study 25,Site 72,Subject 532,Study 25,ASIA,CHN,0.0,2.0,24.0,Baseline (1),Screen Failure
Study 25,Site 72,Subject 533,Study 25,ASIA,CHN,0.0,1.0,12.0,Screening,Screen Failure
Study 25,Site 72,Subject 534,Study 25,ASIA,CHN,0.0,13.0,107.0,EOS (1),Completed
Study 25,Site 72,Subject 535,Study 25,ASIA,CHN,0.0,6.0,53.0,EOS (1),Discontinued
Study 25,Site 72,Subject 536,Study 25,ASIA,CHN,0.0,13.0,104.0,EOS (1),Completed
Study 25,Site 72,Subject 537,Study 25,ASIA,CHN,0.0,13.0,138.0,EOS (1),Completed
Study 25,Site 73,Subject 544,Study 25,ASIA,CHN,0.0,2.0,29.0,Baseline (1),Screen Failure
Study 25,Site 73,Subject 545,Study 25,ASIA,CHN,0.0,6.0,72.0,Unplanned Visit (3),Discontinued
Study 25,Site 73,Subject 546,Study 25,ASIA,CHN,0.0,13.0,118.0,EOS (1),Completed
Study 25,Site 73,Subject 547,Study 25,ASIA,CHN,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 73,Subject 548,Study 25,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 73,Subject 549,Study 25,ASIA,CHN,0.0,7.0,65.0,EOS (1),Discontinued
Study 25,Site 75,Subject 3800,Study 25,ASIA,CHN,0.0,13.0,111.0,EOS (1),Completed
Study 25,Site 75,Subject 47775,Study 25,ASIA,CHN,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 75,Subject 47776,Study 25,ASIA,CHN,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 75,Subject 47777,Study 25,ASIA,CHN,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 75,Subject 47778,Study 25,ASIA,CHN,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 75,Subject 47779,Study 25,ASIA,CHN,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 75,Subject 567,Study 25,ASIA,CHN,0.0,2.0,30.0,Baseline (1),Screen Failure
Study 25,Site 75,Subject 568,Study 25,ASIA,CHN,0.0,13.0,106.0,EOS (1),Completed
Study 25,Site 75,Subject 569,Study 25,ASIA,CHN,0.0,13.0,104.0,EOS (1),Completed
Study 25,Site 75,Subject 570,Study 25,ASIA,CHN,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 75,Subject 571,Study 25,ASIA,CHN,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 75,Subject 572,Study 25,ASIA,CHN,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 776,Subject 31500,Study 25,EMEA,DNK,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 776,Subject 31501,Study 25,EMEA,DNK,0.0,13.0,121.0,EOS (1),Completed
Study 25,Site 776,Subject 4753,Study 25,EMEA,DNK,0.0,1.0,19.0,Unplanned Visit (1),Screen Failure
Study 25,Site 776,Subject 4754,Study 25,EMEA,DNK,0.0,13.0,122.0,EOS (1),Completed
Study 25,Site 776,Subject 4755,Study 25,EMEA,DNK,0.0,13.0,138.0,EOS (1),Completed
Study 25,Site 777,Subject 31496,Study 25,EMEA,DNK,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 777,Subject 4881,Study 25,EMEA,DNK,0.0,13.0,129.0,EOS (1),Completed
Study 25,Site 777,Subject 4882,Study 25,EMEA,DNK,0.0,2.0,33.0,Baseline (1),Screen Failure
Study 25,Site 777,Subject 4883,Study 25,EMEA,DNK,0.0,13.0,133.0,EOS (1),Completed
Study 25,Site 778,Subject 4884,Study 25,EMEA,FIN,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 780,Subject 4888,Study 25,EMEA,ISR,0.0,1.0,10.0,Screening,Screen Failure
Study 25,Site 780,Subject 4889,Study 25,EMEA,ISR,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 780,Subject 4890,Study 25,EMEA,ISR,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 780,Subject 4891,Study 25,EMEA,ISR,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 780,Subject 4892,Study 25,EMEA,ISR,0.0,1.0,13.0,Screening,Screen Failure
Study 25,Site 780,Subject 4893,Study 25,EMEA,ISR,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 780,Subject 4894,Study 25,EMEA,ISR,0.0,13.0,127.0,EOS (1),Completed
Study 25,Site 780,Subject 4895,Study 25,EMEA,ISR,0.0,2.0,37.0,Baseline (1),Screen Failure
Study 25,Site 780,Subject 4896,Study 25,EMEA,ISR,0.0,13.0,130.0,EOS (1),Completed
Study 25,Site 780,Subject 4897,Study 25,EMEA,ISR,0.0,13.0,132.0,EOS (1),Completed
Study 25,Site 781,Subject 4898,Study 25,ASIA,KOR,0.0,13.0,135.0,EOS (1),Completed
Study 25,Site 781,Subject 8248,Study 25,ASIA,KOR,0.0,1.0,14.0,Screening,Screen Failure
Study 25,Site 781,Subject 8249,Study 25,ASIA,KOR,0.0,13.0,150.0,Unplanned Visit (9),Completed
Study 25,Site 781,Subject 8250,Study 25,ASIA,KOR,0.0,2.0,33.0,Baseline (1),Screen Failure
Study 25,Site 783,Subject 4903,Study 25,ASIA,KOR,0.0,13.0,138.0,EOS (1),Completed
Study 25,Site 783,Subject 4904,Study 25,ASIA,KOR,0.0,13.0,122.0,EOS (1),Completed
Study 25,Site 783,Subject 8116,Study 25,ASIA,KOR,0.0,13.0,128.0,EOS (1),Completed
Study 25,Site 783,Subject 8117,Study 25,ASIA,KOR,0.0,2.0,26.0,Baseline (1),Screen Failure
Study 25,Site 783,Subject 8118,Study 25,ASIA,KOR,0.0,13.0,128.0,EOS (1),Completed
Study 25,Site 783,Subject 8119,Study 25,ASIA,KOR,0.0,1.0,25.0,Unplanned Visit (1),Screen Failure
Study 25,Site 783,Subject 8120,Study 25,ASIA,KOR,0.0,13.0,116.0,EOS (1),Completed
Study 25,Site 783,Subject 8121,Study 25,ASIA,KOR,0.0,13.0,131.0,EOS (1),Completed
Study 25,Site 783,Subject 8122,Study 25,ASIA,KOR,0.0,13.0,117.0,EOS (1),Completed
Study 25,Site 784,Subject 4905,Study 25,ASIA,KOR,0.0,1.0,22.0,Unplanned Visit (1),Screen Failure
Study 25,Site 784,Subject 4906,Study 25,ASIA,KOR,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 784,Subject 8154,Study 25,ASIA,KOR,0.0,13.0,136.0,EOS (1),Completed
Study 25,Site 784,Subject 8155,Study 25,ASIA,KOR,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 784,Subject 8156,Study 25,ASIA,KOR,0.0,2.0,33.0,Unplanned Visit (1),Screen Failure
Study 25,Site 784,Subject 8157,Study 25,ASIA,KOR,0.0,13.0,148.0,EOS (1),Completed
Study 25,Site 784,Subject 8158,Study 25,ASIA,KOR,0.0,13.0,137.0,EOS (1),Completed
Study 25,Site 784,Subject 8159,Study 25,ASIA,KOR,0.0,13.0,131.0,EOS (1),Completed
Study 25,Site 785,Subject 4907,Study 25,ASIA,KOR,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 785,Subject 8177,Study 25,ASIA,KOR,0.0,6.0,70.0,Unplanned Visit (1),Discontinued
Study 25,Site 785,Subject 8178,Study 25,ASIA,KOR,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 79,Subject 587,Study 25,AMERICA,COL,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 79,Subject 588,Study 25,AMERICA,COL,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 79,Subject 589,Study 25,AMERICA,COL,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 79,Subject 590,Study 25,AMERICA,COL,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 79,Subject 591,Study 25,AMERICA,COL,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 79,Subject 592,Study 25,AMERICA,COL,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 79,Subject 593,Study 25,AMERICA,COL,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 79,Subject 6153,Study 25,AMERICA,COL,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 79,Subject 6154,Study 25,AMERICA,COL,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 79,Subject 6155,Study 25,AMERICA,COL,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 79,Subject 6156,Study 25,AMERICA,COL,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 79,Subject 6157,Study 25,AMERICA,COL,0.0,13.0,122.0,EOS (1),Completed
Study 25,Site 79,Subject 6158,Study 25,AMERICA,COL,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 79,Subject 6159,Study 25,AMERICA,COL,0.0,2.0,21.0,Baseline (1),Screen Failure
Study 25,Site 79,Subject 6160,Study 25,AMERICA,COL,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 79,Subject 6161,Study 25,AMERICA,COL,0.0,13.0,131.0,Unplanned Visit (4),Completed
Study 25,Site 79,Subject 6162,Study 25,AMERICA,COL,0.0,13.0,128.0,EOS (1),Completed
Study 25,Site 79,Subject 6163,Study 25,AMERICA,COL,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 79,Subject 6164,Study 25,AMERICA,COL,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 79,Subject 6165,Study 25,AMERICA,COL,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 801,Subject 6417,Study 25,EMEA,DEU,0.0,13.0,122.0,EOS (1),Completed
Study 25,Site 801,Subject 6418,Study 25,EMEA,DEU,0.0,13.0,139.0,EOS (1),Completed
Study 25,Site 801,Subject 6419,Study 25,EMEA,DEU,0.0,13.0,132.0,EOS (1),Completed
Study 25,Site 801,Subject 6420,Study 25,EMEA,DEU,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 801,Subject 6422,Study 25,EMEA,DEU,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 806,Subject 6676,Study 25,ASIA,IND,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 806,Subject 6677,Study 25,ASIA,IND,0.0,2.0,24.0,Baseline (1),Screen Failure
Study 25,Site 806,Subject 6678,Study 25,ASIA,IND,0.0,1.0,25.0,Screening,Screen Failure
Study 25,Site 806,Subject 6679,Study 25,ASIA,IND,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 806,Subject 6680,Study 25,ASIA,IND,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 846,Subject 7465,Study 25,ASIA,JPN,0.0,13.0,125.0,EOS (1),Completed
Study 25,Site 846,Subject 7466,Study 25,ASIA,JPN,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 847,Subject 7499,Study 25,ASIA,JPN,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 847,Subject 7500,Study 25,ASIA,JPN,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 848,Subject 7548,Study 25,ASIA,JPN,0.0,2.0,31.0,Baseline (1),Screen Failure
Study 25,Site 848,Subject 7549,Study 25,ASIA,JPN,0.0,1.0,13.0,Screening,Screen Failure
Study 25,Site 848,Subject 7550,Study 25,ASIA,JPN,0.0,1.0,14.0,Screening,Screen Failure
Study 25,Site 848,Subject 7551,Study 25,ASIA,JPN,0.0,13.0,136.0,EOS (1),Completed
Study 25,Site 848,Subject 7552,Study 25,ASIA,JPN,0.0,13.0,157.0,EOS (1),Completed
Study 25,Site 852,Subject 7660,Study 25,ASIA,JPN,0.0,1.0,15.0,Screening,Screen Failure
Study 25,Site 852,Subject 7661,Study 25,ASIA,JPN,0.0,2.0,25.0,Baseline (1),Screen Failure
Study 25,Site 852,Subject 7662,Study 25,ASIA,JPN,0.0,13.0,125.0,EOS (1),Completed
Study 25,Site 852,Subject 7663,Study 25,ASIA,JPN,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 852,Subject 7664,Study 25,ASIA,JPN,0.0,2.0,26.0,Baseline (1),Screen Failure
Study 25,Site 852,Subject 7665,Study 25,ASIA,JPN,0.0,1.0,11.0,Screening,Screen Failure
Study 25,Site 852,Subject 7666,Study 25,ASIA,JPN,0.0,2.0,32.0,Baseline (1),Screen Failure
Study 25,Site 852,Subject 7667,Study 25,ASIA,JPN,0.0,2.0,27.0,Baseline (1),Screen Failure
Study 25,Site 852,Subject 7668,Study 25,ASIA,JPN,0.0,13.0,125.0,EOS (1),Completed
Study 25,Site 852,Subject 7669,Study 25,ASIA,JPN,0.0,13.0,125.0,EOS (1),Completed
Study 25,Site 854,Subject 7758,Study 25,ASIA,JPN,0.0,13.0,134.0,EOS (1),Completed
Study 25,Site 854,Subject 7759,Study 25,ASIA,JPN,0.0,1.0,14.0,Unplanned Visit (2),Screen Failure
Study 25,Site 854,Subject 7760,Study 25,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 857,Subject 7869,Study 25,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 857,Subject 7870,Study 25,ASIA,JPN,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 857,Subject 7871,Study 25,ASIA,JPN,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 859,Subject 8066,Study 25,ASIA,KOR,0.0,13.0,126.0,EOS (1),Completed
Study 25,Site 859,Subject 8067,Study 25,ASIA,KOR,0.0,13.0,131.0,EOS (1),Completed
Study 25,Site 859,Subject 8068,Study 25,ASIA,KOR,0.0,1.0,24.0,Unplanned Visit (2),Screen Failure
Study 25,Site 859,Subject 8069,Study 25,ASIA,KOR,0.0,1.0,22.0,Screening,Screen Failure
Study 25,Site 859,Subject 8070,Study 25,ASIA,KOR,0.0,8.0,87.0,EOS (1),Discontinued
Study 25,Site 859,Subject 8071,Study 25,ASIA,KOR,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 859,Subject 8072,Study 25,ASIA,KOR,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 859,Subject 8073,Study 25,ASIA,KOR,0.0,13.0,119.0,EOS (1),Completed
Study 25,Site 859,Subject 8074,Study 25,ASIA,KOR,0.0,2.0,26.0,Baseline (1),Screen Failure
Study 25,Site 860,Subject 8101,Study 25,ASIA,KOR,0.0,13.0,131.0,EOS (1),Completed
Study 25,Site 860,Subject 8102,Study 25,ASIA,KOR,0.0,13.0,145.0,Unplanned Visit (8),Completed
Study 25,Site 860,Subject 8103,Study 25,ASIA,KOR,0.0,13.0,148.0,Unplanned Visit (8),Completed
Study 25,Site 860,Subject 8104,Study 25,ASIA,KOR,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 860,Subject 8105,Study 25,ASIA,KOR,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 860,Subject 8106,Study 25,ASIA,KOR,0.0,1.0,20.0,Unplanned Visit (1),Screen Failure
Study 25,Site 860,Subject 8107,Study 25,ASIA,KOR,0.0,13.0,127.0,EOS (1),Completed
Study 25,Site 861,Subject 8132,Study 25,ASIA,KOR,0.0,13.0,132.0,EOS (1),Completed
Study 25,Site 861,Subject 8133,Study 25,ASIA,KOR,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 861,Subject 8134,Study 25,ASIA,KOR,0.0,13.0,140.0,EOS (1),Completed
Study 25,Site 861,Subject 8135,Study 25,ASIA,KOR,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 862,Subject 8195,Study 25,ASIA,KOR,0.0,7.0,94.0,Unplanned Visit (2),Discontinued
Study 25,Site 862,Subject 8196,Study 25,ASIA,KOR,0.0,13.0,136.0,EOS (1),Completed
Study 25,Site 863,Subject 8221,Study 25,ASIA,KOR,0.0,13.0,130.0,EOS (1),Completed
Study 25,Site 863,Subject 8222,Study 25,ASIA,KOR,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 863,Subject 8223,Study 25,ASIA,KOR,0.0,2.0,33.0,Baseline (1),Screen Failure
Study 25,Site 863,Subject 8224,Study 25,ASIA,KOR,0.0,1.0,21.0,Screening,Screen Failure
Study 25,Site 863,Subject 8225,Study 25,ASIA,KOR,0.0,13.0,119.0,EOS (1),Completed
Study 25,Site 873,Subject 8831,Study 25,EMEA,NOR,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 873,Subject 8832,Study 25,EMEA,NOR,0.0,13.0,117.0,EOS (1),Completed
Study 25,Site 873,Subject 8833,Study 25,EMEA,NOR,0.0,13.0,126.0,EOS (1),Completed
Study 25,Site 873,Subject 8834,Study 25,EMEA,NOR,0.0,1.0,16.0,Screening,Screen Failure
Study 25,Site 923,Subject 11748,Study 25,AMERICA,USA,0.0,11.0,120.0,EOS (1),Completed
Study 25,Site 923,Subject 11749,Study 25,AMERICA,USA,0.0,2.0,34.0,Baseline (1),Screen Failure
Study 25,Site 923,Subject 11750,Study 25,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 923,Subject 11751,Study 25,AMERICA,USA,0.0,1.0,15.0,Screening,Screen Failure
Study 25,Site 923,Subject 11752,Study 25,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 924,Subject 11904,Study 25,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 924,Subject 11905,Study 25,AMERICA,USA,0.0,0.0,14.0,Screening,Screen Failure
Study 25,Site 924,Subject 11906,Study 25,AMERICA,USA,0.0,1.0,18.0,Screening,Screen Failure
Study 25,Site 926,Subject 12154,Study 25,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 926,Subject 12155,Study 25,AMERICA,USA,0.0,13.0,122.0,EOS (1),Completed
Study 25,Site 926,Subject 12156,Study 25,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 926,Subject 12157,Study 25,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 926,Subject 12158,Study 25,AMERICA,USA,0.0,1.0,15.0,Screening,Screen Failure
Study 25,Site 926,Subject 12159,Study 25,AMERICA,USA,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 926,Subject 12160,Study 25,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 926,Subject 12161,Study 25,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 25,Site 926,Subject 12162,Study 25,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 929,Subject 12368,Study 25,AMERICA,USA,0.0,13.0,130.0,EOS (1),Completed
Study 25,Site 932,Subject 12733,Study 25,AMERICA,USA,0.0,2.0,26.0,Baseline (1),Screen Failure
Study 25,Site 932,Subject 12734,Study 25,AMERICA,USA,0.0,1.0,11.0,Screening,Screen Failure
Study 25,Site 932,Subject 12735,Study 25,AMERICA,USA,0.0,13.0,130.0,EOS (1),Completed
Study 25,Site 932,Subject 12736,Study 25,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 932,Subject 12737,Study 25,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 933,Subject 12807,Study 25,AMERICA,USA,0.0,1.0,15.0,Screening,Screen Failure
Study 25,Site 933,Subject 12808,Study 25,AMERICA,USA,0.0,13.0,131.0,EOS (1),Completed
Study 25,Site 933,Subject 12809,Study 25,AMERICA,USA,0.0,2.0,32.0,Baseline (1),Screen Failure
Study 25,Site 937,Subject 12998,Study 25,AMERICA,USA,0.0,1.0,12.0,Unplanned Visit (1),Screen Failure
Study 25,Site 937,Subject 12999,Study 25,AMERICA,USA,0.0,13.0,147.0,EOS (1),Completed
Study 25,Site 937,Subject 13000,Study 25,AMERICA,USA,0.0,13.0,130.0,EOS (1),Completed
Study 25,Site 937,Subject 13001,Study 25,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 937,Subject 13002,Study 25,AMERICA,USA,0.0,2.0,33.0,Baseline (1),Screen Failure
Study 25,Site 937,Subject 13003,Study 25,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 937,Subject 13004,Study 25,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 939,Subject 13093,Study 25,AMERICA,USA,0.0,13.0,131.0,EOS (1),Completed
Study 25,Site 939,Subject 13094,Study 25,AMERICA,USA,0.0,1.0,20.0,Screening,Screen Failure
Study 25,Site 939,Subject 13095,Study 25,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 939,Subject 13096,Study 25,AMERICA,USA,0.0,13.0,124.0,EOS (1),Completed
Study 25,Site 941,Subject 13177,Study 25,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 941,Subject 13178,Study 25,AMERICA,USA,0.0,2.0,24.0,Baseline (1),Screen Failure
Study 25,Site 941,Subject 13179,Study 25,AMERICA,USA,0.0,1.0,17.0,Screening,Screen Failure
Study 25,Site 942,Subject 13231,Study 25,AMERICA,USA,0.0,2.0,25.0,Baseline (1),Screen Failure
Study 25,Site 943,Subject 13273,Study 25,AMERICA,USA,0.0,13.0,138.0,EOS (1),Completed
Study 25,Site 943,Subject 13274,Study 25,AMERICA,USA,0.0,1.0,10.0,Screening,Screen Failure
Study 25,Site 943,Subject 13275,Study 25,AMERICA,USA,0.0,13.0,130.0,EOS (1),Completed
Study 25,Site 943,Subject 13276,Study 25,AMERICA,USA,0.0,9.0,110.0,Month 12 (1),Discontinued
Study 25,Site 943,Subject 13277,Study 25,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 943,Subject 13278,Study 25,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 943,Subject 13279,Study 25,AMERICA,USA,0.0,1.0,22.0,Screening,Screen Failure
Study 25,Site 943,Subject 13280,Study 25,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 943,Subject 13281,Study 25,AMERICA,USA,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 943,Subject 13282,Study 25,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 25,Site 945,Subject 13347,Study 25,AMERICA,USA,0.0,2.0,36.0,Baseline (1),Screen Failure
Study 25,Site 945,Subject 13348,Study 25,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 945,Subject 13349,Study 25,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 945,Subject 13350,Study 25,AMERICA,USA,0.0,2.0,35.0,Unplanned Visit (1),Screen Failure
Study 25,Site 945,Subject 13351,Study 25,AMERICA,USA,0.0,2.0,36.0,Unplanned Visit (1),Screen Failure
Study 25,Site 945,Subject 13352,Study 25,AMERICA,USA,0.0,1.0,19.0,Screening,Screen Failure
Study 25,Site 945,Subject 13353,Study 25,AMERICA,USA,0.0,1.0,6.0,Screening,Screen Failure
Study 25,Site 945,Subject 13354,Study 25,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 25,Site 954,Subject 13657,Study 25,AMERICA,USA,0.0,13.0,136.0,EOS (1),Completed
Study 25,Site 954,Subject 13658,Study 25,AMERICA,USA,0.0,2.0,35.0,Unplanned Visit (1),Screen Failure
Study 25,Site 954,Subject 13659,Study 25,AMERICA,USA,0.0,13.0,153.0,EOS (1),Completed
Study 25,Site 954,Subject 13660,Study 25,AMERICA,USA,0.0,1.0,23.0,Unplanned Visit (1),Screen Failure
Study 25,Site 954,Subject 13661,Study 25,AMERICA,USA,0.0,13.0,131.0,EOS (1),Completed
Study 25,Site 955,Subject 13667,Study 25,AMERICA,USA,0.0,1.0,21.0,Unplanned Visit (1),Screen Failure
Study 25,Site 958,Subject 13700,Study 25,AMERICA,USA,0.0,2.0,34.0,Baseline (1),Screen Failure
Study 25,Site 958,Subject 13701,Study 25,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 25,Site 995,Subject 14547,Study 25,AMERICA,CHL,0.0,13.0,120.0,EOS (1),Completed
Study 25,Site 995,Subject 14548,Study 25,AMERICA,CHL,0.0,13.0,131.0,EOS (1),Completed
Study 25,Site 995,Subject 14549,Study 25,AMERICA,CHL,0.0,13.0,119.0,EOS (1),Completed
Study 25,Site 995,Subject 14550,Study 25,AMERICA,CHL,0.0,12.0,127.0,EOS (1),Completed
Study 25,Site 995,Subject 14551,Study 25,AMERICA,CHL,0.0,13.0,117.0,EOS (1),Completed
Study 5,Site 14,Subject 25,Study 5,EMEA,AUT,0.0,11.0,58.0,EOT2/Safety FU (42D) (1),Follow-Up
Study 5,Site 15,Subject 39,Study 5,EMEA,AUT,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 15,Subject 40,Study 5,EMEA,AUT,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 15,Subject 41,Study 5,EMEA,AUT,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 15,Subject 42,Study 5,EMEA,AUT,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 15,Subject 43,Study 5,EMEA,AUT,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 15,Subject 44,Study 5,EMEA,AUT,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 15,Subject 45,Study 5,EMEA,AUT,0.0,8.0,54.0,Cycle 3 Week 1 (1),On Trial
Study 5,Site 165,Subject 1512,Study 5,AMERICA,ARG,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 165,Subject 1513,Study 5,AMERICA,ARG,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 165,Subject 2586,Study 5,AMERICA,ARG,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 165,Subject 2587,Study 5,AMERICA,ARG,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 165,Subject 2588,Study 5,AMERICA,ARG,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 165,Subject 2589,Study 5,AMERICA,ARG,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 165,Subject 2590,Study 5,AMERICA,ARG,0.0,2.0,0.0,First Fraction (SBRT) (1),On Trial
Study 5,Site 165,Subject 2591,Study 5,AMERICA,ARG,0.0,1.0,0.0,Screening,
Study 5,Site 179,Subject 1604,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 179,Subject 1605,Study 5,AMERICA,USA,0.0,13.0,85.0,Efficacy FU 1 (1),Follow-Up
Study 5,Site 179,Subject 1606,Study 5,AMERICA,USA,0.0,13.0,93.0,Efficacy FU 1 (1),Follow-Up
Study 5,Site 179,Subject 1607,Study 5,AMERICA,USA,0.0,8.0,53.0,Cycle 3 Week 1 (1),On Trial
Study 5,Site 18,Subject 63,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 18,Subject 64,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 18,Subject 65,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 18,Subject 66,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 18,Subject 67,Study 5,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 18,Subject 68,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 5,Site 180,Subject 1610,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 181,Subject 1614,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 181,Subject 2670,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 181,Subject 2671,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 181,Subject 2672,Study 5,AMERICA,USA,0.0,1.0,6.0,Screening,Screen Failure
Study 5,Site 181,Subject 2673,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 181,Subject 2674,Study 5,AMERICA,USA,0.0,12.0,93.0,Unplanned visit (6),Follow-Up
Study 5,Site 181,Subject 2675,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 181,Subject 2676,Study 5,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 181,Subject 2677,Study 5,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 181,Subject 2678,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 181,Subject 2679,Study 5,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 181,Subject 2680,Study 5,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 181,Subject 2681,Study 5,AMERICA,USA,0.0,5.0,13.0,Cycle 1 Week 3 (1),On Trial
Study 5,Site 181,Subject 2682,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 187,Subject 1635,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 187,Subject 1636,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 187,Subject 2710,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 187,Subject 2711,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 187,Subject 2712,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 187,Subject 2713,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 5,Site 189,Subject 1639,Study 5,AMERICA,USA,0.0,0.0,0.0,,
Study 5,Site 19,Subject 77,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 19,Subject 78,Study 5,AMERICA,USA,0.0,5.0,38.0,Cycle 1 Week 3 (1),On Trial
Study 5,Site 191,Subject 1668,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 191,Subject 1669,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 191,Subject 1670,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 191,Subject 1671,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 191,Subject 1672,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 191,Subject 1673,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 191,Subject 1674,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 191,Subject 1675,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 191,Subject 1676,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 191,Subject 1677,Study 5,ASIA,JPN,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 191,Subject 1678,Study 5,ASIA,JPN,0.0,0.0,0.0,,
Study 5,Site 192,Subject 1689,Study 5,ASIA,JPN,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 192,Subject 1690,Study 5,ASIA,JPN,0.0,14.0,0.0,Efficacy FU 2 (1),Follow-Up
Study 5,Site 192,Subject 1691,Study 5,ASIA,JPN,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 192,Subject 1692,Study 5,ASIA,JPN,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 192,Subject 1693,Study 5,ASIA,JPN,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 192,Subject 2773,Study 5,ASIA,JPN,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 192,Subject 2774,Study 5,ASIA,JPN,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 192,Subject 2775,Study 5,ASIA,JPN,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 192,Subject 2776,Study 5,ASIA,JPN,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 192,Subject 2777,Study 5,ASIA,JPN,0.0,5.0,0.0,Cycle 1 Week 3 (1),On Trial
Study 5,Site 192,Subject 2778,Study 5,ASIA,JPN,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 193,Subject 1698,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 193,Subject 2780,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 193,Subject 2781,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 193,Subject 2782,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 193,Subject 2783,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 193,Subject 2784,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 193,Subject 2785,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 193,Subject 2786,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 193,Subject 2787,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 193,Subject 2788,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 193,Subject 2789,Study 5,ASIA,JPN,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 193,Subject 2790,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 193,Subject 2791,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 193,Subject 2792,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 193,Subject 2793,Study 5,ASIA,JPN,0.0,4.0,43.0,Cycle 1 Week 1 (1),On Trial
Study 5,Site 196,Subject 1712,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 196,Subject 1713,Study 5,ASIA,JPN,0.0,12.0,54.0,EOT2/Safety FU (42D) (1),Follow-Up
Study 5,Site 196,Subject 1714,Study 5,ASIA,JPN,0.0,1.0,6.0,Screening,
Study 5,Site 196,Subject 1715,Study 5,ASIA,JPN,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 197,Subject 1717,Study 5,ASIA,JPN,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 197,Subject 1718,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 197,Subject 1719,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 197,Subject 1720,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 197,Subject 1721,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 197,Subject 1722,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 197,Subject 2810,Study 5,ASIA,JPN,0.0,10.0,49.0,Cycle 4 Week 1 (1),On Trial
Study 5,Site 198,Subject 1723,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 198,Subject 1724,Study 5,ASIA,JPN,0.0,13.0,104.0,Efficacy FU 1 (1),Follow-Up
Study 5,Site 198,Subject 1725,Study 5,ASIA,JPN,0.0,6.0,67.0,Efficacy FU 2 (1),Follow-Up
Study 5,Site 198,Subject 1726,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 2,Subject 2,Study 5,ASIA,AUS,0.0,10.0,81.0,Efficacy FU 1 (1),Follow-Up
Study 5,Site 2,Subject 3,Study 5,ASIA,AUS,0.0,14.0,107.0,Efficacy FU 2 (1),Follow-Up
Study 5,Site 2,Subject 4,Study 5,ASIA,AUS,0.0,9.0,71.0,EOT2/Safety FU (42D) (1),Follow-Up
Study 5,Site 2,Subject 5,Study 5,ASIA,AUS,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 2,Subject 99,Study 5,ASIA,AUS,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 200,Subject 1744,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 200,Subject 1745,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 200,Subject 1746,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 200,Subject 1747,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 200,Subject 1748,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 200,Subject 1749,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 200,Subject 1750,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 200,Subject 1751,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 200,Subject 2811,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 200,Subject 2812,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 200,Subject 2813,Study 5,ASIA,JPN,0.0,3.0,23.0,Last Fraction (EOT1) (1),On Trial
Study 5,Site 24,Subject 2701,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 24,Subject 2702,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 24,Subject 90,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 25,Subject 1694,Study 5,ASIA,JPN,0.0,13.0,114.0,Efficacy FU 1 (1),Follow-Up
Study 5,Site 25,Subject 1695,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 25,Subject 1696,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 25,Subject 1697,Study 5,ASIA,JPN,0.0,4.0,33.0,Cycle 1 Week 1 (1),On Trial
Study 5,Site 25,Subject 2779,Study 5,ASIA,JPN,0.0,1.0,5.0,Screening,Screen Failure
Study 5,Site 25,Subject 91,Study 5,ASIA,JPN,0.0,1.0,12.0,Screening,Screen Failure
Study 5,Site 25,Subject 92,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 259,Subject 2236,Study 5,ASIA,AUS,0.0,1.0,0.0,Screening,
Study 5,Site 260,Subject 2237,Study 5,ASIA,SGP,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 261,Subject 2238,Study 5,ASIA,SGP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 261,Subject 2239,Study 5,ASIA,SGP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 261,Subject 2240,Study 5,ASIA,SGP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 261,Subject 2241,Study 5,ASIA,SGP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 261,Subject 2242,Study 5,ASIA,SGP,0.0,15.0,102.0,Long term safety FU 1 (1),Follow-Up
Study 5,Site 261,Subject 2243,Study 5,ASIA,SGP,0.0,14.0,97.0,Efficacy FU 2 (1),Follow-Up
Study 5,Site 261,Subject 2244,Study 5,ASIA,SGP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 261,Subject 2245,Study 5,ASIA,SGP,0.0,12.0,69.0,EOT2/Safety FU (42D) (1),Follow-Up
Study 5,Site 261,Subject 2246,Study 5,ASIA,SGP,0.0,12.0,66.0,EOT2/Safety FU (42D) (1),Follow-Up
Study 5,Site 261,Subject 2247,Study 5,ASIA,SGP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 261,Subject 2248,Study 5,ASIA,SGP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 261,Subject 2249,Study 5,ASIA,SGP,0.0,1.0,3.0,Screening,Screen Failure
Study 5,Site 261,Subject 2250,Study 5,ASIA,SGP,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 261,Subject 2251,Study 5,ASIA,SGP,0.0,1.0,0.0,Screening,Enrolled
Study 5,Site 262,Subject 2252,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 262,Subject 2253,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 262,Subject 2254,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 262,Subject 2255,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 262,Subject 2256,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 262,Subject 2257,Study 5,ASIA,TWN,0.0,10.0,71.0,Cycle 4 Week 1 (1),Discontinued
Study 5,Site 262,Subject 2258,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 262,Subject 2259,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 262,Subject 2260,Study 5,ASIA,TWN,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 263,Subject 2261,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 263,Subject 2262,Study 5,ASIA,TWN,0.0,13.0,78.0,Efficacy FU 1 (1),Follow-Up
Study 5,Site 263,Subject 2263,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 263,Subject 2264,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 263,Subject 2265,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 263,Subject 2266,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 263,Subject 2267,Study 5,ASIA,TWN,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 263,Subject 2268,Study 5,ASIA,TWN,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 263,Subject 2269,Study 5,ASIA,TWN,0.0,5.0,0.0,Cycle 1 Week 3 (1),On Trial
Study 5,Site 264,Subject 2270,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 264,Subject 2271,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 264,Subject 2272,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 264,Subject 2273,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 264,Subject 2274,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 264,Subject 2275,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 264,Subject 2276,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 264,Subject 2277,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 264,Subject 2278,Study 5,ASIA,TWN,0.0,1.0,4.0,Screening,Screen Failure
Study 5,Site 265,Subject 2279,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 265,Subject 2280,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 265,Subject 2281,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 265,Subject 2282,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 265,Subject 2283,Study 5,ASIA,TWN,0.0,3.0,38.0,Last Fraction (EOT1) (1),Discontinued
Study 5,Site 265,Subject 2284,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 265,Subject 2285,Study 5,ASIA,TWN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 265,Subject 2286,Study 5,ASIA,TWN,0.0,1.0,3.0,Screening,
Study 5,Site 266,Subject 2287,Study 5,ASIA,MYS,0.0,1.0,23.0,Screening,Screen Failure
Study 5,Site 266,Subject 2288,Study 5,ASIA,MYS,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 266,Subject 2289,Study 5,ASIA,MYS,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 266,Subject 2290,Study 5,ASIA,MYS,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 266,Subject 2291,Study 5,ASIA,MYS,0.0,8.0,64.0,Cycle 3 Week 1 (1),On Trial
Study 5,Site 266,Subject 2292,Study 5,ASIA,MYS,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 266,Subject 2293,Study 5,ASIA,MYS,0.0,1.0,7.0,Screening,
Study 5,Site 267,Subject 2294,Study 5,ASIA,MYS,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 268,Subject 2295,Study 5,EMEA,BEL,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 268,Subject 2296,Study 5,EMEA,BEL,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 268,Subject 2297,Study 5,EMEA,BEL,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 268,Subject 2298,Study 5,EMEA,BEL,0.0,12.0,96.0,EOT2/Safety FU (42D) (1),Follow-Up
Study 5,Site 268,Subject 2299,Study 5,EMEA,BEL,0.0,12.0,91.0,EOT2/Safety FU (42D) (1),Follow-Up
Study 5,Site 268,Subject 2300,Study 5,EMEA,BEL,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 268,Subject 2301,Study 5,EMEA,BEL,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 268,Subject 2302,Study 5,EMEA,BEL,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 268,Subject 2303,Study 5,EMEA,BEL,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 268,Subject 2304,Study 5,EMEA,BEL,0.0,9.0,66.0,Cycle 3 Week 3 (1),On Trial
Study 5,Site 268,Subject 2305,Study 5,EMEA,BEL,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 268,Subject 2306,Study 5,EMEA,BEL,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 268,Subject 2307,Study 5,EMEA,BEL,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 268,Subject 2308,Study 5,EMEA,BEL,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 268,Subject 2309,Study 5,EMEA,BEL,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 268,Subject 2310,Study 5,EMEA,BEL,0.0,1.0,0.0,Screening,
Study 5,Site 269,Subject 2311,Study 5,EMEA,BEL,0.0,1.0,2.0,Screening,Screen Failure
Study 5,Site 269,Subject 2312,Study 5,EMEA,BEL,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 270,Subject 2313,Study 5,EMEA,CZE,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 270,Subject 2314,Study 5,EMEA,CZE,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 270,Subject 2315,Study 5,EMEA,CZE,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 271,Subject 2316,Study 5,EMEA,CZE,0.0,1.0,12.0,Screening,Screen Failure
Study 5,Site 271,Subject 2317,Study 5,EMEA,CZE,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 271,Subject 2318,Study 5,EMEA,CZE,0.0,11.0,90.0,Cycle 4 Week 3 (1),On Trial
Study 5,Site 271,Subject 2319,Study 5,EMEA,CZE,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 271,Subject 2320,Study 5,EMEA,CZE,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 271,Subject 2321,Study 5,EMEA,CZE,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 271,Subject 2322,Study 5,EMEA,CZE,0.0,7.0,63.0,Cycle 2 Week 3 (1),On Trial
Study 5,Site 271,Subject 2323,Study 5,EMEA,CZE,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 271,Subject 2324,Study 5,EMEA,CZE,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 271,Subject 2325,Study 5,EMEA,CZE,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 271,Subject 2326,Study 5,EMEA,CZE,0.0,1.0,2.0,Screening,Screen Failure
Study 5,Site 271,Subject 2327,Study 5,EMEA,CZE,0.0,1.0,4.0,Screening,Screen Failure
Study 5,Site 272,Subject 2328,Study 5,EMEA,CZE,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 272,Subject 2329,Study 5,EMEA,CZE,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 272,Subject 2330,Study 5,EMEA,CZE,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 272,Subject 2331,Study 5,EMEA,CZE,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 272,Subject 2332,Study 5,EMEA,CZE,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 272,Subject 2333,Study 5,EMEA,CZE,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 273,Subject 2334,Study 5,EMEA,FRA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 273,Subject 2335,Study 5,EMEA,FRA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 274,Subject 2336,Study 5,EMEA,FRA,0.0,12.0,77.0,EOT2/Safety FU (42D) (1),On Trial
Study 5,Site 275,Subject 2337,Study 5,EMEA,FRA,0.0,1.0,6.0,Screening,Screen Failure
Study 5,Site 276,Subject 2338,Study 5,EMEA,FRA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 277,Subject 2339,Study 5,EMEA,FRA,0.0,14.0,76.0,Efficacy FU 2 (1),Follow-Up
Study 5,Site 277,Subject 2340,Study 5,EMEA,FRA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 277,Subject 2341,Study 5,EMEA,FRA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 277,Subject 2342,Study 5,EMEA,FRA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 277,Subject 2343,Study 5,EMEA,FRA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 277,Subject 2344,Study 5,EMEA,FRA,0.0,1.0,1.0,Screening,Screen Failure
Study 5,Site 277,Subject 2345,Study 5,EMEA,FRA,0.0,10.0,1.0,Cycle 4 Week 1 (1),On Trial
Study 5,Site 277,Subject 2346,Study 5,EMEA,FRA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 277,Subject 2347,Study 5,EMEA,FRA,0.0,5.0,1.0,Cycle 2 Week 1 (1),On Trial
Study 5,Site 277,Subject 2348,Study 5,EMEA,FRA,0.0,7.0,0.0,Cycle 2 Week 3 (1),On Trial
Study 5,Site 277,Subject 2349,Study 5,EMEA,FRA,0.0,0.0,0.0,,
Study 5,Site 278,Subject 2350,Study 5,EMEA,FRA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 278,Subject 2351,Study 5,EMEA,FRA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 278,Subject 2352,Study 5,EMEA,FRA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 278,Subject 2353,Study 5,EMEA,FRA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 278,Subject 2354,Study 5,EMEA,FRA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 279,Subject 2355,Study 5,EMEA,DEU,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 279,Subject 2356,Study 5,EMEA,DEU,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 279,Subject 2357,Study 5,EMEA,DEU,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 28,Subject 107,Study 5,ASIA,AUS,0.0,13.0,101.0,Long term safety FU 1 (1),Follow-Up
Study 5,Site 28,Subject 108,Study 5,ASIA,AUS,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 28,Subject 2233,Study 5,ASIA,AUS,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 28,Subject 2234,Study 5,ASIA,AUS,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 28,Subject 2235,Study 5,ASIA,AUS,0.0,6.0,40.0,Cycle 2 Week 1 (1),On Trial
Study 5,Site 280,Subject 2358,Study 5,EMEA,DEU,0.0,1.0,3.0,Screening,
Study 5,Site 280,Subject 2359,Study 5,EMEA,DEU,0.0,1.0,3.0,Screening,
Study 5,Site 280,Subject 2360,Study 5,EMEA,DEU,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 280,Subject 2361,Study 5,EMEA,DEU,0.0,1.0,0.0,Screening,
Study 5,Site 280,Subject 2362,Study 5,EMEA,DEU,0.0,1.0,0.0,Screening,
Study 5,Site 280,Subject 2363,Study 5,EMEA,DEU,0.0,1.0,0.0,Screening,
Study 5,Site 281,Subject 2364,Study 5,EMEA,DEU,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 281,Subject 2365,Study 5,EMEA,DEU,0.0,5.0,3.0,Cycle 1 Week 3 (1),On Trial
Study 5,Site 281,Subject 2366,Study 5,EMEA,DEU,0.0,2.0,0.0,First Fraction (SBRT) (1),On Trial
Study 5,Site 282,Subject 2367,Study 5,EMEA,DEU,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 282,Subject 2368,Study 5,EMEA,DEU,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 282,Subject 2369,Study 5,EMEA,DEU,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 282,Subject 2370,Study 5,EMEA,DEU,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 282,Subject 2371,Study 5,EMEA,DEU,0.0,1.0,5.0,Screening,Screen Failure
Study 5,Site 282,Subject 2372,Study 5,EMEA,DEU,0.0,9.0,13.0,Cycle 3 Week 3 (1),On Trial
Study 5,Site 282,Subject 2373,Study 5,EMEA,DEU,0.0,7.0,1.0,Cycle 2 Week 3 (1),On Trial
Study 5,Site 282,Subject 2374,Study 5,EMEA,DEU,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 283,Subject 2375,Study 5,EMEA,DEU,0.0,1.0,0.0,Screening,
Study 5,Site 283,Subject 2376,Study 5,EMEA,DEU,0.0,1.0,0.0,Screening,
Study 5,Site 284,Subject 2377,Study 5,EMEA,HUN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 284,Subject 2378,Study 5,EMEA,HUN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 284,Subject 2379,Study 5,EMEA,HUN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 284,Subject 2380,Study 5,EMEA,HUN,0.0,13.0,92.0,Efficacy FU 1 (1),Follow-Up
Study 5,Site 284,Subject 2381,Study 5,EMEA,HUN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 284,Subject 2382,Study 5,EMEA,HUN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 284,Subject 2383,Study 5,EMEA,HUN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 284,Subject 2384,Study 5,EMEA,HUN,0.0,1.0,2.0,Screening,Screen Failure
Study 5,Site 285,Subject 2385,Study 5,EMEA,HUN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 286,Subject 2386,Study 5,EMEA,HUN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 286,Subject 2387,Study 5,EMEA,HUN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 286,Subject 2388,Study 5,EMEA,HUN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 286,Subject 2389,Study 5,EMEA,HUN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 286,Subject 2390,Study 5,EMEA,HUN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 287,Subject 2391,Study 5,EMEA,ISR,0.0,1.0,7.0,Screening,Discontinued
Study 5,Site 287,Subject 2392,Study 5,EMEA,ISR,0.0,1.0,5.0,Screening,Screen Failure
Study 5,Site 287,Subject 2393,Study 5,EMEA,ISR,0.0,1.0,6.0,Screening,Screen Failure
Study 5,Site 287,Subject 2394,Study 5,EMEA,ISR,0.0,1.0,6.0,Screening,Screen Failure
Study 5,Site 287,Subject 2395,Study 5,EMEA,ISR,0.0,1.0,6.0,Screening,Screen Failure
Study 5,Site 287,Subject 2396,Study 5,EMEA,ISR,0.0,1.0,6.0,Screening,Screen Failure
Study 5,Site 287,Subject 2397,Study 5,EMEA,ISR,0.0,12.0,44.0,EOT2/Safety FU (42D) (1),On Trial
Study 5,Site 288,Subject 2398,Study 5,EMEA,ISR,0.0,10.0,65.0,Cycle 4 Week 1 (1),On Trial
Study 5,Site 289,Subject 2399,Study 5,EMEA,ISR,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 289,Subject 2400,Study 5,EMEA,ISR,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 289,Subject 2401,Study 5,EMEA,ISR,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 289,Subject 2402,Study 5,EMEA,ISR,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 289,Subject 2403,Study 5,EMEA,ISR,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 289,Subject 2404,Study 5,EMEA,ISR,0.0,1.0,2.0,Screening,Screen Failure
Study 5,Site 290,Subject 2405,Study 5,EMEA,ISR,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 290,Subject 2406,Study 5,EMEA,ISR,0.0,15.0,106.0,Long term safety FU 1 (1),Follow-Up
Study 5,Site 290,Subject 2407,Study 5,EMEA,ISR,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 290,Subject 2408,Study 5,EMEA,ISR,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 290,Subject 2409,Study 5,EMEA,ISR,0.0,1.0,5.0,Screening,Screen Failure
Study 5,Site 290,Subject 2410,Study 5,EMEA,ISR,0.0,1.0,6.0,Screening,Screen Failure
Study 5,Site 290,Subject 2411,Study 5,EMEA,ISR,0.0,1.0,0.0,Screening,
Study 5,Site 290,Subject 2412,Study 5,EMEA,ISR,0.0,1.0,0.0,Screening,
Study 5,Site 291,Subject 2413,Study 5,EMEA,ISR,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 291,Subject 2414,Study 5,EMEA,ISR,0.0,1.0,5.0,Screening,
Study 5,Site 291,Subject 2415,Study 5,EMEA,ISR,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 291,Subject 2416,Study 5,EMEA,ISR,0.0,1.0,0.0,Screening,
Study 5,Site 292,Subject 2417,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 292,Subject 2418,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 292,Subject 2419,Study 5,EMEA,ITA,0.0,12.0,75.0,EOT2/Safety FU (42D) (1),Follow-Up
Study 5,Site 292,Subject 2420,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 293,Subject 2421,Study 5,EMEA,ITA,0.0,1.0,0.0,Screening,
Study 5,Site 294,Subject 2422,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 294,Subject 2423,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 294,Subject 2424,Study 5,EMEA,ITA,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 295,Subject 2425,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 295,Subject 2426,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 295,Subject 2427,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 295,Subject 2428,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 295,Subject 2429,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 295,Subject 2430,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 295,Subject 2431,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 295,Subject 2432,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 295,Subject 2433,Study 5,EMEA,ITA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 296,Subject 2434,Study 5,EMEA,ITA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 296,Subject 2435,Study 5,EMEA,ITA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 297,Subject 2436,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 297,Subject 2437,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 297,Subject 2438,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 297,Subject 2439,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 297,Subject 2440,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 297,Subject 2441,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 297,Subject 2442,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 297,Subject 2443,Study 5,EMEA,ITA,0.0,12.0,80.0,EOT2/Safety FU (42D) (1),Follow-Up
Study 5,Site 297,Subject 2444,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 297,Subject 2445,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 297,Subject 2446,Study 5,EMEA,ITA,0.0,9.0,61.0,Cycle 3 Week 3 (1),On Trial
Study 5,Site 297,Subject 2447,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 297,Subject 2448,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 297,Subject 2449,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 297,Subject 2450,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 297,Subject 2451,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 297,Subject 2452,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 297,Subject 2453,Study 5,EMEA,ITA,0.0,4.0,40.0,Cycle 1 Week 1 (1),On Trial
Study 5,Site 297,Subject 2454,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 297,Subject 2455,Study 5,EMEA,ITA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 297,Subject 2456,Study 5,EMEA,ITA,0.0,4.0,27.0,Cycle 1 Week 1 (1),On Trial
Study 5,Site 297,Subject 2457,Study 5,EMEA,ITA,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 297,Subject 2458,Study 5,EMEA,ITA,0.0,1.0,9.0,Screening,Screen Failure
Study 5,Site 297,Subject 2459,Study 5,EMEA,ITA,0.0,3.0,4.0,Last Fraction (EOT1) (1),On Trial
Study 5,Site 297,Subject 2460,Study 5,EMEA,ITA,0.0,1.0,3.0,Screening,Screen Failure
Study 5,Site 297,Subject 2461,Study 5,EMEA,ITA,0.0,1.0,3.0,Screening,
Study 5,Site 297,Subject 2462,Study 5,EMEA,ITA,0.0,1.0,0.0,Screening,
Study 5,Site 297,Subject 2463,Study 5,EMEA,ITA,0.0,1.0,0.0,Screening,
Study 5,Site 298,Subject 2464,Study 5,EMEA,SVK,0.0,13.0,129.0,Efficacy FU 1 (1),Follow-Up
Study 5,Site 299,Subject 2465,Study 5,EMEA,SVK,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 299,Subject 2466,Study 5,EMEA,SVK,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 299,Subject 2467,Study 5,EMEA,SVK,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 299,Subject 2468,Study 5,EMEA,SVK,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 299,Subject 2469,Study 5,EMEA,SVK,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 299,Subject 2470,Study 5,EMEA,SVK,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 299,Subject 2471,Study 5,EMEA,SVK,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 299,Subject 2472,Study 5,EMEA,SVK,0.0,7.0,64.0,Cycle 2 Week 3 (1),On Trial
Study 5,Site 299,Subject 2473,Study 5,EMEA,SVK,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 299,Subject 2474,Study 5,EMEA,SVK,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 299,Subject 2475,Study 5,EMEA,SVK,0.0,1.0,4.0,Screening,Screen Failure
Study 5,Site 299,Subject 2476,Study 5,EMEA,SVK,0.0,1.0,2.0,Screening,Screen Failure
Study 5,Site 3,Subject 6,Study 5,ASIA,AUS,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 3,Subject 7,Study 5,ASIA,AUS,0.0,1.0,0.0,Screening,
Study 5,Site 300,Subject 2477,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 300,Subject 2478,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 300,Subject 2479,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 300,Subject 2480,Study 5,EMEA,ESP,0.0,16.0,121.0,Efficacy FU 3 (1),Follow-Up
Study 5,Site 300,Subject 2481,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 300,Subject 2482,Study 5,EMEA,ESP,0.0,1.0,9.0,Screening,Screen Failure
Study 5,Site 300,Subject 2483,Study 5,EMEA,ESP,0.0,1.0,9.0,Screening,Discontinued
Study 5,Site 300,Subject 2484,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 300,Subject 2485,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 300,Subject 2486,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 300,Subject 2487,Study 5,EMEA,ESP,0.0,14.0,123.0,Efficacy FU 2 (1),Follow-Up
Study 5,Site 300,Subject 2488,Study 5,EMEA,ESP,0.0,14.0,125.0,Efficacy FU 2 (1),Follow-Up
Study 5,Site 300,Subject 2489,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 300,Subject 2490,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 300,Subject 2491,Study 5,EMEA,ESP,0.0,13.0,110.0,Efficacy FU 2 (1),Follow-Up
Study 5,Site 300,Subject 2492,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 300,Subject 2493,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 300,Subject 2494,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 300,Subject 2495,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 300,Subject 2496,Study 5,EMEA,ESP,0.0,13.0,100.0,Efficacy FU 1 (1),Follow-Up
Study 5,Site 300,Subject 2497,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 300,Subject 2498,Study 5,EMEA,ESP,0.0,13.0,101.0,Efficacy FU 1 (1),Follow-Up
Study 5,Site 300,Subject 2499,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 300,Subject 2500,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 300,Subject 2501,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 300,Subject 2502,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 300,Subject 2503,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 300,Subject 2504,Study 5,EMEA,ESP,0.0,11.0,88.0,Cycle 4 Week 3 (1),On Trial
Study 5,Site 300,Subject 2505,Study 5,EMEA,ESP,0.0,9.0,76.0,Cycle 3 Week 3 (1),On Trial
Study 5,Site 300,Subject 2506,Study 5,EMEA,ESP,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 300,Subject 2507,Study 5,EMEA,ESP,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 300,Subject 2508,Study 5,EMEA,ESP,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 300,Subject 2509,Study 5,EMEA,ESP,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 300,Subject 2510,Study 5,EMEA,ESP,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 300,Subject 2511,Study 5,EMEA,ESP,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 300,Subject 2512,Study 5,EMEA,ESP,0.0,4.0,43.0,Cycle 1 Week 1 (1),On Trial
Study 5,Site 301,Subject 2513,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 301,Subject 2514,Study 5,EMEA,ESP,0.0,13.0,100.0,Efficacy FU 1 (1),Follow-Up
Study 5,Site 301,Subject 2515,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 302,Subject 2516,Study 5,EMEA,ESP,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 302,Subject 2517,Study 5,EMEA,ESP,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 302,Subject 2518,Study 5,EMEA,ESP,0.0,12.0,0.0,EOT2/Safety FU (42D) (1),Follow-Up
Study 5,Site 302,Subject 2519,Study 5,EMEA,ESP,0.0,1.0,0.0,Screening,
Study 5,Site 302,Subject 2520,Study 5,EMEA,ESP,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 302,Subject 2521,Study 5,EMEA,ESP,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 302,Subject 2522,Study 5,EMEA,ESP,0.0,1.0,0.0,Screening,
Study 5,Site 302,Subject 2523,Study 5,EMEA,ESP,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 302,Subject 2524,Study 5,EMEA,ESP,0.0,1.0,0.0,Screening,
Study 5,Site 302,Subject 2525,Study 5,EMEA,ESP,0.0,1.0,0.0,Screening,
Study 5,Site 302,Subject 2526,Study 5,EMEA,ESP,0.0,1.0,0.0,Screening,
Study 5,Site 303,Subject 2527,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 303,Subject 2528,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 303,Subject 2529,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 303,Subject 2530,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 303,Subject 2531,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 303,Subject 2532,Study 5,EMEA,ESP,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 303,Subject 2533,Study 5,EMEA,ESP,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 303,Subject 2534,Study 5,EMEA,ESP,0.0,0.0,5.0,Screening,Screen Failure
Study 5,Site 303,Subject 2535,Study 5,EMEA,ESP,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 303,Subject 2536,Study 5,EMEA,ESP,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 303,Subject 2537,Study 5,EMEA,ESP,0.0,1.0,0.0,Screening,
Study 5,Site 303,Subject 2538,Study 5,EMEA,ESP,0.0,0.0,0.0,,
Study 5,Site 304,Subject 2539,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 304,Subject 2540,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 304,Subject 2541,Study 5,EMEA,ESP,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 305,Subject 2542,Study 5,EMEA,ESP,0.0,5.0,56.0,Cycle 1 Week 3 (1),Discontinued
Study 5,Site 305,Subject 2543,Study 5,EMEA,ESP,0.0,1.0,6.0,Screening,Screen Failure
Study 5,Site 305,Subject 2544,Study 5,EMEA,ESP,0.0,1.0,4.0,Screening,Screen Failure
Study 5,Site 305,Subject 2545,Study 5,EMEA,ESP,0.0,1.0,0.0,Screening,
Study 5,Site 306,Subject 2546,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 306,Subject 2547,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 306,Subject 2548,Study 5,EMEA,ESP,0.0,1.0,9.0,Screening,Discontinued
Study 5,Site 306,Subject 2549,Study 5,EMEA,ESP,0.0,14.0,112.0,Efficacy FU 2 (1),Follow-Up
Study 5,Site 306,Subject 2550,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 306,Subject 2551,Study 5,EMEA,ESP,0.0,14.0,104.0,Efficacy FU 2 (1),Follow-Up
Study 5,Site 306,Subject 2552,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 306,Subject 2553,Study 5,EMEA,ESP,0.0,13.0,94.0,Efficacy FU 1 (1),Follow-Up
Study 5,Site 306,Subject 2554,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 306,Subject 2555,Study 5,EMEA,ESP,0.0,12.0,95.0,EOT2/Safety FU (42D) (1),Follow-Up
Study 5,Site 306,Subject 2556,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 306,Subject 2557,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 306,Subject 2558,Study 5,EMEA,ESP,0.0,6.0,49.0,Cycle 2 Week 1 (1),On Trial
Study 5,Site 306,Subject 2559,Study 5,EMEA,ESP,0.0,5.0,50.0,Cycle 1 Week 3 (1),On Trial
Study 5,Site 306,Subject 2560,Study 5,EMEA,ESP,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 306,Subject 2561,Study 5,EMEA,ESP,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 306,Subject 2562,Study 5,EMEA,ESP,0.0,0.0,0.0,,
Study 5,Site 307,Subject 2563,Study 5,EMEA,ESP,0.0,1.0,5.0,Screening,Screen Failure
Study 5,Site 307,Subject 2564,Study 5,EMEA,ESP,0.0,1.0,5.0,Screening,Screen Failure
Study 5,Site 307,Subject 2565,Study 5,EMEA,ESP,0.0,1.0,5.0,Screening,Screen Failure
Study 5,Site 307,Subject 2566,Study 5,EMEA,ESP,0.0,1.0,2.0,Screening,Screen Failure
Study 5,Site 307,Subject 2567,Study 5,EMEA,ESP,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 307,Subject 2568,Study 5,EMEA,ESP,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 307,Subject 2569,Study 5,EMEA,ESP,0.0,10.0,0.0,EOT2/Safety FU (42D) (1),Follow-Up
Study 5,Site 307,Subject 2570,Study 5,EMEA,ESP,0.0,11.0,0.0,Cycle 4 Week 3 (1),On Trial
Study 5,Site 307,Subject 2571,Study 5,EMEA,ESP,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 307,Subject 2572,Study 5,EMEA,ESP,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 307,Subject 2573,Study 5,EMEA,ESP,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 307,Subject 2574,Study 5,EMEA,ESP,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 307,Subject 2575,Study 5,EMEA,ESP,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 307,Subject 2576,Study 5,EMEA,ESP,0.0,1.0,0.0,Screening,
Study 5,Site 307,Subject 2577,Study 5,EMEA,ESP,0.0,1.0,0.0,Screening,
Study 5,Site 308,Subject 2578,Study 5,EMEA,GBR,0.0,0.0,0.0,,
Study 5,Site 309,Subject 2579,Study 5,EMEA,GBR,0.0,3.0,0.0,Last Fraction (EOT1) (1),Follow-Up
Study 5,Site 310,Subject 2580,Study 5,EMEA,GBR,0.0,1.0,0.0,Screening,
Study 5,Site 311,Subject 2581,Study 5,EMEA,CHE,0.0,11.0,96.0,Unplanned visit (1),Discontinued
Study 5,Site 312,Subject 2582,Study 5,EMEA,CHE,0.0,9.0,39.0,Cycle 3 Week 3 (1),On Trial
Study 5,Site 312,Subject 2583,Study 5,EMEA,CHE,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 313,Subject 2584,Study 5,EMEA,CHE,0.0,12.0,101.0,EOT2/Safety FU (42D) (1),Follow-Up
Study 5,Site 314,Subject 2585,Study 5,EMEA,NLD,0.0,8.0,70.0,Cycle 3 Week 1 (1),On Trial
Study 5,Site 315,Subject 2592,Study 5,AMERICA,ARG,0.0,1.0,0.0,Screening,
Study 5,Site 315,Subject 2593,Study 5,AMERICA,ARG,0.0,0.0,0.0,,
Study 5,Site 315,Subject 2594,Study 5,AMERICA,ARG,0.0,1.0,0.0,Screening,
Study 5,Site 316,Subject 2595,Study 5,AMERICA,ARG,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 316,Subject 2596,Study 5,AMERICA,ARG,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 316,Subject 2597,Study 5,AMERICA,ARG,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 316,Subject 2598,Study 5,AMERICA,ARG,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 316,Subject 2599,Study 5,AMERICA,ARG,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 316,Subject 2600,Study 5,AMERICA,ARG,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 317,Subject 2601,Study 5,AMERICA,CAN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 317,Subject 2602,Study 5,AMERICA,CAN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 317,Subject 2603,Study 5,AMERICA,CAN,0.0,12.0,105.0,EOT2/Safety FU (42D) (1),Follow-Up
Study 5,Site 317,Subject 2604,Study 5,AMERICA,CAN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 317,Subject 2605,Study 5,AMERICA,CAN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 317,Subject 2606,Study 5,AMERICA,CAN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 317,Subject 2607,Study 5,AMERICA,CAN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 317,Subject 2608,Study 5,AMERICA,CAN,0.0,11.0,74.0,Cycle 4 Week 3 (1),On Trial
Study 5,Site 317,Subject 2609,Study 5,AMERICA,CAN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 317,Subject 2610,Study 5,AMERICA,CAN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 317,Subject 2611,Study 5,AMERICA,CAN,0.0,1.0,9.0,Screening,Screen Failure
Study 5,Site 318,Subject 2612,Study 5,AMERICA,CAN,0.0,1.0,9.0,Screening,Screen Failure
Study 5,Site 318,Subject 2613,Study 5,AMERICA,CAN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 318,Subject 2614,Study 5,AMERICA,CAN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 318,Subject 2615,Study 5,AMERICA,CAN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 318,Subject 2616,Study 5,AMERICA,CAN,0.0,9.0,82.0,Cycle 3 Week 3 (1),On Trial
Study 5,Site 319,Subject 2617,Study 5,AMERICA,CAN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 320,Subject 2618,Study 5,AMERICA,CAN,0.0,12.0,106.0,EOT2/Safety FU (42D) (1),On Trial
Study 5,Site 320,Subject 2619,Study 5,AMERICA,CAN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 320,Subject 2620,Study 5,AMERICA,CAN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 320,Subject 2621,Study 5,AMERICA,CAN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 320,Subject 2622,Study 5,AMERICA,CAN,0.0,9.0,74.0,Unplanned visit (1),On Trial
Study 5,Site 321,Subject 2623,Study 5,AMERICA,CAN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 321,Subject 2624,Study 5,AMERICA,CAN,0.0,1.0,13.0,Screening,Screen Failure
Study 5,Site 321,Subject 2625,Study 5,AMERICA,CAN,0.0,1.0,7.0,Screening,
Study 5,Site 322,Subject 2626,Study 5,AMERICA,CAN,0.0,15.0,96.0,Efficacy FU 3 (1),Survival
Study 5,Site 322,Subject 2627,Study 5,AMERICA,CAN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 322,Subject 2628,Study 5,AMERICA,CAN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 322,Subject 2629,Study 5,AMERICA,CAN,0.0,13.0,89.0,Efficacy FU 1 (1),Follow-Up
Study 5,Site 322,Subject 2630,Study 5,AMERICA,CAN,0.0,13.0,97.0,Efficacy FU 1 (1),Follow-Up
Study 5,Site 322,Subject 2631,Study 5,AMERICA,CAN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 322,Subject 2632,Study 5,AMERICA,CAN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 322,Subject 2633,Study 5,AMERICA,CAN,0.0,10.0,54.0,Cycle 4 Week 1 (1),On Trial
Study 5,Site 322,Subject 2634,Study 5,AMERICA,CAN,0.0,9.0,47.0,Cycle 3 Week 3 (1),On Trial
Study 5,Site 322,Subject 2635,Study 5,AMERICA,CAN,0.0,0.0,0.0,,
Study 5,Site 322,Subject 2636,Study 5,AMERICA,CAN,0.0,1.0,0.0,Screening,
Study 5,Site 323,Subject 2637,Study 5,AMERICA,CAN,0.0,0.0,0.0,Screening,Discontinued
Study 5,Site 324,Subject 2638,Study 5,AMERICA,BRA,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 324,Subject 2639,Study 5,AMERICA,BRA,0.0,1.0,12.0,Screening,Screen Failure
Study 5,Site 324,Subject 2640,Study 5,AMERICA,BRA,0.0,7.0,65.0,Cycle 2 Week 3 (1),On Trial
Study 5,Site 324,Subject 2641,Study 5,AMERICA,BRA,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 324,Subject 2642,Study 5,AMERICA,BRA,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 324,Subject 2643,Study 5,AMERICA,BRA,0.0,1.0,6.0,Screening,
Study 5,Site 324,Subject 2644,Study 5,AMERICA,BRA,0.0,1.0,7.0,Screening,
Study 5,Site 324,Subject 2645,Study 5,AMERICA,BRA,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 324,Subject 2646,Study 5,AMERICA,BRA,0.0,1.0,5.0,Screening,
Study 5,Site 324,Subject 2647,Study 5,AMERICA,BRA,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 325,Subject 2648,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 325,Subject 2649,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 325,Subject 2650,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 325,Subject 2651,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 326,Subject 2652,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 326,Subject 2653,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 326,Subject 2654,Study 5,AMERICA,USA,0.0,14.0,100.0,Efficacy FU 2 (1),Follow-Up
Study 5,Site 326,Subject 2655,Study 5,AMERICA,USA,0.0,14.0,109.0,Efficacy FU 2 (1),Follow-Up
Study 5,Site 326,Subject 2656,Study 5,AMERICA,USA,0.0,12.0,112.0,EOT2/Safety FU (42D) (1),Follow-Up
Study 5,Site 326,Subject 2657,Study 5,AMERICA,USA,0.0,12.0,110.0,EOT2/Safety FU (42D) (1),Follow-Up
Study 5,Site 326,Subject 2658,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 326,Subject 2659,Study 5,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 326,Subject 2660,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 326,Subject 2661,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 326,Subject 2662,Study 5,AMERICA,USA,0.0,3.0,40.0,Last Fraction (EOT1) (1),Discontinued
Study 5,Site 326,Subject 2663,Study 5,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 327,Subject 2664,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 327,Subject 2665,Study 5,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 5,Site 327,Subject 2666,Study 5,AMERICA,USA,0.0,5.0,0.0,Cycle 1 Week 3 (1),On Trial
Study 5,Site 327,Subject 2667,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 328,Subject 2668,Study 5,AMERICA,USA,0.0,10.0,86.0,Cycle 4 Week 1 (1),On Trial
Study 5,Site 328,Subject 2669,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 329,Subject 2683,Study 5,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 329,Subject 2684,Study 5,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 329,Subject 2685,Study 5,AMERICA,USA,0.0,15.0,89.0,Long term safety FU 1 (1),Follow-Up
Study 5,Site 329,Subject 2686,Study 5,AMERICA,USA,0.0,13.0,65.0,Efficacy FU 1 (1),Follow-Up
Study 5,Site 329,Subject 2687,Study 5,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 329,Subject 2688,Study 5,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 329,Subject 2689,Study 5,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 329,Subject 2690,Study 5,AMERICA,USA,0.0,12.0,65.0,EOT2/Safety FU (42D) (1),Survival
Study 5,Site 329,Subject 2691,Study 5,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 329,Subject 2692,Study 5,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 329,Subject 2693,Study 5,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 329,Subject 2694,Study 5,AMERICA,USA,0.0,12.0,60.0,EOT2/Safety FU (42D) (1),Follow-Up
Study 5,Site 329,Subject 2695,Study 5,AMERICA,USA,0.0,12.0,40.0,EOT2/Safety FU (42D) (1),Follow-Up
Study 5,Site 329,Subject 2696,Study 5,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 329,Subject 2697,Study 5,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 329,Subject 2698,Study 5,AMERICA,USA,0.0,11.0,36.0,Cycle 4 Week 3 (1),On Trial
Study 5,Site 329,Subject 2699,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 329,Subject 2700,Study 5,AMERICA,USA,0.0,0.0,0.0,,
Study 5,Site 330,Subject 2703,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 331,Subject 2704,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 331,Subject 2705,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 331,Subject 2706,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 331,Subject 2707,Study 5,AMERICA,USA,0.0,1.0,18.0,Screening,Screen Failure
Study 5,Site 331,Subject 2708,Study 5,AMERICA,USA,0.0,1.0,5.0,Screening,Screen Failure
Study 5,Site 331,Subject 2709,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 332,Subject 2714,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 332,Subject 2715,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 332,Subject 2716,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 332,Subject 2717,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 332,Subject 2718,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 333,Subject 2719,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 333,Subject 2720,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 333,Subject 2721,Study 5,AMERICA,USA,0.0,13.0,127.0,Efficacy FU 1 (1),Follow-Up
Study 5,Site 333,Subject 2722,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 333,Subject 2723,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 333,Subject 2724,Study 5,AMERICA,USA,0.0,9.0,77.0,Cycle 3 Week 3 (1),On Trial
Study 5,Site 333,Subject 2725,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 333,Subject 2726,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 333,Subject 2727,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 333,Subject 2728,Study 5,AMERICA,USA,0.0,5.0,45.0,Cycle 1 Week 3 (1),On Trial
Study 5,Site 334,Subject 2729,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 335,Subject 2730,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 335,Subject 2731,Study 5,AMERICA,USA,0.0,12.0,104.0,EOT2/Safety FU (42D) (1),Follow-Up
Study 5,Site 335,Subject 2732,Study 5,AMERICA,USA,0.0,1.0,10.0,Screening,Discontinued
Study 5,Site 335,Subject 2733,Study 5,AMERICA,USA,0.0,8.0,75.0,Cycle 4 Week 1 (1),On Trial
Study 5,Site 335,Subject 2734,Study 5,AMERICA,USA,0.0,1.0,24.0,Screening,Screen Failure
Study 5,Site 335,Subject 2735,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 335,Subject 2736,Study 5,AMERICA,USA,0.0,5.0,48.0,Cycle 1 Week 3 (1),On Trial
Study 5,Site 335,Subject 2737,Study 5,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 335,Subject 2738,Study 5,AMERICA,USA,0.0,1.0,3.0,Screening,
Study 5,Site 336,Subject 2739,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 336,Subject 2740,Study 5,AMERICA,USA,0.0,6.0,0.0,Cycle 2 Week 1 (1),On Trial
Study 5,Site 336,Subject 2741,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 336,Subject 2742,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 336,Subject 2743,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 5,Site 337,Subject 2744,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 337,Subject 2745,Study 5,AMERICA,USA,0.0,10.0,0.0,Cycle 4 Week 1 (1),On Trial
Study 5,Site 337,Subject 2746,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 337,Subject 2747,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 337,Subject 2748,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 338,Subject 2749,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 338,Subject 2750,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 338,Subject 2751,Study 5,AMERICA,USA,0.0,4.0,0.0,Cycle 1 Week 1 (1),On Trial
Study 5,Site 338,Subject 2752,Study 5,AMERICA,USA,0.0,4.0,0.0,Cycle 1 Week 1 (1),On Trial
Study 5,Site 338,Subject 2753,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 338,Subject 2754,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 338,Subject 2755,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 338,Subject 2756,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 5,Site 338,Subject 2757,Study 5,AMERICA,USA,0.0,0.0,0.0,,
Study 5,Site 338,Subject 2758,Study 5,AMERICA,USA,0.0,0.0,0.0,,
Study 5,Site 338,Subject 2759,Study 5,AMERICA,USA,0.0,0.0,0.0,,
Study 5,Site 339,Subject 2760,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 339,Subject 2761,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 5,Site 339,Subject 2762,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Enrolled
Study 5,Site 340,Subject 2763,Study 5,AMERICA,USA,0.0,5.0,0.0,Cycle 1 Week 3 (1),On Trial
Study 5,Site 340,Subject 2764,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 340,Subject 2765,Study 5,AMERICA,USA,0.0,0.0,0.0,,
Study 5,Site 340,Subject 2766,Study 5,AMERICA,USA,0.0,0.0,0.0,,
Study 5,Site 340,Subject 2767,Study 5,AMERICA,USA,0.0,0.0,0.0,,
Study 5,Site 340,Subject 2768,Study 5,AMERICA,USA,0.0,0.0,0.0,,
Study 5,Site 341,Subject 2769,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,Screen Failure
Study 5,Site 342,Subject 2770,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 5,Site 343,Subject 2771,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 5,Site 343,Subject 2772,Study 5,AMERICA,USA,0.0,1.0,0.0,Screening,
Study 5,Site 344,Subject 2794,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 344,Subject 2795,Study 5,ASIA,JPN,0.0,1.0,9.0,Screening,Discontinued
Study 5,Site 344,Subject 2796,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 344,Subject 2797,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 344,Subject 2798,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 344,Subject 2799,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 344,Subject 2800,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 344,Subject 2801,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 344,Subject 2802,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 345,Subject 2803,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 345,Subject 2804,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 345,Subject 2805,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 345,Subject 2806,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 345,Subject 2807,Study 5,ASIA,JPN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 345,Subject 2808,Study 5,ASIA,JPN,0.0,1.0,6.0,Screening,Screen Failure
Study 5,Site 345,Subject 2809,Study 5,ASIA,JPN,0.0,1.0,2.0,Screening,
Study 5,Site 346,Subject 2814,Study 5,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 346,Subject 2815,Study 5,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 346,Subject 2816,Study 5,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 346,Subject 2817,Study 5,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 346,Subject 2818,Study 5,ASIA,CHN,0.0,1.0,0.0,Screening,
Study 5,Site 346,Subject 2819,Study 5,ASIA,CHN,0.0,1.0,0.0,Screening,
Study 5,Site 346,Subject 2820,Study 5,ASIA,CHN,0.0,0.0,0.0,,
Study 5,Site 346,Subject 2821,Study 5,ASIA,CHN,0.0,0.0,0.0,,
Study 5,Site 347,Subject 2822,Study 5,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 347,Subject 2823,Study 5,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 347,Subject 2824,Study 5,ASIA,CHN,0.0,1.0,8.0,Screening,Screen Failure
Study 5,Site 348,Subject 2825,Study 5,ASIA,CHN,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 348,Subject 2826,Study 5,ASIA,CHN,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 348,Subject 2827,Study 5,ASIA,CHN,0.0,1.0,7.0,Screening,Screen Failure
Study 5,Site 348,Subject 2828,Study 5,ASIA,CHN,0.0,1.0,0.0,Screening,Screen Failure
Study 6,Site 14,Subject 25,Study 6,ASIA,AUS,0.0,1.0,9.0,Screening,Screen Failure
Study 6,Site 14,Subject 26,Study 6,ASIA,AUS,0.0,9.0,83.0,Cycle 2 Week 7 (1),On Trial
Study 6,Site 14,Subject 27,Study 6,ASIA,AUS,0.0,11.0,82.0,Safety follow-up (1),Follow-Up
Study 6,Site 14,Subject 28,Study 6,ASIA,AUS,0.0,1.0,8.0,Screening,Screen Failure
Study 6,Site 14,Subject 29,Study 6,ASIA,AUS,0.0,7.0,58.0,Cycle 2 Week 1 (1),On Trial
Study 6,Site 14,Subject 30,Study 6,ASIA,AUS,0.0,5.0,56.0,Cycle 1 Week 7 (1),On Trial
Study 6,Site 14,Subject 31,Study 6,ASIA,AUS,0.0,5.0,27.0,Cycle 1 Week 7 (1),On Trial
Study 6,Site 14,Subject 32,Study 6,ASIA,AUS,0.0,4.0,37.0,Cycle 1 Week 5 (1),On Trial
Study 6,Site 14,Subject 33,Study 6,ASIA,AUS,0.0,4.0,41.0,Cycle 1 Week 5 (1),On Trial
Study 6,Site 14,Subject 34,Study 6,ASIA,AUS,0.0,1.0,0.0,Screening,Screen Failure
Study 6,Site 14,Subject 35,Study 6,ASIA,AUS,0.0,1.0,0.0,Screening,Screening
Study 6,Site 14,Subject 36,Study 6,ASIA,AUS,0.0,1.0,0.0,Screening,Screening
Study 6,Site 15,Subject 39,Study 6,ASIA,AUS,0.0,11.0,29.0,Cycle 3 Week 1 (1),On Trial
Study 6,Site 15,Subject 40,Study 6,ASIA,AUS,0.0,9.0,19.0,Cycle 2 Week 5 (1),On Trial
Study 6,Site 15,Subject 41,Study 6,ASIA,AUS,0.0,5.0,0.0,Cycle 1 Week 7 (1),On Trial
Study 6,Site 15,Subject 42,Study 6,ASIA,AUS,0.0,0.0,0.0,,
Study 6,Site 165,Subject 1512,Study 6,ASIA,CHN,0.0,1.0,9.0,Screening,Screen Failure
Study 6,Site 165,Subject 1513,Study 6,ASIA,CHN,0.0,15.0,171.0,Cycle 4 Week 1 (1),On Trial
Study 6,Site 165,Subject 2586,Study 6,ASIA,CHN,0.0,2.0,69.0,Unplanned Visit (5),Discontinued
Study 6,Site 165,Subject 2587,Study 6,ASIA,CHN,0.0,1.0,10.0,Screening,Screening
Study 6,Site 168,Subject 1520,Study 6,ASIA,CHN,0.0,1.0,14.0,Screening,Screen Failure
Study 6,Site 191,Subject 1668,Study 6,ASIA,JPN,0.0,6.0,54.0,Cycle 1 Week 8 (1),On Trial
Study 6,Site 191,Subject 1669,Study 6,ASIA,JPN,0.0,1.0,9.0,Screening,Screen Failure
Study 6,Site 193,Subject 1698,Study 6,ASIA,JPN,0.0,3.0,0.0,Cycle 1 Week 3 (1),On Trial
Study 6,Site 193,Subject 2780,Study 6,ASIA,JPN,0.0,1.0,0.0,Screening,Screening
Study 6,Site 193,Subject 2781,Study 6,ASIA,JPN,0.0,1.0,0.0,Screening,Screen Failure
Study 6,Site 194,Subject 1699,Study 6,ASIA,JPN,0.0,6.0,76.0,Cycle 1 Week 8 (1),On Trial
Study 6,Site 194,Subject 1700,Study 6,ASIA,JPN,0.0,1.0,0.0,Screening,Screening
Study 6,Site 20,Subject 1601,Study 6,AMERICA,USA,0.0,6.0,57.0,Cycle 1 Week 8 (1),On Trial
Study 6,Site 20,Subject 1602,Study 6,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 6,Site 20,Subject 1603,Study 6,AMERICA,USA,0.0,1.0,14.0,Screening,Screen Failure
Study 6,Site 20,Subject 2840,Study 6,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 6,Site 20,Subject 2841,Study 6,AMERICA,USA,0.0,1.0,40.0,Screening,Discontinued
Study 6,Site 20,Subject 2842,Study 6,AMERICA,USA,0.0,1.0,9.0,Screening,Screen Failure
Study 6,Site 20,Subject 82,Study 6,AMERICA,USA,0.0,7.0,58.0,Cycle 2 Week 1 (1),On Trial
Study 6,Site 345,Subject 2803,Study 6,ASIA,JPN,0.0,2.0,17.0,Cycle 1 Week 1 (1),On Trial
Study 6,Site 349,Subject 2829,Study 6,ASIA,SGP,0.0,1.0,9.0,Screening,Screen Failure
Study 6,Site 349,Subject 2830,Study 6,ASIA,SGP,0.0,7.0,99.0,Safety follow-up (1),Discontinued
Study 6,Site 349,Subject 2831,Study 6,ASIA,SGP,0.0,1.0,9.0,Screening,Screen Failure
Study 6,Site 349,Subject 2832,Study 6,ASIA,SGP,0.0,1.0,7.0,Screening,Screen Failure
Study 6,Site 349,Subject 2833,Study 6,ASIA,SGP,0.0,1.0,7.0,Screening,Screen Failure
Study 6,Site 349,Subject 2834,Study 6,ASIA,SGP,0.0,1.0,9.0,Screening,Screen Failure
Study 6,Site 349,Subject 2835,Study 6,ASIA,SGP,0.0,2.0,46.0,Cycle 1 Week 1 (1),On Trial
Study 6,Site 350,Subject 2836,Study 6,ASIA,SGP,0.0,1.0,0.0,Screening,Screen Failure
Study 6,Site 351,Subject 2837,Study 6,ASIA,TWN,0.0,7.0,72.0,Cycle 2 Week 1 (1),On Trial
Study 6,Site 351,Subject 2838,Study 6,ASIA,TWN,0.0,6.0,64.0,Cycle 1 Week 8 (1),On Trial
Study 6,Site 351,Subject 2839,Study 6,ASIA,TWN,0.0,1.0,9.0,Screening,Screen Failure
Study 6,Site 352,Subject 2843,Study 6,ASIA,JPN,0.0,3.0,0.0,Cycle 1 Week 3 (1),On Trial
Study 6,Site 62,Subject 380,Study 6,EMEA,ISR,0.0,1.0,9.0,Screening,Screen Failure
Study 6,Site 62,Subject 381,Study 6,EMEA,ISR,0.0,1.0,7.0,Screening,Screen Failure
Study 6,Site 62,Subject 382,Study 6,EMEA,ISR,0.0,1.0,7.0,Screening,Screen Failure
Study 6,Site 62,Subject 383,Study 6,EMEA,ISR,0.0,1.0,13.0,Screening,Screen Failure
Study 6,Site 62,Subject 384,Study 6,EMEA,ISR,0.0,1.0,6.0,Screening,Screen Failure
Study 7,Site 110,Subject 893,Study 7,ASIA,AUS,0.0,0.0,0.0,,Screening
Study 7,Site 12,Subject 22,Study 7,ASIA,SGP,0.0,3.0,50.0,Cycle 1 Week 5 (1),Screening
Study 7,Site 12,Subject 2846,Study 7,ASIA,SGP,0.0,2.0,42.0,Cycle 1 Week 1 (1),Screening
Study 7,Site 12,Subject 2847,Study 7,ASIA,SGP,0.0,1.0,9.0,Screening Visit,Screening
Study 7,Site 14,Subject 25,Study 7,ASIA,CHN,0.0,5.0,89.0,Cycle 2 Week 5 (1),Screening
Study 7,Site 14,Subject 26,Study 7,ASIA,CHN,0.0,5.0,107.0,Cycle 2 Week 5 (1),Screening
Study 7,Site 14,Subject 27,Study 7,ASIA,CHN,0.0,5.0,102.0,Cycle 2 Week 5 (1),Screening
Study 7,Site 14,Subject 28,Study 7,ASIA,CHN,0.0,2.0,80.0,Unplanned_Recist (1),Follow-Up
Study 7,Site 14,Subject 29,Study 7,ASIA,CHN,0.0,3.0,57.0,Cycle 1 Week 5 (1),Screening
Study 7,Site 14,Subject 30,Study 7,ASIA,CHN,0.0,1.0,7.0,Screening Visit,Screen Failure
Study 7,Site 14,Subject 31,Study 7,ASIA,CHN,0.0,3.0,67.0,Cycle 1 Week 5 (1),Screening
Study 7,Site 14,Subject 32,Study 7,ASIA,CHN,0.0,1.0,6.0,Screening Visit,Screen Failure
Study 7,Site 14,Subject 33,Study 7,ASIA,CHN,0.0,1.0,7.0,Screening Visit,Screen Failure
Study 7,Site 14,Subject 34,Study 7,ASIA,CHN,0.0,1.0,11.0,Screening Visit,Enrolled
Study 7,Site 14,Subject 35,Study 7,ASIA,CHN,0.0,1.0,0.0,Screening Visit,
Study 7,Site 148,Subject 1393,Study 7,ASIA,TWN,0.0,2.0,45.0,Cycle 1 Week 1 (1),Screening
Study 7,Site 148,Subject 1394,Study 7,ASIA,TWN,0.0,1.0,31.0,Screening Visit,Screening
Study 7,Site 164,Subject 1498,Study 7,ASIA,CHN,0.0,1.0,0.0,Screening Visit,Screening
Study 7,Site 164,Subject 1499,Study 7,ASIA,CHN,0.0,0.0,0.0,,
Study 7,Site 17,Subject 60,Study 7,ASIA,CHN,0.0,1.0,6.0,Screening Visit,Screen Failure
Study 7,Site 17,Subject 61,Study 7,ASIA,CHN,0.0,2.0,1.0,Cycle 1 Week 1 (1),Screening
Study 7,Site 17,Subject 62,Study 7,ASIA,CHN,0.0,1.0,0.0,Screening Visit,Screening
Study 7,Site 353,Subject 2844,Study 7,ASIA,SGP,0.0,1.0,0.0,Screening Visit,Screening
Study 7,Site 353,Subject 2845,Study 7,ASIA,SGP,0.0,1.0,0.0,Screening Visit,Screen Failure
Study 7,Site 354,Subject 2848,Study 7,ASIA,CHN,0.0,1.0,7.0,Screening Visit,Screen Failure
Study 7,Site 354,Subject 2849,Study 7,ASIA,CHN,0.0,1.0,7.0,Screening Visit,Screen Failure
Study 7,Site 354,Subject 2850,Study 7,ASIA,CHN,0.0,3.0,65.0,Cycle 1 Week 5 (1),Screening
Study 7,Site 354,Subject 2851,Study 7,ASIA,CHN,0.0,1.0,4.0,Screening Visit,Screening
Study 7,Site 355,Subject 2852,Study 7,ASIA,CHN,0.0,1.0,0.0,Screening Visit,Screen Failure
Study 7,Site 356,Subject 2853,Study 7,ASIA,JPN,0.0,3.0,43.0,Cycle 1 Week 5 (1),Screening
Study 7,Site 87,Subject 627,Study 7,ASIA,AUS,0.0,5.0,38.0,Cycle 2 Week 1 (1),Screening
Study 7,Site 93,Subject 674,Study 7,ASIA,CHN,0.0,1.0,0.0,Screening Visit,Screening
Study 7,Site 95,Subject 682,Study 7,ASIA,TWN,0.0,1.0,0.0,Screening Visit,Screening
Study 8,Site 1,Subject 1,Study 8,AMERICA,ARG,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 1,Subject 169,Study 8,AMERICA,ARG,0.0,13.0,101.0,Week 108 (1),Enrolled
Study 8,Site 1,Subject 752,Study 8,AMERICA,ARG,0.0,13.0,91.0,Week 108 (1),Enrolled
Study 8,Site 1,Subject 753,Study 8,AMERICA,ARG,0.0,12.0,115.0,Week 96 (1),Enrolled
Study 8,Site 1,Subject 754,Study 8,AMERICA,ARG,0.0,13.0,135.0,Week 108 (1),Enrolled
Study 8,Site 1,Subject 755,Study 8,AMERICA,ARG,0.0,4.0,67.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 1,Subject 756,Study 8,AMERICA,ARG,0.0,9.0,149.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 1,Subject 757,Study 8,AMERICA,ARG,0.0,10.0,94.0,Week 72 (1),Enrolled
Study 8,Site 10,Subject 17,Study 8,EMEA,BGR,0.0,14.0,124.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 10,Subject 18,Study 8,EMEA,BGR,0.0,15.0,116.0,Week 132 (1),Enrolled
Study 8,Site 10,Subject 19,Study 8,EMEA,BGR,0.0,15.0,136.0,Week 132 (1),Enrolled
Study 8,Site 10,Subject 851,Study 8,EMEA,BGR,0.0,14.0,115.0,Week 120 (1),Enrolled
Study 8,Site 10,Subject 852,Study 8,EMEA,BGR,0.0,14.0,125.0,Week 120 (1),Enrolled
Study 8,Site 10,Subject 853,Study 8,EMEA,BGR,0.0,14.0,104.0,Week 120 (1),Enrolled
Study 8,Site 10,Subject 854,Study 8,EMEA,BGR,0.0,1.0,23.0,Screening,Screen Failure
Study 8,Site 10,Subject 855,Study 8,EMEA,BGR,0.0,13.0,95.0,Week 108 (1),Enrolled
Study 8,Site 10,Subject 856,Study 8,EMEA,BGR,0.0,9.0,103.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 10,Subject 857,Study 8,EMEA,BGR,0.0,12.0,107.0,Week 96 (1),Enrolled
Study 8,Site 10,Subject 858,Study 8,EMEA,BGR,0.0,11.0,80.0,Week 84 (1),Enrolled
Study 8,Site 10,Subject 859,Study 8,EMEA,BGR,0.0,10.0,107.0,Unplanned visit (15),Screening
Study 8,Site 10,Subject 860,Study 8,EMEA,BGR,0.0,7.0,77.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 110,Subject 893,Study 8,EMEA,BGR,0.0,12.0,100.0,Unplanned visit (12),Enrolled
Study 8,Site 110,Subject 894,Study 8,EMEA,BGR,0.0,12.0,81.0,Week 96 (1),Enrolled
Study 8,Site 111,Subject 897,Study 8,EMEA,DEU,0.0,10.0,67.0,Week 72 (1),Enrolled
Study 8,Site 112,Subject 898,Study 8,EMEA,DEU,0.0,14.0,100.0,Week 120 (1),Enrolled
Study 8,Site 112,Subject 899,Study 8,EMEA,DEU,0.0,12.0,88.0,Week 96 (1),Enrolled
Study 8,Site 113,Subject 911,Study 8,EMEA,ITA,0.0,13.0,94.0,Week 108 (1),Enrolled
Study 8,Site 113,Subject 912,Study 8,EMEA,ITA,0.0,13.0,85.0,Week 108 (1),Enrolled
Study 8,Site 113,Subject 913,Study 8,EMEA,ITA,0.0,12.0,78.0,Week 96 (1),Enrolled
Study 8,Site 113,Subject 914,Study 8,EMEA,ITA,0.0,11.0,71.0,Week 84 (1),Enrolled
Study 8,Site 113,Subject 915,Study 8,EMEA,ITA,0.0,11.0,71.0,Week 84 (1),Enrolled
Study 8,Site 113,Subject 916,Study 8,EMEA,ITA,0.0,10.0,65.0,Week 72 (1),Enrolled
Study 8,Site 113,Subject 917,Study 8,EMEA,ITA,0.0,10.0,67.0,Week 72 (1),Enrolled
Study 8,Site 167,Subject 1519,Study 8,ASIA,KOR,0.0,14.0,115.0,Week 120 (1),Enrolled
Study 8,Site 167,Subject 3292,Study 8,ASIA,KOR,0.0,14.0,202.0,Week 120 (1),Enrolled
Study 8,Site 167,Subject 3293,Study 8,ASIA,KOR,0.0,3.0,45.0,EOT (1),Discontinued
Study 8,Site 167,Subject 3294,Study 8,ASIA,KOR,0.0,13.0,182.0,Week 108 (1),Enrolled
Study 8,Site 167,Subject 3295,Study 8,ASIA,KOR,0.0,13.0,106.0,Week 108 (1),Enrolled
Study 8,Site 167,Subject 3296,Study 8,ASIA,KOR,0.0,13.0,97.0,Week 108 (1),Enrolled
Study 8,Site 167,Subject 3297,Study 8,ASIA,KOR,0.0,3.0,43.0,EOT (1),Discontinued
Study 8,Site 167,Subject 3298,Study 8,ASIA,KOR,0.0,1.0,7.0,Screening,Screen Failure
Study 8,Site 167,Subject 3299,Study 8,ASIA,KOR,0.0,12.0,105.0,Week 96 (1),Enrolled
Study 8,Site 167,Subject 3300,Study 8,ASIA,KOR,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 167,Subject 3301,Study 8,ASIA,KOR,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 167,Subject 3302,Study 8,ASIA,KOR,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 167,Subject 3303,Study 8,ASIA,KOR,0.0,10.0,98.0,Week 72 (1),Enrolled
Study 8,Site 167,Subject 3304,Study 8,ASIA,KOR,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 167,Subject 3305,Study 8,ASIA,KOR,0.0,10.0,104.0,Week 72 (1),Enrolled
Study 8,Site 167,Subject 3306,Study 8,ASIA,KOR,0.0,10.0,102.0,Week 72 (1),Enrolled
Study 8,Site 167,Subject 3307,Study 8,ASIA,KOR,0.0,1.0,12.0,Unplanned visit (1),Screen Failure
Study 8,Site 167,Subject 3308,Study 8,ASIA,KOR,0.0,10.0,117.0,Week 72 (1),Enrolled
Study 8,Site 167,Subject 3309,Study 8,ASIA,KOR,0.0,1.0,7.0,Screening,Screen Failure
Study 8,Site 167,Subject 3310,Study 8,ASIA,KOR,0.0,10.0,81.0,Week 72 (1),Enrolled
Study 8,Site 174,Subject 1577,Study 8,ASIA,MYS,0.0,8.0,113.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 174,Subject 1578,Study 8,ASIA,MYS,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 174,Subject 1579,Study 8,ASIA,MYS,0.0,10.0,83.0,Week 72 (1),Enrolled
Study 8,Site 175,Subject 1591,Study 8,ASIA,MYS,0.0,1.0,11.0,Unplanned visit (1),Discontinued
Study 8,Site 176,Subject 1592,Study 8,ASIA,IND,0.0,13.0,103.0,Week 108 (1),Enrolled
Study 8,Site 176,Subject 3368,Study 8,ASIA,IND,0.0,12.0,100.0,Week 96 (1),Enrolled
Study 8,Site 176,Subject 3369,Study 8,ASIA,IND,0.0,7.0,120.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 176,Subject 3370,Study 8,ASIA,IND,0.0,11.0,96.0,Week 84 (1),Enrolled
Study 8,Site 176,Subject 3371,Study 8,ASIA,IND,0.0,10.0,85.0,Week 72 (1),Enrolled
Study 8,Site 178,Subject 1600,Study 8,AMERICA,USA,0.0,11.0,89.0,Week 84 (1),Enrolled
Study 8,Site 178,Subject 3393,Study 8,AMERICA,USA,0.0,8.0,96.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 178,Subject 3394,Study 8,AMERICA,USA,0.0,10.0,82.0,Week 72 (1),Enrolled
Study 8,Site 180,Subject 1610,Study 8,AMERICA,USA,0.0,13.0,110.0,Week 108 (1),Enrolled
Study 8,Site 180,Subject 1611,Study 8,AMERICA,USA,0.0,11.0,107.0,Week 84 (1),Enrolled
Study 8,Site 181,Subject 1614,Study 8,AMERICA,USA,0.0,13.0,98.0,Week 108 (1),Enrolled
Study 8,Site 181,Subject 2670,Study 8,AMERICA,USA,0.0,12.0,96.0,Week 96 (1),Enrolled
Study 8,Site 182,Subject 1615,Study 8,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 183,Subject 1616,Study 8,AMERICA,USA,0.0,12.0,86.0,Week 96 (1),Enrolled
Study 8,Site 183,Subject 1617,Study 8,AMERICA,USA,0.0,1.0,6.0,Screening,Screen Failure
Study 8,Site 185,Subject 1628,Study 8,AMERICA,USA,0.0,11.0,73.0,Week 84 (1),Enrolled
Study 8,Site 185,Subject 1629,Study 8,AMERICA,USA,0.0,10.0,69.0,Week 72 (1),Enrolled
Study 8,Site 2,Subject 2,Study 8,AMERICA,ARG,0.0,15.0,111.0,Week 132 (1),Enrolled
Study 8,Site 2,Subject 3,Study 8,AMERICA,ARG,0.0,6.0,85.0,Unplanned visit (2),Discontinued
Study 8,Site 2,Subject 4,Study 8,AMERICA,ARG,0.0,14.0,125.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 28,Subject 107,Study 8,AMERICA,ARG,0.0,14.0,131.0,Week 120 (1),Enrolled
Study 8,Site 28,Subject 108,Study 8,AMERICA,ARG,0.0,14.0,109.0,Week 120 (1),Enrolled
Study 8,Site 28,Subject 2233,Study 8,AMERICA,ARG,0.0,13.0,110.0,Week 108 (1),Enrolled
Study 8,Site 28,Subject 2234,Study 8,AMERICA,ARG,0.0,12.0,96.0,Week 96 (1),Enrolled
Study 8,Site 28,Subject 2235,Study 8,AMERICA,ARG,0.0,11.0,97.0,Week 84 (1),Enrolled
Study 8,Site 3,Subject 102,Study 8,AMERICA,ARG,0.0,12.0,94.0,Week 96 (1),Enrolled
Study 8,Site 3,Subject 103,Study 8,AMERICA,ARG,0.0,1.0,7.0,Screening,Screen Failure
Study 8,Site 3,Subject 104,Study 8,AMERICA,ARG,0.0,11.0,90.0,Week 84 (1),Enrolled
Study 8,Site 3,Subject 6,Study 8,AMERICA,ARG,0.0,13.0,129.0,Week 108 (1),Enrolled
Study 8,Site 3,Subject 7,Study 8,AMERICA,ARG,0.0,13.0,93.0,Week 108 (1),Enrolled
Study 8,Site 3,Subject 774,Study 8,AMERICA,ARG,0.0,11.0,91.0,Week 84 (1),Enrolled
Study 8,Site 3,Subject 775,Study 8,AMERICA,ARG,0.0,10.0,89.0,Week 72 (1),Enrolled
Study 8,Site 3,Subject 8,Study 8,AMERICA,ARG,0.0,12.0,110.0,Unplanned visit (6),Enrolled
Study 8,Site 31,Subject 118,Study 8,AMERICA,CAN,0.0,11.0,112.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 31,Subject 119,Study 8,AMERICA,CAN,0.0,13.0,110.0,Week 108 (1),Enrolled
Study 8,Site 31,Subject 120,Study 8,AMERICA,CAN,0.0,10.0,128.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 31,Subject 2854,Study 8,AMERICA,CAN,0.0,11.0,94.0,Unplanned visit (1),Enrolled
Study 8,Site 31,Subject 2855,Study 8,AMERICA,CAN,0.0,10.0,109.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 31,Subject 2856,Study 8,AMERICA,CAN,0.0,7.0,112.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 31,Subject 2857,Study 8,AMERICA,CAN,0.0,10.0,82.0,Week 72 (1),Enrolled
Study 8,Site 31,Subject 2858,Study 8,AMERICA,CAN,0.0,10.0,81.0,Week 72 (1),Enrolled
Study 8,Site 31,Subject 2859,Study 8,AMERICA,CAN,0.0,10.0,89.0,Week 72 (1),Enrolled
Study 8,Site 316,Subject 2595,Study 8,ASIA,KOR,0.0,1.0,23.0,Screening,Screen Failure
Study 8,Site 316,Subject 2596,Study 8,ASIA,KOR,0.0,15.0,152.0,Week 132 (1),Enrolled
Study 8,Site 316,Subject 2597,Study 8,ASIA,KOR,0.0,15.0,129.0,Week 132 (1),Enrolled
Study 8,Site 316,Subject 2598,Study 8,ASIA,KOR,0.0,14.0,114.0,Week 120 (1),Enrolled
Study 8,Site 316,Subject 2599,Study 8,ASIA,KOR,0.0,1.0,18.0,Screening,Screen Failure
Study 8,Site 316,Subject 2600,Study 8,ASIA,KOR,0.0,13.0,94.0,Week 108 (1),Enrolled
Study 8,Site 316,Subject 3311,Study 8,ASIA,KOR,0.0,11.0,100.0,Week 84 (1),Enrolled
Study 8,Site 316,Subject 3312,Study 8,ASIA,KOR,0.0,1.0,5.0,Screening,Screen Failure
Study 8,Site 316,Subject 3313,Study 8,ASIA,KOR,0.0,10.0,97.0,Week 72 (1),Enrolled
Study 8,Site 317,Subject 2601,Study 8,EMEA,ZAF,0.0,13.0,100.0,Week 108 (1),Enrolled
Study 8,Site 317,Subject 2602,Study 8,EMEA,ZAF,0.0,13.0,92.0,Week 108 (1),Enrolled
Study 8,Site 317,Subject 2603,Study 8,EMEA,ZAF,0.0,8.0,134.0,Unplanned visit (15),Discontinued
Study 8,Site 317,Subject 2604,Study 8,EMEA,ZAF,0.0,11.0,101.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 317,Subject 2605,Study 8,EMEA,ZAF,0.0,12.0,81.0,Week 96 (1),Enrolled
Study 8,Site 317,Subject 2606,Study 8,EMEA,ZAF,0.0,10.0,124.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 317,Subject 2607,Study 8,EMEA,ZAF,0.0,6.0,68.0,EOT (1),Discontinued
Study 8,Site 317,Subject 2608,Study 8,EMEA,ZAF,0.0,9.0,113.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 317,Subject 2609,Study 8,EMEA,ZAF,0.0,11.0,83.0,Week 84 (1),Enrolled
Study 8,Site 317,Subject 2610,Study 8,EMEA,ZAF,0.0,11.0,76.0,Week 84 (1),Enrolled
Study 8,Site 317,Subject 2611,Study 8,EMEA,ZAF,0.0,10.0,81.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 318,Subject 2612,Study 8,EMEA,ZAF,0.0,12.0,139.0,Unplanned visit (12),Enrolled
Study 8,Site 318,Subject 2613,Study 8,EMEA,ZAF,0.0,12.0,121.0,Week 96 (1),Enrolled
Study 8,Site 318,Subject 2614,Study 8,EMEA,ZAF,0.0,8.0,86.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 318,Subject 2615,Study 8,EMEA,ZAF,0.0,8.0,112.0,Unplanned visit (8),Discontinued
Study 8,Site 318,Subject 2616,Study 8,EMEA,ZAF,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 318,Subject 3350,Study 8,EMEA,ZAF,0.0,10.0,120.0,Week 72 (1),Enrolled
Study 8,Site 323,Subject 2637,Study 8,EMEA,ARE,0.0,11.0,96.0,Week 84 (1),Enrolled
Study 8,Site 323,Subject 3361,Study 8,EMEA,ARE,0.0,11.0,97.0,Week 84 (1),Enrolled
Study 8,Site 326,Subject 2652,Study 8,AMERICA,USA,0.0,11.0,93.0,Week 84 (1),Enrolled
Study 8,Site 327,Subject 2664,Study 8,AMERICA,USA,0.0,13.0,101.0,Week 108 (1),Enrolled
Study 8,Site 327,Subject 2665,Study 8,AMERICA,USA,0.0,13.0,102.0,Week 108 (1),Enrolled
Study 8,Site 327,Subject 2666,Study 8,AMERICA,USA,0.0,13.0,106.0,EOT (1),Enrolled
Study 8,Site 327,Subject 2667,Study 8,AMERICA,USA,0.0,7.0,84.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 327,Subject 3395,Study 8,AMERICA,USA,0.0,6.0,88.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 327,Subject 3396,Study 8,AMERICA,USA,0.0,10.0,89.0,Week 72 (1),Enrolled
Study 8,Site 330,Subject 2703,Study 8,AMERICA,USA,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 357,Subject 2860,Study 8,AMERICA,CAN,0.0,10.0,90.0,Week 72 (1),Enrolled
Study 8,Site 357,Subject 2861,Study 8,AMERICA,CAN,0.0,10.0,82.0,Week 72 (1),Enrolled
Study 8,Site 358,Subject 2862,Study 8,EMEA,BGR,0.0,15.0,113.0,Week 132 (1),Enrolled
Study 8,Site 358,Subject 2863,Study 8,EMEA,BGR,0.0,12.0,100.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 358,Subject 2864,Study 8,EMEA,BGR,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 358,Subject 2865,Study 8,EMEA,BGR,0.0,8.0,72.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 358,Subject 2866,Study 8,EMEA,BGR,0.0,13.0,105.0,Week 108 (1),Enrolled
Study 8,Site 358,Subject 2867,Study 8,EMEA,BGR,0.0,11.0,107.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 358,Subject 2868,Study 8,EMEA,BGR,0.0,11.0,103.0,Week 84 (1),Enrolled
Study 8,Site 358,Subject 2869,Study 8,EMEA,BGR,0.0,10.0,80.0,Week 72 (1),Enrolled
Study 8,Site 359,Subject 2870,Study 8,EMEA,BGR,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 359,Subject 2871,Study 8,EMEA,BGR,0.0,12.0,97.0,Week 96 (1),Enrolled
Study 8,Site 359,Subject 2872,Study 8,EMEA,BGR,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 359,Subject 2873,Study 8,EMEA,BGR,0.0,12.0,93.0,Week 96 (1),Enrolled
Study 8,Site 360,Subject 2874,Study 8,EMEA,CZE,0.0,16.0,118.0,Week 144 (1),Enrolled
Study 8,Site 360,Subject 2875,Study 8,EMEA,CZE,0.0,15.0,111.0,Week 132 (1),Enrolled
Study 8,Site 360,Subject 2876,Study 8,EMEA,CZE,0.0,10.0,82.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 360,Subject 2877,Study 8,EMEA,CZE,0.0,13.0,98.0,Week 108 (1),Enrolled
Study 8,Site 360,Subject 2878,Study 8,EMEA,CZE,0.0,10.0,85.0,Unplanned visit (1),Enrolled
Study 8,Site 361,Subject 2879,Study 8,EMEA,CZE,0.0,14.0,105.0,Week 120 (1),Enrolled
Study 8,Site 361,Subject 2880,Study 8,EMEA,CZE,0.0,12.0,193.0,Week 96 (1),Enrolled
Study 8,Site 361,Subject 2881,Study 8,EMEA,CZE,0.0,12.0,161.0,Week 96 (1),Enrolled
Study 8,Site 361,Subject 2882,Study 8,EMEA,CZE,0.0,12.0,153.0,Week 96 (1),Enrolled
Study 8,Site 362,Subject 2883,Study 8,EMEA,CZE,0.0,13.0,102.0,Week 108 (1),Enrolled
Study 8,Site 362,Subject 2884,Study 8,EMEA,CZE,0.0,8.0,91.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 362,Subject 2885,Study 8,EMEA,CZE,0.0,11.0,87.0,Week 84 (1),Enrolled
Study 8,Site 362,Subject 2886,Study 8,EMEA,CZE,0.0,1.0,7.0,Screening,Screen Failure
Study 8,Site 362,Subject 2887,Study 8,EMEA,CZE,0.0,12.0,94.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 362,Subject 2888,Study 8,EMEA,CZE,0.0,10.0,86.0,Week 72 (1),Enrolled
Study 8,Site 363,Subject 2889,Study 8,EMEA,CZE,0.0,15.0,111.0,Week 132 (1),Enrolled
Study 8,Site 363,Subject 2890,Study 8,EMEA,CZE,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 363,Subject 2891,Study 8,EMEA,CZE,0.0,14.0,105.0,Week 120 (1),Enrolled
Study 8,Site 363,Subject 2892,Study 8,EMEA,CZE,0.0,14.0,106.0,Week 120 (1),Enrolled
Study 8,Site 363,Subject 2893,Study 8,EMEA,CZE,0.0,13.0,99.0,Week 108 (1),Enrolled
Study 8,Site 363,Subject 2894,Study 8,EMEA,CZE,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 363,Subject 2895,Study 8,EMEA,CZE,0.0,12.0,96.0,Week 96 (1),Enrolled
Study 8,Site 363,Subject 2896,Study 8,EMEA,CZE,0.0,12.0,93.0,Week 96 (1),Enrolled
Study 8,Site 363,Subject 2897,Study 8,EMEA,CZE,0.0,12.0,89.0,Week 96 (1),Enrolled
Study 8,Site 363,Subject 2898,Study 8,EMEA,CZE,0.0,12.0,91.0,Week 96 (1),Enrolled
Study 8,Site 363,Subject 2899,Study 8,EMEA,CZE,0.0,11.0,127.0,Week 84 (1),Enrolled
Study 8,Site 363,Subject 2900,Study 8,EMEA,CZE,0.0,11.0,105.0,Week 84 (1),Enrolled
Study 8,Site 363,Subject 2901,Study 8,EMEA,CZE,0.0,11.0,96.0,Week 84 (1),Enrolled
Study 8,Site 363,Subject 2902,Study 8,EMEA,CZE,0.0,11.0,84.0,Week 84 (1),Enrolled
Study 8,Site 363,Subject 2903,Study 8,EMEA,CZE,0.0,11.0,88.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 363,Subject 2904,Study 8,EMEA,CZE,0.0,10.0,77.0,Week 72 (1),Enrolled
Study 8,Site 364,Subject 2905,Study 8,EMEA,FRA,0.0,16.0,125.0,Week 144 (1),Enrolled
Study 8,Site 364,Subject 2906,Study 8,EMEA,FRA,0.0,14.0,105.0,Week 120 (1),Enrolled
Study 8,Site 364,Subject 2907,Study 8,EMEA,FRA,0.0,13.0,102.0,Week 108 (1),Enrolled
Study 8,Site 364,Subject 2908,Study 8,EMEA,FRA,0.0,12.0,95.0,Week 96 (1),Enrolled
Study 8,Site 364,Subject 2909,Study 8,EMEA,FRA,0.0,6.0,103.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 364,Subject 2910,Study 8,EMEA,FRA,0.0,9.0,84.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 364,Subject 2911,Study 8,EMEA,FRA,0.0,11.0,88.0,Week 84 (1),Enrolled
Study 8,Site 364,Subject 2912,Study 8,EMEA,FRA,0.0,11.0,87.0,Week 84 (1),Enrolled
Study 8,Site 364,Subject 3007,Study 8,EMEA,FRA,0.0,14.0,110.0,Week 120 (1),Enrolled
Study 8,Site 365,Subject 2913,Study 8,EMEA,FRA,0.0,15.0,106.0,Week 132 (1),Enrolled
Study 8,Site 365,Subject 2914,Study 8,EMEA,FRA,0.0,13.0,144.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 365,Subject 2915,Study 8,EMEA,FRA,0.0,14.0,98.0,Week 120 (1),Enrolled
Study 8,Site 365,Subject 2916,Study 8,EMEA,FRA,0.0,14.0,89.0,Week 120 (1),Enrolled
Study 8,Site 365,Subject 2917,Study 8,EMEA,FRA,0.0,13.0,92.0,Week 120 (1),Enrolled
Study 8,Site 365,Subject 2918,Study 8,EMEA,FRA,0.0,10.0,83.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 365,Subject 2919,Study 8,EMEA,FRA,0.0,1.0,25.0,Screening,Enrolled
Study 8,Site 365,Subject 2920,Study 8,EMEA,FRA,0.0,11.0,80.0,Week 96 (1),Enrolled
Study 8,Site 365,Subject 2921,Study 8,EMEA,FRA,0.0,11.0,81.0,Week 84 (1),Enrolled
Study 8,Site 365,Subject 2922,Study 8,EMEA,FRA,0.0,11.0,70.0,Week 84 (1),Enrolled
Study 8,Site 365,Subject 2923,Study 8,EMEA,FRA,0.0,11.0,69.0,Week 84 (1),Enrolled
Study 8,Site 365,Subject 2924,Study 8,EMEA,FRA,0.0,11.0,76.0,Week 84 (1),Enrolled
Study 8,Site 365,Subject 2925,Study 8,EMEA,FRA,0.0,10.0,75.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 365,Subject 2926,Study 8,EMEA,FRA,0.0,10.0,63.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 365,Subject 2927,Study 8,EMEA,FRA,0.0,9.0,73.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 365,Subject 2928,Study 8,EMEA,FRA,0.0,10.0,80.0,Week 72 (1),Enrolled
Study 8,Site 366,Subject 2929,Study 8,EMEA,FRA,0.0,7.0,116.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 366,Subject 2930,Study 8,EMEA,FRA,0.0,1.0,9.0,Screening,Screen Failure
Study 8,Site 366,Subject 2931,Study 8,EMEA,FRA,0.0,7.0,107.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 366,Subject 2932,Study 8,EMEA,FRA,0.0,14.0,108.0,Week 120 (1),Enrolled
Study 8,Site 366,Subject 2933,Study 8,EMEA,FRA,0.0,12.0,100.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 366,Subject 2934,Study 8,EMEA,FRA,0.0,1.0,7.0,Screening,Screen Failure
Study 8,Site 366,Subject 2935,Study 8,EMEA,FRA,0.0,4.0,88.0,Unplanned visit (6),Discontinued
Study 8,Site 366,Subject 2936,Study 8,EMEA,FRA,0.0,13.0,100.0,Week 108 (1),Enrolled
Study 8,Site 366,Subject 2937,Study 8,EMEA,FRA,0.0,6.0,82.0,After 24 Weeks Day 169 (1),Discontinued
Study 8,Site 366,Subject 2938,Study 8,EMEA,FRA,0.0,12.0,94.0,Week 96 (1),Enrolled
Study 8,Site 366,Subject 2939,Study 8,EMEA,FRA,0.0,12.0,93.0,Week 96 (1),Enrolled
Study 8,Site 366,Subject 2940,Study 8,EMEA,FRA,0.0,11.0,87.0,Week 84 (1),Enrolled
Study 8,Site 366,Subject 2941,Study 8,EMEA,FRA,0.0,11.0,91.0,Week 84 (1),Enrolled
Study 8,Site 366,Subject 2942,Study 8,EMEA,FRA,0.0,11.0,84.0,30 Days Safety follow-up (1),Enrolled
Study 8,Site 367,Subject 2943,Study 8,EMEA,FRA,0.0,15.0,100.0,Week 132 (1),Enrolled
Study 8,Site 367,Subject 2944,Study 8,EMEA,FRA,0.0,4.0,68.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 367,Subject 2945,Study 8,EMEA,FRA,0.0,14.0,91.0,Week 120 (1),Enrolled
Study 8,Site 367,Subject 2946,Study 8,EMEA,FRA,0.0,12.0,105.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 367,Subject 2947,Study 8,EMEA,FRA,0.0,14.0,94.0,Week 120 (1),Enrolled
Study 8,Site 367,Subject 2948,Study 8,EMEA,FRA,0.0,7.0,72.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 367,Subject 2949,Study 8,EMEA,FRA,0.0,7.0,71.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 367,Subject 2950,Study 8,EMEA,FRA,0.0,3.0,35.0,EOT (1),Discontinued
Study 8,Site 367,Subject 2951,Study 8,EMEA,FRA,0.0,11.0,105.0,Week 84 (1),Enrolled
Study 8,Site 367,Subject 2952,Study 8,EMEA,FRA,0.0,10.0,65.0,Week 72 (1),Enrolled
Study 8,Site 368,Subject 2953,Study 8,EMEA,FRA,0.0,16.0,104.0,Week 144 (1),Enrolled
Study 8,Site 368,Subject 2954,Study 8,EMEA,FRA,0.0,16.0,104.0,Week 144 (1),Enrolled
Study 8,Site 368,Subject 2955,Study 8,EMEA,FRA,0.0,13.0,102.0,EOT (1),Discontinued
Study 8,Site 368,Subject 2956,Study 8,EMEA,FRA,0.0,1.0,5.0,Screening,Screen Failure
Study 8,Site 368,Subject 2957,Study 8,EMEA,FRA,0.0,1.0,5.0,Screening,Screen Failure
Study 8,Site 368,Subject 2958,Study 8,EMEA,FRA,0.0,1.0,5.0,Screening,Screen Failure
Study 8,Site 368,Subject 2959,Study 8,EMEA,FRA,0.0,11.0,72.0,Week 84 (1),Enrolled
Study 8,Site 368,Subject 2960,Study 8,EMEA,FRA,0.0,1.0,6.0,Screening,Screen Failure
Study 8,Site 369,Subject 2961,Study 8,EMEA,FRA,0.0,8.0,86.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 369,Subject 2962,Study 8,EMEA,FRA,0.0,13.0,82.0,Week 108 (1),Enrolled
Study 8,Site 369,Subject 2963,Study 8,EMEA,FRA,0.0,13.0,84.0,Week 108 (1),Enrolled
Study 8,Site 369,Subject 2964,Study 8,EMEA,FRA,0.0,13.0,89.0,Week 108 (1),Enrolled
Study 8,Site 369,Subject 2965,Study 8,EMEA,FRA,0.0,11.0,75.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 370,Subject 2966,Study 8,EMEA,FRA,0.0,15.0,119.0,Week 132 (1),Enrolled
Study 8,Site 370,Subject 2967,Study 8,EMEA,FRA,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 370,Subject 2968,Study 8,EMEA,FRA,0.0,6.0,77.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 370,Subject 2969,Study 8,EMEA,FRA,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 370,Subject 2970,Study 8,EMEA,FRA,0.0,14.0,107.0,Week 120 (1),Enrolled
Study 8,Site 370,Subject 2971,Study 8,EMEA,FRA,0.0,10.0,109.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 370,Subject 2972,Study 8,EMEA,FRA,0.0,14.0,110.0,Week 120 (1),Enrolled
Study 8,Site 370,Subject 2973,Study 8,EMEA,FRA,0.0,7.0,91.0,Unplanned visit (2),Discontinued
Study 8,Site 370,Subject 2974,Study 8,EMEA,FRA,0.0,14.0,99.0,Week 120 (1),Enrolled
Study 8,Site 370,Subject 2975,Study 8,EMEA,FRA,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 370,Subject 2976,Study 8,EMEA,FRA,0.0,13.0,104.0,Week 108 (1),Enrolled
Study 8,Site 370,Subject 2977,Study 8,EMEA,FRA,0.0,12.0,96.0,Week 108 (1),Enrolled
Study 8,Site 370,Subject 2978,Study 8,EMEA,FRA,0.0,12.0,101.0,Week 96 (1),Enrolled
Study 8,Site 370,Subject 2979,Study 8,EMEA,FRA,0.0,12.0,94.0,Week 96 (1),Enrolled
Study 8,Site 370,Subject 2980,Study 8,EMEA,FRA,0.0,8.0,78.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 370,Subject 2981,Study 8,EMEA,FRA,0.0,6.0,70.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 370,Subject 2982,Study 8,EMEA,FRA,0.0,9.0,79.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 370,Subject 2983,Study 8,EMEA,FRA,0.0,10.0,81.0,Week 72 (1),Enrolled
Study 8,Site 370,Subject 2984,Study 8,EMEA,FRA,0.0,10.0,76.0,Week 72 (1),Enrolled
Study 8,Site 371,Subject 2985,Study 8,EMEA,FRA,0.0,12.0,91.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 371,Subject 2986,Study 8,EMEA,FRA,0.0,14.0,93.0,Week 120 (1),Enrolled
Study 8,Site 371,Subject 2987,Study 8,EMEA,FRA,0.0,12.0,79.0,Week 96 (1),Enrolled
Study 8,Site 372,Subject 2988,Study 8,EMEA,FRA,0.0,11.0,116.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 372,Subject 2989,Study 8,EMEA,FRA,0.0,15.0,106.0,Week 132 (1),Enrolled
Study 8,Site 372,Subject 2990,Study 8,EMEA,FRA,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 372,Subject 2991,Study 8,EMEA,FRA,0.0,12.0,102.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 372,Subject 2992,Study 8,EMEA,FRA,0.0,11.0,103.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 372,Subject 2993,Study 8,EMEA,FRA,0.0,12.0,99.0,Week 96 (1),Enrolled
Study 8,Site 372,Subject 2994,Study 8,EMEA,FRA,0.0,11.0,95.0,Week 84 (1),Enrolled
Study 8,Site 373,Subject 2995,Study 8,EMEA,FRA,0.0,16.0,128.0,Week 144 (1),Enrolled
Study 8,Site 373,Subject 2996,Study 8,EMEA,FRA,0.0,15.0,113.0,Week 132 (1),Enrolled
Study 8,Site 373,Subject 2997,Study 8,EMEA,FRA,0.0,7.0,91.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 373,Subject 2998,Study 8,EMEA,FRA,0.0,11.0,93.0,Week 84 (1),Enrolled
Study 8,Site 373,Subject 2999,Study 8,EMEA,FRA,0.0,6.0,62.0,EOT (1),Discontinued
Study 8,Site 374,Subject 3000,Study 8,EMEA,FRA,0.0,15.0,114.0,Week 132 (1),Enrolled
Study 8,Site 374,Subject 3001,Study 8,EMEA,FRA,0.0,15.0,113.0,Week 132 (1),Enrolled
Study 8,Site 374,Subject 3002,Study 8,EMEA,FRA,0.0,15.0,113.0,Week 132 (1),Enrolled
Study 8,Site 374,Subject 3003,Study 8,EMEA,FRA,0.0,15.0,118.0,Week 132 (1),Enrolled
Study 8,Site 374,Subject 3004,Study 8,EMEA,FRA,0.0,15.0,114.0,Week 132 (1),Enrolled
Study 8,Site 374,Subject 3005,Study 8,EMEA,FRA,0.0,15.0,110.0,Week 132 (1),Enrolled
Study 8,Site 374,Subject 3006,Study 8,EMEA,FRA,0.0,14.0,110.0,Week 120 (1),Enrolled
Study 8,Site 374,Subject 3008,Study 8,EMEA,FRA,0.0,12.0,100.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 374,Subject 3009,Study 8,EMEA,FRA,0.0,13.0,104.0,Week 108 (1),Enrolled
Study 8,Site 374,Subject 3010,Study 8,EMEA,FRA,0.0,1.0,11.0,Unplanned visit (1),Screen Failure
Study 8,Site 374,Subject 3011,Study 8,EMEA,FRA,0.0,11.0,92.0,Week 84 (1),Enrolled
Study 8,Site 374,Subject 3012,Study 8,EMEA,FRA,0.0,11.0,88.0,Week 84 (1),Enrolled
Study 8,Site 374,Subject 3013,Study 8,EMEA,FRA,0.0,10.0,88.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 374,Subject 3014,Study 8,EMEA,FRA,0.0,9.0,89.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 374,Subject 3015,Study 8,EMEA,FRA,0.0,11.0,89.0,Week 84 (1),Enrolled
Study 8,Site 374,Subject 3016,Study 8,EMEA,FRA,0.0,11.0,89.0,Week 84 (1),Enrolled
Study 8,Site 374,Subject 3017,Study 8,EMEA,FRA,0.0,10.0,85.0,Week 72 (1),Enrolled
Study 8,Site 374,Subject 3018,Study 8,EMEA,FRA,0.0,10.0,89.0,Week 72 (1),Enrolled
Study 8,Site 375,Subject 3019,Study 8,EMEA,FRA,0.0,15.0,113.0,Week 132 (1),Enrolled
Study 8,Site 375,Subject 3020,Study 8,EMEA,FRA,0.0,15.0,113.0,Week 132 (1),Enrolled
Study 8,Site 375,Subject 3021,Study 8,EMEA,FRA,0.0,14.0,107.0,Week 120 (1),Enrolled
Study 8,Site 375,Subject 3022,Study 8,EMEA,FRA,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 375,Subject 3023,Study 8,EMEA,FRA,0.0,8.0,94.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 375,Subject 3024,Study 8,EMEA,FRA,0.0,7.0,89.0,EOT (1),Discontinued
Study 8,Site 375,Subject 3025,Study 8,EMEA,FRA,0.0,13.0,104.0,Week 108 (1),Enrolled
Study 8,Site 375,Subject 3026,Study 8,EMEA,FRA,0.0,12.0,95.0,Week 96 (1),Enrolled
Study 8,Site 375,Subject 3027,Study 8,EMEA,FRA,0.0,11.0,97.0,Week 84 (1),Enrolled
Study 8,Site 375,Subject 3028,Study 8,EMEA,FRA,0.0,7.0,118.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 375,Subject 3029,Study 8,EMEA,FRA,0.0,11.0,89.0,Week 84 (1),Enrolled
Study 8,Site 375,Subject 3030,Study 8,EMEA,FRA,0.0,10.0,83.0,Week 72 (1),Enrolled
Study 8,Site 375,Subject 3031,Study 8,EMEA,FRA,0.0,10.0,83.0,Week 72 (1),Enrolled
Study 8,Site 375,Subject 3032,Study 8,EMEA,FRA,0.0,9.0,77.0,Week 60 (1),Enrolled
Study 8,Site 375,Subject 3033,Study 8,EMEA,FRA,0.0,9.0,77.0,Week 60 (1),Enrolled
Study 8,Site 376,Subject 3034,Study 8,EMEA,FRA,0.0,14.0,106.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 376,Subject 3035,Study 8,EMEA,FRA,0.0,14.0,109.0,Week 120 (1),Enrolled
Study 8,Site 376,Subject 3036,Study 8,EMEA,FRA,0.0,8.0,106.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 376,Subject 3037,Study 8,EMEA,FRA,0.0,12.0,101.0,Week 96 (1),Enrolled
Study 8,Site 376,Subject 3038,Study 8,EMEA,FRA,0.0,12.0,93.0,Week 96 (1),Enrolled
Study 8,Site 376,Subject 3039,Study 8,EMEA,FRA,0.0,12.0,93.0,Week 96 (1),Enrolled
Study 8,Site 376,Subject 3040,Study 8,EMEA,FRA,0.0,11.0,91.0,Week 84 (1),Enrolled
Study 8,Site 376,Subject 3041,Study 8,EMEA,FRA,0.0,10.0,81.0,Week 72 (1),Enrolled
Study 8,Site 376,Subject 3042,Study 8,EMEA,FRA,0.0,10.0,81.0,Week 72 (1),Enrolled
Study 8,Site 376,Subject 3043,Study 8,EMEA,FRA,0.0,7.0,81.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 376,Subject 3044,Study 8,EMEA,FRA,0.0,11.0,90.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 377,Subject 3045,Study 8,EMEA,DEU,0.0,8.0,128.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 377,Subject 3046,Study 8,EMEA,DEU,0.0,16.0,118.0,Week 144 (1),Enrolled
Study 8,Site 377,Subject 3047,Study 8,EMEA,DEU,0.0,9.0,93.0,Week 60 (1),Discontinued
Study 8,Site 377,Subject 3048,Study 8,EMEA,DEU,0.0,1.0,9.0,Screening,Discontinued
Study 8,Site 377,Subject 3049,Study 8,EMEA,DEU,0.0,15.0,110.0,Week 132 (1),Enrolled
Study 8,Site 377,Subject 3050,Study 8,EMEA,DEU,0.0,14.0,126.0,Week 120 (1),Enrolled
Study 8,Site 377,Subject 3051,Study 8,EMEA,DEU,0.0,14.0,117.0,Week 120 (1),Enrolled
Study 8,Site 377,Subject 3052,Study 8,EMEA,DEU,0.0,14.0,110.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 377,Subject 3053,Study 8,EMEA,DEU,0.0,13.0,95.0,Week 108 (1),Enrolled
Study 8,Site 377,Subject 3054,Study 8,EMEA,DEU,0.0,12.0,141.0,Week 96 (1),Enrolled
Study 8,Site 377,Subject 3055,Study 8,EMEA,DEU,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 377,Subject 3056,Study 8,EMEA,DEU,0.0,11.0,96.0,Week 84 (1),Enrolled
Study 8,Site 377,Subject 3057,Study 8,EMEA,DEU,0.0,11.0,100.0,Week 84 (1),Enrolled
Study 8,Site 377,Subject 3058,Study 8,EMEA,DEU,0.0,11.0,93.0,Week 84 (1),Enrolled
Study 8,Site 377,Subject 3059,Study 8,EMEA,DEU,0.0,11.0,106.0,Week 84 (1),Enrolled
Study 8,Site 377,Subject 3060,Study 8,EMEA,DEU,0.0,10.0,90.0,Week 72 (1),Enrolled
Study 8,Site 378,Subject 3061,Study 8,EMEA,DEU,0.0,7.0,65.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 378,Subject 3062,Study 8,EMEA,DEU,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 378,Subject 3063,Study 8,EMEA,DEU,0.0,13.0,109.0,Week 108 (1),Enrolled
Study 8,Site 378,Subject 3064,Study 8,EMEA,DEU,0.0,13.0,109.0,Week 108 (1),Enrolled
Study 8,Site 378,Subject 3065,Study 8,EMEA,DEU,0.0,13.0,101.0,Week 108 (1),Enrolled
Study 8,Site 378,Subject 3066,Study 8,EMEA,DEU,0.0,7.0,115.0,Unplanned visit (14),Discontinued
Study 8,Site 378,Subject 3067,Study 8,EMEA,DEU,0.0,10.0,87.0,Week 72 (1),Enrolled
Study 8,Site 379,Subject 3068,Study 8,EMEA,DEU,0.0,15.0,116.0,Week 132 (1),Enrolled
Study 8,Site 379,Subject 3069,Study 8,EMEA,DEU,0.0,15.0,118.0,Week 132 (1),Enrolled
Study 8,Site 379,Subject 3070,Study 8,EMEA,DEU,0.0,14.0,100.0,Week 120 (1),Enrolled
Study 8,Site 379,Subject 3071,Study 8,EMEA,DEU,0.0,12.0,130.0,Week 96 (1),Enrolled
Study 8,Site 380,Subject 3072,Study 8,EMEA,DEU,0.0,15.0,114.0,Week 132 (1),Enrolled
Study 8,Site 380,Subject 3073,Study 8,EMEA,DEU,0.0,15.0,110.0,Week 132 (1),Enrolled
Study 8,Site 380,Subject 3074,Study 8,EMEA,DEU,0.0,15.0,112.0,Week 132 (1),Enrolled
Study 8,Site 380,Subject 3075,Study 8,EMEA,DEU,0.0,14.0,114.0,Week 132 (1),Enrolled
Study 8,Site 380,Subject 3076,Study 8,EMEA,DEU,0.0,15.0,111.0,Week 132 (1),Enrolled
Study 8,Site 380,Subject 3077,Study 8,EMEA,DEU,0.0,15.0,107.0,Week 132 (1),Enrolled
Study 8,Site 380,Subject 3078,Study 8,EMEA,DEU,0.0,14.0,107.0,Week 120 (1),Enrolled
Study 8,Site 380,Subject 3079,Study 8,EMEA,DEU,0.0,14.0,109.0,Week 120 (1),Enrolled
Study 8,Site 380,Subject 3080,Study 8,EMEA,DEU,0.0,13.0,103.0,Week 108 (1),Enrolled
Study 8,Site 380,Subject 3081,Study 8,EMEA,DEU,0.0,13.0,99.0,Week 108 (1),Enrolled
Study 8,Site 380,Subject 3082,Study 8,EMEA,DEU,0.0,13.0,102.0,Week 108 (1),Enrolled
Study 8,Site 380,Subject 3083,Study 8,EMEA,DEU,0.0,13.0,96.0,Week 108 (1),Enrolled
Study 8,Site 380,Subject 3084,Study 8,EMEA,DEU,0.0,13.0,95.0,Week 108 (1),Enrolled
Study 8,Site 380,Subject 3085,Study 8,EMEA,DEU,0.0,12.0,92.0,Week 96 (1),Enrolled
Study 8,Site 380,Subject 3086,Study 8,EMEA,DEU,0.0,12.0,98.0,Week 96 (1),Enrolled
Study 8,Site 380,Subject 3087,Study 8,EMEA,DEU,0.0,12.0,97.0,Week 96 (1),Enrolled
Study 8,Site 380,Subject 3088,Study 8,EMEA,DEU,0.0,12.0,97.0,Week 96 (1),Enrolled
Study 8,Site 380,Subject 3089,Study 8,EMEA,DEU,0.0,7.0,73.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 380,Subject 3090,Study 8,EMEA,DEU,0.0,11.0,106.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 380,Subject 3091,Study 8,EMEA,DEU,0.0,11.0,89.0,Week 84 (1),Enrolled
Study 8,Site 380,Subject 3092,Study 8,EMEA,DEU,0.0,11.0,84.0,Week 84 (1),Enrolled
Study 8,Site 380,Subject 3093,Study 8,EMEA,DEU,0.0,11.0,92.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 380,Subject 3094,Study 8,EMEA,DEU,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 380,Subject 3095,Study 8,EMEA,DEU,0.0,11.0,86.0,Week 84 (1),Enrolled
Study 8,Site 380,Subject 3096,Study 8,EMEA,DEU,0.0,11.0,93.0,Week 84 (1),Enrolled
Study 8,Site 380,Subject 3097,Study 8,EMEA,DEU,0.0,1.0,7.0,Screening,Screen Failure
Study 8,Site 380,Subject 3098,Study 8,EMEA,DEU,0.0,11.0,73.0,Unplanned visit (1),Discontinued
Study 8,Site 380,Subject 3099,Study 8,EMEA,DEU,0.0,10.0,80.0,Week 72 (1),Enrolled
Study 8,Site 380,Subject 3100,Study 8,EMEA,DEU,0.0,10.0,74.0,Week 72 (1),Enrolled
Study 8,Site 380,Subject 3137,Study 8,EMEA,DEU,0.0,16.0,121.0,Week 144 (1),Enrolled
Study 8,Site 381,Subject 3101,Study 8,EMEA,DEU,0.0,11.0,124.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 381,Subject 3102,Study 8,EMEA,DEU,0.0,13.0,134.0,Week 108 (1),Enrolled
Study 8,Site 381,Subject 3103,Study 8,EMEA,DEU,0.0,7.0,119.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 381,Subject 3104,Study 8,EMEA,DEU,0.0,13.0,149.0,Week 108 (1),Enrolled
Study 8,Site 381,Subject 3105,Study 8,EMEA,DEU,0.0,7.0,116.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 382,Subject 3106,Study 8,EMEA,DEU,0.0,1.0,24.0,Screening,Discontinued
Study 8,Site 382,Subject 3107,Study 8,EMEA,DEU,0.0,14.0,101.0,Week 120 (1),Enrolled
Study 8,Site 382,Subject 3108,Study 8,EMEA,DEU,0.0,13.0,102.0,Week 108 (1),Enrolled
Study 8,Site 382,Subject 3109,Study 8,EMEA,DEU,0.0,13.0,107.0,Week 108 (1),Enrolled
Study 8,Site 382,Subject 3110,Study 8,EMEA,DEU,0.0,4.0,84.0,Unplanned visit (3),Discontinued
Study 8,Site 382,Subject 3111,Study 8,EMEA,DEU,0.0,10.0,99.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 382,Subject 3112,Study 8,EMEA,DEU,0.0,11.0,86.0,Unplanned visit (1),Enrolled
Study 8,Site 382,Subject 3113,Study 8,EMEA,DEU,0.0,10.0,89.0,Week 72 (1),Enrolled
Study 8,Site 383,Subject 3114,Study 8,EMEA,DEU,0.0,8.0,129.0,Unplanned visit (10),Discontinued
Study 8,Site 383,Subject 3115,Study 8,EMEA,DEU,0.0,11.0,67.0,Week 84 (1),Enrolled
Study 8,Site 384,Subject 3116,Study 8,EMEA,DEU,0.0,13.0,100.0,Week 108 (1),Enrolled
Study 8,Site 384,Subject 3117,Study 8,EMEA,DEU,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 384,Subject 3118,Study 8,EMEA,DEU,0.0,12.0,92.0,Week 96 (1),Enrolled
Study 8,Site 384,Subject 3119,Study 8,EMEA,DEU,0.0,10.0,85.0,Week 72 (1),Enrolled
Study 8,Site 384,Subject 3120,Study 8,EMEA,DEU,0.0,6.0,77.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 384,Subject 3121,Study 8,EMEA,DEU,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 385,Subject 3122,Study 8,EMEA,DEU,0.0,7.0,110.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 385,Subject 3123,Study 8,EMEA,DEU,0.0,1.0,26.0,Screening,Discontinued
Study 8,Site 385,Subject 3124,Study 8,EMEA,DEU,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 385,Subject 3125,Study 8,EMEA,DEU,0.0,11.0,95.0,Week 84 (1),Enrolled
Study 8,Site 386,Subject 3126,Study 8,EMEA,DEU,0.0,16.0,135.0,Week 144 (1),Enrolled
Study 8,Site 386,Subject 3127,Study 8,EMEA,DEU,0.0,1.0,7.0,Screening,Screen Failure
Study 8,Site 386,Subject 3128,Study 8,EMEA,DEU,0.0,15.0,114.0,Week 132 (1),Enrolled
Study 8,Site 386,Subject 3129,Study 8,EMEA,DEU,0.0,7.0,138.0,Unplanned visit (13),Discontinued
Study 8,Site 386,Subject 3130,Study 8,EMEA,DEU,0.0,6.0,112.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 386,Subject 3131,Study 8,EMEA,DEU,0.0,12.0,97.0,Week 96 (1),Enrolled
Study 8,Site 386,Subject 3132,Study 8,EMEA,DEU,0.0,1.0,13.0,Screening,Discontinued
Study 8,Site 387,Subject 3133,Study 8,EMEA,DEU,0.0,7.0,138.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 387,Subject 3134,Study 8,EMEA,DEU,0.0,6.0,162.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 388,Subject 3135,Study 8,EMEA,DEU,0.0,13.0,110.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 389,Subject 3136,Study 8,EMEA,DEU,0.0,15.0,118.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 389,Subject 3138,Study 8,EMEA,DEU,0.0,9.0,109.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 389,Subject 3139,Study 8,EMEA,DEU,0.0,15.0,105.0,Week 132 (1),Enrolled
Study 8,Site 389,Subject 3140,Study 8,EMEA,DEU,0.0,12.0,92.0,Week 96 (1),Enrolled
Study 8,Site 389,Subject 3141,Study 8,EMEA,DEU,0.0,10.0,86.0,Week 72 (1),Enrolled
Study 8,Site 390,Subject 3142,Study 8,EMEA,DEU,0.0,13.0,103.0,Week 108 (1),Enrolled
Study 8,Site 390,Subject 3143,Study 8,EMEA,DEU,0.0,10.0,82.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 391,Subject 3144,Study 8,EMEA,DEU,0.0,16.0,127.0,Week 144 (1),Enrolled
Study 8,Site 391,Subject 3145,Study 8,EMEA,DEU,0.0,1.0,5.0,Screening,Screen Failure
Study 8,Site 392,Subject 3146,Study 8,EMEA,DEU,0.0,9.0,88.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 392,Subject 3147,Study 8,EMEA,DEU,0.0,12.0,84.0,Week 96 (1),Enrolled
Study 8,Site 392,Subject 3148,Study 8,EMEA,DEU,0.0,12.0,87.0,Week 96 (1),Enrolled
Study 8,Site 392,Subject 3149,Study 8,EMEA,DEU,0.0,1.0,18.0,Screening,Screen Failure
Study 8,Site 393,Subject 3150,Study 8,EMEA,DEU,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 393,Subject 3151,Study 8,EMEA,DEU,0.0,10.0,81.0,Week 72 (1),Enrolled
Study 8,Site 394,Subject 3152,Study 8,EMEA,DEU,0.0,14.0,125.0,Week 120 (1),Enrolled
Study 8,Site 394,Subject 3153,Study 8,EMEA,DEU,0.0,1.0,9.0,Screening,Discontinued
Study 8,Site 395,Subject 3154,Study 8,EMEA,DEU,0.0,1.0,28.0,Unplanned visit (1),Enrolled
Study 8,Site 395,Subject 3155,Study 8,EMEA,DEU,0.0,11.0,123.0,Week 84 (1),Enrolled
Study 8,Site 396,Subject 3156,Study 8,EMEA,DEU,0.0,10.0,96.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 397,Subject 3157,Study 8,EMEA,DEU,0.0,15.0,136.0,Week 132 (1),Enrolled
Study 8,Site 397,Subject 3158,Study 8,EMEA,DEU,0.0,13.0,105.0,Week 108 (1),Enrolled
Study 8,Site 398,Subject 3159,Study 8,EMEA,DEU,0.0,15.0,142.0,Week 132 (1),Enrolled
Study 8,Site 398,Subject 3160,Study 8,EMEA,DEU,0.0,13.0,111.0,Week 108 (1),Enrolled
Study 8,Site 398,Subject 3161,Study 8,EMEA,DEU,0.0,12.0,100.0,Week 96 (1),Enrolled
Study 8,Site 398,Subject 3162,Study 8,EMEA,DEU,0.0,4.0,70.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 398,Subject 3163,Study 8,EMEA,DEU,0.0,1.0,4.0,Screening,Enrolled
Study 8,Site 399,Subject 3164,Study 8,EMEA,DEU,0.0,12.0,94.0,Week 96 (1),Enrolled
Study 8,Site 4,Subject 10,Study 8,AMERICA,ARG,0.0,12.0,98.0,Week 96 (1),Enrolled
Study 8,Site 4,Subject 9,Study 8,AMERICA,ARG,0.0,10.0,91.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 400,Subject 3165,Study 8,EMEA,DEU,0.0,10.0,101.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 400,Subject 3166,Study 8,EMEA,DEU,0.0,14.0,109.0,Week 120 (1),Enrolled
Study 8,Site 400,Subject 3167,Study 8,EMEA,DEU,0.0,13.0,92.0,Week 108 (1),Enrolled
Study 8,Site 400,Subject 3168,Study 8,EMEA,DEU,0.0,10.0,99.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 401,Subject 3169,Study 8,EMEA,DEU,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 401,Subject 3170,Study 8,EMEA,DEU,0.0,7.0,88.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 401,Subject 3171,Study 8,EMEA,DEU,0.0,12.0,101.0,Week 96 (1),Enrolled
Study 8,Site 401,Subject 3172,Study 8,EMEA,DEU,0.0,12.0,109.0,Week 96 (1),Enrolled
Study 8,Site 401,Subject 3173,Study 8,EMEA,DEU,0.0,12.0,119.0,Week 96 (1),Enrolled
Study 8,Site 401,Subject 3174,Study 8,EMEA,DEU,0.0,11.0,111.0,Week 84 (1),Enrolled
Study 8,Site 402,Subject 3175,Study 8,EMEA,DEU,0.0,14.0,106.0,Week 120 (1),Enrolled
Study 8,Site 402,Subject 3176,Study 8,EMEA,DEU,0.0,12.0,143.0,Week 96 (1),Enrolled
Study 8,Site 402,Subject 3177,Study 8,EMEA,DEU,0.0,7.0,104.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 402,Subject 3178,Study 8,EMEA,DEU,0.0,10.0,102.0,Unplanned visit (4),Discontinued
Study 8,Site 403,Subject 3179,Study 8,EMEA,DEU,0.0,15.0,113.0,Week 132 (1),Enrolled
Study 8,Site 403,Subject 3180,Study 8,EMEA,DEU,0.0,13.0,102.0,Week 108 (1),Enrolled
Study 8,Site 404,Subject 3181,Study 8,EMEA,DEU,0.0,15.0,120.0,Week 132 (1),Enrolled
Study 8,Site 404,Subject 3182,Study 8,EMEA,DEU,0.0,12.0,93.0,Week 96 (1),Enrolled
Study 8,Site 405,Subject 3183,Study 8,EMEA,DEU,0.0,13.0,109.0,Week 108 (1),Enrolled
Study 8,Site 405,Subject 3184,Study 8,EMEA,DEU,0.0,13.0,94.0,Week 108 (1),Enrolled
Study 8,Site 405,Subject 3185,Study 8,EMEA,DEU,0.0,10.0,81.0,Week 72 (1),Enrolled
Study 8,Site 406,Subject 3186,Study 8,EMEA,GRC,0.0,9.0,106.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 406,Subject 3187,Study 8,EMEA,GRC,0.0,8.0,108.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 406,Subject 3189,Study 8,EMEA,GRC,0.0,14.0,104.0,Week 120 (1),Enrolled
Study 8,Site 407,Subject 3188,Study 8,EMEA,GRC,0.0,5.0,78.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 407,Subject 3190,Study 8,EMEA,GRC,0.0,11.0,102.0,Week 84 (1),Enrolled
Study 8,Site 408,Subject 3191,Study 8,EMEA,GRC,0.0,13.0,119.0,Week 108 (1),Enrolled
Study 8,Site 408,Subject 3192,Study 8,EMEA,GRC,0.0,12.0,165.0,Week 96 (1),Enrolled
Study 8,Site 408,Subject 3193,Study 8,EMEA,GRC,0.0,12.0,93.0,Week 96 (1),Enrolled
Study 8,Site 408,Subject 3194,Study 8,EMEA,GRC,0.0,11.0,91.0,Week 84 (1),Enrolled
Study 8,Site 408,Subject 3195,Study 8,EMEA,GRC,0.0,10.0,95.0,Week 72 (1),Enrolled
Study 8,Site 408,Subject 3196,Study 8,EMEA,GRC,0.0,10.0,82.0,Week 72 (1),Enrolled
Study 8,Site 409,Subject 3197,Study 8,EMEA,GRC,0.0,11.0,86.0,Week 84 (1),Enrolled
Study 8,Site 410,Subject 3198,Study 8,EMEA,GRC,0.0,4.0,73.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 410,Subject 3199,Study 8,EMEA,GRC,0.0,10.0,85.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 410,Subject 3200,Study 8,EMEA,GRC,0.0,9.0,85.0,EOT (1),Discontinued
Study 8,Site 410,Subject 3201,Study 8,EMEA,GRC,0.0,10.0,93.0,Unplanned visit (5),Discontinued
Study 8,Site 411,Subject 3202,Study 8,EMEA,HUN,0.0,15.0,120.0,Week 132 (1),Enrolled
Study 8,Site 411,Subject 3203,Study 8,EMEA,HUN,0.0,16.0,129.0,EOT (1),Discontinued
Study 8,Site 411,Subject 3204,Study 8,EMEA,HUN,0.0,15.0,117.0,Week 132 (1),Enrolled
Study 8,Site 411,Subject 3205,Study 8,EMEA,HUN,0.0,15.0,108.0,Week 132 (1),Enrolled
Study 8,Site 411,Subject 3206,Study 8,EMEA,HUN,0.0,13.0,114.0,Week 108 (1),Enrolled
Study 8,Site 411,Subject 3207,Study 8,EMEA,HUN,0.0,12.0,115.0,Unplanned visit (4),Enrolled
Study 8,Site 411,Subject 3208,Study 8,EMEA,HUN,0.0,11.0,99.0,Week 84 (1),Enrolled
Study 8,Site 412,Subject 3209,Study 8,EMEA,HUN,0.0,15.0,132.0,Week 132 (1),Enrolled
Study 8,Site 412,Subject 3210,Study 8,EMEA,HUN,0.0,12.0,109.0,Week 96 (1),Discontinued
Study 8,Site 412,Subject 3211,Study 8,EMEA,HUN,0.0,11.0,95.0,Unplanned visit (6),Enrolled
Study 8,Site 413,Subject 3212,Study 8,EMEA,HUN,0.0,10.0,91.0,EOT (1),Discontinued
Study 8,Site 413,Subject 3213,Study 8,EMEA,HUN,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 414,Subject 3214,Study 8,EMEA,ITA,0.0,12.0,110.0,Week 96 (1),Enrolled
Study 8,Site 414,Subject 3215,Study 8,EMEA,ITA,0.0,7.0,87.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 414,Subject 3216,Study 8,EMEA,ITA,0.0,11.0,90.0,Week 84 (1),Enrolled
Study 8,Site 414,Subject 3217,Study 8,EMEA,ITA,0.0,10.0,113.0,Unplanned visit (11),Enrolled
Study 8,Site 415,Subject 3218,Study 8,EMEA,ITA,0.0,13.0,120.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 415,Subject 3219,Study 8,EMEA,ITA,0.0,10.0,119.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 415,Subject 3220,Study 8,EMEA,ITA,0.0,11.0,132.0,Week 84 (1),Enrolled
Study 8,Site 415,Subject 3221,Study 8,EMEA,ITA,0.0,10.0,83.0,Week 72 (1),Enrolled
Study 8,Site 415,Subject 3222,Study 8,EMEA,ITA,0.0,10.0,85.0,Week 72 (1),Enrolled
Study 8,Site 415,Subject 3223,Study 8,EMEA,ITA,0.0,10.0,93.0,Week 72 (1),Enrolled
Study 8,Site 415,Subject 3224,Study 8,EMEA,ITA,0.0,9.0,73.0,Week 60 (1),Enrolled
Study 8,Site 416,Subject 3225,Study 8,EMEA,ITA,0.0,10.0,82.0,Week 72 (1),Enrolled
Study 8,Site 416,Subject 3226,Study 8,EMEA,ITA,0.0,10.0,89.0,Week 72 (1),Enrolled
Study 8,Site 417,Subject 3227,Study 8,EMEA,ITA,0.0,12.0,92.0,Week 96 (1),Enrolled
Study 8,Site 417,Subject 3228,Study 8,EMEA,ITA,0.0,11.0,87.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 417,Subject 3229,Study 8,EMEA,ITA,0.0,10.0,87.0,Week 72 (1),Enrolled
Study 8,Site 417,Subject 3230,Study 8,EMEA,ITA,0.0,5.0,79.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 418,Subject 3231,Study 8,EMEA,ROU,0.0,13.0,99.0,Week 108 (1),Enrolled
Study 8,Site 418,Subject 3232,Study 8,EMEA,ROU,0.0,9.0,90.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 419,Subject 3233,Study 8,EMEA,ROU,0.0,12.0,95.0,Week 96 (1),Enrolled
Study 8,Site 420,Subject 3234,Study 8,EMEA,ROU,0.0,12.0,92.0,Week 96 (1),Enrolled
Study 8,Site 421,Subject 3235,Study 8,EMEA,ROU,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 421,Subject 3236,Study 8,EMEA,ROU,0.0,12.0,93.0,Week 96 (1),Enrolled
Study 8,Site 421,Subject 3237,Study 8,EMEA,ROU,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 421,Subject 3238,Study 8,EMEA,ROU,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 421,Subject 3239,Study 8,EMEA,ROU,0.0,10.0,94.0,Unplanned visit (4),Enrolled
Study 8,Site 421,Subject 3240,Study 8,EMEA,ROU,0.0,10.0,83.0,Unplanned visit (1),Enrolled
Study 8,Site 421,Subject 3241,Study 8,EMEA,ROU,0.0,10.0,80.0,Week 72 (1),Enrolled
Study 8,Site 421,Subject 3242,Study 8,EMEA,ROU,0.0,10.0,77.0,Week 72 (1),Enrolled
Study 8,Site 422,Subject 3243,Study 8,EMEA,ROU,0.0,1.0,23.0,Screening,Screen Failure
Study 8,Site 422,Subject 3244,Study 8,EMEA,ROU,0.0,11.0,112.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 423,Subject 3245,Study 8,EMEA,ROU,0.0,12.0,95.0,Week 96 (1),Enrolled
Study 8,Site 423,Subject 3246,Study 8,EMEA,ROU,0.0,12.0,115.0,Week 96 (1),Enrolled
Study 8,Site 423,Subject 3247,Study 8,EMEA,ROU,0.0,12.0,101.0,Week 96 (1),Enrolled
Study 8,Site 424,Subject 3248,Study 8,EMEA,ROU,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 424,Subject 3249,Study 8,EMEA,ROU,0.0,14.0,115.0,Week 120 (1),Enrolled
Study 8,Site 424,Subject 3250,Study 8,EMEA,ROU,0.0,11.0,93.0,Week 84 (1),Enrolled
Study 8,Site 424,Subject 3251,Study 8,EMEA,ROU,0.0,11.0,88.0,Week 84 (1),Enrolled
Study 8,Site 424,Subject 3252,Study 8,EMEA,ROU,0.0,7.0,73.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 424,Subject 3253,Study 8,EMEA,ROU,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 424,Subject 3254,Study 8,EMEA,ROU,0.0,10.0,83.0,Week 72 (1),Enrolled
Study 8,Site 424,Subject 3255,Study 8,EMEA,ROU,0.0,10.0,86.0,Week 72 (1),Enrolled
Study 8,Site 425,Subject 3256,Study 8,EMEA,ROU,0.0,12.0,95.0,Week 96 (1),Enrolled
Study 8,Site 426,Subject 3257,Study 8,EMEA,SVK,0.0,16.0,135.0,Week 144 (1),Enrolled
Study 8,Site 426,Subject 3258,Study 8,EMEA,SVK,0.0,5.0,87.0,Unplanned visit (2),Discontinued
Study 8,Site 426,Subject 3259,Study 8,EMEA,SVK,0.0,9.0,106.0,Unplanned visit (3),Discontinued
Study 8,Site 426,Subject 3260,Study 8,EMEA,SVK,0.0,11.0,97.0,Week 84 (1),Enrolled
Study 8,Site 427,Subject 3261,Study 8,EMEA,SVK,0.0,1.0,24.0,Screening,Screen Failure
Study 8,Site 427,Subject 3262,Study 8,EMEA,SVK,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 427,Subject 3263,Study 8,EMEA,SVK,0.0,1.0,9.0,Screening,Screen Failure
Study 8,Site 428,Subject 3264,Study 8,EMEA,CHE,0.0,13.0,78.0,Week 108 (1),Enrolled
Study 8,Site 428,Subject 3265,Study 8,EMEA,CHE,0.0,12.0,79.0,Week 96 (1),Enrolled
Study 8,Site 428,Subject 3266,Study 8,EMEA,CHE,0.0,11.0,70.0,Week 84 (1),Enrolled
Study 8,Site 428,Subject 3267,Study 8,EMEA,CHE,0.0,9.0,77.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 429,Subject 3268,Study 8,EMEA,GBR,0.0,1.0,8.0,Screening,Discontinued
Study 8,Site 429,Subject 3269,Study 8,EMEA,GBR,0.0,10.0,150.0,Unplanned visit (22),Enrolled
Study 8,Site 430,Subject 3270,Study 8,EMEA,GBR,0.0,11.0,96.0,Week 84 (1),Enrolled
Study 8,Site 430,Subject 3271,Study 8,EMEA,GBR,0.0,10.0,83.0,Week 72 (1),Enrolled
Study 8,Site 431,Subject 3272,Study 8,EMEA,GBR,0.0,13.0,94.0,Week 108 (1),Enrolled
Study 8,Site 431,Subject 3273,Study 8,EMEA,GBR,0.0,12.0,95.0,Week 96 (1),Enrolled
Study 8,Site 431,Subject 3274,Study 8,EMEA,GBR,0.0,11.0,86.0,Week 84 (1),Enrolled
Study 8,Site 432,Subject 3275,Study 8,EMEA,GBR,0.0,10.0,126.0,Week 72 (1),Enrolled
Study 8,Site 433,Subject 3276,Study 8,EMEA,GBR,0.0,14.0,106.0,Week 120 (1),Enrolled
Study 8,Site 433,Subject 3277,Study 8,EMEA,GBR,0.0,13.0,83.0,Week 108 (1),Enrolled
Study 8,Site 433,Subject 3278,Study 8,EMEA,GBR,0.0,1.0,5.0,Screening,Screen Failure
Study 8,Site 433,Subject 3279,Study 8,EMEA,GBR,0.0,11.0,72.0,Week 84 (1),Enrolled
Study 8,Site 434,Subject 3280,Study 8,EMEA,NLD,0.0,1.0,5.0,Screening,Screen Failure
Study 8,Site 434,Subject 3281,Study 8,EMEA,NLD,0.0,4.0,66.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 434,Subject 3282,Study 8,EMEA,NLD,0.0,11.0,80.0,Week 84 (1),Enrolled
Study 8,Site 434,Subject 3283,Study 8,EMEA,NLD,0.0,10.0,84.0,Week 72 (1),Enrolled
Study 8,Site 435,Subject 3284,Study 8,EMEA,JOR,0.0,14.0,125.0,Week 120 (1),Enrolled
Study 8,Site 435,Subject 3285,Study 8,EMEA,JOR,0.0,1.0,21.0,Unplanned visit (1),Screen Failure
Study 8,Site 435,Subject 3286,Study 8,EMEA,JOR,0.0,1.0,29.0,Screening,Screen Failure
Study 8,Site 435,Subject 3287,Study 8,EMEA,JOR,0.0,13.0,125.0,Unplanned visit (8),Enrolled
Study 8,Site 435,Subject 3288,Study 8,EMEA,JOR,0.0,1.0,12.0,Unplanned visit (1),Screen Failure
Study 8,Site 435,Subject 3289,Study 8,EMEA,JOR,0.0,13.0,141.0,Week 108 (1),Enrolled
Study 8,Site 435,Subject 3290,Study 8,EMEA,JOR,0.0,11.0,122.0,Unplanned visit (10),Enrolled
Study 8,Site 435,Subject 3291,Study 8,EMEA,JOR,0.0,10.0,112.0,Week 72 (1),Enrolled
Study 8,Site 436,Subject 3314,Study 8,ASIA,MYS,0.0,10.0,105.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 436,Subject 3315,Study 8,ASIA,MYS,0.0,14.0,130.0,Week 120 (1),Enrolled
Study 8,Site 436,Subject 3316,Study 8,ASIA,MYS,0.0,13.0,156.0,Week 108 (1),Enrolled
Study 8,Site 436,Subject 3317,Study 8,ASIA,MYS,0.0,12.0,129.0,Week 96 (1),Enrolled
Study 8,Site 436,Subject 3318,Study 8,ASIA,MYS,0.0,1.0,21.0,Screening,Screen Failure
Study 8,Site 436,Subject 3319,Study 8,ASIA,MYS,0.0,11.0,111.0,Week 84 (1),Enrolled
Study 8,Site 436,Subject 3320,Study 8,ASIA,MYS,0.0,10.0,149.0,Week 72 (1),Enrolled
Study 8,Site 436,Subject 3321,Study 8,ASIA,MYS,0.0,10.0,165.0,Week 72 (1),Enrolled
Study 8,Site 437,Subject 3322,Study 8,ASIA,MYS,0.0,13.0,109.0,Week 108 (1),Enrolled
Study 8,Site 437,Subject 3323,Study 8,ASIA,MYS,0.0,13.0,103.0,Week 108 (1),Enrolled
Study 8,Site 437,Subject 3324,Study 8,ASIA,MYS,0.0,9.0,110.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 437,Subject 3325,Study 8,ASIA,MYS,0.0,1.0,23.0,Unplanned visit (1),Screen Failure
Study 8,Site 437,Subject 3326,Study 8,ASIA,MYS,0.0,11.0,136.0,Week 84 (1),Enrolled
Study 8,Site 437,Subject 3327,Study 8,ASIA,MYS,0.0,7.0,146.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 437,Subject 3328,Study 8,ASIA,MYS,0.0,10.0,117.0,Week 72 (1),Enrolled
Study 8,Site 438,Subject 3329,Study 8,ASIA,MYS,0.0,10.0,87.0,Week 72 (1),Screening
Study 8,Site 439,Subject 3330,Study 8,ASIA,SGP,0.0,14.0,99.0,Week 120 (1),Enrolled
Study 8,Site 439,Subject 3331,Study 8,ASIA,SGP,0.0,14.0,97.0,Unplanned visit (5),Enrolled
Study 8,Site 439,Subject 3332,Study 8,ASIA,SGP,0.0,13.0,92.0,Week 108 (1),Enrolled
Study 8,Site 439,Subject 3333,Study 8,ASIA,SGP,0.0,13.0,105.0,Week 108 (1),Enrolled
Study 8,Site 439,Subject 3334,Study 8,ASIA,SGP,0.0,12.0,85.0,Week 96 (1),Enrolled
Study 8,Site 439,Subject 3335,Study 8,ASIA,SGP,0.0,11.0,82.0,Week 84 (1),Enrolled
Study 8,Site 439,Subject 3336,Study 8,ASIA,SGP,0.0,10.0,76.0,Week 72 (1),Enrolled
Study 8,Site 439,Subject 3337,Study 8,ASIA,SGP,0.0,10.0,69.0,Week 72 (1),Enrolled
Study 8,Site 439,Subject 3338,Study 8,ASIA,SGP,0.0,10.0,70.0,Week 72 (1),Enrolled
Study 8,Site 439,Subject 3339,Study 8,ASIA,SGP,0.0,10.0,69.0,Week 72 (1),Enrolled
Study 8,Site 440,Subject 3340,Study 8,ASIA,SGP,0.0,13.0,133.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 440,Subject 3341,Study 8,ASIA,SGP,0.0,6.0,95.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 440,Subject 3342,Study 8,ASIA,SGP,0.0,11.0,96.0,Week 84 (1),Enrolled
Study 8,Site 440,Subject 3343,Study 8,ASIA,SGP,0.0,11.0,92.0,Week 84 (1),Enrolled
Study 8,Site 440,Subject 3344,Study 8,ASIA,SGP,0.0,4.0,84.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 440,Subject 3345,Study 8,ASIA,SGP,0.0,8.0,133.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 441,Subject 3346,Study 8,ASIA,SGP,0.0,9.0,125.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 441,Subject 3347,Study 8,ASIA,SGP,0.0,14.0,100.0,Week 120 (1),Enrolled
Study 8,Site 441,Subject 3348,Study 8,ASIA,SGP,0.0,1.0,24.0,Screening,Screen Failure
Study 8,Site 441,Subject 3349,Study 8,ASIA,SGP,0.0,12.0,91.0,Week 96 (1),Enrolled
Study 8,Site 442,Subject 3351,Study 8,EMEA,OMN,0.0,15.0,139.0,Week 132 (1),Enrolled
Study 8,Site 442,Subject 3352,Study 8,EMEA,OMN,0.0,1.0,19.0,Screening,Screen Failure
Study 8,Site 442,Subject 3353,Study 8,EMEA,OMN,0.0,4.0,69.0,After 4 Weeks Day 29 (1),Discontinued
Study 8,Site 442,Subject 3354,Study 8,EMEA,OMN,0.0,11.0,112.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 442,Subject 3355,Study 8,EMEA,OMN,0.0,1.0,26.0,Screening,Enrolled
Study 8,Site 442,Subject 3356,Study 8,EMEA,OMN,0.0,13.0,142.0,Week 108 (1),Enrolled
Study 8,Site 442,Subject 3357,Study 8,EMEA,OMN,0.0,12.0,96.0,Week 96 (1),Enrolled
Study 8,Site 442,Subject 3358,Study 8,EMEA,OMN,0.0,12.0,113.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 442,Subject 3359,Study 8,EMEA,OMN,0.0,7.0,117.0,Unplanned visit (12),Discontinued
Study 8,Site 442,Subject 3360,Study 8,EMEA,OMN,0.0,10.0,112.0,Week 72 (1),Enrolled
Study 8,Site 443,Subject 3362,Study 8,EMEA,TUR,0.0,6.0,128.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 443,Subject 3363,Study 8,EMEA,TUR,0.0,10.0,116.0,Unplanned visit (10),Enrolled
Study 8,Site 444,Subject 3364,Study 8,EMEA,TUR,0.0,10.0,112.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 444,Subject 3365,Study 8,EMEA,TUR,0.0,10.0,92.0,Week 72 (1),Enrolled
Study 8,Site 445,Subject 3366,Study 8,EMEA,TUR,0.0,10.0,126.0,Unplanned visit (21),Enrolled
Study 8,Site 445,Subject 3367,Study 8,EMEA,TUR,0.0,1.0,8.0,Screening,Screen Failure
Study 8,Site 446,Subject 3372,Study 8,ASIA,IND,0.0,7.0,94.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 446,Subject 3373,Study 8,ASIA,IND,0.0,12.0,94.0,Week 96 (1),Enrolled
Study 8,Site 447,Subject 3374,Study 8,ASIA,IND,0.0,1.0,22.0,Screening,Screen Failure
Study 8,Site 447,Subject 3375,Study 8,ASIA,IND,0.0,12.0,97.0,Week 96 (1),Enrolled
Study 8,Site 447,Subject 3376,Study 8,ASIA,IND,0.0,12.0,94.0,Week 96 (1),Enrolled
Study 8,Site 447,Subject 3377,Study 8,ASIA,IND,0.0,10.0,83.0,Week 72 (1),Enrolled
Study 8,Site 447,Subject 3378,Study 8,ASIA,IND,0.0,1.0,9.0,Unplanned visit (1),Screen Failure
Study 8,Site 448,Subject 3379,Study 8,ASIA,IND,0.0,12.0,103.0,Week 96 (1),Enrolled
Study 8,Site 448,Subject 3380,Study 8,ASIA,IND,0.0,13.0,126.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 448,Subject 3381,Study 8,ASIA,IND,0.0,11.0,109.0,Week 84 (1),Enrolled
Study 8,Site 449,Subject 3382,Study 8,ASIA,IND,0.0,13.0,105.0,Week 108 (1),Enrolled
Study 8,Site 449,Subject 3383,Study 8,ASIA,IND,0.0,1.0,12.0,Unplanned visit (2),Screen Failure
Study 8,Site 449,Subject 3384,Study 8,ASIA,IND,0.0,13.0,104.0,Week 108 (1),Enrolled
Study 8,Site 449,Subject 3385,Study 8,ASIA,IND,0.0,13.0,107.0,Week 108 (1),Enrolled
Study 8,Site 449,Subject 3386,Study 8,ASIA,IND,0.0,13.0,101.0,Week 108 (1),Enrolled
Study 8,Site 449,Subject 3387,Study 8,ASIA,IND,0.0,13.0,106.0,Week 108 (1),Enrolled
Study 8,Site 449,Subject 3388,Study 8,ASIA,IND,0.0,13.0,94.0,Week 108 (1),Enrolled
Study 8,Site 449,Subject 3389,Study 8,ASIA,IND,0.0,13.0,98.0,Week 108 (1),Enrolled
Study 8,Site 449,Subject 3390,Study 8,ASIA,IND,0.0,12.0,96.0,Week 96 (1),Enrolled
Study 8,Site 449,Subject 3391,Study 8,ASIA,IND,0.0,12.0,142.0,Week 96 (1),Enrolled
Study 8,Site 449,Subject 3392,Study 8,ASIA,IND,0.0,12.0,94.0,Week 96 (1),Enrolled
Study 8,Site 450,Subject 3397,Study 8,AMERICA,USA,0.0,8.0,81.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 450,Subject 3398,Study 8,AMERICA,USA,0.0,1.0,7.0,Screening,Screen Failure
Study 8,Site 450,Subject 77,Study 8,AMERICA,USA,0.0,14.0,149.0,Week 120 (1),Enrolled
Study 8,Site 450,Subject 78,Study 8,AMERICA,USA,0.0,11.0,104.0,Week 96 (1),Enrolled
Study 8,Site 450,Subject 79,Study 8,AMERICA,USA,0.0,7.0,84.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 88,Subject 632,Study 8,EMEA,BGR,0.0,1.0,5.0,Screening,Screen Failure
Study 8,Site 88,Subject 633,Study 8,EMEA,BGR,0.0,12.0,79.0,Week 96 (1),Enrolled
Study 8,Site 88,Subject 634,Study 8,EMEA,BGR,0.0,11.0,96.0,Week 84 (1),Enrolled
Study 8,Site 88,Subject 635,Study 8,EMEA,BGR,0.0,8.0,134.0,30 Days Safety follow-up (1),Discontinued
Study 8,Site 88,Subject 636,Study 8,EMEA,BGR,0.0,10.0,75.0,Week 72 (1),Enrolled
Study 9,Site 110,Subject 3413,Study 9,EMEA,CIV,0.0,10.0,120.0,EOS Part A (1),Completed
Study 9,Site 110,Subject 3414,Study 9,EMEA,CIV,0.0,10.0,120.0,EOS Part A (1),Completed
Study 9,Site 110,Subject 3415,Study 9,EMEA,CIV,0.0,4.0,57.0,Inpatient FUP 2/Day 3 (1),Discontinued
Study 9,Site 110,Subject 3416,Study 9,EMEA,CIV,0.0,10.0,120.0,EOS Part A (1),Completed
Study 9,Site 110,Subject 3417,Study 9,EMEA,CIV,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 110,Subject 3418,Study 9,EMEA,CIV,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 110,Subject 3419,Study 9,EMEA,CIV,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 110,Subject 3420,Study 9,EMEA,CIV,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 110,Subject 3421,Study 9,EMEA,CIV,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 110,Subject 3422,Study 9,EMEA,CIV,0.0,5.0,65.0,Outpatient FUP 1/Day 4 (1),Discontinued
Study 9,Site 110,Subject 3423,Study 9,EMEA,CIV,0.0,10.0,119.0,EOS Part A (1),Completed
Study 9,Site 110,Subject 3424,Study 9,EMEA,CIV,0.0,1.0,19.0,Screening,Discontinued
Study 9,Site 110,Subject 3425,Study 9,EMEA,CIV,0.0,10.0,123.0,EOS Part A (1),Completed
Study 9,Site 110,Subject 3426,Study 9,EMEA,CIV,0.0,10.0,120.0,EOS Part A (1),Completed
Study 9,Site 110,Subject 3427,Study 9,EMEA,CIV,0.0,1.0,10.0,Screening,Screen Failure
Study 9,Site 110,Subject 3428,Study 9,EMEA,CIV,0.0,1.0,10.0,Screening,Screen Failure
Study 9,Site 110,Subject 3429,Study 9,EMEA,CIV,0.0,2.0,33.0,Screening,Discontinued
Study 9,Site 110,Subject 3430,Study 9,EMEA,CIV,0.0,10.0,120.0,EOS Part A (1),Completed
Study 9,Site 110,Subject 3431,Study 9,EMEA,CIV,0.0,2.0,35.0,Screening,Discontinued
Study 9,Site 110,Subject 3432,Study 9,EMEA,CIV,0.0,1.0,7.0,Screening,Screen Failure
Study 9,Site 110,Subject 3433,Study 9,EMEA,CIV,0.0,9.0,109.0,EOS Part A (1),Completed
Study 9,Site 110,Subject 893,Study 9,EMEA,CIV,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 110,Subject 894,Study 9,EMEA,CIV,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 110,Subject 895,Study 9,EMEA,CIV,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 110,Subject 896,Study 9,EMEA,CIV,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 14,Subject 25,Study 9,EMEA,GAB,0.0,10.0,121.0,EOS Part A (1),Completed
Study 9,Site 14,Subject 26,Study 9,EMEA,GAB,0.0,10.0,122.0,EOS Part A (1),Completed
Study 9,Site 14,Subject 27,Study 9,EMEA,GAB,0.0,1.0,10.0,Screening,Screen Failure
Study 9,Site 14,Subject 28,Study 9,EMEA,GAB,0.0,1.0,10.0,Screening,Screen Failure
Study 9,Site 14,Subject 29,Study 9,EMEA,GAB,0.0,10.0,110.0,EOS Part A (1),Completed
Study 9,Site 14,Subject 30,Study 9,EMEA,GAB,0.0,12.0,132.0,EOS Part A (1),Completed
Study 9,Site 14,Subject 31,Study 9,EMEA,GAB,0.0,10.0,116.0,EOS Part A (1),Completed
Study 9,Site 14,Subject 32,Study 9,EMEA,GAB,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 14,Subject 33,Study 9,EMEA,GAB,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 15,Subject 3434,Study 9,EMEA,GAB,0.0,11.0,137.0,EOS Part B (1),Completed
Study 9,Site 15,Subject 39,Study 9,EMEA,GAB,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 15,Subject 40,Study 9,EMEA,GAB,0.0,1.0,10.0,Screening,Screen Failure
Study 9,Site 15,Subject 41,Study 9,EMEA,GAB,0.0,1.0,10.0,Screening,Screen Failure
Study 9,Site 15,Subject 42,Study 9,EMEA,GAB,0.0,1.0,10.0,Screening,Screen Failure
Study 9,Site 15,Subject 43,Study 9,EMEA,GAB,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 15,Subject 44,Study 9,EMEA,GAB,0.0,11.0,134.0,EOS Part B (1),Completed
Study 9,Site 15,Subject 45,Study 9,EMEA,GAB,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 15,Subject 46,Study 9,EMEA,GAB,0.0,11.0,148.0,EOS Part B (1),Completed
Study 9,Site 15,Subject 47,Study 9,EMEA,GAB,0.0,11.0,137.0,EOS Part B (1),Completed
Study 9,Site 15,Subject 48,Study 9,EMEA,GAB,0.0,11.0,133.0,EOS Part B (1),Completed
Study 9,Site 15,Subject 49,Study 9,EMEA,GAB,0.0,1.0,10.0,Screening,Screen Failure
Study 9,Site 15,Subject 50,Study 9,EMEA,GAB,0.0,11.0,131.0,EOS Part B (1),Completed
Study 9,Site 15,Subject 51,Study 9,EMEA,GAB,0.0,11.0,136.0,EOS Part B (1),Completed
Study 9,Site 15,Subject 52,Study 9,EMEA,GAB,0.0,1.0,13.0,Screening,Discontinued
Study 9,Site 15,Subject 53,Study 9,EMEA,GAB,0.0,11.0,141.0,EOS Part B (1),Completed
Study 9,Site 15,Subject 54,Study 9,EMEA,GAB,0.0,11.0,137.0,EOS Part B (1),Completed
Study 9,Site 165,Subject 1512,Study 9,EMEA,GHA,0.0,1.0,10.0,Screening,Screen Failure
Study 9,Site 165,Subject 1513,Study 9,EMEA,GHA,0.0,1.0,10.0,Screening,Screen Failure
Study 9,Site 165,Subject 2586,Study 9,EMEA,GHA,0.0,1.0,9.0,Screening,Screen Failure
Study 9,Site 165,Subject 2587,Study 9,EMEA,GHA,0.0,10.0,118.0,EOS Part A (1),Completed
Study 9,Site 165,Subject 2588,Study 9,EMEA,GHA,0.0,10.0,118.0,EOS Part A (1),Completed
Study 9,Site 165,Subject 2589,Study 9,EMEA,GHA,0.0,1.0,10.0,Screening,Screen Failure
Study 9,Site 165,Subject 2590,Study 9,EMEA,GHA,0.0,1.0,10.0,Screening,Screen Failure
Study 9,Site 165,Subject 2591,Study 9,EMEA,GHA,0.0,10.0,118.0,EOS Part A (1),Completed
Study 9,Site 165,Subject 3435,Study 9,EMEA,GHA,0.0,10.0,117.0,EOS Part A (1),Completed
Study 9,Site 165,Subject 3436,Study 9,EMEA,GHA,0.0,10.0,117.0,EOS Part A (1),Completed
Study 9,Site 165,Subject 3437,Study 9,EMEA,GHA,0.0,10.0,117.0,EOS Part A (1),Completed
Study 9,Site 165,Subject 3438,Study 9,EMEA,GHA,0.0,1.0,12.0,Screening,Screen Failure
Study 9,Site 165,Subject 3439,Study 9,EMEA,GHA,0.0,10.0,117.0,EOS Part A (1),Completed
Study 9,Site 165,Subject 3440,Study 9,EMEA,GHA,0.0,10.0,118.0,EOS Part A (1),Completed
Study 9,Site 165,Subject 3441,Study 9,EMEA,GHA,0.0,10.0,118.0,EOS Part A (1),Completed
Study 9,Site 165,Subject 3442,Study 9,EMEA,GHA,0.0,1.0,10.0,Screening,Screen Failure
Study 9,Site 165,Subject 3443,Study 9,EMEA,GHA,0.0,10.0,118.0,EOS Part A (1),Completed
Study 9,Site 165,Subject 3444,Study 9,EMEA,GHA,0.0,10.0,117.0,EOS Part A (1),Completed
Study 9,Site 165,Subject 3445,Study 9,EMEA,GHA,0.0,7.0,79.0,EOS Part A (1),Completed
Study 9,Site 165,Subject 3446,Study 9,EMEA,GHA,0.0,1.0,9.0,Screening,Screen Failure
Study 9,Site 165,Subject 3447,Study 9,EMEA,GHA,0.0,1.0,16.0,Screening,Discontinued
Study 9,Site 177,Subject 1593,Study 9,EMEA,KEN,0.0,10.0,128.0,EOS Part A (1),Completed
Study 9,Site 177,Subject 1594,Study 9,EMEA,KEN,0.0,10.0,127.0,EOS Part A (1),Completed
Study 9,Site 177,Subject 1595,Study 9,EMEA,KEN,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 177,Subject 1596,Study 9,EMEA,KEN,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 177,Subject 1597,Study 9,EMEA,KEN,0.0,10.0,126.0,EOS Part A (1),Completed
Study 9,Site 177,Subject 1598,Study 9,EMEA,KEN,0.0,10.0,127.0,EOS Part A (1),Completed
Study 9,Site 177,Subject 1599,Study 9,EMEA,KEN,0.0,1.0,10.0,Screening,Screen Failure
Study 9,Site 177,Subject 3448,Study 9,EMEA,KEN,0.0,10.0,127.0,EOS Part A (1),Completed
Study 9,Site 177,Subject 3449,Study 9,EMEA,KEN,0.0,10.0,127.0,EOS Part A (1),Completed
Study 9,Site 177,Subject 3450,Study 9,EMEA,KEN,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 177,Subject 3451,Study 9,EMEA,KEN,0.0,10.0,127.0,EOS Part A (1),Completed
Study 9,Site 177,Subject 3452,Study 9,EMEA,KEN,0.0,10.0,127.0,EOS Part A (1),Completed
Study 9,Site 177,Subject 3453,Study 9,EMEA,KEN,0.0,10.0,127.0,EOS Part A (1),Completed
Study 9,Site 177,Subject 3454,Study 9,EMEA,KEN,0.0,10.0,132.0,EOS Part A (1),Completed
Study 9,Site 177,Subject 3455,Study 9,EMEA,KEN,0.0,10.0,127.0,EOS Part A (1),Completed
Study 9,Site 177,Subject 3456,Study 9,EMEA,KEN,0.0,1.0,9.0,Screening,Screen Failure
Study 9,Site 177,Subject 3457,Study 9,EMEA,KEN,0.0,1.0,9.0,Screening,Screen Failure
Study 9,Site 18,Subject 3458,Study 9,EMEA,KEN,0.0,11.0,140.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 3459,Study 9,EMEA,KEN,0.0,11.0,145.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 3460,Study 9,EMEA,KEN,0.0,11.0,155.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 3461,Study 9,EMEA,KEN,0.0,11.0,151.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 3462,Study 9,EMEA,KEN,0.0,11.0,155.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 3463,Study 9,EMEA,KEN,0.0,11.0,152.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 3464,Study 9,EMEA,KEN,0.0,12.0,149.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 3465,Study 9,EMEA,KEN,0.0,13.0,161.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 3466,Study 9,EMEA,KEN,0.0,11.0,151.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 3467,Study 9,EMEA,KEN,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 18,Subject 3468,Study 9,EMEA,KEN,0.0,11.0,141.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 3469,Study 9,EMEA,KEN,0.0,11.0,140.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 3470,Study 9,EMEA,KEN,0.0,11.0,156.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 3471,Study 9,EMEA,KEN,0.0,11.0,152.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 3472,Study 9,EMEA,KEN,0.0,11.0,141.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 3473,Study 9,EMEA,KEN,0.0,11.0,141.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 3474,Study 9,EMEA,KEN,0.0,11.0,141.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 63,Study 9,EMEA,KEN,0.0,13.0,161.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 64,Study 9,EMEA,KEN,0.0,11.0,151.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 65,Study 9,EMEA,KEN,0.0,11.0,136.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 66,Study 9,EMEA,KEN,0.0,11.0,149.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 67,Study 9,EMEA,KEN,0.0,11.0,151.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 68,Study 9,EMEA,KEN,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 18,Subject 69,Study 9,EMEA,KEN,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 18,Subject 70,Study 9,EMEA,KEN,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 18,Subject 71,Study 9,EMEA,KEN,0.0,11.0,145.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 72,Study 9,EMEA,KEN,0.0,11.0,141.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 73,Study 9,EMEA,KEN,0.0,11.0,154.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 74,Study 9,EMEA,KEN,0.0,11.0,151.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 75,Study 9,EMEA,KEN,0.0,11.0,151.0,EOS Part B (1),Completed
Study 9,Site 18,Subject 76,Study 9,EMEA,KEN,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 2,Subject 100,Study 9,EMEA,BFA,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 2,Subject 101,Study 9,EMEA,BFA,0.0,10.0,119.0,EOS Part A (1),Completed
Study 9,Site 2,Subject 2,Study 9,EMEA,BFA,0.0,10.0,119.0,EOS Part A (1),Completed
Study 9,Site 2,Subject 3,Study 9,EMEA,BFA,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 2,Subject 3399,Study 9,EMEA,BFA,0.0,10.0,119.0,EOS Part A (1),Completed
Study 9,Site 2,Subject 3400,Study 9,EMEA,BFA,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 2,Subject 3401,Study 9,EMEA,BFA,0.0,10.0,119.0,EOS Part A (1),Completed
Study 9,Site 2,Subject 3402,Study 9,EMEA,BFA,0.0,10.0,119.0,EOS Part A (1),Completed
Study 9,Site 2,Subject 3403,Study 9,EMEA,BFA,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 2,Subject 3404,Study 9,EMEA,BFA,0.0,10.0,119.0,EOS Part A (1),Completed
Study 9,Site 2,Subject 3405,Study 9,EMEA,BFA,0.0,1.0,9.0,Screening,Screen Failure
Study 9,Site 2,Subject 3406,Study 9,EMEA,BFA,0.0,10.0,135.0,Outpatient FUP 6/Day 29 (1),On Trial
Study 9,Site 2,Subject 3407,Study 9,EMEA,BFA,0.0,10.0,138.0,Outpatient FUP 6/Day 29 (1),On Trial
Study 9,Site 2,Subject 3408,Study 9,EMEA,BFA,0.0,10.0,138.0,Outpatient FUP 6/Day 29 (1),On Trial
Study 9,Site 2,Subject 3409,Study 9,EMEA,BFA,0.0,10.0,130.0,Outpatient FUP 6/Day 29 (1),On Trial
Study 9,Site 2,Subject 3410,Study 9,EMEA,BFA,0.0,1.0,9.0,Screening,Screen Failure
Study 9,Site 2,Subject 3411,Study 9,EMEA,BFA,0.0,8.0,110.0,Outpatient FUP 4/Day 16 (1),On Trial
Study 9,Site 2,Subject 3412,Study 9,EMEA,BFA,0.0,8.0,110.0,Outpatient FUP 4/Day 16 (1),On Trial
Study 9,Site 2,Subject 4,Study 9,EMEA,BFA,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 2,Subject 5,Study 9,EMEA,BFA,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 2,Subject 99,Study 9,EMEA,BFA,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 347,Subject 2822,Study 9,EMEA,UGA,0.0,1.0,7.0,Screening,Screen Failure
Study 9,Site 347,Subject 2823,Study 9,EMEA,UGA,0.0,1.0,9.0,Screening,Discontinued
Study 9,Site 347,Subject 2824,Study 9,EMEA,UGA,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 347,Subject 3475,Study 9,EMEA,UGA,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 347,Subject 3476,Study 9,EMEA,UGA,0.0,1.0,7.0,Screening,Discontinued
Study 9,Site 347,Subject 3477,Study 9,EMEA,UGA,0.0,1.0,8.0,Screening,Screen Failure
Study 9,Site 347,Subject 3478,Study 9,EMEA,UGA,0.0,10.0,117.0,EOS Part A (1),Completed
Study 9,Site 347,Subject 3479,Study 9,EMEA,UGA,0.0,12.0,129.0,EOS Part A (1),Completed
Study 9,Site 347,Subject 3480,Study 9,EMEA,UGA,0.0,10.0,109.0,EOS Part A (1),Completed
Study 9,Site 347,Subject 3481,Study 9,EMEA,UGA,0.0,1.0,6.0,Screening,Screen Failure
Study 9,Site 347,Subject 3482,Study 9,EMEA,UGA,0.0,1.0,7.0,Screening,Screen Failure
Study 9,Site 347,Subject 3483,Study 9,EMEA,UGA,0.0,5.0,64.0,Outpatient FUP 1/Day 4 (1),Discontinued
Study 9,Site 87,Subject 627,Study 9,EMEA,CIV,0.0,11.0,141.0,EOS Part B (1),Completed
Study 9,Site 87,Subject 628,Study 9,EMEA,CIV,0.0,11.0,140.0,EOS Part B (1),Completed
Study 9,Site 87,Subject 629,Study 9,EMEA,CIV,0.0,11.0,140.0,EOS Part B (1),Completed
Study 9,Site 87,Subject 630,Study 9,EMEA,CIV,0.0,11.0,142.0,EOS Part B (1),Completed
Study 9,Site 87,Subject 631,Study 9,EMEA,CIV,0.0,7.0,99.0,Outpatient FUP 3/Day 12 (1),Discontinued
Study 9,Site 87,Subject 863,Study 9,EMEA,CIV,0.0,11.0,153.0,EOS Part B (1),Completed
Study 9,Site 87,Subject 864,Study 9,EMEA,CIV,0.0,11.0,153.0,EOS Part B (1),Completed
Study 9,Site 87,Subject 865,Study 9,EMEA,CIV,0.0,11.0,141.0,EOS Part B (1),Completed
Study 9,Site 87,Subject 866,Study 9,EMEA,CIV,0.0,1.0,11.0,Screening,Screen Failure
Study 9,Site 87,Subject 867,Study 9,EMEA,CIV,0.0,11.0,151.0,EOS Part B (1),Completed
Study 9,Site 87,Subject 868,Study 9,EMEA,CIV,0.0,11.0,140.0,EOS Part B (1),Completed
Study 9,Site 87,Subject 869,Study 9,EMEA,CIV,0.0,11.0,153.0,EOS Part B (1),Completed
Study 9,Site 87,Subject 870,Study 9,EMEA,CIV,0.0,11.0,153.0,EOS Part B (1),Completed
Study 9,Site 87,Subject 871,Study 9,EMEA,CIV,0.0,1.0,10.0,Screening,Screen Failure
Study 9,Site 87,Subject 872,Study 9,EMEA,CIV,0.0,11.0,142.0,EOS Part B (1),Completed
Study 9,Site 87,Subject 873,Study 9,EMEA,CIV,0.0,11.0,153.0,EOS Part B (1),Completed
Study 9,Site 87,Subject 874,Study 9,EMEA,CIV,0.0,11.0,142.0,EOS Part B (1),Completed
Study 9,Site 87,Subject 875,Study 9,EMEA,CIV,0.0,11.0,153.0,EOS Part B (1),Completed
Study 9,Site 87,Subject 876,Study 9,EMEA,CIV,0.0,11.0,142.0,EOS Part B (1),Completed
Study 9,Site 87,Subject 877,Study 9,EMEA,CIV,0.0,11.0,153.0,EOS Part B (1),Completed
Study 9,Site 87,Subject 878,Study 9,EMEA,CIV,0.0,11.0,142.0,EOS Part B (1),Completed
Study 9,Site 87,Subject 879,Study 9,EMEA,CIV,0.0,11.0,153.0,EOS Part B (1),Completed
Study 9,Site 87,Subject 880,Study 9,EMEA,CIV,0.0,11.0,155.0,EOS Part B (1),Completed
Study 9,Site 87,Subject 881,Study 9,EMEA,CIV,0.0,6.0,101.0,Outpatient FUP 2/Day 8 (1),Discontinued
Study 9,Site 87,Subject 882,Study 9,EMEA,CIV,0.0,11.0,142.0,EOS Part B (1),Completed
Study 9,Site 87,Subject 883,Study 9,EMEA,CIV,0.0,11.0,152.0,EOS Part B (1),Completed
Study 9,Site 87,Subject 884,Study 9,EMEA,CIV,0.0,11.0,140.0,EOS Part B (1),Completed
nan,2,3,None,None,None,0.0,7.0,18.0,Total:,
nan,2,93,None,None,None,0.0,100.0,0.0,Total:,
nan,2,213,None,None,None,0.0,623.0,0.0,Total:,
nan,9,180,None,None,None,0.0,1244.0,15655.0,Total:,
nan,12,22,None,None,None,0.0,52.0,147.0,Total:,
nan,13,22,None,None,None,0.0,163.0,1610.0,Total:,
nan,13,33,None,None,None,0.0,61.0,881.0,Total:,
nan,14,48,None,None,None,0.0,132.0,901.0,Total:,
nan,14,53,None,None,None,0.0,171.0,1443.0,Total:,
nan,18,79,None,None,None,0.0,1355.0,13319.0,Total:,
nan,27,98,None,None,None,0.0,615.0,0.0,Total:,
nan,34,81,None,None,None,0.0,242.0,0.0,Total:,
nan,112,661,None,None,None,0.0,2535.0,13849.0,Total:,
nan,112,678,None,None,None,0.0,1691.0,10611.0,Total:,
nan,123,652,None,None,None,0.0,6475.0,57884.0,Total:,
nan,148,483,None,None,None,0.0,8861.0,72134.0,Total:,
nan,176,670,None,None,None,0.0,7700.0,39290.0,Total:,
nan,225,1374,None,None,None,0.0,7535.0,77525.0,Total:,
